<SEC-DOCUMENT>0001628280-23-015692.txt : 20230504
<SEC-HEADER>0001628280-23-015692.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504160051
ACCESSION NUMBER:		0001628280-23-015692
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23888447

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>crdf-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762,d:67cc85fac64c47748f00d75862a9f9fe--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:crdf="http://www.cardiffoncology.com/20230331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y180LTEtMS0xLTQ2NzA5_eb9de4f7-8096-4b8f-a472-203623a25c2e">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y183LTEtMS0xLTQ2NzA5_b2bd98d2-22a8-44a5-bba0-11c47cdb9f6a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y184LTEtMS0xLTQ2NzA5_2d4f31e6-8369-43dc-943e-e7b48eaf49e3">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y18xMi0xLTEtMS00NjcwOQ_b22f8e55-8b5f-4fa0-b8e7-62fe875e95cc">2023</ix:nonNumeric><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y18xMy0xLTEtMS00NjcwOQ_4b41f755-68f6-4b87-9bd8-684653852990">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffbad54a6e314ec7a91b4f82d14d8c58_I20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id39cc1c335a2480bb994dbe1468e726e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i625cb66267e34938aa47627512641649_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513f89ebc35b472384751be31e33c9f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad5f47b73dd845b2a15839bc67e13da2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f054b7c0fba4ca390235d3bcec938b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3499e99d669043a3a672f5cc7e2b80b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9369609104e54b8f8837281b23259c18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c82f644f9548afad75b06a3b3e3078_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6cd88fbdbf46e5b08b5efb099ce7cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef2a38416fe413590b0a41deaabca5d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d580a3c0da44ca5948a74430fd58deb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2ae96f6ece4865b96a161ff3cc5b3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db1c32cd33f4668b275596ad8be6a6a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i520146e8778c40ae9eb4a93caac2fe59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i418e8e7b86764323b476f1d50de103ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec11a5a664c422a8f8bb66e71f667c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312615150ad54e8b8d7ee70fc2dcedbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba4a48706535442182a401a22e0833cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42050ca6d82e4a29b7edc3cb14f3acbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id339c48d6a3a4d6592fec24cc7e87bb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac3d1f533bf441187db6cfa7f411097_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655faf9854f5497db018bcda11ed5d2a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fd1e0a05b74674a646b0e7b49d5719_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icecb01efdaee4f5eb0d5b8746d4473bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8eb414426a4def9317db8dd1cd7e44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1f50eb8e1b461e962af45f4e1a5c62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd1787e90ae440190ac383d58430aa1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7e74213a944e54a6eee24c81cf7d25_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763f3b32bb3545939639acdaf8121701_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4251f19c164493b2b76424bd16af85_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1205c295fa4d9794c43e94594a82e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdced6a9590488d8697eadc09ac6fa3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054cdb809097460ca761353ae6210cc9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a56f311afa4d95bf226426a02fdbd6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73118633db044fc86e52f359f9c2460_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia393d1580134431ba101c107da135d75_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83c4f0e9e4a451ca913256b9e5f597f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ac5b81410b4bf28610539018816ecd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbe5009217d4badb543dd22d06f60e2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a893b54a584722bc9f379ccff4de09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0e4ef118b14652a430f88a52c45456_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e3433f486c24b5a9838fa5cba54506f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a18ba240d5446bc8347fa7f49ec834c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9255f0347be4834bcce2c2deeec2732_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8aae50d3074837b6dd46d96505a08b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3f8c1e34bb4619a3c18a295e8be522_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4b24ac3b0b445db0c74e63f0dfa82d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ba2ec1957f486fb4644d20669a8566_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6a34a9ab63435e9e30203c9e13b9cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1e0f24df864659b5fbe3ec7f9f9dc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59231fb89fe4a75a07204111d7f9e85_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic878b552744b4b8daa3463b73139acb6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec7632bb7d2489d8455f7f8065f000c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i802ba24afa954ef4826966d738099742_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc3dabb65af4dd0aa0f9da83cd7e7fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa38a89ab23143729bc687fe3de028af_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76de84abd4642d6912042f6e398c5f2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b403184690c419ca8ad63e8f06ff051_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892bc082ed364fbcaf928358c35a36a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ef9ba624674f31b18f18a906991514_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a4d10a2ed2244df86b13b190473888e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida80c3febeab4dc4a386f3c9f4d1da86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f13704c46b54f4fbf4035b2d602b428_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e672eae8a32483281e04e1d168d302e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513e270303294364a1063483a8eeb9c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia539bc90716e46c09badc816a75cecca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480abc2b1cc54cd6b4b92497a9b2b557_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a288026edfb48cf85b99f21c805ca40_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c2764d1efaa46eb9c63af6bc2f8f380_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26052de731df412fb0a0af634dfdb211_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f0fe39986f424cb855eb97e5214800_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e187a8a013f49e79490f667b361da3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402153b7427c4b18b5c17b418ea38847_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377211d696ec45e693cc525f829d66a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a48087fd894a06a7d66a19e113dfe3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018fdf48beb241fb957140c7fcaac86f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7faedaea947747a5a4e0f9b27f03b9cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ead035a27f4309bd93a8a213d35ec8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48c99f9f8d74d1f9306f416c00c75e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16048614cfcc4e4fa5865a9839662003_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ef613858db4f6888a94e03efa94a80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8d6d09727649149a6395ee1730cce9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e061d7484e40f7b79b0410a81d34ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f0f79dc42ce4acdbb7a7a3d6e44d0ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5569fef827456f88c86fc64506a47e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ed6fd9046d4b9aad7e2742322a47d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9703732e3290451893b9ecbdcd26e17b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1499c884251e45e7a08301c1113c2751_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8910674f7c1d4eb3baab8a3e1449ffcd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efc9d19f6324825ba0f19f6c6910ca8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib717e8f89b554e5eb31a6287f9e82e85_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697c1cde53a841b785441aa2b8d391c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8083c2b5a8b7482f8d5695f5d867a671_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257ef2c7502e4c17b99a926adafc1eaa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf26532bf0944c0db1e554d2d335e401_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28bed919b46e4cecb29c4d54fde5db47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c11618796914158ab65134841e05e6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e356158c614afd81168c0f32199528_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179bfe81b1274a7a937ce14950a79b45_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib47a6f257b464e95b0785df5d930d8e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c7a694fbd140b28864630b1eb4070b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5126a1d0a76b4750b3c4596fed29b417_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71dab6497dbc4a9cad98744b1d6939ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12564752dbbc4764bc02ded3b8f49b4c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5702ca6a9f36479296c15ba3f0c29b9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib815e5c326e04a1ca507261df4fef728_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159aae27f4f5465b9e015d53d086eadd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ieaeff0f9b3d243b4a63f8742a58aa35b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0322636ad15484f8481e2fe8512a156_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65d202a9f424f4cbe0609279095d19a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4a5e322fb148e2b3a3f3d9b7aff411_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70854879aa3545448398e24f78c213d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6ecc60f1194619954b3f1533e7e224_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7083de34860a440bb7091d697390058a_I20220609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1bf0ee8aea9404384a42f661f35f008_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027341bbc88b4f83ab80a25ed8de872e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0886b6ea844e829c14276a57c0e37f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d8a3984a4442faa0609e1a6e8e6e77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09428b9805e4498b813fd5573384236f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7d01a9fe044b8e98c079c7e41f1974_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0242e50efc164b19b23a214ef33fdeea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if640bbe0a9704fa8a6e92d02c5bd50ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de3c3d99592416a9ecb1656c220de10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7223daf79bf460387c65ef8a997c31b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1b8cd013904ade8b00a3ec6d18c509_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i67cc85fac64c47748f00d75862a9f9fe_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU1_845e64f5-28ae-4076-815a-f32faea8fee5">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmEzMTA2MjI5NzE3NGM1MmI4OTAwNGUwNjFiODgwNTcvdGFibGVyYW5nZToyYTMxMDYyMjk3MTc0YzUyYjg5MDA0ZTA2MWI4ODA1N18wLTAtMS0xLTQ2NzA5_4a6edcbc-bcc8-4257-a673-927c3580de50">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xMzc_bf362698-c85e-4e7e-84f3-1744face817a">March 31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6OTIwZDc2YjQ0YzRjNDBiZGIyZGY1YjgxZjk3OWYyZDEvdGFibGVyYW5nZTo5MjBkNzZiNDRjNGM0MGJkYjJkZjViODFmOTc5ZjJkMV8wLTAtMS0xLTQ2NzA5_5258bfa7-ea6f-47e0-9c0d-07d21992f3a4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU2_e34a64d4-d637-4ecc-9b7f-557b59fc66a6">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU4_fb6c1b92-168a-4702-b6cd-5436ac24484f">CARDIFF ONCOLOGY,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8wLTAtMS0xLTQ2NzA5_b756b45a-37e9-48b9-8c1c-c7019818b00c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8wLTItMS0xLTQ2NzA5_5881b576-9a86-4fa0-84df-26ffccd68e8d">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfNA_cfd94e54-89d5-4826-b78d-29fbfccfa236">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfOA_3686e1df-4ad5-4b5d-b42b-faa7f63e2657">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfMTI_33d6d70a-85c3-4d3a-9ba3-0c26ce0dbf46">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTItMS0xLTQ2NzA5_146aac41-c892-4ced-84c7-3d444685fb12">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF82LTAtMS0xLTQ2NzA5L3RleHRyZWdpb246ODYzOWIwNjM1NzQwNDIzNzlkMmVmMDNlYzYwMmYwOWJfNQ_c6ce76f9-1c1d-487b-bff0-8e35ab7aaeee">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF82LTAtMS0xLTQ2NzA5L3RleHRyZWdpb246ODYzOWIwNjM1NzQwNDIzNzlkMmVmMDNlYzYwMmYwOWJfOQ_f19c1db7-d7ed-4725-b956-439d8920c5e6">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:31.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmVjMjQwMTI1N2MxNDlkNGIxZDU0ZDkzY2MyNDJlNmQvdGFibGVyYW5nZToyZWMyNDAxMjU3YzE0OWQ0YjFkNTRkOTNjYzI0MmU2ZF8xLTAtMS0xLTQ2NzA5_eb8d0fc6-742b-4027-8811-fe24d2369479">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmVjMjQwMTI1N2MxNDlkNGIxZDU0ZDkzY2MyNDJlNmQvdGFibGVyYW5nZToyZWMyNDAxMjU3YzE0OWQ0YjFkNTRkOTNjYzI0MmU2ZF8xLTItMS0xLTQ2NzA5_7914bc18-6a0a-4b05-8c13-422d0b7743ba">CRDF</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the issuer (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU5_8c95d943-0c1a-47fb-bf61-90de139caa63">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODYw_7af636af-1b6a-4555-993a-f4a95c604540">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTQtMS0xLTQ2NzA5L3RleHRyZWdpb246YTY1NTA2OTRiNzFlNGYxMTk2NzFkNWNjYjY5NGZhNTVfNA_a99bbdf3-2652-4251-9b91-d8a88573cd9f">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTYtMS0xLTQ2NzA5L3RleHRyZWdpb246OGQzMjdkM2M5M2NkNDg3ODhjNjFjM2IyOTk4NzBjNDFfMzA_6a592384-d164-4d6b-94d2-3a6e79c73dd7">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTgtMS0xLTQ2NzA5L3RleHRyZWdpb246YzczZTg3NzYwMDJiNDY3YWIxZGRhNTI1YmNkOGE4NDlfMjg_ba873b12-1e13-451c-80d4-70eddad04f37">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODYx_36809457-bb46-42ef-aa9a-b6ec7e279b9c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;27, 2023, the issuer had <ix:nonFraction unitRef="shares" contextRef="iffbad54a6e314ec7a91b4f82d14d8c58_I20230427" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODA1_2d734aea-635a-4363-8b67-cc06792ea37c">44,677,169</ix:nonFraction> shares of Common Stock issued and outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_10">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_13">Item 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_16">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_19">Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_22">Condensed Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_31">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_31">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_37">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_37">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_73">Item 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_73">17</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_97">Item 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_94">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_100">Item 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_100">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_103">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_103">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_106">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_106">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_109">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_109">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_112">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_112">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_115">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_118">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_121">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_121">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_121">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_124">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_124">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMy0xLTEtMS00NjcwOQ_365c950d-402d-4e19-b61f-c7dcb97430a9">15,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMy0zLTEtMS00NjcwOQ_efd19d6f-6317-4c56-b6fd-666372a6bd5f">16,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNC0xLTEtMS00NjcwOQ_ce62fbe0-f32b-4990-81f8-e675258be77e">81,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNC0zLTEtMS00NjcwOQ_589a4143-19df-4df1-93d5-bfdba6592b06">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNS0xLTEtMS00NjcwOQ_1bc6f67f-dcc5-4089-a8aa-f2da67dc5f13">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNS0zLTEtMS00NjcwOQ_0e7aa078-8e83-44d5-8457-72e80996f785">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNi0xLTEtMS00NjcwOQ_92cdc9fb-33aa-4ba9-b821-54afc5fc5ee1">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNi0zLTEtMS00NjcwOQ_c5f6035a-bed4-493b-bf89-8b8eaee2c080">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNy0xLTEtMS00NjcwOQ_4b69c1d5-9e05-4b60-8ee3-5f26e158ea2b">101,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNy0zLTEtMS00NjcwOQ_db653099-4c8d-49c2-9c76-0f52df7cbc79">111,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfOC0xLTEtMS00NjcwOQ_4578dab8-b1b4-4b70-b017-732c28eb801e">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfOC0zLTEtMS00NjcwOQ_db2be495-e4c2-4927-96d8-83cbab8ae738">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTAtMS0xLTEtNDY3MDk_b053479a-3bde-4339-a254-2e5be5b54aa0">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTAtMy0xLTEtNDY3MDk_44b53dcd-8bc2-4737-b6c5-5c462749e02e">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTEtMS0xLTEtNDY3MDk_f13445c1-8636-403f-93b5-5fdd215bcbc4">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTEtMy0xLTEtNDY3MDk_a8d914cf-361b-4126-bbce-05824a7aa61c">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTItMS0xLTEtNDY3MDk_10effa23-aeaf-48c1-bf77-d21181045c2a">106,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTItMy0xLTEtNDY3MDk_7cf1a2c1-1961-41de-933e-4847eb780cbc">116,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTYtMS0xLTEtNDY3MDk_dd6b0014-3f70-4959-830e-3f296ac051f6">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTYtMy0xLTEtNDY3MDk_f5d8ea72-67be-48a5-b79a-8d41d57f7f41">1,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTctMS0xLTEtNDY3MDk_0321e66a-4e5c-41c7-a1dd-956a1031d97e">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTctMy0xLTEtNDY3MDk_fdbdd07b-320c-4f4e-b19b-081217a11361">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTktMS0xLTEtNDY3MDk_a3eec2f8-6bab-449a-ad22-ea57b3c21780">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTktMy0xLTEtNDY3MDk_6ac0792b-5e1f-474e-b032-3a5d276b5a3a">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjItMS0xLTEtNDY3MDk_16ad5c5b-88a2-4b31-b738-03048f611f43">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjItMy0xLTEtNDY3MDk_2fac596c-77da-4ad3-92f2-c6c8ab0f21d7">7,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjUtMS0xLTEtNDY3MDk_76856503-b6e3-4c85-8cda-d0de93ba7d28">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjUtMy0xLTEtNDY3MDk_260c5b38-745b-49a3-a619-9b1b1a414b77">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjgtMS0xLTEtNDY3MDk_6faf91b2-b9fd-48c7-a1fb-7b7106739b19">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjgtMy0xLTEtNDY3MDk_9643d62f-3493-4f84-a6a0-adabb597d520">9,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzAtMS0xLTEtNDY3MDk_ed5ca265-d121-4dbf-b673-2ac41d8585b6"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzAtMy0xLTEtNDY3MDk_94d03d79-6ec0-4013-a8a3-3a996f178ca0"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMQ_51399c98-a3f9-45fe-a788-64ca11400c1b"><ix:nonFraction unitRef="shares" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMQ_754d0594-3876-40a8-abc0-9d69c4d31965">20,000</ix:nonFraction></ix:nonFraction> shares authorized; Series A Convertible Preferred Stock liquidation preference $<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMTk5MDIzMjU1Nzgw_01708ab1-cc08-42e5-9b53-421e7478a2c4">1,050</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMTk5MDIzMjU1Nzk4_3580daf3-3592-4334-bcc6-fbfc3e8d1e0d">1,044</ix:nonFraction> at March&#160;31, 2023 and December&#160;31, 2022, respectively (Note 6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMS0xLTEtNDY3MDk_fb0fc4b1-1b66-47a7-9230-b8c3b1cbd828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMy0xLTEtNDY3MDk_d2878e80-3574-4f13-9881-8313bf60bccb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8xOQ_8eb6159b-ef24-4e82-8fc0-cffc377b81f2"><ix:nonFraction unitRef="usdPerShare" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8xOQ_e4f61aea-65af-4c47-93d8-529575da4cfa">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8zMw_14c6846b-35cb-4ca0-8e18-a7f0ef7a90ef"><ix:nonFraction unitRef="shares" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8zMw_d1d7e29c-6323-4ce7-835d-165d1b970957">150,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml81NQ_0ab653fb-7da9-46bf-a6d9-c10a4a4f03d2"><ix:nonFraction unitRef="shares" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml81NQ_90046ad1-42aa-47a7-9faf-f6b52d0e3d18">44,677</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml82Mg_0983402b-d36a-4839-a81e-55aa3798e924"><ix:nonFraction unitRef="shares" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml82Mg_961a079c-4f29-48c5-ad8a-284498f59810">44,677</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMS0xLTEtNDY3MDk_b5d719a0-69bf-449a-b3ac-cdf79c0f0910">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMy0xLTEtNDY3MDk_fcaf2f8a-1d71-4f44-930b-af8b0ca3a2b0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzUtMS0xLTEtNDY3MDk_3df9baca-8663-48f9-9409-3357d5016808">405,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzUtMy0xLTEtNDY3MDk_0eeb5fff-1af1-4fc0-8984-565008a3c372">404,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzctMS0xLTEtNDY3MDk_10338a09-c589-409b-8a22-df646a52a6af">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzctMy0xLTEtNDY3MDk_9be5d440-cd8b-4f33-8e3a-84a2211abc07">395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzgtMS0xLTEtNDY3MDk_986be885-e612-492f-8a1e-5c9e063305bd">309,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzgtMy0xLTEtNDY3MDk_c9bdd195-eb33-4e13-a059-427fdcab7e00">298,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzktMS0xLTEtNDY3MDk_19d68850-bce0-4dd7-8823-7bf945ae34b7">96,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzktMy0xLTEtNDY3MDk_ea269e5a-d645-45ca-b54e-a7a112161d1a">106,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNDAtMS0xLTEtNDY3MDk_51d713c0-400d-4d64-b3b3-8f57bc2552cd">106,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNDAtMy0xLTEtNDY3MDk_de76ac11-42f5-49db-8139-80f212a7d15f">116,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfNS01LTEtMS00NjcwOQ_4cafd4aa-f9ba-4314-b2f3-f0e81e713cb7">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfNS03LTEtMS00NjcwOQ_afcf6862-31f6-4704-aa3e-e10caf0c51cf">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOC01LTEtMS00NjcwOQ_51503775-48df-4be8-9fbe-676a94fa555e">9,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOC03LTEtMS00NjcwOQ_689d00df-649b-430b-9c5c-1d4b0eae4452">7,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOS01LTEtMS00NjcwOQ_09dcb377-0009-4c04-afc4-290c07419a8a">3,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOS03LTEtMS00NjcwOQ_58a3012c-f2af-4131-95a2-d4d5bcbe0bd6">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTItNS0xLTEtNDY3MDk_1ea0decc-700e-427c-bc78-9e024764cc60">12,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTItNy0xLTEtNDY3MDk_db618a86-8392-4378-9970-23d342798b09">11,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTQtNS0xLTEtNDY3MDk_032cde07-8750-4d06-b95c-643e57bfc005">12,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTQtNy0xLTEtNDY3MDk_4981b203-7192-4811-ad6c-e9db6ebb9a3d">11,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTctNS0xLTEtNDY3MDk_e19e054f-bd88-4c47-9472-2a32b35d8575">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTctNy0xLTEtNDY3MDk_2023c176-3a47-491d-9afd-6c9fd7c67123">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjEtNS0xLTEtNDY3MDk_3a2a5cc9-2a09-40f1-a0e6-ab7c2fc9797c">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjEtNy0xLTEtNDY3MDk_2a3fc105-4d0c-4339-9a48-89f99570a5d8">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjItNS0xLTEtNDY3MDk_befd520a-818c-490a-95ea-b6cc5f1dc2df">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjItNy0xLTEtNDY3MDk_01a90832-0db3-4eb2-bbab-ffbc6fcc13b6">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjQtNS0xLTEtNDY3MDk_b04f4aea-836b-48cc-9c3d-a1829065b685">11,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjQtNy0xLTEtNDY3MDk_3e716ea3-ebbe-4a08-8b6c-4f944f99fa84">10,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjYtNS0xLTEtNDY3MDk_9162aec0-a93a-4434-acf3-f1a8df9e64b5">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjYtNy0xLTEtNDY3MDk_83e59611-ef5d-447b-bfe2-481af252222e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzItNS0xLTEtNDY3MDk_6b30937e-dbcc-44ab-bdcf-0c8dc2c44105">11,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzItNy0xLTEtNDY3MDk_ffae240c-6625-4c62-b50b-632323c3d9f2">10,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNS0xLTEtNDY3MDk_8924ab59-8b4b-46cb-9e3f-6cd6978af34f"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNS0xLTEtNDY3MDk_b3e1fb7a-619d-437e-b255-3daf66adc741">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNy0xLTEtNDY3MDk_842c0eba-c626-4ed9-b86b-5db64e82b3b5"><ix:nonFraction unitRef="usdPerShare" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNy0xLTEtNDY3MDk_bda18a5f-33a6-4ad5-bf29-9ed3ced3343c">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNS0xLTEtNDY3MDk_3c23de98-359e-40bd-8a2c-4db4a2365c29"><ix:nonFraction unitRef="shares" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNS0xLTEtNDY3MDk_90b96cd4-afe3-4239-b657-60c996553489">44,677</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNy0xLTEtNDY3MDk_d50da61f-167e-46de-a618-f32c0a4d4686"><ix:nonFraction unitRef="shares" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNy0xLTEtNDY3MDk_e3709f2b-1138-4f94-99c0-7db9d59d283e">43,231</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMi01LTEtMS00NjcwOQ_8a1b5ed9-e051-4a9b-84ab-46c0499d9b84">11,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMi03LTEtMS00NjcwOQ_6d72013a-70cf-4023-b707-59fe74e0b1e8">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) on securities available-for-sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNC01LTEtMS00NjcwOQ_83dc247b-0c9e-4a73-b728-9556525bf199">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNC03LTEtMS00NjcwOQ_d7ea76a3-f334-45b3-8807-88cfb1cdaf08">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNS01LTEtMS00NjcwOQ_8b73eaae-6656-48a6-94eb-6955af048dd3">10,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNS03LTEtMS00NjcwOQ_0ea19ad5-a6c2-4ce1-9473-d8f583ad1b5c">11,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNy01LTEtMS00NjcwOQ_cfb53f3b-930f-4005-bff9-1b1bf2b29881">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNy03LTEtMS00NjcwOQ_08b94da2-28d3-4af3-aa34-c82738bb0243">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMTMtNS0xLTEtNDY3MDk_f6afed7f-2e42-4bf1-905f-e4e5c85688b5">10,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMTMtNy0xLTEtNDY3MDk_786af4de-43ae-4132-aed6-8aec582b4574">11,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i513f89ebc35b472384751be31e33c9f9_I20221231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xLTEtMS00OTkzOA_526db02d-c85a-4f5b-a0f0-4b6124252da8">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513f89ebc35b472384751be31e33c9f9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0zLTEtMS00OTkzOA_ff627922-b186-4b74-a421-c935c8fc443a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad5f47b73dd845b2a15839bc67e13da2_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS01LTEtMS00OTkzOA_fe079e66-9791-4e63-b999-30d82d8a33fd">44,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5f47b73dd845b2a15839bc67e13da2_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS03LTEtMS00OTkzOA_a9f780a7-e517-4bb6-b0e0-da30406cce50">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f054b7c0fba4ca390235d3bcec938b5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS05LTEtMS00OTkzOA_6e301625-672e-44e4-81f6-46eb4cbfa009">404,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3499e99d669043a3a672f5cc7e2b80b7_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xMy0xLTEtNDk5Mzg_7a0a4c45-faca-40c7-87b0-3207359b08a4">395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9369609104e54b8f8837281b23259c18_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xNS0xLTEtNDk5Mzg_442474c3-50db-48fd-8a51-7feae474aa2e">298,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xNy0xLTEtNDk5Mzg_adb197d0-1512-4721-887b-af3a5b845255">106,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c82f644f9548afad75b06a3b3e3078_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMi05LTEtMS00OTkzOA_8e88c6ad-5b72-4521-bd13-bfd717cf4866">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMi0xNy0xLTEtNDk5Mzg_398739a9-b222-4d7a-a49c-94ad6e29ec94">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6cd88fbdbf46e5b08b5efb099ce7cd_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMy0xMy0xLTEtNDk5Mzg_f8b7b19a-80f8-4216-9704-d1d37247c04b">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMy0xNy0xLTEtNDk5Mzg_cabfdb30-002f-4562-b09f-5a884547251b">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaef2a38416fe413590b0a41deaabca5d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNC0xNS0xLTEtNDk5Mzg_7302a67c-b31d-4373-bf16-f166f3b365a3">11,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNC0xNy0xLTEtNDk5Mzg_8e41a08a-92e4-4d5e-8719-530aeb44f2d5">11,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xLTEtMS01MzgyMA_74bbee38-7033-4ed7-859d-53b619872f89">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0zLTEtMS01MzgyMA_fc1fc7b5-58c3-401d-9d07-e4d7321c3e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d580a3c0da44ca5948a74430fd58deb_I20230331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS01LTEtMS01MzgyMA_86197836-a388-4ba6-917d-8ca971d5fc15">44,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d580a3c0da44ca5948a74430fd58deb_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS03LTEtMS01MzgyMA_806eb9ce-ba25-4d5e-80c5-c11247a1516b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2ae96f6ece4865b96a161ff3cc5b3e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS05LTEtMS01MzgyMA_44733045-bddd-49b8-9de2-91550a6d119f">405,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5db1c32cd33f4668b275596ad8be6a6a_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xMy0xLTEtNTM4MjA_a21375cc-6d14-40d6-b685-3aa5a677e0b8">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i520146e8778c40ae9eb4a93caac2fe59_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xNS0xLTEtNTM4MjA_6d7980ab-a78b-4482-91df-a3e27569e272">309,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xNy0xLTEtNTM4MjA_bc7b9b10-2b2a-40d6-b472-ba224a1f7721">96,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:21.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i418e8e7b86764323b476f1d50de103ca_I20211231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xLTEtMS00NjcwOQ_7e8ff0c7-f505-4f82-ad42-08d833f5e0d5">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418e8e7b86764323b476f1d50de103ca_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0zLTEtMS00NjcwOQ_b6015bec-c577-4b2f-b8fa-7a171a145264">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icec11a5a664c422a8f8bb66e71f667c9_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS01LTEtMS00NjcwOQ_ff4db6ad-61a8-43aa-81bc-e0c12755f5eb">41,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec11a5a664c422a8f8bb66e71f667c9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS03LTEtMS00NjcwOQ_e3a5f38b-73a8-446a-ab34-8a296c828fcb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312615150ad54e8b8d7ee70fc2dcedbb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS05LTEtMS00NjcwOQ_63bc3388-c430-4266-8e0f-40de703f5b83">400,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba4a48706535442182a401a22e0833cf_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xMS0xLTEtNDY3MDk_19b0c25d-0cd6-4e03-84cd-18b06ad0b083">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42050ca6d82e4a29b7edc3cb14f3acbc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xMy0xLTEtNDY3MDk_3917ba0d-86ba-4b88-ae29-01ca9fdd3d32">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id339c48d6a3a4d6592fec24cc7e87bb6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xNS0xLTEtNDY3MDk_a733d5fa-0d32-477a-b991-cc423d3bf6e6">259,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac3d1f533bf441187db6cfa7f411097_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xNy0xLTEtNDY3MDk_6b2afd19-84fc-471e-9fa7-20348cb1141a">140,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655faf9854f5497db018bcda11ed5d2a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMi05LTEtMS00NjcwOQ_e10cbd83-e713-49f9-b0e4-e3570ee7c6bd">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMi0xNy0xLTEtNDY3MDk_f2165a0e-0e02-44ca-9850-cb5356d38b51">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01fd1e0a05b74674a646b0e7b49d5719_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNi0xMy0xLTEtNDY3MDk_dcf87e49-4d22-4631-b84c-a437eded55c4">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNi0xNy0xLTEtNDY3MDk_93495e4f-797f-4a18-b3b3-caf7e42d995b">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0xLTEtMS00NjcwOQ_dd8eac65-59c5-49fa-8a57-566729cf3481">328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0zLTEtMS00NjcwOQ_3bc465a2-8c90-41a0-8632-1191979ddfed">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icecb01efdaee4f5eb0d5b8746d4473bd_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy01LTEtMS00NjcwOQ_0d81b330-cff3-4ec9-813a-051d1921785f">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0xNy0xLTEtNDY3MDk_aeb63c85-8930-4335-9aa0-35a3aeb5550e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOC0xNS0xLTEtNDY3MDk_5047658a-cf1c-42c5-8106-d3d09147c660">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOC0xNy0xLTEtNDY3MDk_5f0c060a-e260-49cd-a3e0-af9af2030d0e">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8eb414426a4def9317db8dd1cd7e44_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOS0xMS0xLTEtNDY3MDk_6b0324dc-0d5a-4970-8fe5-0dc840571c3a">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOS0xNy0xLTEtNDY3MDk_c03c7e4d-15d1-4d9e-96b9-6f6f2e03e449">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTAtMTUtMS0xLTQ2NzA5_eefee823-e791-431e-accc-d67b539edb7e">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTAtMTctMS0xLTQ2NzA5_69b0923a-e75a-492b-a9b2-778d262cc0f1">10,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMS0xLTEtNDY3MDk_36a4b3e7-96c4-46d4-8d7e-9a18b2fa79b4">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMy0xLTEtNDY3MDk_c593be98-4363-4f41-abc3-b4fc50fbe9d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtNS0xLTEtNDY3MDk_13f62bbd-8661-4ef4-8ccd-dae12e9ffef0">43,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtNy0xLTEtNDY3MDk_93f81e2b-fcd9-494b-b0c0-f4dec3b7a5f4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1f50eb8e1b461e962af45f4e1a5c62_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtOS0xLTEtNDY3MDk_2972af58-8b14-4adf-82bd-66951cb37ef9">401,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd1787e90ae440190ac383d58430aa1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTEtMS0xLTQ2NzA5_109f4c58-3830-428b-9dbc-02f2a91c26e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c7e74213a944e54a6eee24c81cf7d25_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTMtMS0xLTQ2NzA5_5f61a56f-bcfe-40ff-92e7-2e3824325dbf">748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i763f3b32bb3545939639acdaf8121701_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTUtMS0xLTQ2NzA5_4fea6f94-dde5-4dd1-b82e-ae227c484768">270,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTctMS0xLTQ2NzA5_8ae9595a-76af-47da-b949-a42d23e1e19f">130,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_31"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMy0xLTEtMS00NjcwOQ_0601e1be-133f-4045-91fd-7be90d65bed2">11,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMy0zLTEtMS00NjcwOQ_b9474388-d1ee-4d72-b97d-47e46f3fbcdc">10,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNy0xLTEtMS00NjcwOQ_4ba63316-99fd-4a45-8e0c-2874a84d5a0e">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNy0zLTEtMS00NjcwOQ_babe4710-0f31-4a33-8f57-54e91c76ca66">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfOS0xLTEtMS00NjcwOQ_d10b21f1-4374-46ba-a6bf-6faa56a5f619">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfOS0zLTEtMS00NjcwOQ_5f5a98a2-c9ed-407d-8e43-b2fe277997c3">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums (discounts) on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTQtMS0xLTEtNDY3MDk_e2d001d3-604c-474a-a8a4-9f4a82fe7139">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTQtMy0xLTEtNDY3MDk_847e4bdd-6a43-40ba-8ffc-31ef721d2f14">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTgtMS0xLTEtNDY3MDk_3c0ef3cd-bb4d-432c-a690-f9e5e742aeb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTgtMy0xLTEtNDY3MDk_1e12908b-8a2f-4aff-8b21-bfcc1979ce3a">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjAtMS0xLTEtNDY3MDk_be4ab83e-0838-4748-814a-7edb1fe75b58">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjAtMy0xLTEtNDY3MDk_cba24d62-da28-4ceb-96ba-29b75fa8efec">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjEtMS0xLTEtNDY3MDk_b09f01ba-186e-474d-8284-8c04beadf5b3">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjEtMy0xLTEtNDY3MDk_3e17c03c-ea61-48bf-8859-facacdb8d414">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjItMS0xLTEtNDY3MDk_a0486333-96a4-4915-bfc2-5d8c7e9f8860">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjItMy0xLTEtNDY3MDk_2df3e33b-1b0e-4d92-a45b-fd0a646332e5">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjMtMS0xLTEtNDY3MDk_df72d14f-545c-49cc-ac2e-e63c067677c7">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjMtMy0xLTEtNDY3MDk_246e7655-9545-4597-8769-8d1d3bd100a3">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjQtMS0xLTEtNDY3MDk_37401aa4-ecde-4b6d-b8e1-4901d182db08">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjQtMy0xLTEtNDY3MDk_ec41a9ca-f593-41be-bb2c-a96e742c64b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjUtMS0xLTEtNDY3MDk_909aa1bb-b8d6-4f8a-ab50-1c1d3b65616c">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjUtMy0xLTEtNDY3MDk_99b08376-d5b1-4504-a7a3-eacd2dfcf852">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjYtMS0xLTEtNDY3MDk_39a97d18-7566-49e4-90ee-247b9dde1684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjYtMy0xLTEtNDY3MDk_ed669a55-9e51-4f5d-aa2c-d01730bff6c2">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjctMS0xLTEtNDY3MDk_d7087bcc-b588-40d9-9d13-c2ac81421bc4">8,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjctMy0xLTEtNDY3MDk_d9be7edd-8643-4382-bdda-f2f95ea9960d">10,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzEtMS0xLTEtNDY3MDk_22f5bc92-6e59-4974-9452-221036846d77">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzEtMy0xLTEtNDY3MDk_31e4a4b0-a7d0-4a3e-b067-58b152575f4f">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzMtMS0xLTEtNDY3MDk_007677c6-8eb7-4b34-ad99-40dd13328c98">42,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzMtMy0xLTEtNDY3MDk_ad2c328b-8bf1-4247-9877-60cec9681c97">38,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzQtMS0xLTEtNDY3MDk_5b9d5992-ab3d-46f7-a2e1-beb22b5c4ab5">37,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzQtMy0xLTEtNDY3MDk_86aeffb8-c528-4108-98cf-5edad54aea71">36,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzUtMS0xLTEtNDY3MDk_7db9c6f8-ca36-44e0-862c-f629ebf60817">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzUtMy0xLTEtNDY3MDk_2281f1ee-2195-4554-a5b1-f4da10c1194c">17,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzYtMS0xLTEtNDY3MDk_55b51683-37d1-4ed1-b2b0-009938c94f6c">7,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzYtMy0xLTEtNDY3MDk_f731b3d1-f21f-4935-a367-8aad542d5c54">18,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNDktMS0xLTEtNDY3MDk_16e5d6dc-6c1d-4244-b32b-60025f9aabef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNDktMy0xLTEtNDY3MDk_33db6b36-e819-4cce-9694-abcbaf702d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTEtMS0xLTEtNDY3MDk_02734f72-da72-4923-9c80-1a4d020cbfc4">1,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTEtMy0xLTEtNDY3MDk_514bc07e-49eb-47ea-8949-f1cacf705f61">8,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTItMS0xLTEtNDY3MDk_47dcfdac-6b9e-4cb3-b887-479d10208aa7">16,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac3d1f533bf441187db6cfa7f411097_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTItMy0xLTEtNDY3MDk_152e6ac6-7bd0-470d-b216-94dd59cc0e4c">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTMtMS0xLTEtNDY3MDk_227cae87-8931-40d9-be1f-42e3faaed5c5">15,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTMtMy0xLTEtNDY3MDk_99f98495-bd9f-4c02-b906-33d536ab5511">20,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTYtMS0xLTEtNDY3MDk_36cc6edb-e6cf-42bd-86db-12e8fb2190d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTYtMy0xLTEtNDY3MDk_b643f3f5-192e-405c-981d-d47e1a09fbb6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTktMS0xLTEtNDY3MDk_aeb11fd2-b863-474f-a835-57066e569c1f">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTktMy0xLTEtNDY3MDk_25a6239c-fb1f-4aec-9be6-41ee1a7a3b1b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:83.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80MC9mcmFnOmZhN2QwMjgxZWU0NDRjODBiMmRjMmM2ODRiMGU3NmNlL3RleHRyZWdpb246ZmE3ZDAyODFlZTQ0NGM4MGIyZGMyYzY4NGIwZTc2Y2VfMzMyMQ_cb84f05b-e9a0-4b97-87bd-7acfe8874312" continuedAt="i3d62b15ca82c4b86b6a5cbb64fa4d4f3" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i3d62b15ca82c4b86b6a5cbb64fa4d4f3" continuedAt="ie940bcfa9df44fd3a1ac092518d72d6e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard-of-care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard-of-care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2022, has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2022, included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on March&#160;2, 2023.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80MC9mcmFnOmZhN2QwMjgxZWU0NDRjODBiMmRjMmM2ODRiMGU3NmNlL3RleHRyZWdpb246ZmE3ZDAyODFlZTQ0NGM4MGIyZGMyYzY4NGIwZTc2Y2VfMjY1Nw_efc96411-612a-468b-b562-830148343985">97.0</ix:nonFraction>&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie940bcfa9df44fd3a1ac092518d72d6e">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.</ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk3MQ_8a130a27-cacb-49cb-ab86-47fcf9aecee1" continuedAt="i0867986ddde349779961d4e39025f61d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i0867986ddde349779961d4e39025f61d" continuedAt="i13bc21f1b8b4425f92fe82d7bfaa5246"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk3NA_b0ab1984-b397-41ae-9e7b-da326810df56" continuedAt="ie5e0bd674e7c48f2b9278efdb43b7b34" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5e0bd674e7c48f2b9278efdb43b7b34">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="i13bc21f1b8b4425f92fe82d7bfaa5246"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk4MA_b93f3cf5-cc4c-494c-ae8f-90692675a985" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d1205c295fa4d9794c43e94594a82e8_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMi0xLTEtMS00NjcwOQ_d7b38277-de07-48e0-a08a-5271b153e507">6,396,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdced6a9590488d8697eadc09ac6fa3_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMi0zLTEtMS00NjcwOQ_c5530f2d-c398-41f2-84d4-baa435c8fe12">5,467,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i054cdb809097460ca761353ae6210cc9_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMy0xLTEtMS00NjcwOQ_db30dc8e-fb14-4a24-a0db-2499c49acbc1">4,296,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a56f311afa4d95bf226426a02fdbd6_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMy0zLTEtMS00NjcwOQ_1ebd6ee6-dc11-4393-b111-f8f2e733ec41">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73118633db044fc86e52f359f9c2460_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNS0xLTEtMS00NjcwOQ_1cfdbbc7-f83d-450c-be07-3e51555d12c1">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia393d1580134431ba101c107da135d75_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNS0zLTEtMS00NjcwOQ_8a4870a9-5923-410c-9a4b-e5ef04f9e13d">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id83c4f0e9e4a451ca913256b9e5f597f_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNy0xLTEtMS00NjcwOQ_ae4c0a0b-1a3c-40e3-9347-62972838e11b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06ac5b81410b4bf28610539018816ecd_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNy0zLTEtMS00NjcwOQ_a2b705d5-c563-498d-a693-66a6883ba263">1,342,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfOC0xLTEtMS00NjcwOQ_e1e2ec68-f217-4235-a7cf-1f862c0a0eed">10,694,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfOC0zLTEtMS00NjcwOQ_ae62b760-0936-413e-9b86-b4aad97a8451">11,300,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk2OA_32e44293-f562-46b3-89ab-3db3a2564e91" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures, and will adopt this standard on January 1, 2024.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RleHRyZWdpb246N2NlMzgxZDhlNjY2NDkzZGI1YWMzNGU0NzE0MjAzODdfNTY5_6c2b4f03-3dbd-4e01-bbb8-53c65ccc9f91" continuedAt="ifabf29b00a514414a1b3ee9427832a2e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ifabf29b00a514414a1b3ee9427832a2e" continuedAt="i001fa0877a524ef2a88488bdd4bb3374"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RleHRyZWdpb246N2NlMzgxZDhlNjY2NDkzZGI1YWMzNGU0NzE0MjAzODdfNTcw_51adc1e2-2ada-45ea-afb9-19ee63fe9275" continuedAt="i5912a24e87b94406b9063f2d44415c54" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2023, and December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbe5009217d4badb543dd22d06f60e2_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy0xLTEtMS00NjcwOQ_30cd3b26-b0b8-4131-81fc-ff41633190c6">14,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a893b54a584722bc9f379ccff4de09_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy0zLTEtMS00NjcwOQ_c0f3e08a-f14a-4871-aab9-27b77dae3f86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0e4ef118b14652a430f88a52c45456_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy01LTEtMS00NjcwOQ_66ef14e5-31f9-4dd2-b977-c376be492bf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3433f486c24b5a9838fa5cba54506f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy03LTEtMS00NjcwOQ_e6840fda-60a0-4615-af0b-62ddc86d2642">14,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS0xLTEtMS00NjcwOQ_407a7f4d-fb38-40dc-86ec-244dba9f6745">14,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS0zLTEtMS00NjcwOQ_8b79dd54-8681-4b88-87b6-d23f08343fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS01LTEtMS00NjcwOQ_df1bb1d0-5024-49ef-b6c1-8a27951f1521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS03LTEtMS00NjcwOQ_f00b2378-d124-4dd5-b278-1407c3dcd132">14,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3f8c1e34bb4619a3c18a295e8be522_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC0xLTEtMS00NjcwOQ_4865c7db-3528-46ee-8839-4cf694e3ed34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4b24ac3b0b445db0c74e63f0dfa82d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC0zLTEtMS00NjcwOQ_62ee7908-6707-4748-bb8b-ea6071a6fa1e">13,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ba2ec1957f486fb4644d20669a8566_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC01LTEtMS00NjcwOQ_10f390d1-b9ba-4405-9d63-2e8fe7e197ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6a34a9ab63435e9e30203c9e13b9cd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC03LTEtMS00NjcwOQ_e04dee57-377e-4f29-b789-aa8deda18452">13,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1e0f24df864659b5fbe3ec7f9f9dc1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS0xLTEtMS00NjcwOQ_8f8710b3-93df-4caf-9e5c-dcbcabb5b6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59231fb89fe4a75a07204111d7f9e85_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS0zLTEtMS00NjcwOQ_c57d8970-6aab-47d6-b865-dce2db9ced2a">32,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic878b552744b4b8daa3463b73139acb6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS01LTEtMS00NjcwOQ_33c1592c-cc73-4fe6-b0c7-22cde74f8075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec7632bb7d2489d8455f7f8065f000c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS03LTEtMS00NjcwOQ_a7a29659-6ece-41e7-a28f-044ed1c8a3a2">32,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i802ba24afa954ef4826966d738099742_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtMS0xLTEtNDY3MDk_740b5161-4d7e-46d6-b8cd-2b79b1fde12c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc3dabb65af4dd0aa0f9da83cd7e7fc_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtMy0xLTEtNDY3MDk_9d3246de-715b-45ab-b685-771dac81c1c6">10,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa38a89ab23143729bc687fe3de028af_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtNS0xLTEtNDY3MDk_f803436b-3a0f-48d9-b716-e78cf3a4f666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76de84abd4642d6912042f6e398c5f2_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtNy0xLTEtNDY3MDk_be16e89e-5c9a-4f12-add7-84ef4a2cf6b0">10,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b403184690c419ca8ad63e8f06ff051_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMS0xLTEtNTAwNDY_61d5fb17-1b2a-499b-9de9-4236c1f00035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892bc082ed364fbcaf928358c35a36a1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMy0xLTEtNTAwNDY_bfc38b22-b7a3-4410-b37b-edae7cccb0bd">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib9ef9ba624674f31b18f18a906991514_I20230331" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNS0xLTEtNTM4MTY_dd0ee9f5-9d47-473d-8d9d-1bd449da9f27"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a4d10a2ed2244df86b13b190473888e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNy0xLTEtNTAwNDY_acb45fac-f14d-46ab-858a-050af65f3941">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida80c3febeab4dc4a386f3c9f4d1da86_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMS0xLTEtNDY3MDk_458c371c-4558-4f77-8a5c-9486d7aeec3c">16,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f13704c46b54f4fbf4035b2d602b428_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMy0xLTEtNDY3MDk_4b151a85-efca-42ef-8cf9-646fd5835d7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e672eae8a32483281e04e1d168d302e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNS0xLTEtNDY3MDk_02a1d0c3-caa3-48d9-ba60-e282e96bf242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513e270303294364a1063483a8eeb9c1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNy0xLTEtNDY3MDk_000c110f-b7c9-4e46-a613-3440604ef7bb">16,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtMS0xLTEtNDY3MDk_86694ebd-ff52-417d-a74a-ffa6cf7c3619">16,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtMy0xLTEtNDY3MDk_efd1e3db-066e-48ea-836e-e9acf445c281">64,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtNS0xLTEtNDY3MDk_2ab47361-e0e8-4e1b-aaf8-2369b7906126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtNy0xLTEtNDY3MDk_cd3bf29c-69d1-44e6-9d48-a02fb9f4c7ca">81,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtMS0xLTEtNDY3MDk_82183953-e3c6-4582-b7f4-94f7971c28d5">31,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtMy0xLTEtNDY3MDk_00d33249-9d17-400a-8848-f9139a3db4f1">64,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtNS0xLTEtNDY3MDk_53e51092-b9ca-47f0-b6ff-25c3fbd658cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtNy0xLTEtNDY3MDk_9095011b-a9bb-489b-bf92-44968f6b8ea9">96,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="i001fa0877a524ef2a88488bdd4bb3374" continuedAt="iab93195df4ac48089ea9069b06cb7898"><div style="margin-top:5pt"><ix:continuation id="i5912a24e87b94406b9063f2d44415c54" continuedAt="i724373353bed4f59b1f75abd670926f3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia539bc90716e46c09badc816a75cecca_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy0xLTEtMS00NjcwOQ_138006b2-e29e-4b78-8102-af556901de13">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480abc2b1cc54cd6b4b92497a9b2b557_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy0zLTEtMS00NjcwOQ_7426c3a5-f218-4160-b66a-57c4d7c67106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a288026edfb48cf85b99f21c805ca40_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy01LTEtMS00NjcwOQ_242875ec-185d-48bc-b6e8-dd33fb2a256a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2764d1efaa46eb9c63af6bc2f8f380_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy03LTEtMS00NjcwOQ_68c902ff-dc0e-4501-928e-4853ba4b1f4a">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26052de731df412fb0a0af634dfdb211_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS0xLTEtMS00NjcwOQ_b6320dce-0f74-4970-be56-d1edfd240c1d">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS0zLTEtMS00NjcwOQ_b7f6c02a-cc2c-4cfe-b12a-a9c8179e0f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS01LTEtMS00NjcwOQ_5a948854-f901-4b3d-9021-2bffd13639d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS03LTEtMS00NjcwOQ_0247661e-fde2-46fc-9059-650b5375287b">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377211d696ec45e693cc525f829d66a5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC0xLTEtMS00NjcwOQ_3b8b8d8f-bfcd-49ac-b33a-c44609d79fe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a48087fd894a06a7d66a19e113dfe3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC0zLTEtMS00NjcwOQ_6f8c853b-a4b5-4945-b21d-17940cc5b164">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018fdf48beb241fb957140c7fcaac86f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC01LTEtMS00NjcwOQ_59da48b5-5c2b-40ac-a3d5-e237aa1fa2a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7faedaea947747a5a4e0f9b27f03b9cb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC03LTEtMS00NjcwOQ_499bf55d-7d92-4d8b-a331-6ee9a73c6dec">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ead035a27f4309bd93a8a213d35ec8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS0xLTEtMS00NjcwOQ_3da8d3d7-8f53-4604-859e-4d41eaafca21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48c99f9f8d74d1f9306f416c00c75e2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS0zLTEtMS00NjcwOQ_b00b9a04-307a-4bed-b3a2-be4e558978b3">49,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16048614cfcc4e4fa5865a9839662003_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS01LTEtMS00NjcwOQ_4e36f9b1-2ef0-4df1-a73c-410ea8c66b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef613858db4f6888a94e03efa94a80_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS03LTEtMS00NjcwOQ_8cb0dcf6-9e75-4685-939e-d4114a43e5bc">49,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8d6d09727649149a6395ee1730cce9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtMS0xLTEtNDY3MDk_92d0c17e-b354-4dfb-9b74-3360b1460ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e061d7484e40f7b79b0410a81d34ce_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtMy0xLTEtNDY3MDk_b6cfad38-cabd-4fb3-9d09-7d0153b6bb9f">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0f79dc42ce4acdbb7a7a3d6e44d0ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtNS0xLTEtNDY3MDk_66ecc51f-b4e0-46cb-98a6-9b098ab53c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5569fef827456f88c86fc64506a47e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtNy0xLTEtNDY3MDk_3af53731-21ad-4a10-8518-c1448f03beae">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ed6fd9046d4b9aad7e2742322a47d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtMS0xLTEtNDY3MDk_c86c84eb-09dd-46af-a967-557e76ba8746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9703732e3290451893b9ecbdcd26e17b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtMy0xLTEtNDY3MDk_44b7d2b2-3ba2-4fe9-b594-b4fc6ae660f0">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1499c884251e45e7a08301c1113c2751_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtNS0xLTEtNDY3MDk_be9ce39d-5485-4ad7-b9d5-0a05715e1328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8910674f7c1d4eb3baab8a3e1449ffcd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtNy0xLTEtNDY3MDk_a038f068-f4b4-423a-a5e7-3200defa4796">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc9d19f6324825ba0f19f6c6910ca8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItMS0xLTEtNDY3MDk_44d171a7-131a-4430-9e9b-11916196070a">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib717e8f89b554e5eb31a6287f9e82e85_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItMy0xLTEtNDY3MDk_f33c3298-424a-4049-b325-aeba9adb42d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697c1cde53a841b785441aa2b8d391c5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItNS0xLTEtNDY3MDk_9c26f8db-2d3d-4f67-b75b-9f967b09c5d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8083c2b5a8b7482f8d5695f5d867a671_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItNy0xLTEtNDY3MDk_db8e1e38-8b6f-4cc1-b3fd-731b0d786249">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26052de731df412fb0a0af634dfdb211_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtMS0xLTEtNDY3MDk_79daf600-bb9d-4b50-87b1-038debdfccad">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtMy0xLTEtNDY3MDk_2ac18254-9abf-4a65-8cbc-714ea776f035">81,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtNS0xLTEtNDY3MDk_913a2b2d-8517-43c7-9426-a7a87254b7c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtNy0xLTEtNDY3MDk_f2bda5f6-1748-41a2-bc3b-9f9308f45194">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26052de731df412fb0a0af634dfdb211_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtMS0xLTEtNDY3MDk_16dee509-bda4-487f-bc43-c94e40d70aef">23,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtMy0xLTEtNDY3MDk_112cd88b-d642-483e-8b0d-344dffb58153">81,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtNS0xLTEtNDY3MDk_fcaba531-3042-4c09-98a1-50dfaae21509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtNy0xLTEtNDY3MDk_49019ce8-5b56-4ac8-b04a-6458a409faa0">104,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i724373353bed4f59b1f75abd670926f3">(1) Included in short-term investments in the accompanying balance sheets.</ix:continuation> </span></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iab93195df4ac48089ea9069b06cb7898">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2023</ix:continuation>.</span></div><div style="margin-top:5pt;text-indent:36pt"><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_49"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ5_ca313ec5-65cd-44e2-a1d0-28f275d7682c" continuedAt="i28cccc05773a4a54a9d9c3cf3a7a299c" escape="true">Supplementary Balance Sheet Information</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i28cccc05773a4a54a9d9c3cf3a7a299c" continuedAt="i4e4ca7e22ad54df5ad0bf9ddaea18c58"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments available for sale</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ1_b6b8ed62-63ca-4179-9f5f-c54e879c84ac" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy0xLTEtMS00NjcwOQ_50a44503-f684-4ad0-a2df-b2199502541d">13,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy0zLTEtMS00NjcwOQ_257457c8-5422-413e-81c2-c580719a5087">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy01LTEtMS00NjcwOQ_83f9dda6-3592-47ae-8f0e-2f88401a3415">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy03LTEtMS00NjcwOQ_79934e7d-dd81-4a41-8e5d-36f80057dc55">13,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC0xLTEtMS00NjcwOQ_d2d257d7-f0bd-4f25-bd41-9bcf136f4a46">22,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC0zLTEtMS00NjcwOQ_e1118f1e-a1d7-41df-b33a-0cbdd6c9b2e2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC01LTEtMS00NjcwOQ_118bf0f5-8d94-488b-ba39-1a24e5b7fbdd">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC03LTEtMS00NjcwOQ_41dd9262-13e7-44f4-b099-9b80e5fc6e40">22,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS0xLTEtMS00NjcwOQ_24b58e64-090d-4269-afea-74d3c4367d09">10,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS0zLTEtMS00NjcwOQ_035b0303-9f5c-4e79-96de-0fd85679e77f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS01LTEtMS00NjcwOQ_1efce7f3-a6e3-4fb6-b857-3c517d3286de">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS03LTEtMS00NjcwOQ_5ae6d552-c5dc-41e7-90f7-b86604c20c82">10,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy0xLTEtMS01MDE4Mg_50712c2f-8def-44f3-af9f-7a14ab24eca1">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy0zLTEtMS01MDE4Mg_b0be871f-9a62-45bc-ad4b-e44549a75635">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy01LTEtMS01MDE4Mg_b07677dd-53eb-49f6-a0a0-accee7c80f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy03LTEtMS01MDE4Mg_53d9fd3e-5c2a-488d-8c9b-6b506b2914ea">4,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC0xLTEtMS00NjcwOQ_4107190b-fa2d-4c9a-89a1-ed673b3ce25f">50,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC0zLTEtMS00NjcwOQ_b7f8018d-b77b-4ae3-83a7-a498327ed257">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC01LTEtMS00NjcwOQ_c24de179-374a-464a-a369-a59155bd42a3">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC03LTEtMS00NjcwOQ_58c7b45f-af1e-458d-b21c-01663b4f0cc1">50,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtMS0xLTEtNDY3MDk_364f8599-a3d9-40c0-993d-aa0fc943d270">10,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtMy0xLTEtNDY3MDk_7c54e43e-1f88-469c-9484-0b572913f490">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtNS0xLTEtNDY3MDk_c5cb83b9-7527-40c0-a07c-d97f817e361c">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtNy0xLTEtNDY3MDk_d0ddae49-4d93-4682-b015-74455b4ae5b2">10,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMS0xLTEtNTAxNjY_b761840e-7f6c-4764-aebd-cc82fe0180a9">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMy0xLTEtNTAxNjY_cbf4e1fd-b882-4e8c-adec-fddb67e4c35e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNS0xLTEtNTAxNjY_43dd7f25-7731-47c8-a5b8-5b6b7ad499df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNy0xLTEtNTAxNjY_81060b00-4e43-4f34-91d5-1f5316fbfa56">3,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMS0xLTEtNDY3MDk_6f943016-ad21-4752-aa9a-ba3a9267fa1b">16,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMy0xLTEtNDY3MDk_5d3f0207-089c-4439-b86f-c5bdf968e0be">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNS0xLTEtNDY3MDk_be3f3b9b-90ea-4887-9836-1a48029e3fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNy0xLTEtNDY3MDk_06cdc28a-66cc-4bfd-9848-b9923f4e0f99">16,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItMS0xLTEtNDY3MDk_35ab6203-e8ed-44e2-9965-d42e454ee16e">31,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItMy0xLTEtNDY3MDk_dcd587f7-468b-4622-8e77-62facd94f2d5">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItNS0xLTEtNDY3MDk_02d91f36-2fbe-4875-852f-6289a6321887">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItNy0xLTEtNDY3MDk_08de4ae7-8518-49c3-ac6b-c0dd8618d7a6">31,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtMS0xLTEtNDY3MDk_3764ddba-8a6b-4dd0-a138-357818eb89e4">82,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtMy0xLTEtNDY3MDk_fcbf8041-94ee-4b32-b318-c30fe2449556">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtNS0xLTEtNDY3MDk_df134491-c256-43ec-b1d0-8544c1ac1f2c">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtNy0xLTEtNDY3MDk_76d64a23-2395-4a43-b39c-3826735022c3">81,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c11618796914158ab65134841e05e6c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy0xLTEtMS00NjcwOQ_2aa53f9e-ba04-492a-a604-74c3dc2ce70b">16,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c11618796914158ab65134841e05e6c_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy0zLTEtMS00NjcwOQ_ca752c8e-825e-4239-87bf-8fbf2f9f2059">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c11618796914158ab65134841e05e6c_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy01LTEtMS00NjcwOQ_a84c1a07-74eb-4dc2-be00-240445c1852f">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c11618796914158ab65134841e05e6c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy03LTEtMS00NjcwOQ_781fd62a-89f8-4a02-8c94-aa13a3fd1aec">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC0xLTEtMS00NjcwOQ_29e18d80-74af-466f-bb84-31ac6f5e5507">44,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC0zLTEtMS00NjcwOQ_f8467924-c8a1-4af5-859d-6adf8ebfe13a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC01LTEtMS00NjcwOQ_da973679-73b7-4528-9e71-6faffa0d6d7f">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC03LTEtMS00NjcwOQ_99fd3e9e-b0f6-4737-8277-f5b157fa0223">44,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS0xLTEtMS00NjcwOQ_bb3b3a65-aa37-48fc-8106-c04fc0bcea2d">13,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS0zLTEtMS00NjcwOQ_bfe9907c-8b56-4379-b906-f9d81187ec7e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS01LTEtMS00NjcwOQ_cb3df61a-0823-440e-99a7-3f3d690d960c">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS03LTEtMS00NjcwOQ_96b906ed-7197-48ea-ac1a-dee8fd761a20">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi0xLTEtMS00NjcwOQ_d678359a-b39e-4887-9ac8-87b16ee8e7dc">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi0zLTEtMS00NjcwOQ_46cdd498-2efd-40f7-b96e-aca75a919df4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi01LTEtMS00NjcwOQ_8b5f8beb-f015-4dcc-b135-5e35c4fcb01f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi03LTEtMS00NjcwOQ_408a2a5a-237d-4882-acd2-7b8df9749e40">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy0xLTEtMS00NjcwOQ_e7da5c6d-7d3c-4493-a2af-b9b8dc83b595">7,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy0zLTEtMS00NjcwOQ_72e20181-4d91-4834-b70c-af6987aebdc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy01LTEtMS00NjcwOQ_6b8a1d97-2aee-492a-8dc3-451c44ee8c99">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy03LTEtMS00NjcwOQ_0468c5d3-8e46-4156-8c43-003ecee4bc15">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC0xLTEtMS00NjcwOQ_e2a38226-83a0-4ece-886f-7d4aa2ac7a68">84,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC0zLTEtMS00NjcwOQ_5033ed02-267b-44a1-92d6-abe70ca22452">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC01LTEtMS00NjcwOQ_702becf0-293f-4c76-a490-58213c0f9215">394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC03LTEtMS00NjcwOQ_df95ec6e-98b1-42d9-b6d4-77747e5375a9">83,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtMS0xLTEtNDY3MDk_070f46f9-d5d7-4dbe-be75-33476de8a240">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtMy0xLTEtNDY3MDk_ad27f1b6-1514-445f-9b03-5bfff382c9a4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtNS0xLTEtNDY3MDk_0c48d594-c046-4a59-895a-126380974924">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e356158c614afd81168c0f32199528_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtNy0xLTEtNDY3MDk_46769219-bc08-4d7c-b291-38f5f6d306c1">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItMS0xLTEtNDY3MDk_4981078a-bfd6-49b3-91a7-add6a08777cd">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItMy0xLTEtNDY3MDk_8f64e3ee-efc1-4589-98fb-aaa00b3cd52c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItNS0xLTEtNDY3MDk_94696363-b21d-4597-98aa-3e286f60e196">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItNy0xLTEtNDY3MDk_0d0aebd2-dbb8-4582-920e-35f1ae1a6751">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtMS0xLTEtNDY3MDk_c03e4359-5cdb-4668-b692-ae78871f7071">89,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtMy0xLTEtNDY3MDk_92fb2c01-c5fc-4267-8ead-34ad5c5a4316">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtNS0xLTEtNDY3MDk_8b2fe51f-d33a-43c7-b3d9-2a74287ef06e">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtNy0xLTEtNDY3MDk_c9c33138-41f8-4606-af36-0c907dd642ee">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses in investments available for sale debt securities at March&#160;31, 2023, were substantially due to increases in interest rates, not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="i4e4ca7e22ad54df5ad0bf9ddaea18c58"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ0_0e482f45-6be3-4f50-8fd8-3a5d05fbda58" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmQyNTIyYTFiZmExZTQ0ZWFiYmNkNzg4YjllZWQ4OGNlL3RhYmxlcmFuZ2U6ZDI1MjJhMWJmYTFlNDRlYWJiY2Q3ODhiOWVlZDg4Y2VfMy0xLTEtMS00NjcwOQ_86f34a95-c71c-4514-be12-613e57c87e30">8,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmQyNTIyYTFiZmExZTQ0ZWFiYmNkNzg4YjllZWQ4OGNlL3RhYmxlcmFuZ2U6ZDI1MjJhMWJmYTFlNDRlYWJiY2Q3ODhiOWVlZDg4Y2VfMy0zLTEtMS00NjcwOQ_5e58bfba-0dfa-4e80-8705-e411cb044fec">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODM5_c3e32121-da8d-4370-a25d-1d593af7014e" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5126a1d0a76b4750b3c4596fed29b417_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMS0xLTEtMS00NjcwOQ_4e2966de-bc9b-40de-8379-3fc4db0f4a0f">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71dab6497dbc4a9cad98744b1d6939ff_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMS0zLTEtMS00NjcwOQ_81d5c020-20d7-4b8a-b5b7-4b118854adc5">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12564752dbbc4764bc02ded3b8f49b4c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMi0xLTEtMS00NjcwOQ_9ee19013-dc1a-4a7f-8d23-6eb9003d8a1f">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5702ca6a9f36479296c15ba3f0c29b9d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMi0zLTEtMS00NjcwOQ_e94849ff-cb94-4133-8430-9d56cb6b5d7a">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib815e5c326e04a1ca507261df4fef728_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMy0xLTEtMS00NjcwOQ_6bb8cfae-d998-41a5-b5d2-828e29fed8aa">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159aae27f4f5465b9e015d53d086eadd_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMy0zLTEtMS00NjcwOQ_10e775e4-e13f-4b85-8057-f29a0f35db1c">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNC0xLTEtMS00NjcwOQ_e1fd60c2-179e-4968-a1a0-1baa44a16648">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNC0zLTEtMS00NjcwOQ_8235c970-ed34-4473-8104-4869e30ea070">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNS0xLTEtMS00NjcwOQ_22b36df8-5841-4f19-a209-b63cfc3a2a6b">3,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNS0zLTEtMS00NjcwOQ_fe9715c0-294a-41ab-a2c1-15c71f9550c2">3,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNi0xLTEtMS00NjcwOQ_aed883ed-af66-4c13-b62b-efc2ae3b1ae2">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNi0zLTEtMS00NjcwOQ_7fe35d14-d8ee-4e1f-9086-ffe454bebfaf">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ4_30a300c3-e1a5-4dee-b43f-895a878ea202" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMS0xLTEtMS00NjcwOQ_f3769189-da0b-465c-aa93-6b92af3020de">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMS0zLTEtMS00NjcwOQ_f6d4a77a-dd79-4afa-9e8c-5f08d9bd4c5b">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMy0xLTEtMS00NjcwOQ_d175082b-8e04-4eef-9b42-b080bf2c05da">2,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMy0zLTEtMS00NjcwOQ_e6d54f89-f537-4d00-acb6-a8147897458a">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:AccruedResearchAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNC0xLTEtMS00NjcwOQ_368ea328-f73b-4ba4-a145-6602cd238297">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:AccruedResearchAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNC0zLTEtMS00NjcwOQ_fe7f5949-7b97-47ba-9e39-ec9fff3c03a6">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:AccruedDirectorFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNS0xLTEtMS00NjcwOQ_ee5d745e-90f1-44ba-acb8-b915e739b462">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:AccruedDirectorFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNS0zLTEtMS00NjcwOQ_dea147d2-b21d-4874-a00b-4e6f116db708">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:PatentLicenseAndOtherFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNy0xLTEtMS00NjcwOQ_1ed083c6-0c89-4496-8c73-bb2770176fef">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="crdf:PatentLicenseAndOtherFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNy0zLTEtMS00NjcwOQ_080ff5d3-73f9-4b85-961a-96b75f062671">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfOS0xLTEtMS00NjcwOQ_86d3fe0d-a80c-4a65-ac8c-a7f7cb3d4337">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfOS0zLTEtMS00NjcwOQ_dd4f3c33-ab0b-43cf-980b-dddbcde63420">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMTAtMS0xLTEtNDY3MDk_245d2e66-a362-4ec5-826d-1609cd35e22a">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMTAtMy0xLTEtNDY3MDk_ba638a98-8af7-4b7c-b72a-a94411ff9bff">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzcy_49f7edbc-b888-4329-a6b5-2ead1d339a6e" continuedAt="i2a68bf28e91f412aa017071a90951c19" escape="true"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzc3_5f35621f-09fe-48dd-a927-5cdeebacdacd" continuedAt="ia17e2840aedf4ae19c07eaa09184af42" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i2a68bf28e91f412aa017071a90951c19" continuedAt="ic679db83e3804d4285980093ab7cc6cb"><ix:continuation id="ia17e2840aedf4ae19c07eaa09184af42" continuedAt="i9d5b5384ce5d42e3bdaf22b9363bd427"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfMzc2_e5686d4d-d448-4f9a-ab2e-7990f779d5e8">61,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfMzk0_115227dc-5c1b-4a94-b4de-7be0369abe61">3</ix:nonFraction>% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzcz_f43c8b19-0738-4bb0-9c24-9213af7ad799" continuedAt="i30e116950b024a20b7a5811da4476422" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfMi01LTEtMS00NjcwOQ_283b69d4-6c39-47ec-ab80-bda242362e65">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfMi03LTEtMS00NjcwOQ_4b09625d-47ec-490f-ace4-cf532934a1a2">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfNC01LTEtMS00NjcwOQ_b66db059-4154-4b3e-91fd-170bc3f0e509">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfNC03LTEtMS00NjcwOQ_51baef62-94c6-4d1c-8b5f-506a191f5f9e">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="ic679db83e3804d4285980093ab7cc6cb"><ix:continuation id="i9d5b5384ce5d42e3bdaf22b9363bd427"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="crdf:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzY4_0c2943a0-1071-4052-a119-8241ea565e6f" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMS0xLTEtMS00NjcwOQ_00a88e89-ef69-4001-8968-941eeaee9975">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMS0zLTEtMS00NjcwOQ_2692443b-9d51-4e37-ab20-ff02c869255d">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMy0xLTEtMS00NjcwOQ_1f1ee8b0-c505-4b76-a18c-a0efb33caac9">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMy0zLTEtMS00NjcwOQ_3a630c04-f18b-4fbd-a021-85564a9f6c19">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNC0xLTEtMS00NjcwOQ_5e128f6a-485a-4ac4-b5f9-f8b9a625777b">1,898</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNC0zLTEtMS00NjcwOQ_6cb23390-c471-4d2e-883d-340f4ee0db13">2,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNS0xLTEtMS00NjcwOQ_b9d3b909-f043-4f30-81d4-438e2e3158fc">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNS0zLTEtMS00NjcwOQ_dd44e147-734c-4483-8a88-92d44bc4c5b9">2,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNy0xLTEtMS00NjcwOQ_584d6549-8d82-43b7-bae8-cf6dbbd75b63">3.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNy0zLTEtMS00NjcwOQ_85f9c522-9792-4e04-8554-653e0c218993">4.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfOC0xLTEtMS00NjcwOQ_d854f8c7-c637-4389-a588-55d671915d2f">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfOC0zLTEtMS00NjcwOQ_85d128e5-593e-4a80-a805-6922368aedae">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="i30e116950b024a20b7a5811da4476422"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOmE2OGQ4MjUwYzRmOTRhYzA5OGFjZmFlYmM1ZDhlODU5L3RhYmxlcmFuZ2U6YTY4ZDgyNTBjNGY5NGFjMDk4YWNmYWViYzVkOGU4NTlfMy01LTEtMS00NjcwOQ_9d4fdefb-9012-4ad4-866e-faaa6d2fad7f">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOmE2OGQ4MjUwYzRmOTRhYzA5OGFjZmFlYmM1ZDhlODU5L3RhYmxlcmFuZ2U6YTY4ZDgyNTBjNGY5NGFjMDk4YWNmYWViYzVkOGU4NTlfMy03LTEtMS00NjcwOQ_c6a22a3c-576b-40b9-9eb2-9c1b61c6ae3d">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzY0_4e800014-c771-452c-b9ef-8928741e399e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNC0xLTEtMS00NjcwOQ_6542f794-8065-43b0-bbec-f8cd48db76b5">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNS0xLTEtMS00NjcwOQ_0716b6d8-22b2-431b-ad0e-59c83d57438d">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNi0xLTEtMS00NjcwOQ_4c185e43-e2fc-4e0e-82e6-f226631efb33">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNy0xLTEtMS00NjcwOQ_4b5c3376-71ae-4c68-9b40-c4375c5abeb8">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfOS0xLTEtMS00NjcwOQ_d6f005f7-0cf3-4c79-969c-3a0aaf179ad3">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTAtMS0xLTEtNDY3MDk_70044bf6-56f9-4946-95f8-67ca16b50f6c">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTEtMS0xLTEtNDY3MDk_09076220-f427-4eac-b9d6-663010ba8aa2">375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTItMS0xLTEtNDY3MDk_78de2b20-c611-4b79-8321-67f47ab7d575">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY4Mg_bad3e109-314c-45e1-ae2c-ba4ba09197aa" continuedAt="i16a863f6939443feb876e8dc54d94a79" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i16a863f6939443feb876e8dc54d94a79" continuedAt="i2345627bb8b74f889678e489fa0939a9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY4NA_2ea42fb3-1d5a-4a04-a88a-d1f3e59dcf59" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaeff0f9b3d243b4a63f8742a58aa35b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfMy01LTEtMS00NjcwOQ_eae3bfaf-3136-4d01-be06-d75764fbb7b1">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0322636ad15484f8481e2fe8512a156_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfMy03LTEtMS00NjcwOQ_34b7313d-e4fb-42f2-9da5-af4118c0f730">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65d202a9f424f4cbe0609279095d19a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNC01LTEtMS00NjcwOQ_50f2b2ab-8408-4c09-8e6d-e9320028daff">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4a5e322fb148e2b3a3f3d9b7aff411_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNC03LTEtMS00NjcwOQ_50cf1f11-7994-49c1-b322-f33bf6c8966d">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNy01LTEtMS00NjcwOQ_4bb3d810-ee09-4375-8ccb-1af99690ad23">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNy03LTEtMS00NjcwOQ_1d403a6c-2dab-4876-a5b8-7ddeb90fdcb4">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2023, net of estimated forfeitures, was $<ix:nonFraction unitRef="usd" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMzA2_68e474fc-5410-4f40-b6b9-1956fc43283e">10.1</ix:nonFraction> million, which is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMzk3_781081c7-cf5f-4329-ac57-c33ad3c0ff66">2.7</ix:nonNumeric> years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2023, was approximately </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="i2345627bb8b74f889678e489fa0939a9" continuedAt="ib2e431af5c7a4f8da60c8ad0ab1d1a6e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTAw_c76a1730-451e-4604-b051-07390d88dd51">8.5</ix:nonNumeric> years. The total fair value of stock options vested during the three months ended March 31, 2023 and 2022, were $<ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTc2_f84341bf-2243-44d7-82d6-888791ab5f76">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTgz_7dda679b-0aa7-43db-bfae-53fb4499ddba">1,000</ix:nonFraction>, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2Ng_a6641ba4-57ed-4d49-9f6f-c2b373c718c3" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMi0xLTEtMS00NjcwOQ_7cfc1494-98cd-4263-af5b-d88d5cb9c8a4">3.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMi0zLTEtMS00NjcwOQ_00b71b79-10f6-4d70-a08c-a0f4ff905c23">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMy0xLTEtMS00NjcwOQ_e3d06aa0-5966-4aaf-87c1-9350bc96381c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMy0zLTEtMS00NjcwOQ_e707703e-d278-4c51-a2c4-af558db1db12">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNC0xLTEtMS00NjcwOQ_239c891f-8633-4600-92b1-88a262e20605">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNC0zLTEtMS00NjcwOQ_1096459f-83d3-406b-af50-761ced7bd68f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNS0xLTEtMS00NjcwOQ_6f556fcd-f79b-4b56-b403-c1c095d783df">5.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNS0zLTEtMS00NjcwOQ_7fd62302-bc06-4bb0-8632-14b6759f5890">6.0</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The expected term for options granted after January 1, 2023 is estimated based on the Company's historical employee data. Prior to January 1, 2023, the Company used the "simplified method" to estimate expected term. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2Mw_41f04b5d-4f24-42f7-be90-af08b23837b9" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS0xLTEtMS00NjcwOQ_f472371c-686b-488d-9b0f-48d84a1047ec">5,069,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS0zLTEtMS00NjcwOQ_7eb66b98-1ddb-46e8-b534-90dcfba653dd">5.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS01LTEtMS00NjcwOQ_6b8d19bf-00c1-45e9-b348-215f94129653">19,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMi0xLTEtMS00NjcwOQ_2c8fe54f-c14c-420c-aa6f-10d4c519219a">1,806,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMi0zLTEtMS00NjcwOQ_737eb0f1-fd5c-4f02-9285-924532ef14be">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNC0xLTEtMS00NjcwOQ_b15ae540-559d-4f92-a41a-22199f293a8f">1,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNC0zLTEtMS00NjcwOQ_22167702-db54-4317-9a07-5856543ee740">7.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="INF" name="crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNS0xLTEtMS00NjcwOQ_9e177c93-b21d-4d96-b25e-05544c189e71">476,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331" decimals="2" name="crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNS0zLTEtMS00NjcwOQ_312bf183-306d-458f-8b7c-0f1c887ce188">6.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi0xLTEtMS00NjcwOQ_28192e46-bc9b-4117-aafc-140da1ba1c49">6,396,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi0zLTEtMS00NjcwOQ_dd37f680-e4fc-416a-b7f3-01bf975b63a8">4.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi01LTEtMS00NjcwOQ_ae43bde6-3bd9-42ef-8844-247f087733e3">34,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy0xLTEtMS00NjcwOQ_1044a72a-c6c0-44d8-a30d-552e9d257af9">2,427,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy0zLTEtMS00NjcwOQ_c1c2146a-0ee2-4c8b-8c63-db11594f9998">6.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy01LTEtMS00NjcwOQ_cf7669e8-f234-4ee3-ac53-bcd2c439500e">20,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC0xLTEtMS00NjcwOQ_8d6538bb-afcf-4ef9-987f-c359738e7f2f">6,187,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC0zLTEtMS00NjcwOQ_beb67409-2c87-4349-80e3-72d6e17b1649">4.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC01LTEtMS00NjcwOQ_3d55169f-5f19-4357-8d71-116ed2d4e303">33,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) <ix:nonFraction unitRef="shares" contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTEzNQ_49166e77-e9fa-4d16-a1a7-9caa3ef74062">3,150,000</ix:nonFraction> shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022, the shareholders approved an increase of shares authorized in the 2021 Plan to <ix:nonFraction unitRef="shares" contextRef="i7083de34860a440bb7091d697390058a_I20220609" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQyOA_d2c1d105-1b81-47b1-803b-808447940338">5,150,000</ix:nonFraction> from <ix:nonFraction unitRef="shares" contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQzNg_49166e77-e9fa-4d16-a1a7-9caa3ef74062">3,150,000</ix:nonFraction>. As of March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="ic1bf0ee8aea9404384a42f661f35f008_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQ2MQ_c29d97e8-5c52-4fef-ab40-baa9a803bbb1">2,180,898</ix:nonFraction> shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2023, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i027341bbc88b4f83ab80a25ed8de872e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTgzNw_3f77d7a0-00fc-497f-8656-7c85a3cc335c">1,345,208</ix:nonFraction> shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><ix:continuation id="ib2e431af5c7a4f8da60c8ad0ab1d1a6e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY3NA_9e929aa2-ac83-46f0-b926-b9902c52d475" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS0xLTEtMS00NjcwOQ_889e82c4-b511-44b7-b5ba-2cd2b34da8b3">4,360,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS0zLTEtMS00NjcwOQ_40e7e44b-66e8-426f-9cdf-3b25316cc6ea">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide0886b6ea844e829c14276a57c0e37f_D20220101-20221231" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS01LTEtMS00NjcwOQ_d38223f7-24ec-451e-b789-a0c5b5120bb9">2.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="INF" name="crdf:ClassOfWarrantOrRightExpiredDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNC0xLTEtMS00NjcwOQ_ec33050d-d9c8-4039-898a-bdebacb84bc7">64,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNC0zLTEtMS00NjcwOQ_c6028de2-0051-486f-afb9-fe73c4ae39a9">101.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS0xLTEtMS00NjcwOQ_60715707-89aa-41a5-9708-cffb24ad1627">4,296,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS0zLTEtMS00NjcwOQ_0d78233f-a72e-4bbf-a2cf-94491106b199">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS01LTEtMS00NjcwOQ_97080410-f80a-4d5d-9c48-a1c624f4dfc8">1.8</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2OQ_997a9b9c-cac5-4c49-9188-78202f235a2f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi0yLTEtMS00NjcwOQ_0ea89f27-f71c-4488-91c5-abd8ad4637ad">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi00LTEtMS00NjcwOQ_2edd3d29-3dca-4985-8e71-24dd0faa1876">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi04LTEtMS00NjcwOQ_8d775004-d2c2-41ba-9f19-75bee170e798">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d8a3984a4442faa0609e1a6e8e6e77_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi0xMC0xLTEtNDY3MDk_1ec0fe85-5529-426a-bdc7-aef34203fc74">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i09428b9805e4498b813fd5573384236f_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy0yLTEtMS00NjcwOQ_5ddf6de1-ef0a-482b-bc31-25cb5dbb9a66">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09428b9805e4498b813fd5573384236f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy00LTEtMS00NjcwOQ_7c392638-136e-4788-a941-d3d426e414da">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09428b9805e4498b813fd5573384236f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy04LTEtMS00NjcwOQ_a65b42e6-5835-49ba-86f0-1c95fc53ea15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7d01a9fe044b8e98c079c7e41f1974_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy0xMC0xLTEtNDY3MDk_19e0acee-0cb7-4c8b-9360-8c32d667d973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC0yLTEtMS00NjcwOQ_2f33b071-c067-439a-a405-ca85468d004f">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC00LTEtMS00NjcwOQ_1bdc49a6-f702-4869-b360-48fa2791ffb4">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC04LTEtMS00NjcwOQ_08983c2e-fcee-4386-a78b-12cdd1305b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if640bbe0a9704fa8a6e92d02c5bd50ac_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC0xMC0xLTEtNDY3MDk_026985c7-9a69-4a8f-b00c-0c7bb950421a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS0yLTEtMS00NjcwOQ_49eeb84c-e1c5-42d3-a3a9-013737b3c623">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS00LTEtMS00NjcwOQ_28b7da63-ad11-403e-b372-02191487b69c">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS04LTEtMS00NjcwOQ_da5b49a7-2cb3-454c-a33b-771fd9351966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1de3c3d99592416a9ecb1656c220de10_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS0xMC0xLTEtNDY3MDk_265597f8-9858-409a-a3fe-9269763ac50f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi0yLTEtMS00NjcwOQ_64589c39-7f42-4840-9788-25af8917503c">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi00LTEtMS00NjcwOQ_da9dcf6e-2461-4db5-acfe-fc299429f81c">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi04LTEtMS00NjcwOQ_784b3516-8c1f-4785-b54d-2fc73768c40f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a1b8cd013904ade8b00a3ec6d18c509_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi0xMC0xLTEtNDY3MDk_d7d07e25-5a4e-4e39-b16b-44eab2d887a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTk0Mg_1a1b90f9-a87e-4126-9292-296618618be4" continuedAt="i4169fe26d76d438f876ac5543f85c9df" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4169fe26d76d438f876ac5543f85c9df" continuedAt="i9a5fe8fb1df84453b2b2bca703dbcc0b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: (a) dosing of the first subject in the first Phase III Clinical Trial for the first Product, a registration enabling Phase II Clinical Trial, or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and (b) upon filing of the first NDA or equivalent for the first product candidate. During the three months ended March&#160;31, 2023 and 2022 <ix:nonFraction unitRef="usd" contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331" decimals="-3" name="crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTA5OTUxMTYzMTAyOQ_355e6bfd-8c96-48b3-a94b-ffbc58af9b37"><ix:nonFraction unitRef="usd" contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331" decimals="-3" name="crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTA5OTUxMTYzMTAyOQ_ba71fe4b-0896-4d19-b49e-1b0b7b9b5ea0">no</ix:nonFraction></ix:nonFraction> milestone or royalty payments were made. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2023 and 2022, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a5fe8fb1df84453b2b2bca703dbcc0b">from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</ix:continuation></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.&#160;These forward-looking statements are subject to a number of risks, uncertainties and assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business and financial performance may be affected by the factors that are discussed under &#8220;Risk Factors&#8221; in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed on March&#160;2, 2023.&#160;Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events.&#160;We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur.&#160;Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form&#160;10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.&#160;Such discussion represents only the best present assessment of our management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard of care ("SoC") therapeutics. We are focusing our clinical program in indications such as KRAS/NRAS-mutated metastatic colorectal cancer ("mCRC") and metastatic pancreatic ductal adenocarcinoma ("mPDAC"), as well as in investigator-initiated trials in triple negative breast cancer ("TNBC") and small cell lung cancer ("SCLC"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Lead Drug Candidate, Onvansertib</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> = 2nM; IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&gt;10,000 nM);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is orally bioavailable, allowing for relative ease and flexibility of dosing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib has a relatively short drug half-life of 24 hours, allowing for flexible dosing and scheduling which has shown favorable safety and tolerability across multiple clinical trials;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination studies have confirmed the positive results obtained </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil ("5-FU"), abiraterone, PARP inhibitors, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated. Combining onvansertib with standard of care cancer agents provides opportunities for synergy with many cancer therapies.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five ongoing clinical trials of onvansertib: two trials (TROV-054 and ONSEMBLE) in second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer ("mCRC"), one trial in second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma ("mPDAC"), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer ("TNBC") and relapsed Small Cell Lung Cancer ("SCLC").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1b/2 Clinical Trial in KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center. This trial completed enrollment in October 2022. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objectives of this trial are to evaluate the Dose-Limiting Toxicities ("DLTs"), maximum tolerated dose ("MTD") and recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab patients with KRAS-mutated mCRC (Phase 2).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this Phase 1b/2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of multiple drugs results in an unexpected greater activity than an expected additive effect of the individual drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC in vivo models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to repair DNA damage from chemotherapy and then replicate. For more information, please visit NCT03829410 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on September 12, 2022, provided an update of the ongoing TROV-054 Phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Objective response rate ("ORR") across all evaluable patients was 35%, with 17 of 48 evaluable patients achieving an objective response. Responses have been observed across multiple KRAS variants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median duration of response ("mDoR") across all evaluable patients was 11.7 months (95% confidence interval ("CI"): 8.9 &#8211; not reached);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median progression free survival ("mPFS") across all evaluable patients was 9.3 months (95% CI: 7.6 &#8211; 13.5). Historical control trials of different drug combinations, including the standard-of-care ("SOC") of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 &#8211; 13% and ~4.5 &#8211; 5.7 months, respectively.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A subgroup analysis of patients who were bevacizumab na&#239;ve when they entered 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line therapy vs patients who had received prior bevacizumab in 1st line therapy showed that patients who were bevacizumab na&#239;ve (n=13) had an ORR of 69% and mPFS of 13.5 months, which is well above historical controls. In contrast, patients previously treated with bevacizumab (n=35) had an ORR of 23% and mPFS of 7.8 months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Randomized Clinical Trial in KRAS-mutated mCRC (the ONSEMBLE trial)</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ONSEMBLE trial (CRDF-003), is a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated mCRC. The trial is currently open for enrollment and will be conducted at approximately 40 clinical trial sites across the U.S. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objectives of the ONSEMBLE trial is to evaluate onvansertib&#8217;s safety and efficacy in combination with the standard-of-care FOLFIRI/bevacizumab regimen in patients with second-line KRAS/NRAS-mutated mCRC. The trial is expected to enroll approximately 150 patients who will be randomized 1:1:1 to receive standard of care alone, standard of care plus 20 mg onvansertib, or standard of care plus 30 mg onvansertib, with onvansertib administered on days 1-5 and 15-19 of 28-day treatment cycles. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial is objective response rate, defined as a tumor reduction in size of at least 30% as per RECIST 1.1. Progression-free survival and duration of response will be key secondary endpoints. The trial was activated during the fourth quarter of 2022, with topline data anticipated in the second-half of 2024. For more information, please visit NCT05593328 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in the ONSEMBLE trial during March 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial in mPDAC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in June 2021. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients. For more information, please visit NCT04752696 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data presented on September 12, 2022 provided an update of the ongoing CRDF-001 Phase 2 open label clinical trial in mPDAC:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Preliminary data from 5 evaluable patients showed 1 patient achieving an initial partial response ("PR") and 3 patients achieving stable disease ("SD");</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The 4 patients achieving SD or PR remain on study; the fifth evaluable patient discontinued treatment due to disease progression and an additional 3 patients remain on study awaiting their first post-baseline scan;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Additional data is expected in mid-2023.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1b/2 Investigator-Initiated Clinical Trial in TNBC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single-arm, Phase 1b/2 trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC is open for enrollment at Dana Farber Cancer Institute ("DFCI"). In Phase 1b, approximately 14-16 patients will be treated with different doses of onvansertib in combination with a fixed dose of paclitaxel to determine the maximum tolerated dose and RP2D of onvansertib. In Phase 2, approximately 34 patients will be treated with the selected onvansertib RP2D in combination with paclitaxel. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of Phase 2 of the trial is ORR, with PFS included as a secondary endpoint. Preliminary data from the trial are expected in the fourth-quarter of 2023 or first-quarter of 2024. For more information, please visit NCT05383196 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Investigator-Initiated Clinical Trial in SCLC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC is open for enrollment at the University of Pittsburgh Medical Center ("UPMC"). The trial is designed to enroll 15 patients in Stage 1, with the study proceeding to Stage 2 if 2 or more Stage 1 patients achieve an objective response. Stage 2 is designed to enroll an additional 20 patients. The primary endpoint of the trial is ORR, while key secondary endpoints include PFS and overall survival. Preliminary data from the trial are expected in mid-2023. For more information, please visit NCT05450965 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Recent Updates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Appointment of Chief Medical Officer</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023, we announced the appointment of Fairooz Kabbinavar, M.D., FACP, as Chief Medical Officer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Scientific Advisory Board</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2023, we formally introduced our Scientific Advisory Board ("SAB"). The SAB is comprised of a distinguished group of academic and industry experts who bring depth and breadth of knowledge in oncology drug development, clinical trial design, translational science and clinical research. In most cases, these individuals have been advising us for several years and will now collectively serve a critical role as we advance the clinical development of onvansertib. We anticipate that over time the membership of the SAB may expand to add additional expertise in new indications or stages of clinical development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS of our Annual Report on Form&#160;10-K as of and for the year ended December&#160;31, 2022, filed with the SEC on March&#160;2, 2023.&#160;There have been no changes to our critical accounting policies since December&#160;31, 2022.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 and 2022 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $83,000 for the three months ended March 31, 2023, as compared to $74,000 for the same period in 2022. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.8 million for the three months ended March 31, 2023, compared to the same period in 2022.&#160;The overall increase in expenses was primarily due to costs associated with clinical programs and outside service costs related to the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to the expansion of our clinical operations team (research and development average headcount grew by 25% over the comparative period). The increase in facilities and other is primarily due to increased allocation of facilities cost resulting from headcount growth compared to the prior period.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased by $0.9 million for the three months ended March 31, 2023, compared to the same period in 2022.&#160;Outside services decreased due to the completion of strategic valuation consulting related to our lead drug candidate, onvansertib, during the prior period. Stock-based compensation decreased due to a change in the timing of stock option grants to our board of directors. Facilities and other costs decreased primarily due to lower insurance costs as compared to the prior period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,223)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,993)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,999)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.2 million increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net loss attributable to common shareholders was primarily the result of an increase in operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023, compared to the same period in 2022. There was no change in basic and diluted net loss per share with the addition of 1.4 million shares of common stock issued from April 1, 2022 through March&#160;31, 2023. </span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2023, was $8.7 million, compared to $10.2 million for the three months ended March&#160;31, 2022.&#160;Our use of cash was primarily a result of the net loss of $11.2 million for the three months ended March 31, 2023, adjusted for non-cash items related to stock-based compensation of $1.1 million. The net change in our operating assets and liabilities was primarily the result of decreasing cash used in operations of $1.6 million.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $7.3 million primarily related to sales and maturities in excess of purchases of marketable securities for the three months ended March 31, 2023, compared to net cash used in investing activities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $18.4 million primarily related to sales and maturities in excess of purchases of marketable securities during the same period in 2022. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities was $0 for the three months ended March 31, 2023, and 2022.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, and December&#160;31, 2022, we had working capital of $93.6 million and $103.5 million, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of March&#160;31, 2023, we had $97.0 million in cash, cash equivalents and short-term investments and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of this Quarterly Report on Form 10-Q. Based on our current projections we expect that our capital resources are sufficient to fund our operations into 2025.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drug candidates.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed an evaluation under the supervision and with the participation of our management, including our principal executive officer (CEO) and principal financial officer (CFO), of the effectiveness of our disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2023, to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control&#160;over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting during the three months ended March&#160;31, 2023, that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in our Form&#160;10-K for the year ended December&#160;31, 2022.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i67cc85fac64c47748f00d75862a9f9fe_124"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033123exhibit311.htm">Certification of Principal Executive Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033123exhibit312.htm">Certification of Principal Financial Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033123exhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-033123exhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, is formatted in Inline XBRL</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i67cc85fac64c47748f00d75862a9f9fe_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i67cc85fac64c47748f00d75862a9f9fe_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>crdf-033123exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6fc2e7efb9144c78891bd65ddb2d62b2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>crdf-033123exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0408606efb1e42668bb1114d27931c7e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Levine, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>crdf-033123exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id75815c97bb84195acc985ca0b337955_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>crdf-033123exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id8ca2b939bd04630bc8756def8cb3731_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, James Levine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>crdf-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230331">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardiffoncology.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000008 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformation" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation">
        <link:definition>0000011 - Disclosure - Supplementary Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cardiffoncology.com/role/Leases">
        <link:definition>0000012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000016 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables">
        <link:definition>0000017 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationTables" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables">
        <link:definition>0000018 - Disclosure - Supplementary Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cardiffoncology.com/role/LeasesTables">
        <link:definition>0000019 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables">
        <link:definition>0000020 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>0000021 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>0000022 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
        <link:definition>0000023 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
        <link:definition>0000024 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1">
        <link:definition>0000024 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails">
        <link:definition>0000025 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
        <link:definition>0000026 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails">
        <link:definition>0000027 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails">
        <link:definition>0000028 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000029 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000030 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000031 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000032 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000032 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>0000033 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails">
        <link:definition>0000034 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>0000035 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>0000036 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000037 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_ClassOfWarrantOrRightExpiredDuringPeriod" abstract="false" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_AccruedResearchAgreements" abstract="false" name="AccruedResearchAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_InducementGrantStockOptionsMember" abstract="true" name="InducementGrantStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="crdf_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" abstract="false" name="ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EquityIncentivePlan2021Member" abstract="true" name="EquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_PatentLicenseAndOtherFeesPayable" abstract="false" name="PatentLicenseAndOtherFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_AccruedClinicalTrial" abstract="false" name="AccruedClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_AccruedDirectorFees" abstract="false" name="AccruedDirectorFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" abstract="false" name="ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>crdf-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4e67802e-4ca3-4ed1-a68d-eeeb3b898342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:to="loc_us-gaap_PreferredStockValue_4e67802e-4ca3-4ed1-a68d-eeeb3b898342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bbd31ece-3318-4617-863f-9eab3bb02022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:to="loc_us-gaap_CommonStockValue_bbd31ece-3318-4617-863f-9eab3bb02022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5909ad-9ab2-4d24-9a24-d42c069f7c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5909ad-9ab2-4d24-9a24-d42c069f7c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0fdf068-3367-4291-bb54-9c16572301fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0fdf068-3367-4291-bb54-9c16572301fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b53e8dc-270f-4ca6-9828-a5c28e48f52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44cf79f8-0fc9-44dc-b6b7-9287d74136f3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b53e8dc-270f-4ca6-9828-a5c28e48f52e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1f6a008e-7aac-44cb-af2d-7c5b2cf98bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c986ed19-2d84-4cf3-af9f-d8ad3fb25d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f6a008e-7aac-44cb-af2d-7c5b2cf98bd1" xlink:to="loc_us-gaap_LiabilitiesCurrent_c986ed19-2d84-4cf3-af9f-d8ad3fb25d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b1e999b-1868-4e70-bfe1-3b59d09de692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f6a008e-7aac-44cb-af2d-7c5b2cf98bd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b1e999b-1868-4e70-bfe1-3b59d09de692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aceaca30-e91d-4f6d-b876-67e040453eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_263c8675-90c5-48fc-99fa-67465204bf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aceaca30-e91d-4f6d-b876-67e040453eb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_263c8675-90c5-48fc-99fa-67465204bf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7aa7ade0-5d00-4607-a076-533a257786e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aceaca30-e91d-4f6d-b876-67e040453eb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7aa7ade0-5d00-4607-a076-533a257786e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5f971cd0-2fcc-4fe4-8bea-949627d15313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aceaca30-e91d-4f6d-b876-67e040453eb0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5f971cd0-2fcc-4fe4-8bea-949627d15313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c05d8af3-55a2-476d-ab77-b4213d194820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aceaca30-e91d-4f6d-b876-67e040453eb0" xlink:to="loc_us-gaap_ShortTermInvestments_c05d8af3-55a2-476d-ab77-b4213d194820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a147a664-adab-4038-b9f4-b37ca0e8b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dc274e94-c668-475f-b6c4-af9dbf84165a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a147a664-adab-4038-b9f4-b37ca0e8b89d" xlink:to="loc_us-gaap_Liabilities_dc274e94-c668-475f-b6c4-af9dbf84165a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_60bbdc01-901c-48d7-b99c-80d7a219df24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a147a664-adab-4038-b9f4-b37ca0e8b89d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_60bbdc01-901c-48d7-b99c-80d7a219df24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ecf14cfa-6006-47a6-9b9d-d14acfe1d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a147a664-adab-4038-b9f4-b37ca0e8b89d" xlink:to="loc_us-gaap_StockholdersEquity_ecf14cfa-6006-47a6-9b9d-d14acfe1d4c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1791c8a8-c3b7-42ff-95e8-b7a793a97afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e37a154-29ec-4d58-85ca-63c8b68f5b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1791c8a8-c3b7-42ff-95e8-b7a793a97afb" xlink:to="loc_us-gaap_AssetsCurrent_0e37a154-29ec-4d58-85ca-63c8b68f5b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fdb7768a-3001-4c39-9394-282ba0c8e32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1791c8a8-c3b7-42ff-95e8-b7a793a97afb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fdb7768a-3001-4c39-9394-282ba0c8e32a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff4c591c-200f-4d6e-9e6d-fe379c4b60dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1791c8a8-c3b7-42ff-95e8-b7a793a97afb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff4c591c-200f-4d6e-9e6d-fe379c4b60dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bc3dcf44-ebec-41bc-a4c7-cf2519bde433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1791c8a8-c3b7-42ff-95e8-b7a793a97afb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bc3dcf44-ebec-41bc-a4c7-cf2519bde433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a2f4bf23-8b67-47a6-9d94-946f84f7e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fde502c9-8f36-4a7c-8e43-f97f06c50c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2f4bf23-8b67-47a6-9d94-946f84f7e76c" xlink:to="loc_us-gaap_AccountsPayableCurrent_fde502c9-8f36-4a7c-8e43-f97f06c50c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3886f7e-9d87-46a1-816d-70318d2aed8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2f4bf23-8b67-47a6-9d94-946f84f7e76c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e3886f7e-9d87-46a1-816d-70318d2aed8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bd38bd11-3c94-4265-9ee9-071330e384f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2f4bf23-8b67-47a6-9d94-946f84f7e76c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bd38bd11-3c94-4265-9ee9-071330e384f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_157ee438-96fc-44d6-8963-a02946d1b840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1f1e7db5-fc6b-4807-b6d0-60a1305586a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_157ee438-96fc-44d6-8963-a02946d1b840" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1f1e7db5-fc6b-4807-b6d0-60a1305586a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ee109725-d6de-4cf4-9bb9-527d8b3b858b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_157ee438-96fc-44d6-8963-a02946d1b840" xlink:to="loc_us-gaap_OperatingIncomeLoss_ee109725-d6de-4cf4-9bb9-527d8b3b858b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49fea3f6-7b9e-4b7a-b7cd-b801e3fa14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ed3457eb-cc80-45b8-b400-20d9d1e10997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49fea3f6-7b9e-4b7a-b7cd-b801e3fa14f1" xlink:to="loc_us-gaap_OperatingExpenses_ed3457eb-cc80-45b8-b400-20d9d1e10997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad09f8f-ebe0-45d0-8e87-b1a409b1c13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49fea3f6-7b9e-4b7a-b7cd-b801e3fa14f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad09f8f-ebe0-45d0-8e87-b1a409b1c13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4aeffd65-5580-466f-86cb-7d7979689585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0a1c2398-af4c-4df3-a500-fc9f6d4587d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4aeffd65-5580-466f-86cb-7d7979689585" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0a1c2398-af4c-4df3-a500-fc9f6d4587d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6ebba0f5-3cf4-414d-93a7-82f4f66799ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4aeffd65-5580-466f-86cb-7d7979689585" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6ebba0f5-3cf4-414d-93a7-82f4f66799ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18732dc5-289e-4157-a906-4becccb7eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8382cacb-741b-4daf-8948-9f96b6b6d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18732dc5-289e-4157-a906-4becccb7eb6c" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8382cacb-741b-4daf-8948-9f96b6b6d51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d426cfc-4006-4ef5-b232-c3de4ce6b9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18732dc5-289e-4157-a906-4becccb7eb6c" xlink:to="loc_us-gaap_NetIncomeLoss_7d426cfc-4006-4ef5-b232-c3de4ce6b9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7118f1da-1fb1-496b-9160-989b00002599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_897acdb4-011d-4d4f-a661-335ee73df823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7118f1da-1fb1-496b-9160-989b00002599" xlink:to="loc_us-gaap_InterestIncomeOperating_897acdb4-011d-4d4f-a661-335ee73df823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ec8fec05-1a74-4fb9-9bea-7339e3aea456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7118f1da-1fb1-496b-9160-989b00002599" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ec8fec05-1a74-4fb9-9bea-7339e3aea456" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_253ea306-d428-4c3f-af9a-0ca545033ffb" xlink:href="crdf-20230331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fbc5f68e-ec5b-486a-8a07-9423a0a8312e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_253ea306-d428-4c3f-af9a-0ca545033ffb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fbc5f68e-ec5b-486a-8a07-9423a0a8312e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_07976feb-3638-46d4-8f3f-7c2e00079d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_253ea306-d428-4c3f-af9a-0ca545033ffb" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_07976feb-3638-46d4-8f3f-7c2e00079d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c0f484f9-da2e-4160-8446-ca2ef0022c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94a615ac-a30a-4c22-95a2-7dd64444d63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c0f484f9-da2e-4160-8446-ca2ef0022c88" xlink:to="loc_us-gaap_NetIncomeLoss_94a615ac-a30a-4c22-95a2-7dd64444d63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6fdf33c8-6d6c-4fad-85df-5693ec933567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c0f484f9-da2e-4160-8446-ca2ef0022c88" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6fdf33c8-6d6c-4fad-85df-5693ec933567" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a909ff2-b756-48a8-8b82-b39df12ae69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a6bd36e-10c2-446b-9dfd-4590f57f6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a909ff2-b756-48a8-8b82-b39df12ae69f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a6bd36e-10c2-446b-9dfd-4590f57f6b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc5852e6-5326-4beb-ad6c-c0e8f56316b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a909ff2-b756-48a8-8b82-b39df12ae69f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc5852e6-5326-4beb-ad6c-c0e8f56316b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c724a019-e0a9-40dd-9dae-b7be2e8cd879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a909ff2-b756-48a8-8b82-b39df12ae69f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c724a019-e0a9-40dd-9dae-b7be2e8cd879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2491226e-9cae-494a-8ec7-220f49c37475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30da785e-413d-435d-a0af-515cb1b6468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2491226e-9cae-494a-8ec7-220f49c37475" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30da785e-413d-435d-a0af-515cb1b6468e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9ded68b8-1209-49f9-b7bc-333688ca6eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2491226e-9cae-494a-8ec7-220f49c37475" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9ded68b8-1209-49f9-b7bc-333688ca6eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_12c35de0-4f75-4715-a3d6-a7150b30f705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2491226e-9cae-494a-8ec7-220f49c37475" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_12c35de0-4f75-4715-a3d6-a7150b30f705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875c19f9-d6c8-493a-ad41-746d2554d1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2491226e-9cae-494a-8ec7-220f49c37475" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875c19f9-d6c8-493a-ad41-746d2554d1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b5f8265-1777-4b66-acae-8283a5105e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_NetIncomeLoss_7b5f8265-1777-4b66-acae-8283a5105e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a0e636dd-62cb-4310-be92-48ea91160913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a0e636dd-62cb-4310-be92-48ea91160913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2db0c7fd-1277-40f9-89c8-d5e958e2c690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_ShareBasedCompensation_2db0c7fd-1277-40f9-89c8-d5e958e2c690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_cfbd9b8a-2f52-4f4d-b4e3-55ed042e24f4" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_cfbd9b8a-2f52-4f4d-b4e3-55ed042e24f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b518b7a-ba1d-4e31-8e8b-f690fad9c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b518b7a-ba1d-4e31-8e8b-f690fad9c6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b630eed-729e-4046-a05c-1395dcc43dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b630eed-729e-4046-a05c-1395dcc43dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_75f67f03-6a3a-45ef-a110-d6fe190f0184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_75f67f03-6a3a-45ef-a110-d6fe190f0184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1acc7c8b-807b-4874-86fe-a3d7c36eac97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1acc7c8b-807b-4874-86fe-a3d7c36eac97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c2de9c4f-abd2-447c-9240-b919d3281875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c2de9c4f-abd2-447c-9240-b919d3281875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d37d429d-846f-45d2-a867-4189d41e22ea" xlink:href="crdf-20230331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d37d429d-846f-45d2-a867-4189d41e22ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_708e3b89-5763-4e1b-b49b-39c84145462e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_708e3b89-5763-4e1b-b49b-39c84145462e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d468db68-7bfb-4713-ba84-56f0d704d23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36e46aa3-4b7c-4925-829d-ee3fb983bd27" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d468db68-7bfb-4713-ba84-56f0d704d23c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7d7ae9fd-4773-4cc6-a8fc-775d99fcfe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882c30d8-b55f-46bd-9b1a-3567fff9ed67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7d7ae9fd-4773-4cc6-a8fc-775d99fcfe2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882c30d8-b55f-46bd-9b1a-3567fff9ed67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f81d149-b8a5-4e4b-a2b5-af9116b5b8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7d7ae9fd-4773-4cc6-a8fc-775d99fcfe2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f81d149-b8a5-4e4b-a2b5-af9116b5b8f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63cba3c2-f3fb-4889-ac79-9b557a86066a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eccf78e8-0b13-4713-ab69-ef16a28f86ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63cba3c2-f3fb-4889-ac79-9b557a86066a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eccf78e8-0b13-4713-ab69-ef16a28f86ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_51cca49e-b75d-447a-965e-010406db610d" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63cba3c2-f3fb-4889-ac79-9b557a86066a" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_51cca49e-b75d-447a-965e-010406db610d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_8d884563-c12d-4d3a-b42f-6ce00cbdd6f3" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63cba3c2-f3fb-4889-ac79-9b557a86066a" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_8d884563-c12d-4d3a-b42f-6ce00cbdd6f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38acce9c-111b-48bd-b732-21510e60152d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2d46e95d-7c01-4492-a869-72b6076e0036" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38acce9c-111b-48bd-b732-21510e60152d" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2d46e95d-7c01-4492-a869-72b6076e0036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_cf23f090-5c71-4aab-88b4-dd3c739e10e9" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38acce9c-111b-48bd-b732-21510e60152d" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_cf23f090-5c71-4aab-88b4-dd3c739e10e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_82e9a7d3-29b6-4c9c-85a4-40721b01bee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_cb29cbc3-e7ab-46ea-957d-5dc50319271c" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_82e9a7d3-29b6-4c9c-85a4-40721b01bee1" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_cb29cbc3-e7ab-46ea-957d-5dc50319271c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_f658498e-c83a-4903-8de8-ed660f9ab115" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_82e9a7d3-29b6-4c9c-85a4-40721b01bee1" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_f658498e-c83a-4903-8de8-ed660f9ab115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_355f4af1-d0f7-4dd5-a01f-cecaaf5afd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c8a20d-2377-46af-a039-dd1e923eeceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_355f4af1-d0f7-4dd5-a01f-cecaaf5afd6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c8a20d-2377-46af-a039-dd1e923eeceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2b8a10aa-6a5c-4505-8f27-bf71fd474a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_355f4af1-d0f7-4dd5-a01f-cecaaf5afd6f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2b8a10aa-6a5c-4505-8f27-bf71fd474a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d5fa4a84-ece6-4ba2-bacd-31e03eadfa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_355f4af1-d0f7-4dd5-a01f-cecaaf5afd6f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d5fa4a84-ece6-4ba2-bacd-31e03eadfa4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d1440199-c3f9-479e-85ce-5ac9da37f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_55f1ecd7-60ff-4a28-b312-f7161f637538" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d1440199-c3f9-479e-85ce-5ac9da37f6b2" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_55f1ecd7-60ff-4a28-b312-f7161f637538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1f5c3d22-1c8f-402f-b66c-715fb3013b5c" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d1440199-c3f9-479e-85ce-5ac9da37f6b2" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1f5c3d22-1c8f-402f-b66c-715fb3013b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f1589530-4031-49db-9de5-2154a710c3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d1440199-c3f9-479e-85ce-5ac9da37f6b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f1589530-4031-49db-9de5-2154a710c3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_29ca2946-0f0e-44ce-8cbf-9cc8a31695c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_de289ab3-4b6a-4640-944a-b15783a2d74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_29ca2946-0f0e-44ce-8cbf-9cc8a31695c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_de289ab3-4b6a-4640-944a-b15783a2d74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7037a258-ef76-46ca-a3d7-baeff498877f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_29ca2946-0f0e-44ce-8cbf-9cc8a31695c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7037a258-ef76-46ca-a3d7-baeff498877f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_357859ee-c597-4932-b550-54d35b65b5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_1f2150ba-439c-48bd-b9f9-3390fa02a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_357859ee-c597-4932-b550-54d35b65b5fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_1f2150ba-439c-48bd-b9f9-3390fa02a0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_4d097362-6bcd-4af5-96f0-2d848c108ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_357859ee-c597-4932-b550-54d35b65b5fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_4d097362-6bcd-4af5-96f0-2d848c108ca6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cd3830ea-d5dd-4f30-aedb-f0b17b1ee021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7e6d150b-73c3-4739-8b2a-d88eae484b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cd3830ea-d5dd-4f30-aedb-f0b17b1ee021" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7e6d150b-73c3-4739-8b2a-d88eae484b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7bf7f61-dafe-4607-8b1e-f821b28d53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cd3830ea-d5dd-4f30-aedb-f0b17b1ee021" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7bf7f61-dafe-4607-8b1e-f821b28d53dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_af30323f-b500-409a-a0b1-28dad4608bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_af30323f-b500-409a-a0b1-28dad4608bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8bbb1982-0026-4e3c-aef9-cc9838841495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8bbb1982-0026-4e3c-aef9-cc9838841495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees_59f70d4a-0ca5-45e4-8a9f-c5a57d7960bc" xlink:href="crdf-20230331.xsd#crdf_AccruedDirectorFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_crdf_AccruedDirectorFees_59f70d4a-0ca5-45e4-8a9f-c5a57d7960bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_c6ec96ee-c213-47dc-a4f6-61fcca7a4f6c" xlink:href="crdf-20230331.xsd#crdf_AccruedClinicalTrial"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_crdf_AccruedClinicalTrial_c6ec96ee-c213-47dc-a4f6-61fcca7a4f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements_e3c53e90-c872-4dac-bff8-8f9e8395cfe2" xlink:href="crdf-20230331.xsd#crdf_AccruedResearchAgreements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_crdf_AccruedResearchAgreements_e3c53e90-c872-4dac-bff8-8f9e8395cfe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable_1cd3ae61-9099-4f8c-bd93-e48703f9fdf8" xlink:href="crdf-20230331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_659bac94-8c8b-4bd6-8a79-5129ebd735b3" xlink:to="loc_crdf_PatentLicenseAndOtherFeesPayable_1cd3ae61-9099-4f8c-bd93-e48703f9fdf8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_faa1b9fb-6b15-440c-8f00-32f019d17dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_34c5f1d3-2dd1-49ca-9609-e7bf741e1761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_faa1b9fb-6b15-440c-8f00-32f019d17dd6" xlink:to="loc_us-gaap_OperatingLeaseCost_34c5f1d3-2dd1-49ca-9609-e7bf741e1761" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_acf721af-f555-4d4a-80bc-baa4a7031a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_66e57fee-0aa1-4cb5-97d4-867efc5f11f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_acf721af-f555-4d4a-80bc-baa4a7031a15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_66e57fee-0aa1-4cb5-97d4-867efc5f11f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_794dc77b-60c1-416f-8dd0-faceb7042ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_acf721af-f555-4d4a-80bc-baa4a7031a15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_794dc77b-60c1-416f-8dd0-faceb7042ab1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51a65a60-f14c-4588-933a-3776087f809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51a65a60-f14c-4588-933a-3776087f809f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b759cc79-06ea-4745-b3d9-19bebb8ccb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b759cc79-06ea-4745-b3d9-19bebb8ccb88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a8f185c1-b088-49b0-88c9-be28c0631034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a8f185c1-b088-49b0-88c9-be28c0631034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9671cbea-1cd4-4b38-8bd4-5fc2566bca83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9671cbea-1cd4-4b38-8bd4-5fc2566bca83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_98695a00-0cdf-4de1-acf1-43d3e867ca87" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73cb9cf9-26f5-430d-9c16-f425c24d96d6" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_98695a00-0cdf-4de1-acf1-43d3e867ca87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1df03dc-f88f-48ac-aa0d-8f532ec19db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8962b08-3d6b-46a2-a63c-1f4bdd92428b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1df03dc-f88f-48ac-aa0d-8f532ec19db9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8962b08-3d6b-46a2-a63c-1f4bdd92428b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8e6efdf2-9851-4e6c-8208-ad0e451e3a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1df03dc-f88f-48ac-aa0d-8f532ec19db9" xlink:to="loc_us-gaap_OperatingLeaseLiability_8e6efdf2-9851-4e6c-8208-ad0e451e3a42" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>crdf-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i247b2591472f4faabf7126218439e1cd_CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cfa35020-3f71-403e-a707-0a6d7eac27e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_SharesIssued_cfa35020-3f71-403e-a707-0a6d7eac27e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1018cb9-5434-449e-aacc-db816de77f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockholdersEquity_a1018cb9-5434-449e-aacc-db816de77f0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c532371f-fd8d-4198-b205-d6bb63850fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c532371f-fd8d-4198-b205-d6bb63850fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9da507a-2857-4c56-b83a-8ff1f80302f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9da507a-2857-4c56-b83a-8ff1f80302f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e9508884-ea66-4a19-a2d0-e6f91613b8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e9508884-ea66-4a19-a2d0-e6f91613b8f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ad696adf-efb4-44ef-a6c9-9f95f40d707c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ad696adf-efb4-44ef-a6c9-9f95f40d707c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_018e5be6-5916-4c86-b3fd-f5e4c0ecabac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_DividendsPreferredStock_018e5be6-5916-4c86-b3fd-f5e4c0ecabac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_30947f21-30d2-46a0-986e-f20d48867509" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_30947f21-30d2-46a0-986e-f20d48867509" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_923bc910-057e-46b8-b66b-3197a6a1b0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_NetIncomeLoss_923bc910-057e-46b8-b66b-3197a6a1b0fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ac867dd3-35b2-4d0a-8208-3dee677a0d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9953ffb-6e9b-4b89-99aa-68a07b943d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:to="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68b87a1a-3862-4561-aa9b-d9d77fca48be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:to="loc_us-gaap_EquityComponentDomain_68b87a1a-3862-4561-aa9b-d9d77fca48be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:to="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dba326b8-244f-466a-935a-5b0693190a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_PreferredStockMember_dba326b8-244f-466a-935a-5b0693190a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a68ac851-90f6-46a7-af2e-b58af6a4760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_CommonStockMember_a68ac851-90f6-46a7-af2e-b58af6a4760e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c1376521-fad1-4e41-aac7-3fb3d4113426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c1376521-fad1-4e41-aac7-3fb3d4113426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_690e569a-06df-427f-bbb6-0a969e024b2d" xlink:href="crdf-20230331.xsd#crdf_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_crdf_ServiceReceivableMember_690e569a-06df-427f-bbb6-0a969e024b2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea9694eb-dd2b-4740-ab68-a8d448094532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea9694eb-dd2b-4740-ab68-a8d448094532" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb45cc83-ffaa-4026-92fe-31be58817e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_RetainedEarningsMember_cb45cc83-ffaa-4026-92fe-31be58817e4f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i6c537e3bb0d5413e871526196740dd24_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2982e699-4af0-489e-8958-64216185639a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2982e699-4af0-489e-8958-64216185639a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee33c7f-f0e0-4004-a8a9-6e25e1447401_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee33c7f-f0e0-4004-a8a9-6e25e1447401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13658b0a-302f-4b8b-9bfb-7f8fe0a387b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13658b0a-302f-4b8b-9bfb-7f8fe0a387b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6973a861-7398-4424-86d8-a9d87b40ba4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_WarrantMember_6973a861-7398-4424-86d8-a9d87b40ba4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0856683e-22ce-48fc-b87e-14fa5188252b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0856683e-22ce-48fc-b87e-14fa5188252b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_21923ace-9f2a-4a4e-b58d-b5728048fb85" xlink:href="crdf-20230331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_21923ace-9f2a-4a4e-b58d-b5728048fb85" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i881cde4641c447dd8938f85542aad2e5_FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_849b3214-618d-434d-8c51-4808e26bcdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_849b3214-618d-434d-8c51-4808e26bcdfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_050366e7-4b1d-44dd-82d0-b4112ff6897d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_050366e7-4b1d-44dd-82d0-b4112ff6897d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_da3185b8-62d1-4d50-a5f9-9eadeaa6b897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_da3185b8-62d1-4d50-a5f9-9eadeaa6b897" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_76c4d385-2db7-435a-9df8-d50a57f3b20e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_76c4d385-2db7-435a-9df8-d50a57f3b20e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4abd8428-4a1d-46db-ba9a-4ecd2d232d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4abd8428-4a1d-46db-ba9a-4ecd2d232d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_468b363b-75fd-49f8-bac6-27d8ffc69a02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_468b363b-75fd-49f8-bac6-27d8ffc69a02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86607b06-fd10-4a49-ac7e-3851003d7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86607b06-fd10-4a49-ac7e-3851003d7aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1114756c-3ed1-4946-a7d0-585caed4474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1114756c-3ed1-4946-a7d0-585caed4474f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_af2ce38f-48c5-4256-beb1-6b75529343cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_af2ce38f-48c5-4256-beb1-6b75529343cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fb607e42-e7aa-47ad-b44f-9e5136fafce7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fb607e42-e7aa-47ad-b44f-9e5136fafce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0eb4a0a-082b-4898-bedb-4b6c80647eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0eb4a0a-082b-4898-bedb-4b6c80647eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3a300441-9186-41b6-bdd6-6f069c4adba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3a300441-9186-41b6-bdd6-6f069c4adba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f3cf7d0-1585-454e-8389-5afd9d68574b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f3cf7d0-1585-454e-8389-5afd9d68574b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f53c1c96-5ca6-448d-b8cb-7fd955112cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f53c1c96-5ca6-448d-b8cb-7fd955112cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fe400b2a-949c-40eb-8bd7-70c98d7448bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fe400b2a-949c-40eb-8bd7-70c98d7448bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03724835-5747-4452-ab7b-54808e695adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CommercialPaperMember_03724835-5747-4452-ab7b-54808e695adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_262b9eba-fc49-43a0-8516-c7de5b4c4aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_262b9eba-fc49-43a0-8516-c7de5b4c4aeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c75bddc8-23c1-4e9e-80d5-6b468a1738a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c75bddc8-23c1-4e9e-80d5-6b468a1738a7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended" id="i17f109caaf834225af01db18988ef260_SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8c6498fc-55d9-4fce-8764-64bfcafb5805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8c6498fc-55d9-4fce-8764-64bfcafb5805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_582452a0-1265-45a3-93b9-e5cd6fc7f924" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_582452a0-1265-45a3-93b9-e5cd6fc7f924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e886f0e9-a9b7-493d-873a-810e58df6f0f" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e886f0e9-a9b7-493d-873a-810e58df6f0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8fe5ceba-8ef0-4550-98f9-a6a87757b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8fe5ceba-8ef0-4550-98f9-a6a87757b85d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_4f832528-a059-41e6-9c75-970f81b86b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_4f832528-a059-41e6-9c75-970f81b86b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d544bb04-1809-4fa0-b841-78de04dea205" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d544bb04-1809-4fa0-b841-78de04dea205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_080701ac-00d8-4f87-b019-a8298acca15d" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_080701ac-00d8-4f87-b019-a8298acca15d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_673d657f-a3ff-48a3-81bc-c87feecf152b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_673d657f-a3ff-48a3-81bc-c87feecf152b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58c463a4-afaf-4a84-a2b1-eb1e8de528ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58c463a4-afaf-4a84-a2b1-eb1e8de528ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3ef92f25-9b51-4902-b0f9-16bcefdddb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3ef92f25-9b51-4902-b0f9-16bcefdddb92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d797a179-a6e8-458a-a7ad-dd1bd43ee780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d797a179-a6e8-458a-a7ad-dd1bd43ee780" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c570accd-0da0-4d8f-90e6-24f37c98f1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c570accd-0da0-4d8f-90e6-24f37c98f1e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ef6f560a-bb28-4037-9d03-cc098f9b4824_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ef6f560a-bb28-4037-9d03-cc098f9b4824_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_051d5fc3-b47f-434b-b839-b33f28bfb5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CertificatesOfDepositMember_051d5fc3-b47f-434b-b839-b33f28bfb5d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_67f16639-d4c8-4a0d-ac53-a7166e98d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_67f16639-d4c8-4a0d-ac53-a7166e98d8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1b748f3e-c5d1-4f8d-a7af-b7de8dd60b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CommercialPaperMember_1b748f3e-c5d1-4f8d-a7af-b7de8dd60b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c203c27e-eb3d-42da-99e5-83e32d9a10fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c203c27e-eb3d-42da-99e5-83e32d9a10fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_02722de2-95df-44d1-b471-95c10b18ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_02722de2-95df-44d1-b471-95c10b18ef32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5c4ab5ae-449f-4ddc-a9ec-6886ca83bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5c4ab5ae-449f-4ddc-a9ec-6886ca83bafa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="extended" id="i746f4074ee2e40a3a5f8501105247300_SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_728d1f8f-1b47-42ec-b0c8-dc0c312a82fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_728d1f8f-1b47-42ec-b0c8-dc0c312a82fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_84334903-0f13-431e-b2f7-2fc9d750be6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_84334903-0f13-431e-b2f7-2fc9d750be6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b042c72f-c3d9-45e2-ba2b-6a7f991cb38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b042c72f-c3d9-45e2-ba2b-6a7f991cb38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b17030a5-8bdf-45ff-b3b0-4bfde00da5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b17030a5-8bdf-45ff-b3b0-4bfde00da5e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended" id="i1f02addd49b54b59807830ceffb97634_SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f282fe96-69a4-4fb7-a427-a272b2fc620d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f282fe96-69a4-4fb7-a427-a272b2fc620d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffa1667d-a4df-42ec-a0ce-fca9c56bac85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffa1667d-a4df-42ec-a0ce-fca9c56bac85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_be540059-095f-4714-9dca-0c0801d81857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_be540059-095f-4714-9dca-0c0801d81857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08bd21cd-08bc-4449-993a-1432046d0757_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08bd21cd-08bc-4449-993a-1432046d0757_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_c0cadd2e-e67f-431c-8ec1-3d705f1e67c9" xlink:href="crdf-20230331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_c0cadd2e-e67f-431c-8ec1-3d705f1e67c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0336eb3b-c924-4991-9b13-0abc5e9f8c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0336eb3b-c924-4991-9b13-0abc5e9f8c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_cc643692-9965-4404-b7a2-b1b4767bbc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_us-gaap_EquipmentMember_cc643692-9965-4404-b7a2-b1b4767bbc0e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended" id="ica95ec38bec94112888c8339a08e2e81_StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0596516-2ce2-4b42-bfd7-6e44fb321fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0596516-2ce2-4b42-bfd7-6e44fb321fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_725eedd3-5d16-4453-a544-e48e56b42d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_725eedd3-5d16-4453-a544-e48e56b42d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_761f5f9b-7622-48e0-b9c5-86a3ee435b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_761f5f9b-7622-48e0-b9c5-86a3ee435b5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d77316b9-c9da-4a72-bf40-d83e5b81b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d77316b9-c9da-4a72-bf40-d83e5b81b15f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1fa3115a-93d4-486f-9a58-5356f4271c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1fa3115a-93d4-486f-9a58-5356f4271c14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:to="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f980ee22-f359-4701-9471-c2b3b605e643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f980ee22-f359-4701-9471-c2b3b605e643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ba30a080-8eda-4f00-836d-b82f09f1dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ba30a080-8eda-4f00-836d-b82f09f1dc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d66ad72-11be-4345-8e8c-60d853de103b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d66ad72-11be-4345-8e8c-60d853de103b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8f2b5a17-08b2-4aed-bdf5-4a5b39fb6358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8f2b5a17-08b2-4aed-bdf5-4a5b39fb6358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5bb4c3b4-fe78-447e-8c8b-9f8efd4fb698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5bb4c3b4-fe78-447e-8c8b-9f8efd4fb698" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended" id="i6f9205127d574f328f986b8c2868e9a0_StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ee6d98b-ee0d-4b4b-b6e3-6506bd6af580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ee6d98b-ee0d-4b4b-b6e3-6506bd6af580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8211af3-352a-487b-852c-960eff241592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8211af3-352a-487b-852c-960eff241592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86dc9494-4db5-4909-9ad3-4e1478145dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86dc9494-4db5-4909-9ad3-4e1478145dc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca5592ba-e653-4902-9d5e-f1c751ed336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca5592ba-e653-4902-9d5e-f1c751ed336f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_937ceaf2-c6ee-41c6-9048-29843b376134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_937ceaf2-c6ee-41c6-9048-29843b376134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab0aae39-5bce-4073-867c-9bbfcef998de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab0aae39-5bce-4073-867c-9bbfcef998de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b9ef060-2dd3-4a0d-86e9-5ebbc3bebc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b9ef060-2dd3-4a0d-86e9-5ebbc3bebc99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_283e8836-1a0f-445a-a618-dbd2f24f7908" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_283e8836-1a0f-445a-a618-dbd2f24f7908" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47afb1b6-e37d-4bbe-b54b-04c708753982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c14b31fc-9106-4003-86f8-17e7edd566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c14b31fc-9106-4003-86f8-17e7edd566fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_43cf9b4d-3abb-4267-98cb-0c03073fb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_43cf9b4d-3abb-4267-98cb-0c03073fb3db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d188501-27c3-4f86-915c-129af1800d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d188501-27c3-4f86-915c-129af1800d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_652b3997-6279-4c60-bde0-052019681c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_652b3997-6279-4c60-bde0-052019681c98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4170bcd8-659b-4d35-8ec2-e82f9c9d0124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4170bcd8-659b-4d35-8ec2-e82f9c9d0124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_75e4dc7e-1912-4a44-9c4e-af4553411a15" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_75e4dc7e-1912-4a44-9c4e-af4553411a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb96ebea-c268-41b5-99f2-21a18dd87a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_400484b6-f34f-41fe-883e-bb966e0819bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_400484b6-f34f-41fe-883e-bb966e0819bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_48f45e12-5999-40b1-b5fc-ae23052ea24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_48f45e12-5999-40b1-b5fc-ae23052ea24a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2824940b-0a12-4650-8567-eafb3fbb2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2824940b-0a12-4650-8567-eafb3fbb2bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_769f153b-af32-4f2a-bab1-0e654231ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_769f153b-af32-4f2a-bab1-0e654231ae95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_08eb517d-f022-4b94-8487-243ae0ea7ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_08eb517d-f022-4b94-8487-243ae0ea7ee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_105e7778-f47e-452a-9bd1-9b8f04877a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_105e7778-f47e-452a-9bd1-9b8f04877a6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9d66adcd-72a6-451e-892e-31b06a21f152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9d66adcd-72a6-451e-892e-31b06a21f152" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:to="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_562b8938-b023-4dbd-8a08-2c6577420c5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:to="loc_us-gaap_PlanNameDomain_562b8938-b023-4dbd-8a08-2c6577420c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:to="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_98f903d4-b04c-4a51-91c1-e11a53042c21" xlink:href="crdf-20230331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:to="loc_crdf_EquityIncentivePlan2021Member_98f903d4-b04c-4a51-91c1-e11a53042c21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:to="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_540f6f3a-c563-45c5-9101-d2cda9d4f2d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_540f6f3a-c563-45c5-9101-d2cda9d4f2d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_088db178-500f-40a3-a40e-1362720ddcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:to="loc_us-gaap_EmployeeStockOptionMember_088db178-500f-40a3-a40e-1362720ddcf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_e41759ac-9eab-4445-94c2-3c7de0f319bb" xlink:href="crdf-20230331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:to="loc_crdf_InducementGrantStockOptionsMember_e41759ac-9eab-4445-94c2-3c7de0f319bb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="i8e7311f6b62c4a1b8c04df9626e20d30_StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54725a7a-f005-4cdf-8049-83a02fc5fe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54725a7a-f005-4cdf-8049-83a02fc5fe75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1e4d6cb5-44a6-4063-b8ab-4a9ddf98ed96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1e4d6cb5-44a6-4063-b8ab-4a9ddf98ed96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_080384dc-415d-40d9-9e68-db87e51458a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_080384dc-415d-40d9-9e68-db87e51458a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_68d456ce-7717-499d-8d0a-a8c4cd5228b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_68d456ce-7717-499d-8d0a-a8c4cd5228b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ff29bc6-91ca-4a87-8a96-6dea95e658a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:to="loc_us-gaap_ClassOfStockDomain_8ff29bc6-91ca-4a87-8a96-6dea95e658a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:to="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_dca212cd-a668-44da-99ca-6901313e0937" xlink:href="crdf-20230331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_dca212cd-a668-44da-99ca-6901313e0937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_d762b6d6-6bb8-48d4-96f3-e55a0ff5faea" xlink:href="crdf-20230331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_d762b6d6-6bb8-48d4-96f3-e55a0ff5faea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_2f8a2f78-cabb-46cf-ac54-6d7cc652fa2d" xlink:href="crdf-20230331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_2f8a2f78-cabb-46cf-ac54-6d7cc652fa2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_3016a0fc-f1b6-4648-9a37-69634d49e04f" xlink:href="crdf-20230331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_3016a0fc-f1b6-4648-9a37-69634d49e04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_2a29035a-e7fc-4da9-b298-abcc600ddd75" xlink:href="crdf-20230331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_2a29035a-e7fc-4da9-b298-abcc600ddd75" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>crdf-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_91257dc4-4f6b-457d-8807-8c1af712b6eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity less than 1 year:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6250e457-b1f7-4cd3-b295-11dfe6f077ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ebaf265-46dd-4fe2-8ac7-056fa81872ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c651118f-db98-4cee-bfa9-43e317561f4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_34771b02-38da-4b03-9959-46437090d2cc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_36935977-fb25-4ec6-82ee-c72c34286dba_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1d6ebacf-f978-4f79-a5a9-82fa59f31b50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Available-for-sale in a Continuous Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7ac39547-9eb1-4309-b70a-268ba9c14f44_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fd138a0f-7033-46a1-9b9e-2d48c30395dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29bb38a0-f850-40d6-ad4f-7993166c17cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1d740f99-fca7-4027-a7a0-d9d7cea7e24b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4d0dc455-17bc-44b5-86ea-9208a949b185_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_15f3cd8f-bf1e-4256-bde8-1bd4571edac3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_61619895-d9a0-4797-b734-1d882aa173e3_totalLabel_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to common stockholders</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:href="crdf-20230331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_94567244-02dc-4ae9-9e02-2eb36e7e33d8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c0f3cf87-114f-4954-84e9-380e5eb0b1c7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b2686a1-a96e-4934-aa27-8a32aab45868_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b38554db-24e1-44b0-b800-b3e8c7f39202_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_07cd22ea-3ee4-4f60-b46e-65c69234cff1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term(1)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5a20be6e-c561-4f98-967f-809023df47bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_a5cfd1ef-9a2b-4bb7-9bff-b5abdc19e4f7_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_63456bcf-1719-4cba-aba5-e673fa32779e_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b60fc0-b4e9-459f-89bd-3f9a15918e2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_d065005d-34a1-4acd-9a14-8c558bc4fc2c_terseLabel_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees</link:label>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_label_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:label id="lab_crdf_PatentLicenseAndOtherFeesPayable_documentation_en-US" xlink:label="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable" xlink:href="crdf-20230331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PatentLicenseAndOtherFeesPayable" xlink:to="lab_crdf_PatentLicenseAndOtherFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bc7c414c-0ae5-4abc-9777-e714322fc263_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 44,677 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ecf7458d-4294-48bf-ab91-9d4ff843442c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_99a47733-6392-4214-b3bb-f2984d492239_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_332006d2-181e-4f6b-ad65-e2add15d3d9f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b4dc13c6-da0e-4a7c-bd3f-33e1a3d90ba7_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dc123fab-ad45-4c3a-910c-a425e85af081_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_155df210-be61-4e5c-a26b-80c4f4ed4a91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6223e5c3-32d2-4a6e-91db-50fd6f5b6ee8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ad808064-80e6-419f-addc-38317741f1e8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c2fcf005-5e2b-45eb-b909-f049c6e1c16f_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares designated (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_86722f22-b224-45ec-8576-b1fbd8ca6410_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedClinicalTrial_60bc610b-debc-4dbc-8a59-0704c5071362_terseLabel_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_label_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_documentation_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial" xlink:href="crdf-20230331.xsd#crdf_AccruedClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedClinicalTrial" xlink:to="lab_crdf_AccruedClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a134ded-2ce2-4809-bfd2-5b4c542a88b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10b15df3-dc3a-4119-9277-d68293778548_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cca59f6f-0cf6-4940-98a5-5df03aba1e01_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_16d58b8c-123b-4236-a764-8dfe5fe5d774_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4142f821-259e-406d-9fe2-de923e486031_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_35e28625-a9c1-4cc4-b669-887bed173501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d867af7-106a-49b5-930e-030750140454_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_912c1b33-23c9-4a0b-863d-bafe6c4474a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5eca55ef-6f94-4cc7-b44e-a2bdf61cbdb2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_59faf99f-1a21-4ef9-86e5-4a6a2c0ea937_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1f83402a-5544-4e63-96c7-174ec58d38ef_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a0c61b4c-31e0-4f21-97cf-0f4e0fa8cc79_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_da1c4365-54e3-4395-977f-a3099791f7a0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9a16e7c2-70e9-4fdc-be87-dcb404ccfa69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1bc0a409-d6cf-45b7-90e6-b43743804b93_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11c542f-7ec1-47d3-a834-312a6dfebe48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_306a6fc1-b1e6-443f-af03-7845c6ad97d0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6d5a48c1-5383-47f1-8f06-c73bdbbe78c7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_47e95e97-dabb-4075-8768-b25123b4e736_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7f795c78-9b1e-4c7e-8d4f-6703da0d74c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_27094aa0-bdff-4673-8fd9-6f8714f580c9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18bcd1b2-8106-4f14-a464-5b8f77ea5a41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3580b12c-a030-4112-b86b-ab8008d66c6e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_383bdab5-051a-4306-a58b-6f223b7ba32e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6a506efa-d3e9-4247-b780-2c4b3d2fcc71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_45148394-313a-41d3-8788-194b849590d2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a79a7852-4c86-47ff-bb84-5e104e365682_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3425a130-6ae3-4a74-a0dd-07bb2a13a909_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_b43b7f8b-ba47-4bb9-a53a-82e1db2a2b32_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_686a7279-902d-49bc-90da-b90da5266e33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_901b4925-445a-4540-8c90-a128c51ae4fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba12e4b9-ada4-4435-aad5-5a0d0b77d98e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available for sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50d49934-8985-4d26-969e-9e8b81cd0b44_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d20bae02-b82f-4b97-b449-7a9dc2047c76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2186ef23-9f3b-4844-9430-d561783ff3cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aea15537-2281-4fdd-a6df-d3f0df7be28f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fda4aade-afdf-40a5-9fee-01faa1b04a04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled / Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9e5684a0-180e-427e-9e8b-dc1ff01a1b9a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_669d9f60-6cbc-469e-ba24-eac0759a4bd0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_32e5fff5-a3a5-47d9-baaa-677c15a51606_terseLabel_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_label_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021 [Member]</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_documentation_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member" xlink:href="crdf-20230331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityIncentivePlan2021Member" xlink:to="lab_crdf_EquityIncentivePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f80e4a48-eec1-4ad7-8498-75469e6ff7d2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31, 2023)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_87bbba12-2bf6-4c26-aed1-a3100840e9c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c541a47-ee41-48c8-83c4-9e44c8dca7b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_98574223-fd1a-4943-bd6f-27f4a571ebe1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_1c0e0b05-7582-408d-88c9-c8041526b01e_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b6ac45d1-ba61-4dab-bec0-3c92f8e78819_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f52b5370-e033-4679-8201-5312d3bf07ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f89eb22e-54ff-420f-8124-c17d47fc789a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e134bc0e-50e8-4bf0-86c4-26e9418acaa3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_80d2085c-d70b-4279-8616-922ded1a8a08_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3666bba7-ec81-4428-b395-ebe2d588473f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c614a68-b624-49fe-8fef-ab60113465ef_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dd225bca-2fc5-447d-9007-b0a0caba767f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a1986990-aa95-43cf-a2fb-b2a68010bf5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0aff98e7-1673-4f52-a896-b0f0d7f7dfd9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0f0efedf-189a-4f1f-ba69-b5887db7e21d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_69e094ee-b842-4c6f-a81e-d747b9ba1ea3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4754d6bd-2435-41c6-ae40-9cbb8f9ccd3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_934f70af-0b75-45e2-867e-4c87c94c4d15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_206417fe-494d-420c-ac51-f55b26669447_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_86757d09-294f-44e3-99a7-b0f0e3922121_terseLabel_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward" xlink:href="crdf-20230331.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsAndRightsRollForward" xlink:to="lab_crdf_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_9771f3ce-b980-4388-918f-4194868fb692_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f4f28ff5-e996-4059-86f0-5195d5ccdcb6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b4cd5364-2d07-492e-8be2-a74ce71d9ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f36f5b8-c623-4c24-9cfb-bc5d62f3a7bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e1ab1bd9-149b-4da5-89b0-885c3e12a73d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1cccd750-5643-42ca-9a6f-af4b5435dfc1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_27341f7d-68ff-4f6b-a861-0e68cc642a5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_85702150-f777-406c-87e0-22036bc3ae9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7a3a1bd7-c8d8-47b9-83aa-083cc6973cd1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4bc95741-9a62-4cea-8742-896d84e8f6c0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b7d4a89-d637-45c1-98cf-cd355be8f34b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_74505e1a-7e7f-4978-bf0f-8bb47baa4409_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a27c2ed4-0a71-48af-8d5b-f962eb5fd213_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e12b3e65-2e70-408b-912c-56f60f6682e5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3afc6b45-9248-45a3-a76e-9627d6d4da4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_4de861af-527a-4a94-a55b-ffc46cd20bfb_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_587d7e1f-6066-4d1e-8714-be859b221bf0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_610c8b7b-7372-4345-8a2b-12b177d08442_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fef93d5-417c-4768-a56a-285da7ed74dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9c006fc-8032-4c6a-af12-716721956ebd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_42e936c9-cc30-49df-89cc-f1e97437b2a0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e1daf991-81f3-4c6e-83e2-b4d8d5c52efb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a15372f9-b4f6-4a4c-8770-591736d9a610_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_0877c042-7411-4b4a-a9f0-c112220e680d_periodStartLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_59b81a2c-b920-481f-9b1b-49d45e515099_periodEndLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1eac4aff-c461-44f5-8e0f-ba430eb98e76_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ffe8f54-a66e-463a-91f2-ea8ba9d752ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7e85507d-e266-4550-9795-238198bd891c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8e311fd0-a94c-41e1-bacd-4befc5227a66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5b130d14-9732-431e-8675-ccf7c3499473_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5ee10ed5-21b8-4fde-a926-d25f4886c7c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_180ec920-ac81-4807-81be-232d2e584c3e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_238c34d1-5e80-4d2c-aac0-68a4120f4fb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7472ecb5-35ae-4162-bf48-387809164ad3_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cf805c9-ca2a-4f0f-9a5d-235d8d04ebe2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bf2dbf6b-f815-4606-b109-768bbb16aabd_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f37f6f4-2279-4b54-92f4-d4fc3e75b48a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2bbf7cfb-f5c8-46c3-b568-b133d8224e42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_f6d1de18-5e3f-4814-8ca7-7e102a8bdd14_terseLabel_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and royalty payments made</link:label>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_label_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</link:label>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_documentation_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:href="crdf-20230331.xsd#crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:to="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedResearchAgreements_38bd7375-7124-4c61-b962-aa0c52964b49_terseLabel_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research agreements and services</link:label>
    <link:label id="lab_crdf_AccruedResearchAgreements_label_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:label id="lab_crdf_AccruedResearchAgreements_documentation_en-US" xlink:label="lab_crdf_AccruedResearchAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements" xlink:href="crdf-20230331.xsd#crdf_AccruedResearchAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedResearchAgreements" xlink:to="lab_crdf_AccruedResearchAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivableMember_dd07e582-072e-49db-a6e0-ab087d3187f7_terseLabel_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_label_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_documentation_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember" xlink:href="crdf-20230331.xsd#crdf_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivableMember" xlink:to="lab_crdf_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_79fb2321-0846-4571-879d-c171ad8eead2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fd9ff11f-19a4-487c-af14-e05af84fbafc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_934d3ad9-7f20-4cf2-b1c4-e88b3e09c210_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_08b81e82-6995-4ed6-9fd8-f9e755ad84c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_593c8699-fa4d-44df-a361-31f739063845_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f464a3f0-3b75-45a4-bc58-b3c9ba03635e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_eb0027ee-e5fd-4a6a-b709-9471e8908a82_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7dc29c89-3acd-4692-8f7f-e934dc5208ca_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b39cd49a-15e6-4a26-9cc1-2dd46ddfeb89_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_22d689a6-992f-4d61-b39f-e62ca1b4ed2b_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a4f398e8-a43a-4ca7-a905-a5debf65ccf2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_27ed069c-5d65-4115-93d8-42301592cc8f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a31ce87d-33fd-4979-9c86-43b829dcabbd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ae0d3d75-aa91-4000-914e-a826e4134463_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cc630160-0cb7-43cb-bef5-6b619efb284e_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fe5aaa11-443e-4488-94d9-b0ba30f4a3d8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_81447a5b-5d15-4b73-ad0b-f3d3ed341a15_terseLabel_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="crdf-20230331.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_70f45386-1c2c-4734-95c9-4ea06b200b78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts) on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_20f88140-5300-42cd-af30-1d7c6d8325c0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e974075-f72d-47f7-8a12-69a0d905bd18_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ba98e4fa-d560-4b49-8d12-c839b379f32d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9ec077e4-d8b4-4178-946c-9bdb66d4d281_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2d884a22-1196-470e-8690-3034900a8ae9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_ce3d8143-6287-4efc-87bb-541a4a5ceea6_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Three</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4601d937-73a0-4763-a5ac-3e435f99f1a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a529e0e-abac-47ac-87d2-f69ab0b643e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_12f46a15-a162-49e0-9268-695a7a3ef4bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_8c0e6a67-9fbe-4285-8a39-d14a5a3173a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f4d22ed0-3ff2-48af-ba44-acdc70f8b270_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e7daa6cf-a455-417c-a55f-87c722da5270_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_717be558-465d-4f03-b823-63703c414094_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a50f8fea-d883-41ed-bb9e-49e86da7a1be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod_cd4ad26b-19ff-4d24-b4a0-46888d3a5387_negatedTerseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expired During Period</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightExpiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:to="lab_crdf_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64345e66-6243-4342-8e8b-516ffb324d7d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d3aee0af-c213-4d35-b1ff-7a4c69e3dd19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5fb01e7-ecc1-40d7-aed1-0a58a2e47f1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_09f8e24c-81da-45df-ac24-9a938b425106_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining&#160;Contractual Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Outstanding Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which each class of warrants or rights outstanding may be exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f84144a9-6a43-4456-bb19-75b991399f17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d8968078-d53e-449c-b525-33ffa19ed116_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_45e0742f-8008-4f34-8c3d-01985c4ba468_negatedTerseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="crdf-20230331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27e03ed4-98c5-4312-b0d6-caec392ab690_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bf87925c-589d-456d-a1a7-0c6101edf7cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2107dfa7-aa60-4f06-a579-5d411067ba09_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_45815298-307c-46d5-ba15-d405b00c77a1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ffc02c7f-98c6-4399-b7e3-b67f1ad8847e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c15b9290-4f35-42fa-94c5-8c6c4d5b7416_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_3de5c762-8caf-4db6-9179-33be0fb51379_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7f659600-37dd-4c5b-a71e-4fa1e7eca07b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9e222fc1-9f4f-4818-999b-8a3b4e19ae91_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9e0704d5-52e9-42e8-ad65-234bbc94a786_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1e8cf887-b8ad-41fe-89fb-bfbe6fdb40e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b2f972e-c74c-462c-8b4c-34cf66d6acff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedDirectorFees_aab86c02-1971-4c0c-8073-f0348ac14762_terseLabel_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director fees</link:label>
    <link:label id="lab_crdf_AccruedDirectorFees_label_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:label id="lab_crdf_AccruedDirectorFees_documentation_en-US" xlink:label="lab_crdf_AccruedDirectorFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees" xlink:href="crdf-20230331.xsd#crdf_AccruedDirectorFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedDirectorFees" xlink:to="lab_crdf_AccruedDirectorFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eecbeda8-cc5c-463d-af61-ffe8334774ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining vesting period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_4d8432a5-b693-499c-a267-e8f796c9c65b_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_54c54cf3-cde4-43ae-ac9a-a1052debce4b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6991f2d3-2951-4470-81f5-4deab4185037_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_547dd348-f8a8-4f5d-9cb7-067df87706e5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e85e9e6e-0e06-4262-836c-7cfaf6a5b9f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_eead8128-46b5-4e14-9b77-d7d203a1b86f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d03c36cf-2076-42d0-ad7c-cea799a7117c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff3dc9fc-1279-4e75-b357-b0e73497cbe1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ac2b59af-6d04-4f09-856f-88848ded6e18_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,050 and $1,044 at March&#160;31, 2023 and December&#160;31, 2022, respectively (Note 6)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_fb6b6dcc-17f3-4e58-b796-cd0e76b8df37_terseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8ff1a450-5d6b-4d2a-b209-9f1d641e5808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6b8ee961-7aa6-4910-86bd-80555ee683a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_402d6269-ad53-4ab2-8628-7ff0a6345e69_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cf1aef6b-54b4-45ef-851d-0bbc63798ef2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3aae3ea6-384f-46ab-9364-197324d2baf9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_a91c0877-9d49-439f-a845-2ff109ed835c_terseLabel_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:href="crdf-20230331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_ec7bb98f-b40d-42ae-9d16-5b02602fdb4e_negatedTerseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c7369ade-fb65-4154-a25b-119782788186_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_eb3526d4-5208-44e3-a614-37cc3fec5431_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_508b4951-e6e0-4d9c-a7d8-2c444b86a46d_terseLabel_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_label_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options [Member]</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_documentation_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember" xlink:href="crdf-20230331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_InducementGrantStockOptionsMember" xlink:to="lab_crdf_InducementGrantStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3de1eaa6-c0fb-46b6-a81a-69d2867df59b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8bacae98-1310-4bc3-8153-81b0434c2760_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9581dd60-a808-4b6a-8042-48aec557e05c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0a0ec6ad-cb09-452c-8844-437bf10e4c40_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b1262463-d108-47be-86e8-1bd74ea4e647_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fb56b7e2-fbd3-494d-9cf3-9f0c0745d0c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bdbfcffc-d34b-45a1-97b5-74a2c6e41d96_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f2ab1f75-a84f-44fe-866f-699425e50b84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3417b0ed-5098-4e13-aa87-f1d20ecf4ecc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6b4ca53b-caab-4b95-b5ed-8b7a5432f791_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7b58a158-283a-4f10-93ff-702a84f6079d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8cd194c0-f8c9-4660-9f06-9f722f05f961_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_ab6330ed-4c08-4df3-8977-70968b065812_terseLabel_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:href="crdf-20230331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_9ee931ce-f31f-471a-b87e-9d1e907bd2cc_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87ce093-ccb9-4aed-bd1b-024c26892162_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_82b91b95-b41f-49ab-8457-81e1f4c42250_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_387b4f10-e696-449a-b86f-142b4b79c01c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0ade74e0-4a36-4d70-8271-9dc2a3587893_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a4e28990-3ad4-4ec8-a381-0f630d88e422_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c9df3e17-14ce-49fd-a197-526db544458c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b0ae6308-97ed-46b5-bf10-aa3e740aacb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_64dac632-9c9b-4f9b-926b-6105ec283c42_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_9deb19cd-dd89-41a2-939a-8ef63df23eab_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_8e19e55c-87ed-4cc8-9e6d-6602b0b62413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_422c64ca-8f36-428c-ad3f-3201087e83ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d2e3aabc-5733-4255-939e-003e4d7bd986_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7e58dcaf-053d-4d55-8ac7-9b93d21a247b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6ee1e075-e043-4d00-9e43-c0557ef78be7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f29663c1-ef36-4884-a58b-6729549777ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_915229ba-9177-4d79-8986-d1f80b4aa6b4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_ef9d3d77-3efd-4b8d-aed9-4b47ae671bc8_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity 1 to 2 years:</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Noncurrent [Abstract]</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33e7aa18-b639-4aa0-a187-b7c9d30b0339_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5e6d1fba-6811-4715-9061-0d5fceb2cfa3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_73c1457d-75cd-4f43-ad40-3ecebc9464eb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S. government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dafa0863-2731-49d2-bc64-5c33660539ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1fe3f14b-3690-4fa2-a11f-e82ecd80d41d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_979dd43d-89d4-442e-8e6f-c13bb60686c6_terseLabel_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:href="crdf-20230331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b004b2c0-735f-4233-97bf-5d4de04f61f2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8bbeb178-3a0c-42dd-b508-88e62f76d3ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6c86c967-b00f-4138-b703-b4a4793bf45b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_5d020f53-759f-4085-b7b1-7e86fe634e70_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_961158cd-86e5-42ef-b477-c6c9e32a6f5f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_11539cc7-91a2-483b-b3ef-90fad9f73a0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8deb1825-5e59-463d-8a62-1ec196787c57_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a0fc2a6-5b32-4c5f-946d-e5d701cb3b0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_653f63e3-9c81-423e-89dc-118f9321efdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_db0daa12-9357-4093-a5d2-48998868ef02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f536fa01-9af4-4257-b17e-1d87aab79980_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed5b3e83-001e-490e-8123-713caf23e5ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1e323171-357e-4f4e-9fff-f8a47d86b7e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3c54fe02-1005-4e21-a058-d57cd790adfd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0924912c-e751-40f0-bb37-d1beeb91234e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2594ad2f-40fa-4e2e-b082-6c5eb2c53466_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_284b0bea-7cb9-4320-9443-ba7c0f7f22d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized shares under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7234c99d-c3c8-4c7d-9047-70cc3215dfe4_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_5c4f94a1-4664-41b7-81c5-736a8c4ddc15_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_abed0697-40c2-42f6-987e-4dfc5e8f957c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_23182315-954e-495f-ba24-a630a8643228_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_87d280e0-ca62-4db0-8494-79076bad77f8_terseLabel_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:href="crdf-20230331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:to="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_cf57e955-a05f-4976-af41-2168fafede3b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_628c823d-d695-4588-9f7c-8154677d26a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c8f9fffa-ffdb-4668-8018-6557e506f0c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_75474672-b193-4b27-b97e-c145f7804b73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_bf73c1d9-8a7a-4739-bf7b-c76ff3daa349_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_50a5eea3-e641-45d7-a843-ce9eb2e88986_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8c779a15-d586-4784-957c-d67c1cf803de_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_49700587-0ec5-495c-b0bd-7179a2eefad5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7fc44334-963e-499d-8107-91dcc30fe142_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_80139d74-943a-487e-bba9-528aa7cfc9f3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_25fbe0ce-24fe-48e1-a909-4f0f50cf2025_terseLabel_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:href="crdf-20230331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a91c24bc-e843-4dfb-b96b-a04396dd259b_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d41c94d6-ae2f-4c7c-aa20-66a393504bb5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9c0f1795-ff61-4bfc-a4ad-703cc1d992d0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_95979232-3d1c-41b0-b909-221b4f703ac3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7b863a1f-2107-4122-9e2c-5add9919443d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_813e017b-1337-4d50-87f6-f9e696e15e41_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6b21cdee-ddc9-4051-8b1e-56ed3098ab72_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a51653e5-9872-4ffc-b3c9-5c82104dcc8a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c853ce45-dc2f-443b-a41e-df4094a096d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_075d2de4-36a7-49a7-a42c-db1edb87a098_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod_e874aca9-f1a7-472f-a398-dc84b4acdeda_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Expired During Period</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Expired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f4501201-071a-4f93-90d2-442ee32d265c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_bd1bc1f8-63be-4afb-8ed3-e4641ee24992_terseLabel_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;E Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:href="crdf-20230331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b2f17550-d150-440a-b50f-ef17043773e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_441392d2-87ad-419c-ad2b-dc19bc2920df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_687296be-690b-4af0-b8cd-fd31dbee7983_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e10522fc-41e3-4f35-9b9e-6ba29aa9590c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b17a4fd2-71fd-46a8-a564-53dd1d10b591_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_41c44562-410e-4468-b6e5-6f25ce37f81a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_03d08237-6f31-492c-ac8d-0408a1ed5bd6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0fdeb7c7-d501-45cc-ba2f-9e1db1404ca0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a2eb4e5f-d1ee-40c0-a8b6-bd1c12a08963_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4d9c0088-fc8e-4575-a64e-55469c17ed34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4e8f4d15-c4a5-4a63-87e3-c8d443fb9fc6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7e7e18aa-8911-41ae-b7e8-0431d7043d67_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5eda154-2ad5-451a-a235-2f34d5bbc8f7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3b68e865-ab79-4fbb-a07a-55aa16796e9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8cf6f7a5-2a27-4573-808f-215238b65f4b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28a9052a-cc24-450d-98dc-f78c62bc5b90_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8b895d43-73b1-40ef-90c5-97b783c7586b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_c0f2cd15-488d-4b14-9b75-0db780c2d687_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d5b0dbbe-051b-4180-bc8b-52b154df5dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_498b6568-fe00-4364-a239-a0e6fb7e7c4f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1733faba-e24e-460c-9931-7161ab58bc60_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_57a29765-b71e-45e9-9ab3-9213f686c647_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5c99295d-ff23-4c57-aa66-1c97a582c78b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_a231e965-21be-44e4-b4a3-d0ea6b5b70a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_092c2c56-dfe0-4257-9755-1d9f1cf80cbb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_0d5efd76-e4af-4746-8127-389d4ec06435_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4d383572-e1b7-499c-8115-7fa7c04bf245_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_35a3c138-8b99-4d70-af71-ea19573809dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45f508d8-06da-4b35-a72b-c513ebeb92f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_08ef2c63-906b-408d-978a-87f5d335c4b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2624d6c8-034c-428c-b06f-d21115c645fd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f932dce8-cbd2-4ba8-b2bb-35bcf032772f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90fc90fb-f42f-43e7-b75a-3372b6bf35e2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5824e310-854f-4a7a-b684-e3f844a3ec6a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>crdf-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:37b0733d-f59a-4825-b914-227f0ba790a0,g:a761f88f-271b-46c6-b91d-2f82ec7e6762-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f3c087f0-2525-48b5-abb6-fe9dc4f2085e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentType_f3c087f0-2525-48b5-abb6-fe9dc4f2085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_553cffec-6229-43ef-b26d-67739749c9da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentQuarterlyReport_553cffec-6229-43ef-b26d-67739749c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_da6d6cbe-8e4b-4de6-a95f-42574bcb8ab4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentTransitionReport_da6d6cbe-8e4b-4de6-a95f-42574bcb8ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c4c31bd6-74a4-4b26-b529-0b585bef1ec7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentPeriodEndDate_c4c31bd6-74a4-4b26-b529-0b585bef1ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d89606b8-61e3-42d5-b63a-a3862a370faf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityFileNumber_d89606b8-61e3-42d5-b63a-a3862a370faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_654ebb30-6945-4b74-99d8-eac58371cab4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityRegistrantName_654ebb30-6945-4b74-99d8-eac58371cab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5c76b2a3-e49e-4094-a99c-49aca62c8172" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5c76b2a3-e49e-4094-a99c-49aca62c8172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_49a3e83b-73cc-4333-a229-c13c0d0e74f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityTaxIdentificationNumber_49a3e83b-73cc-4333-a229-c13c0d0e74f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c3d507ed-913a-404b-83a2-847ccb792b82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityAddressAddressLine1_c3d507ed-913a-404b-83a2-847ccb792b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0ceff99-d9c7-4e20-a0e7-c8c82f4a2669" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityAddressCityOrTown_b0ceff99-d9c7-4e20-a0e7-c8c82f4a2669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b37b6371-9de1-4ee2-a8fd-3e23066ea3bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityAddressStateOrProvince_b37b6371-9de1-4ee2-a8fd-3e23066ea3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_23e160c7-8ae6-4e67-8a8e-dddd5b7e2e6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityAddressPostalZipCode_23e160c7-8ae6-4e67-8a8e-dddd5b7e2e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8e43787a-171a-4741-83e6-4e76b1ac0504" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_CityAreaCode_8e43787a-171a-4741-83e6-4e76b1ac0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_177ad868-d0e6-4658-a7ef-93471906f0c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_LocalPhoneNumber_177ad868-d0e6-4658-a7ef-93471906f0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dc427418-b53b-4ba2-ae60-0687d70fe7b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_Security12bTitle_dc427418-b53b-4ba2-ae60-0687d70fe7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7bc318a7-74fe-4649-a94e-d080f9062270" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_TradingSymbol_7bc318a7-74fe-4649-a94e-d080f9062270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a0f7bc2d-ebb5-4d20-9821-d9ab19dc115b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityCurrentReportingStatus_a0f7bc2d-ebb5-4d20-9821-d9ab19dc115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8858659c-e2a6-4ff6-9a3b-3372d493e003" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityInteractiveDataCurrent_8858659c-e2a6-4ff6-9a3b-3372d493e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7dd41f41-1315-4e46-85fd-26b274a8eed4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityFilerCategory_7dd41f41-1315-4e46-85fd-26b274a8eed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7cd32138-df9f-43f5-bed7-51fb8532e1a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntitySmallBusiness_7cd32138-df9f-43f5-bed7-51fb8532e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e30a63a9-505e-4648-b4a0-938e6e0a04ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityEmergingGrowthCompany_e30a63a9-505e-4648-b4a0-938e6e0a04ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_52552fcc-8f00-454d-9983-bd275d2990bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityShellCompany_52552fcc-8f00-454d-9983-bd275d2990bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_34fba74a-c0c4-4210-8645-1be1618ccdbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_34fba74a-c0c4-4210-8645-1be1618ccdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e24ae1ac-92c2-4732-8723-2d51d919380c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_EntityCentralIndexKey_e24ae1ac-92c2-4732-8723-2d51d919380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4a99548c-40b6-4f75-a62c-2e0c08a2c0e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_AmendmentFlag_4a99548c-40b6-4f75-a62c-2e0c08a2c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f3603c27-1c70-4281-941b-9ee7767aa151" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_CurrentFiscalYearEndDate_f3603c27-1c70-4281-941b-9ee7767aa151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_306cc44e-9fc9-4472-a554-5ae08808f48e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentFiscalYearFocus_306cc44e-9fc9-4472-a554-5ae08808f48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e76cbc5-9e01-4355-9721-33b55ff071ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8081d705-bf9d-43e0-a85a-dd292c4335ad" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e76cbc5-9e01-4355-9721-33b55ff071ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68ae3ecf-769a-4e3e-93c6-af981162ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68ae3ecf-769a-4e3e-93c6-af981162ec1a" xlink:to="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4125e035-1417-4b72-b09d-0430f60e5134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4125e035-1417-4b72-b09d-0430f60e5134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f63498fd-51f6-4b93-8312-9ee83ab9099a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:to="loc_us-gaap_ShortTermInvestments_f63498fd-51f6-4b93-8312-9ee83ab9099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_22578b82-d9a2-456e-97a6-62cfe7424f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_22578b82-d9a2-456e-97a6-62cfe7424f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_30d349a6-97ff-4e4e-95ee-a82c375c9f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_30d349a6-97ff-4e4e-95ee-a82c375c9f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bfb8876e-313f-4c81-92e9-8b01cab2ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee10b86d-fc44-4804-8485-3527ff209723" xlink:to="loc_us-gaap_AssetsCurrent_bfb8876e-313f-4c81-92e9-8b01cab2ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_186885be-bb5d-4a91-ada9-1347212eb7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_186885be-bb5d-4a91-ada9-1347212eb7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_df6752a7-0fcf-47ec-b332-cc9d82439267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_df6752a7-0fcf-47ec-b332-cc9d82439267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5b2ca022-4351-4d02-9069-4b9e1adce282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5b2ca022-4351-4d02-9069-4b9e1adce282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_648d7828-8375-4b68-98f0-1bd6237408d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9c7e723-0297-462d-a32c-4bbeb6625bc3" xlink:to="loc_us-gaap_Assets_648d7828-8375-4b68-98f0-1bd6237408d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68ae3ecf-769a-4e3e-93c6-af981162ec1a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_beef321f-12c7-4330-87be-b6561a734a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:to="loc_us-gaap_AccountsPayableCurrent_beef321f-12c7-4330-87be-b6561a734a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_520385f9-f5ca-4d36-9aff-cf973f68aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_520385f9-f5ca-4d36-9aff-cf973f68aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a232eb1-5c3c-4409-a1ed-e60c079880b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a232eb1-5c3c-4409-a1ed-e60c079880b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d86db27c-bfaa-4fa8-a028-5434b7a56794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_34b465db-3496-4043-965e-1ec98de7ec6b" xlink:to="loc_us-gaap_LiabilitiesCurrent_d86db27c-bfaa-4fa8-a028-5434b7a56794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_810a893e-6e95-43f9-b7a5-9c7146cbe553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_810a893e-6e95-43f9-b7a5-9c7146cbe553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1c8967ad-be54-4ca3-9111-ad10342f80be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_Liabilities_1c8967ad-be54-4ca3-9111-ad10342f80be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d7eb7a78-0efd-4c4c-abc8-d5b4c90ebc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d7eb7a78-0efd-4c4c-abc8-d5b4c90ebc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_410090ee-f075-496a-9b60-98042a4a8c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_PreferredStockValue_410090ee-f075-496a-9b60-98042a4a8c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0ca824d4-c544-42a1-9cb8-f838ed7cffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_CommonStockValue_0ca824d4-c544-42a1-9cb8-f838ed7cffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ca662d04-f682-4aa0-bd26-936686b3d076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ca662d04-f682-4aa0-bd26-936686b3d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08c898b5-0931-42cb-aec9-011470a78358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08c898b5-0931-42cb-aec9-011470a78358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_369845a7-1cb2-4919-b216-16098f3e261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_369845a7-1cb2-4919-b216-16098f3e261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43fd3917-5923-4421-95d1-54acf627e65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_244d7506-af66-4449-be9e-d17478a2a764" xlink:to="loc_us-gaap_StockholdersEquity_43fd3917-5923-4421-95d1-54acf627e65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4430dee-0c45-45c9-85fe-30ea44a60b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a3672a8f-d779-4973-9c8c-e27a863603da" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4430dee-0c45-45c9-85fe-30ea44a60b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2aa8c58e-2e60-46da-8034-03fdb760e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2aa8c58e-2e60-46da-8034-03fdb760e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_ed019511-102f-4267-aa32-8114607d74ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_ed019511-102f-4267-aa32-8114607d74ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6955f9d-7b3f-4792-ad95-05d9ccd9f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6955f9d-7b3f-4792-ad95-05d9ccd9f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23ed998d-8f06-429a-9062-76895e35b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23ed998d-8f06-429a-9062-76895e35b5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f808f17d-ed60-4953-85c6-681dd3fcfd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_f808f17d-ed60-4953-85c6-681dd3fcfd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ccae4a77-ed3c-4849-ada1-1a88d921742e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26d7bb06-89a1-4966-9a78-86da862a6c1b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ccae4a77-ed3c-4849-ada1-1a88d921742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0864e48-9a53-401f-bf49-8b14e1eaed47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0864e48-9a53-401f-bf49-8b14e1eaed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a51eb4a3-fdb4-46f7-a440-4ced76ac301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a51eb4a3-fdb4-46f7-a440-4ced76ac301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dd24812b-5b72-4e39-b679-c82855bab977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a51eb4a3-fdb4-46f7-a440-4ced76ac301e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dd24812b-5b72-4e39-b679-c82855bab977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_216e47f1-5d1a-4cee-a206-ea120c3a80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a51eb4a3-fdb4-46f7-a440-4ced76ac301e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_216e47f1-5d1a-4cee-a206-ea120c3a80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b0ec2f71-1fde-413a-89a2-bcd9f82a17a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a51eb4a3-fdb4-46f7-a440-4ced76ac301e" xlink:to="loc_us-gaap_OperatingExpenses_b0ec2f71-1fde-413a-89a2-bcd9f82a17a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e5ef898f-ebe8-4cc6-b00a-5d725f9d9e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_OperatingIncomeLoss_e5ef898f-ebe8-4cc6-b00a-5d725f9d9e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_1dca7ec4-a999-4b4e-b76a-8f4913cbfa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_InterestIncomeOperating_1dca7ec4-a999-4b4e-b76a-8f4913cbfa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d9e2f454-6cf8-493d-85af-18a5c898cdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d9e2f454-6cf8-493d-85af-18a5c898cdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_47a7a95a-bea3-4504-af2e-5c3ce078cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_47a7a95a-bea3-4504-af2e-5c3ce078cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc85e65c-6759-46fc-8f08-cec12f08c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_NetIncomeLoss_bc85e65c-6759-46fc-8f08-cec12f08c62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9105fbd1-a08d-4560-bdaa-960adccb307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9105fbd1-a08d-4560-bdaa-960adccb307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9d835b74-6c0f-4f9d-973e-4ccdc1bec015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9d835b74-6c0f-4f9d-973e-4ccdc1bec015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_82de8b18-ae4e-41da-8f07-1998e3a30129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_EarningsPerShareBasic_82de8b18-ae4e-41da-8f07-1998e3a30129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7f8137b1-42c9-437f-8f02-f9fb670c7fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7f8137b1-42c9-437f-8f02-f9fb670c7fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e63293a9-d6c7-4e08-8460-ef9038a3680a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e63293a9-d6c7-4e08-8460-ef9038a3680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7633210b-c13e-4750-a37e-f8330b9069b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6da6101a-1e18-4767-93a7-82e3cf5d5899" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7633210b-c13e-4750-a37e-f8330b9069b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adc0fc0b-4b5b-4444-8607-e770f5dc4bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:to="loc_us-gaap_NetIncomeLoss_adc0fc0b-4b5b-4444-8607-e770f5dc4bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e443a9a6-d8c0-4a55-9a05-077901dad0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e443a9a6-d8c0-4a55-9a05-077901dad0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_451aa1c4-cdce-4cc4-8b67-17d5da892f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e443a9a6-d8c0-4a55-9a05-077901dad0d0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_451aa1c4-cdce-4cc4-8b67-17d5da892f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bfff6a1e-bb52-4305-a08b-45c2826d6ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bfff6a1e-bb52-4305-a08b-45c2826d6ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_19db01cd-237e-48e3-9404-026fae4d1fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_19db01cd-237e-48e3-9404-026fae4d1fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_bcafecaf-278e-47da-bded-b6f7cdcfe3f9" xlink:href="crdf-20230331.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e55a3f0d-d18d-427b-9fe6-352407e42831" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_bcafecaf-278e-47da-bded-b6f7cdcfe3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f640123d-6c63-43ae-894e-edcd60673206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f640123d-6c63-43ae-894e-edcd60673206" xlink:to="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68b87a1a-3862-4561-aa9b-d9d77fca48be" xlink:to="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dba326b8-244f-466a-935a-5b0693190a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_PreferredStockMember_dba326b8-244f-466a-935a-5b0693190a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a68ac851-90f6-46a7-af2e-b58af6a4760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_CommonStockMember_a68ac851-90f6-46a7-af2e-b58af6a4760e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c1376521-fad1-4e41-aac7-3fb3d4113426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c1376521-fad1-4e41-aac7-3fb3d4113426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_690e569a-06df-427f-bbb6-0a969e024b2d" xlink:href="crdf-20230331.xsd#crdf_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_crdf_ServiceReceivableMember_690e569a-06df-427f-bbb6-0a969e024b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea9694eb-dd2b-4740-ab68-a8d448094532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea9694eb-dd2b-4740-ab68-a8d448094532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb45cc83-ffaa-4026-92fe-31be58817e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ac125bd-5880-4e55-a604-c133f238d55f" xlink:to="loc_us-gaap_RetainedEarningsMember_cb45cc83-ffaa-4026-92fe-31be58817e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f4f9558-7de7-4c88-92be-36cf68e17b4a" xlink:to="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85c26685-d11f-4c62-811c-88d486f77a17" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cfa35020-3f71-403e-a707-0a6d7eac27e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_SharesIssued_cfa35020-3f71-403e-a707-0a6d7eac27e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1018cb9-5434-449e-aacc-db816de77f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockholdersEquity_a1018cb9-5434-449e-aacc-db816de77f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c532371f-fd8d-4198-b205-d6bb63850fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c532371f-fd8d-4198-b205-d6bb63850fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9da507a-2857-4c56-b83a-8ff1f80302f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9da507a-2857-4c56-b83a-8ff1f80302f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e9508884-ea66-4a19-a2d0-e6f91613b8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e9508884-ea66-4a19-a2d0-e6f91613b8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ad696adf-efb4-44ef-a6c9-9f95f40d707c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ad696adf-efb4-44ef-a6c9-9f95f40d707c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_018e5be6-5916-4c86-b3fd-f5e4c0ecabac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_DividendsPreferredStock_018e5be6-5916-4c86-b3fd-f5e4c0ecabac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_30947f21-30d2-46a0-986e-f20d48867509" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_30947f21-30d2-46a0-986e-f20d48867509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_923bc910-057e-46b8-b66b-3197a6a1b0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_NetIncomeLoss_923bc910-057e-46b8-b66b-3197a6a1b0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ac867dd3-35b2-4d0a-8208-3dee677a0d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_SharesIssued_ac867dd3-35b2-4d0a-8208-3dee677a0d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9953ffb-6e9b-4b89-99aa-68a07b943d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f396b5c-eda2-44c6-890c-f1f29bbefdcb" xlink:to="loc_us-gaap_StockholdersEquity_d9953ffb-6e9b-4b89-99aa-68a07b943d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_73c8e77d-c708-4774-8f13-390b296fb6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_73c8e77d-c708-4774-8f13-390b296fb6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1863b4d7-4750-49db-bb99-27a16b94aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_73c8e77d-c708-4774-8f13-390b296fb6f4" xlink:to="loc_us-gaap_NetIncomeLoss_1863b4d7-4750-49db-bb99-27a16b94aba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_73c8e77d-c708-4774-8f13-390b296fb6f4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5c67bc14-250f-40be-b407-e012ddb06e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5c67bc14-250f-40be-b407-e012ddb06e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_785b98df-4b78-4919-8514-38c4ef52532c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:to="loc_us-gaap_ShareBasedCompensation_785b98df-4b78-4919-8514-38c4ef52532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b40bb3bd-f43a-40c8-9002-7ccfb9641855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b40bb3bd-f43a-40c8-9002-7ccfb9641855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_351c6831-8aeb-43a8-9b55-4dc166d1e8ac" xlink:href="crdf-20230331.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_351c6831-8aeb-43a8-9b55-4dc166d1e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_54789c2d-4e78-4376-b482-a6c33b1f586f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_00dbd6ca-8ae8-49af-8bf4-b1a97b822c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_00dbd6ca-8ae8-49af-8bf4-b1a97b822c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8c6161e8-fe22-49a5-996d-d5055f891e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8c6161e8-fe22-49a5-996d-d5055f891e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_798a38e1-f7b1-4e53-8efe-bc6299cbb3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_798a38e1-f7b1-4e53-8efe-bc6299cbb3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_eeac8fc0-4794-4944-9163-aba1c46c96b0" xlink:href="crdf-20230331.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_eeac8fc0-4794-4944-9163-aba1c46c96b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c3d39d66-69be-4e73-aac9-79416c5c9bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c3d39d66-69be-4e73-aac9-79416c5c9bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_507f8b7d-5638-421c-b217-17257dfeb58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_507f8b7d-5638-421c-b217-17257dfeb58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21c87231-fec5-401f-926d-33a5131481bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f08a8a2e-a763-49d4-b507-c66c5731c883" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21c87231-fec5-401f-926d-33a5131481bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34596446-b397-41fe-b2e4-a7121b04698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_73c8e77d-c708-4774-8f13-390b296fb6f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34596446-b397-41fe-b2e4-a7121b04698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a11eab19-2fee-4bee-980e-39c85614f3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a11eab19-2fee-4bee-980e-39c85614f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_681ae49e-f41b-47ce-a2f9-19187a77f3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_681ae49e-f41b-47ce-a2f9-19187a77f3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_781fba25-80c6-4777-963e-4bc357697dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_781fba25-80c6-4777-963e-4bc357697dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_39e2958d-36e0-46f5-a80c-8061df0ec7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_39e2958d-36e0-46f5-a80c-8061df0ec7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5dfd1c60-e78e-4983-be67-7d443091a243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3887ed5e-de17-4aae-860d-54edfc71fe01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5dfd1c60-e78e-4983-be67-7d443091a243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_269d913e-2d33-4ce6-ae14-43e34a363497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_269d913e-2d33-4ce6-ae14-43e34a363497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b95752d-a9e7-46dd-8f3c-5554d663c3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_269d913e-2d33-4ce6-ae14-43e34a363497" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b95752d-a9e7-46dd-8f3c-5554d663c3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9d981dd-c6aa-4d08-a219-1d71c0ed1486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9d981dd-c6aa-4d08-a219-1d71c0ed1486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3a04878-55ba-4bd7-971a-b50595ca75ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f3a04878-55ba-4bd7-971a-b50595ca75ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e525780b-0e23-4622-8e9d-85fb4e62f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e525780b-0e23-4622-8e9d-85fb4e62f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_340523b8-0434-4059-87ea-70b1f9c46c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_340523b8-0434-4059-87ea-70b1f9c46c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a7116238-b011-4ea3-ac12-e991e3ee10a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_340523b8-0434-4059-87ea-70b1f9c46c99" xlink:to="loc_us-gaap_IncomeTaxesPaid_a7116238-b011-4ea3-ac12-e991e3ee10a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bfabd07c-f554-4685-8b40-9ffd3605bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_107444e1-9fc9-4808-9387-86d494b2b4bc" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bfabd07c-f554-4685-8b40-9ffd3605bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5e240dbe-d1af-4c02-bb43-c128cbe1ef67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bfabd07c-f554-4685-8b40-9ffd3605bbd5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5e240dbe-d1af-4c02-bb43-c128cbe1ef67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20230331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8135d575-b363-42e9-bf23-f49f812ae456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d5b26572-d1d7-4c65-afa9-f692404c5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8135d575-b363-42e9-bf23-f49f812ae456" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d5b26572-d1d7-4c65-afa9-f692404c5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ffe6066-7033-404f-8873-0f3967d86319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8eeb5e86-ecfb-4349-94e9-087f5ac5a58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ffe6066-7033-404f-8873-0f3967d86319" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8eeb5e86-ecfb-4349-94e9-087f5ac5a58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85a1aa9b-529d-44d5-8677-d39821f98d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e7e9a494-7bfe-44f1-a1e5-f642ea52e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85a1aa9b-529d-44d5-8677-d39821f98d0e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e7e9a494-7bfe-44f1-a1e5-f642ea52e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3c6f69fc-075f-4b79-a739-7e3a5bee3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e533523f-90d4-4e29-8173-38d06033cd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3c6f69fc-075f-4b79-a739-7e3a5bee3f75" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e533523f-90d4-4e29-8173-38d06033cd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ca9bc5de-4a20-4e61-9110-a3d5479fcdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_19232dae-f72b-4317-bfc9-1ffcbf3a152d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9bc5de-4a20-4e61-9110-a3d5479fcdf2" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_19232dae-f72b-4317-bfc9-1ffcbf3a152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8ec8823f-3eb2-4a29-9220-1463c46c6413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9bc5de-4a20-4e61-9110-a3d5479fcdf2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8ec8823f-3eb2-4a29-9220-1463c46c6413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ca58de30-9163-4915-90e8-ccc3eab00ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fd94385d-b88f-493f-914b-e2a41536c0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ca58de30-9163-4915-90e8-ccc3eab00ff9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fd94385d-b88f-493f-914b-e2a41536c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_95523995-7953-4a00-829a-b748e183c383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5e770c31-1cc9-43eb-aeb9-3f1df13c8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_95523995-7953-4a00-829a-b748e183c383" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5e770c31-1cc9-43eb-aeb9-3f1df13c8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_748f7aa0-0138-4b55-9d80-6821dce275f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4167624-deb7-4cd3-ae75-cdbc353422f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_748f7aa0-0138-4b55-9d80-6821dce275f7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4167624-deb7-4cd3-ae75-cdbc353422f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d407d35b-0e5e-4578-8e6f-787038d35b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_748f7aa0-0138-4b55-9d80-6821dce275f7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d407d35b-0e5e-4578-8e6f-787038d35b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04c03459-3c2a-4bcc-858f-99455b1d47c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9af49f84-da12-4db0-a8f3-387f6fc30b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04c03459-3c2a-4bcc-858f-99455b1d47c0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9af49f84-da12-4db0-a8f3-387f6fc30b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71107778-80d6-40bf-aaf4-cb695b3edc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a5e7fe4f-1c4a-4287-9ac9-a1a14d258c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71107778-80d6-40bf-aaf4-cb695b3edc1c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a5e7fe4f-1c4a-4287-9ac9-a1a14d258c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aedcae3d-20c5-4684-8916-4d217cdb824b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d83cbaa4-a992-44fc-9c74-a795c6e10eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aedcae3d-20c5-4684-8916-4d217cdb824b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d83cbaa4-a992-44fc-9c74-a795c6e10eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b091cf2d-fbe3-431c-bc5a-920a4b525d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aedcae3d-20c5-4684-8916-4d217cdb824b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b091cf2d-fbe3-431c-bc5a-920a4b525d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_af0deff5-a9da-43fe-a3c5-eda053bc16d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aedcae3d-20c5-4684-8916-4d217cdb824b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_af0deff5-a9da-43fe-a3c5-eda053bc16d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b855ea8c-f4bc-4ae5-8f25-35b4986642e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aedcae3d-20c5-4684-8916-4d217cdb824b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b855ea8c-f4bc-4ae5-8f25-35b4986642e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa823094-48a9-460b-a027-e15f10ba7bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_dbfc13b9-4d41-4ae1-a910-a6bce82183a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa823094-48a9-460b-a027-e15f10ba7bfc" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_dbfc13b9-4d41-4ae1-a910-a6bce82183a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_5d4f1d00-a53f-4de1-878d-6d94603a5f79" xlink:href="crdf-20230331.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa823094-48a9-460b-a027-e15f10ba7bfc" xlink:to="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_5d4f1d00-a53f-4de1-878d-6d94603a5f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0c242f7d-32f4-4c58-9c46-327d611a1c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa823094-48a9-460b-a027-e15f10ba7bfc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0c242f7d-32f4-4c58-9c46-327d611a1c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1b18d3af-57f1-44b6-b278-27231104d117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1b18d3af-57f1-44b6-b278-27231104d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_563faac1-8e8e-4625-8b53-5056d44ead89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_563faac1-8e8e-4625-8b53-5056d44ead89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_be7203da-8093-4d81-b9a9-121e6a74eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_be7203da-8093-4d81-b9a9-121e6a74eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d9f0f649-d423-4528-b0f2-137df7635e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d9f0f649-d423-4528-b0f2-137df7635e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_75b2a9e6-499c-43be-bc4f-fc438b2463dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8bfe8954-bbce-49b2-846a-e8a1f7814daa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_75b2a9e6-499c-43be-bc4f-fc438b2463dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279148ca-9455-41b9-acea-4abba3781b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b12850f4-1846-4f75-8d48-266c18bc6a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279148ca-9455-41b9-acea-4abba3781b2d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b12850f4-1846-4f75-8d48-266c18bc6a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43fdee00-8a45-4c62-ab00-70c584cb986a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43fdee00-8a45-4c62-ab00-70c584cb986a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aee33c7f-f0e0-4004-a8a9-6e25e1447401" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13658b0a-302f-4b8b-9bfb-7f8fe0a387b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13658b0a-302f-4b8b-9bfb-7f8fe0a387b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6973a861-7398-4424-86d8-a9d87b40ba4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_WarrantMember_6973a861-7398-4424-86d8-a9d87b40ba4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0856683e-22ce-48fc-b87e-14fa5188252b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0856683e-22ce-48fc-b87e-14fa5188252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_21923ace-9f2a-4a4e-b58d-b5728048fb85" xlink:href="crdf-20230331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3bc91ba9-3d93-46a3-9534-972eb59a0ae2" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_21923ace-9f2a-4a4e-b58d-b5728048fb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a7c02685-6de5-4763-a28a-275328835a10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2982e699-4af0-489e-8958-64216185639a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d4d91220-4d5c-4c38-bf68-193f2491bbe2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2982e699-4af0-489e-8958-64216185639a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6cf25eb9-a45d-4cea-8588-cfda697b7dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6cf25eb9-a45d-4cea-8588-cfda697b7dfd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_76c4d385-2db7-435a-9df8-d50a57f3b20e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4abd8428-4a1d-46db-ba9a-4ecd2d232d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2861ae84-33b2-4984-9c31-25bb118009a5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4abd8428-4a1d-46db-ba9a-4ecd2d232d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_468b363b-75fd-49f8-bac6-27d8ffc69a02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86607b06-fd10-4a49-ac7e-3851003d7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86607b06-fd10-4a49-ac7e-3851003d7aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1114756c-3ed1-4946-a7d0-585caed4474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1114756c-3ed1-4946-a7d0-585caed4474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_af2ce38f-48c5-4256-beb1-6b75529343cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8304b474-c51f-444c-9113-0e6a32944681" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_af2ce38f-48c5-4256-beb1-6b75529343cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fb607e42-e7aa-47ad-b44f-9e5136fafce7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0eb4a0a-082b-4898-bedb-4b6c80647eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0eb4a0a-082b-4898-bedb-4b6c80647eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3a300441-9186-41b6-bdd6-6f069c4adba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f1647995-89c0-48fa-abe3-31de78e85d54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3a300441-9186-41b6-bdd6-6f069c4adba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3cf7d0-1585-454e-8389-5afd9d68574b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f53c1c96-5ca6-448d-b8cb-7fd955112cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f53c1c96-5ca6-448d-b8cb-7fd955112cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fe400b2a-949c-40eb-8bd7-70c98d7448bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fe400b2a-949c-40eb-8bd7-70c98d7448bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03724835-5747-4452-ab7b-54808e695adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_CommercialPaperMember_03724835-5747-4452-ab7b-54808e695adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_262b9eba-fc49-43a0-8516-c7de5b4c4aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_262b9eba-fc49-43a0-8516-c7de5b4c4aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c75bddc8-23c1-4e9e-80d5-6b468a1738a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd47003d-122b-4d84-a40a-05698d8fedff" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c75bddc8-23c1-4e9e-80d5-6b468a1738a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1d4f6ee4-c6b4-4a41-9e00-e2c9223dd6ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f4a471e-f3a9-4171-96b3-93a63ade20c2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_849b3214-618d-434d-8c51-4808e26bcdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_849b3214-618d-434d-8c51-4808e26bcdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_050366e7-4b1d-44dd-82d0-b4112ff6897d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_050366e7-4b1d-44dd-82d0-b4112ff6897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_da3185b8-62d1-4d50-a5f9-9eadeaa6b897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d8b0ee69-6c0d-4b71-876a-2e687c6e023e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_da3185b8-62d1-4d50-a5f9-9eadeaa6b897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a1455f5-df29-4f52-b9bd-7b37c618e6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a1455f5-df29-4f52-b9bd-7b37c618e6a1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ef6f560a-bb28-4037-9d03-cc098f9b4824" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_051d5fc3-b47f-434b-b839-b33f28bfb5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CertificatesOfDepositMember_051d5fc3-b47f-434b-b839-b33f28bfb5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_67f16639-d4c8-4a0d-ac53-a7166e98d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_67f16639-d4c8-4a0d-ac53-a7166e98d8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1b748f3e-c5d1-4f8d-a7af-b7de8dd60b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_CommercialPaperMember_1b748f3e-c5d1-4f8d-a7af-b7de8dd60b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c203c27e-eb3d-42da-99e5-83e32d9a10fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c203c27e-eb3d-42da-99e5-83e32d9a10fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_02722de2-95df-44d1-b471-95c10b18ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_02722de2-95df-44d1-b471-95c10b18ef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5c4ab5ae-449f-4ddc-a9ec-6886ca83bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c259912-0062-4515-9ed5-9d4ec7e1bd81" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5c4ab5ae-449f-4ddc-a9ec-6886ca83bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5d0d84d0-ab72-4d38-aa46-adeb75b31ba1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8c6498fc-55d9-4fce-8764-64bfcafb5805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8c6498fc-55d9-4fce-8764-64bfcafb5805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_582452a0-1265-45a3-93b9-e5cd6fc7f924" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_582452a0-1265-45a3-93b9-e5cd6fc7f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e886f0e9-a9b7-493d-873a-810e58df6f0f" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_e886f0e9-a9b7-493d-873a-810e58df6f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8fe5ceba-8ef0-4550-98f9-a6a87757b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_54ad436e-a8aa-4518-bdc0-873e2318ec10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8fe5ceba-8ef0-4550-98f9-a6a87757b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_4f832528-a059-41e6-9c75-970f81b86b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_4f832528-a059-41e6-9c75-970f81b86b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d544bb04-1809-4fa0-b841-78de04dea205" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_d544bb04-1809-4fa0-b841-78de04dea205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_080701ac-00d8-4f87-b019-a8298acca15d" xlink:href="crdf-20230331.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_080701ac-00d8-4f87-b019-a8298acca15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_673d657f-a3ff-48a3-81bc-c87feecf152b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract_e5ecdd9b-4059-487f-883b-f2af191cd0cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_673d657f-a3ff-48a3-81bc-c87feecf152b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58c463a4-afaf-4a84-a2b1-eb1e8de528ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58c463a4-afaf-4a84-a2b1-eb1e8de528ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3ef92f25-9b51-4902-b0f9-16bcefdddb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3ef92f25-9b51-4902-b0f9-16bcefdddb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d797a179-a6e8-458a-a7ad-dd1bd43ee780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d797a179-a6e8-458a-a7ad-dd1bd43ee780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c570accd-0da0-4d8f-90e6-24f37c98f1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_44e1acc7-b250-43af-9e99-efa1e303e00b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c570accd-0da0-4d8f-90e6-24f37c98f1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e60cf8a2-3b94-44a7-a609-99afee32c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e60cf8a2-3b94-44a7-a609-99afee32c07a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1bd3d2c1-209d-4fdc-9957-66fc9ffcf225" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b042c72f-c3d9-45e2-ba2b-6a7f991cb38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b042c72f-c3d9-45e2-ba2b-6a7f991cb38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b17030a5-8bdf-45ff-b3b0-4bfde00da5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74699fe1-b512-41a4-b35e-a2ff0652b1dc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b17030a5-8bdf-45ff-b3b0-4bfde00da5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_69e02b25-e62a-4bda-b5b0-3c4469e8b519" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_728d1f8f-1b47-42ec-b0c8-dc0c312a82fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_728d1f8f-1b47-42ec-b0c8-dc0c312a82fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_84334903-0f13-431e-b2f7-2fc9d750be6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3ee191d-c1ff-4908-9ada-4b7798407151" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_84334903-0f13-431e-b2f7-2fc9d750be6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b8131d0-3725-4404-970d-51c4a0a1d138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b8131d0-3725-4404-970d-51c4a0a1d138" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08bd21cd-08bc-4449-993a-1432046d0757" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_c0cadd2e-e67f-431c-8ec1-3d705f1e67c9" xlink:href="crdf-20230331.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_c0cadd2e-e67f-431c-8ec1-3d705f1e67c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0336eb3b-c924-4991-9b13-0abc5e9f8c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0336eb3b-c924-4991-9b13-0abc5e9f8c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_cc643692-9965-4404-b7a2-b1b4767bbc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_36f9195c-00c8-49ce-8a67-94581eb565d6" xlink:to="loc_us-gaap_EquipmentMember_cc643692-9965-4404-b7a2-b1b4767bbc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7601902f-2fa8-4074-a5fc-cc25eb52e371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f282fe96-69a4-4fb7-a427-a272b2fc620d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f282fe96-69a4-4fb7-a427-a272b2fc620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffa1667d-a4df-42ec-a0ce-fca9c56bac85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffa1667d-a4df-42ec-a0ce-fca9c56bac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_be540059-095f-4714-9dca-0c0801d81857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_797f11ce-768a-40a6-8e94-deb6f63f916d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_be540059-095f-4714-9dca-0c0801d81857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d3239b25-37a7-4c66-bbe1-71a59b91b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d3239b25-37a7-4c66-bbe1-71a59b91b6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_e38583fb-470d-4f4b-aedf-aef9c54196b5" xlink:href="crdf-20230331.xsd#crdf_AccruedClinicalTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_crdf_AccruedClinicalTrial_e38583fb-470d-4f4b-aedf-aef9c54196b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedResearchAgreements_28c60e20-982f-431b-aa88-fce206cc0509" xlink:href="crdf-20230331.xsd#crdf_AccruedResearchAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_crdf_AccruedResearchAgreements_28c60e20-982f-431b-aa88-fce206cc0509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedDirectorFees_e5443865-fd2f-4dff-a541-9714673e3858" xlink:href="crdf-20230331.xsd#crdf_AccruedDirectorFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_crdf_AccruedDirectorFees_e5443865-fd2f-4dff-a541-9714673e3858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PatentLicenseAndOtherFeesPayable_689e4e6c-4ffa-4e6d-873e-f431687cf8f9" xlink:href="crdf-20230331.xsd#crdf_PatentLicenseAndOtherFeesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_crdf_PatentLicenseAndOtherFeesPayable_689e4e6c-4ffa-4e6d-873e-f431687cf8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b79bb8bb-d7b2-4f14-9507-3cbd7d03edb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b79bb8bb-d7b2-4f14-9507-3cbd7d03edb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_25334a9f-a0dd-453c-a9c9-c3850f749fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613d9b93-bdcb-4e90-b6c5-dd82cebb2ae4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_25334a9f-a0dd-453c-a9c9-c3850f749fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f6d55477-1927-4695-97f9-98a02272fc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_8c3fe131-4d29-4dd1-82a8-f19772e864a4" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6d55477-1927-4695-97f9-98a02272fc4c" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_8c3fe131-4d29-4dd1-82a8-f19772e864a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_fad0d9cd-5d23-4605-ba05-bab233f01301" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6d55477-1927-4695-97f9-98a02272fc4c" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_fad0d9cd-5d23-4605-ba05-bab233f01301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f54cf1d4-fb53-4155-b066-018b8fcb7086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5c40db69-d078-4090-855e-d4fff96b88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f54cf1d4-fb53-4155-b066-018b8fcb7086" xlink:to="loc_us-gaap_OperatingLeaseCost_5c40db69-d078-4090-855e-d4fff96b88c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_699192b4-ea26-4f38-908e-c5fd20975491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f54cf1d4-fb53-4155-b066-018b8fcb7086" xlink:to="loc_us-gaap_LeaseCost_699192b4-ea26-4f38-908e-c5fd20975491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_567c6494-a4ca-4f2e-b993-c4e9f09b356d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_567c6494-a4ca-4f2e-b993-c4e9f09b356d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c572c69-5ed8-40e7-921a-2e7497b8fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c572c69-5ed8-40e7-921a-2e7497b8fda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_80412a31-0012-4fd7-acf3-8a4a33c5fcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_80412a31-0012-4fd7-acf3-8a4a33c5fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_487bd109-d2d4-44bd-8eed-5777bdbbf4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseLiability_487bd109-d2d4-44bd-8eed-5777bdbbf4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0573c9dd-5072-4cbb-96a4-552a61bb9d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0573c9dd-5072-4cbb-96a4-552a61bb9d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ca51a06c-4ccd-49a9-8bd0-0ca062394873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afd645da-f3af-4712-a868-9acd9d206973" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ca51a06c-4ccd-49a9-8bd0-0ca062394873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_78126074-fc07-43fe-ab6b-d51b59f4e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_df375103-6393-4661-b0b9-7eb576278b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_78126074-fc07-43fe-ab6b-d51b59f4e51b" xlink:to="loc_us-gaap_OperatingLeasePayments_df375103-6393-4661-b0b9-7eb576278b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d61070aa-e5d3-4d09-b55f-0d5978e93cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d61070aa-e5d3-4d09-b55f-0d5978e93cab" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1ee86ca8-d46f-4f67-9e2a-eda7e2f5ab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1ee86ca8-d46f-4f67-9e2a-eda7e2f5ab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_32566c46-ac89-4054-b4b3-df94a7b310d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_32566c46-ac89-4054-b4b3-df94a7b310d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ce1938f-f899-4ee6-87bd-cc9b0c18f005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ce1938f-f899-4ee6-87bd-cc9b0c18f005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2b3a478b-25c8-4ff9-9f24-eebe3c33b0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2b3a478b-25c8-4ff9-9f24-eebe3c33b0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4d79f0b8-c35c-4f79-856e-e15b9ab45f8f" xlink:href="crdf-20230331.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4d79f0b8-c35c-4f79-856e-e15b9ab45f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f041949b-e819-46d2-86a2-a90cdbfdf07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f041949b-e819-46d2-86a2-a90cdbfdf07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_56ab2b83-cd10-42ff-a6b5-ced51c28e8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_56ab2b83-cd10-42ff-a6b5-ced51c28e8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a355ab68-1d9f-44d1-ae55-73519b42a77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_88192e16-99c7-4ab3-9776-7c4601ebd196" xlink:to="loc_us-gaap_OperatingLeaseLiability_a355ab68-1d9f-44d1-ae55-73519b42a77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20230331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c7d64de7-2888-4826-a5e1-8f42c13d1ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c7d64de7-2888-4826-a5e1-8f42c13d1ae0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:to="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f980ee22-f359-4701-9471-c2b3b605e643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ba30a080-8eda-4f00-836d-b82f09f1dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09239fd4-1765-4c99-b25c-1750a5a1ba0c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ba30a080-8eda-4f00-836d-b82f09f1dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d66ad72-11be-4345-8e8c-60d853de103b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8f2b5a17-08b2-4aed-bdf5-4a5b39fb6358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8f2b5a17-08b2-4aed-bdf5-4a5b39fb6358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5bb4c3b4-fe78-447e-8c8b-9f8efd4fb698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2ce9832-ffdb-4081-aa60-e714122cff72" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5bb4c3b4-fe78-447e-8c8b-9f8efd4fb698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_547f6e23-21a7-459e-a319-e833ed77ac1f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0596516-2ce2-4b42-bfd7-6e44fb321fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0596516-2ce2-4b42-bfd7-6e44fb321fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_725eedd3-5d16-4453-a544-e48e56b42d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_725eedd3-5d16-4453-a544-e48e56b42d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_761f5f9b-7622-48e0-b9c5-86a3ee435b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_761f5f9b-7622-48e0-b9c5-86a3ee435b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d77316b9-c9da-4a72-bf40-d83e5b81b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d77316b9-c9da-4a72-bf40-d83e5b81b15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1fa3115a-93d4-486f-9a58-5356f4271c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a540b336-ed14-4417-bfae-9513cefa7ac6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1fa3115a-93d4-486f-9a58-5356f4271c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_034bd1c8-ed87-4023-8c44-317c63ab9401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_034bd1c8-ed87-4023-8c44-317c63ab9401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:to="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_562b8938-b023-4dbd-8a08-2c6577420c5a" xlink:to="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_98f903d4-b04c-4a51-91c1-e11a53042c21" xlink:href="crdf-20230331.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_482b013a-7eb9-4fa1-a613-a88a0510600c" xlink:to="loc_crdf_EquityIncentivePlan2021Member_98f903d4-b04c-4a51-91c1-e11a53042c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:to="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_540f6f3a-c563-45c5-9101-d2cda9d4f2d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_088db178-500f-40a3-a40e-1362720ddcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:to="loc_us-gaap_EmployeeStockOptionMember_088db178-500f-40a3-a40e-1362720ddcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_e41759ac-9eab-4445-94c2-3c7de0f319bb" xlink:href="crdf-20230331.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c524f41-aecc-431e-b11c-01f8e4cfd929" xlink:to="loc_crdf_InducementGrantStockOptionsMember_e41759ac-9eab-4445-94c2-3c7de0f319bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8d67a7c-1737-4538-983c-476f513038e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ee6d98b-ee0d-4b4b-b6e3-6506bd6af580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ee6d98b-ee0d-4b4b-b6e3-6506bd6af580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8211af3-352a-487b-852c-960eff241592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d8211af3-352a-487b-852c-960eff241592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86dc9494-4db5-4909-9ad3-4e1478145dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86dc9494-4db5-4909-9ad3-4e1478145dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca5592ba-e653-4902-9d5e-f1c751ed336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26b05b2d-3d1a-48af-b336-cc6312c3e25c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca5592ba-e653-4902-9d5e-f1c751ed336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_937ceaf2-c6ee-41c6-9048-29843b376134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_937ceaf2-c6ee-41c6-9048-29843b376134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab0aae39-5bce-4073-867c-9bbfcef998de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab0aae39-5bce-4073-867c-9bbfcef998de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b9ef060-2dd3-4a0d-86e9-5ebbc3bebc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b9ef060-2dd3-4a0d-86e9-5ebbc3bebc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_283e8836-1a0f-445a-a618-dbd2f24f7908" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_283e8836-1a0f-445a-a618-dbd2f24f7908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47afb1b6-e37d-4bbe-b54b-04c708753982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_04f459b3-4626-4e34-980b-0c87bb57a38f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47afb1b6-e37d-4bbe-b54b-04c708753982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c14b31fc-9106-4003-86f8-17e7edd566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c14b31fc-9106-4003-86f8-17e7edd566fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_43cf9b4d-3abb-4267-98cb-0c03073fb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_43cf9b4d-3abb-4267-98cb-0c03073fb3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d188501-27c3-4f86-915c-129af1800d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d188501-27c3-4f86-915c-129af1800d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_652b3997-6279-4c60-bde0-052019681c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_652b3997-6279-4c60-bde0-052019681c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4170bcd8-659b-4d35-8ec2-e82f9c9d0124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4170bcd8-659b-4d35-8ec2-e82f9c9d0124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_75e4dc7e-1912-4a44-9c4e-af4553411a15" xlink:href="crdf-20230331.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_75e4dc7e-1912-4a44-9c4e-af4553411a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb96ebea-c268-41b5-99f2-21a18dd87a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d68514c2-d650-4919-8c98-89db6ad8f879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb96ebea-c268-41b5-99f2-21a18dd87a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_400484b6-f34f-41fe-883e-bb966e0819bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_400484b6-f34f-41fe-883e-bb966e0819bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_48f45e12-5999-40b1-b5fc-ae23052ea24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_48f45e12-5999-40b1-b5fc-ae23052ea24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2824940b-0a12-4650-8567-eafb3fbb2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2824940b-0a12-4650-8567-eafb3fbb2bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_769f153b-af32-4f2a-bab1-0e654231ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_769f153b-af32-4f2a-bab1-0e654231ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_08eb517d-f022-4b94-8487-243ae0ea7ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_59e8e7a3-d103-4cb0-bb5a-8c7d3c3f90f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_08eb517d-f022-4b94-8487-243ae0ea7ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_105e7778-f47e-452a-9bd1-9b8f04877a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_105e7778-f47e-452a-9bd1-9b8f04877a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9d66adcd-72a6-451e-892e-31b06a21f152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a69e06f-fab6-4379-b5e8-a1f680ccc434" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9d66adcd-72a6-451e-892e-31b06a21f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cf11aa97-910b-44f8-a791-65e41c060fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_e5c33f97-e6cc-48b6-be10-6c08b33ee553" xlink:href="crdf-20230331.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cf11aa97-910b-44f8-a791-65e41c060fe2" xlink:to="loc_crdf_WarrantsAndRightsRollForward_e5c33f97-e6cc-48b6-be10-6c08b33ee553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0231506d-d62b-4e84-8447-d1198dba582d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_e5c33f97-e6cc-48b6-be10-6c08b33ee553" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0231506d-d62b-4e84-8447-d1198dba582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpiredDuringPeriod_561637d4-0d67-4f0c-9552-38c186d9205e" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightExpiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_e5c33f97-e6cc-48b6-be10-6c08b33ee553" xlink:to="loc_crdf_ClassOfWarrantOrRightExpiredDuringPeriod_561637d4-0d67-4f0c-9552-38c186d9205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb10cdeb-63be-41a6-9185-dc5e92f0d272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_e5c33f97-e6cc-48b6-be10-6c08b33ee553" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb10cdeb-63be-41a6-9185-dc5e92f0d272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_1535a840-49b0-457a-b5a9-3f0da1f5fc87" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cf11aa97-910b-44f8-a791-65e41c060fe2" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_1535a840-49b0-457a-b5a9-3f0da1f5fc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_18fd544c-f5ef-4c0d-b6f3-3c7e54b19f47" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_1535a840-49b0-457a-b5a9-3f0da1f5fc87" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_18fd544c-f5ef-4c0d-b6f3-3c7e54b19f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod_67ce9ecd-9f18-4a93-b131-d608872d5346" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_1535a840-49b0-457a-b5a9-3f0da1f5fc87" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod_67ce9ecd-9f18-4a93-b131-d608872d5346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e63eefac-6b60-407b-b9b9-b15043e81157" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_1535a840-49b0-457a-b5a9-3f0da1f5fc87" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e63eefac-6b60-407b-b9b9-b15043e81157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_1ce6a158-bd9e-4e62-adf9-f915545a835e" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cf11aa97-910b-44f8-a791-65e41c060fe2" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_1ce6a158-bd9e-4e62-adf9-f915545a835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_2fadf7cb-ce94-43a9-971a-251834751213" xlink:href="crdf-20230331.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_1ce6a158-bd9e-4e62-adf9-f915545a835e" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_2fadf7cb-ce94-43a9-971a-251834751213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f5c255a8-c01f-4a25-90cc-04827c54d7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f5c255a8-c01f-4a25-90cc-04827c54d7af" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8ff29bc6-91ca-4a87-8a96-6dea95e658a0" xlink:to="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_dca212cd-a668-44da-99ca-6901313e0937" xlink:href="crdf-20230331.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_dca212cd-a668-44da-99ca-6901313e0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_d762b6d6-6bb8-48d4-96f3-e55a0ff5faea" xlink:href="crdf-20230331.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_d762b6d6-6bb8-48d4-96f3-e55a0ff5faea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_2f8a2f78-cabb-46cf-ac54-6d7cc652fa2d" xlink:href="crdf-20230331.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_2f8a2f78-cabb-46cf-ac54-6d7cc652fa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_3016a0fc-f1b6-4648-9a37-69634d49e04f" xlink:href="crdf-20230331.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_3016a0fc-f1b6-4648-9a37-69634d49e04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_2a29035a-e7fc-4da9-b298-abcc600ddd75" xlink:href="crdf-20230331.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cf51d4ea-63be-48d6-85db-9cc8544001ee" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_2a29035a-e7fc-4da9-b298-abcc600ddd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3cd1e457-9049-4ef0-99fb-f2800b5c6d87" xlink:to="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54725a7a-f005-4cdf-8049-83a02fc5fe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54725a7a-f005-4cdf-8049-83a02fc5fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1e4d6cb5-44a6-4063-b8ab-4a9ddf98ed96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1e4d6cb5-44a6-4063-b8ab-4a9ddf98ed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_080384dc-415d-40d9-9e68-db87e51458a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_080384dc-415d-40d9-9e68-db87e51458a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_68d456ce-7717-499d-8d0a-a8c4cd5228b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e456224b-8d44-47f1-87db-3500ce795c9b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_68d456ce-7717-499d-8d0a-a8c4cd5228b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb7310f0-1fde-476a-97d8-68424ff51bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_32bf8eb1-08c6-4d5d-96e4-915ec2ceb276" xlink:href="crdf-20230331.xsd#crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb7310f0-1fde-476a-97d8-68424ff51bdd" xlink:to="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_32bf8eb1-08c6-4d5d-96e4-915ec2ceb276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830267034096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,677,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830264374720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,017<span></span>
</td>
<td class="nump">$ 16,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">81,951<span></span>
</td>
<td class="nump">88,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">5,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">101,753<span></span>
</td>
<td class="nump">111,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">106,549<span></span>
</td>
<td class="nump">116,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,914<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,555<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,148<span></span>
</td>
<td class="nump">7,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">9,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,050 and $1,044 at March&#160;31, 2023 and December&#160;31, 2022, respectively (Note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 44,677 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">405,898<span></span>
</td>
<td class="nump">404,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(309,323)<span></span>
</td>
<td class="num">(298,100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">96,503<span></span>
</td>
<td class="nump">106,343<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 106,549<span></span>
</td>
<td class="nump">$ 116,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266994848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,677,000<span></span>
</td>
<td class="nump">44,677,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,677,000<span></span>
</td>
<td class="nump">44,677,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266905424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">9,052<span></span>
</td>
<td class="nump">7,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,135<span></span>
</td>
<td class="nump">11,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,052)<span></span>
</td>
<td class="num">(11,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income, net</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,223)<span></span>
</td>
<td class="num">(10,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (11,229)<span></span>
</td>
<td class="num">$ (10,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">44,677<span></span>
</td>
<td class="nump">43,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">44,677<span></span>
</td>
<td class="nump">43,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266443040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,223)<span></span>
</td>
<td class="num">$ (10,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on securities available-for-sale</a></td>
<td class="nump">319<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(10,904)<span></span>
</td>
<td class="num">(11,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (10,910)<span></span>
</td>
<td class="num">$ (11,605)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Available To Common Stockholders, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830265314464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">41,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 140,417<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 400,503<span></span>
</td>
<td class="num">$ (139)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
<td class="num">$ (259,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,993)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">43,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2022</a></td>
<td class="nump">130,102<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">401,655<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(748)<span></span>
</td>
<td class="num">(270,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">44,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2022</a></td>
<td class="nump">106,343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">404,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(395)<span></span>
</td>
<td class="num">(298,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">44,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2023</a></td>
<td class="nump">$ 96,503<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 405,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (309,323)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830261391744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,223)<span></span>
</td>
<td class="num">$ (10,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (discounts) on short-term investments</a></td>
<td class="num">(163)<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,659)<span></span>
</td>
<td class="num">(10,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">42,983<span></span>
</td>
<td class="nump">38,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(37,327)<span></span>
</td>
<td class="num">(36,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of short-term investments</a></td>
<td class="nump">1,681<span></span>
</td>
<td class="nump">17,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">7,329<span></span>
</td>
<td class="nump">18,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,330)<span></span>
</td>
<td class="nump">8,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">16,347<span></span>
</td>
<td class="nump">11,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">15,017<span></span>
</td>
<td class="nump">20,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment For Services Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830271436608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard-of-care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard-of-care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2022, has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2022, included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on March&#160;2, 2023.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2023, the Company had $97.0&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div>For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830271565952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,694,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures, and will adopt this standard on January 1, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269993744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2023, and December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Included in short-term investments in the accompanying balance sheets. </span></div>The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269749344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Supplementary Balance Sheet Information</a></td>
<td class="text">Supplementary Balance Sheet Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments available for sale</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,520&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses in investments available for sale debt securities at March&#160;31, 2023, were substantially due to increases in interest rates, not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830270075712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $61,000 per month with 3% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $61,000 per month with 3% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269911872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2023, net of estimated forfeitures, was $10.1 million, which is expected to be recognized over a weighted-average remaining vesting period of 2.7 years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2023, was approximately </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 years. The total fair value of stock options vested during the three months ended March 31, 2023 and 2022, were $1.9 million and $1,000, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The expected term for options granted after January 1, 2023 is estimated based on the Company's historical employee data. Prior to January 1, 2023, the Company used the "simplified method" to estimate expected term. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427,304&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,187,656&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022, the shareholders approved an increase of shares authorized in the 2021 Plan to 5,150,000 from 3,150,000. As of March&#160;31, 2023, there were 2,180,898 shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2023, an aggregate of 1,345,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269747344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: (a) dosing of the first subject in the first Phase III Clinical Trial for the first Product, a registration enabling Phase II Clinical Trial, or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and (b) upon filing of the first NDA or equivalent for the first product candidate. During the three months ended March&#160;31, 2023 and 2022 no milestone or royalty payments were made. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2023 and 2022, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise </span></div>from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830270546944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures, and will adopt this standard on January 1, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830270502640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,694,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269782656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2023, and December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>(1) Included in short-term investments in the accompanying balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830265214624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments Available-for-sale</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,520&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Investments Available-for-sale in a Continuous Unrealized Loss Position</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830270587248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266462656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427,304&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,187,656&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830271484992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830261481920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">10,694,244<span></span>
</td>
<td class="nump">11,300,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">6,396,895<span></span>
</td>
<td class="nump">5,467,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">4,296,472<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series&#160;A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,342,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830261690576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">$ 81,951<span></span>
</td>
<td class="nump">$ 88,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">15,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">81,951<span></span>
</td>
<td class="nump">88,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">96,109<span></span>
</td>
<td class="nump">104,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">13,925<span></span>
</td>
<td class="nump">16,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">32,828<span></span>
</td>
<td class="nump">49,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">10,398<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">7,842<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">16,958<span></span>
</td>
<td class="nump">7,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">15,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">15,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">16,958<span></span>
</td>
<td class="nump">7,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">31,116<span></span>
</td>
<td class="nump">23,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">16,958<span></span>
</td>
<td class="nump">7,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">14,158<span></span>
</td>
<td class="nump">15,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">64,993<span></span>
</td>
<td class="nump">81,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">64,993<span></span>
</td>
<td class="nump">81,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">13,925<span></span>
</td>
<td class="nump">16,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">32,828<span></span>
</td>
<td class="nump">49,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">10,398<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">7,842<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830260831264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Investments Available-for-sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 50,673<span></span>
</td>
<td class="nump">$ 84,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">50,520<span></span>
</td>
<td class="nump">83,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">31,354<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">31,431<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">82,027<span></span>
</td>
<td class="nump">89,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">81,951<span></span>
</td>
<td class="nump">88,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">13,964<span></span>
</td>
<td class="nump">16,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">13,925<span></span>
</td>
<td class="nump">16,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">22,258<span></span>
</td>
<td class="nump">44,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">22,144<span></span>
</td>
<td class="nump">44,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">10,687<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">10,684<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">10,402<span></span>
</td>
<td class="nump">13,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">10,398<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">4,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">3,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">16,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">$ 16,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830264949984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details) - Corporate debt securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Market Value</a></td>
<td class="nump">$ 8,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">$ (58)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830265579648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,779<span></span>
</td>
<td class="nump">$ 4,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation and amortization</a></td>
<td class="num">(3,459)<span></span>
</td>
<td class="num">(3,413)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830260740048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 1,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedClinicalTrial', window );">Clinical trials</a></td>
<td class="nump">2,709<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedResearchAgreements', window );">Research agreements and services</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedDirectorFees', window );">Director fees</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PatentLicenseAndOtherFeesPayable', window );">Patent, license and other fees</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,555<span></span>
</td>
<td class="nump">$ 5,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued director fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PatentLicenseAndOtherFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent, license and other fees payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PatentLicenseAndOtherFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269763184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments</a></td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830267085296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830267116512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 2,115<span></span>
</td>
<td class="nump">$ 2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,577<span></span>
</td>
<td class="nump">$ 2,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830267031312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830267096304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31, 2023)</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">Thereafter</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,577<span></span>
</td>
<td class="nump">$ 2,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830261585472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 1,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested, fair value</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">$ 817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining vesting period for recognition</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830261258784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">106.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term(1)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">5,069,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,806,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(1,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(476,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the end of the period (in shares)</a></td>
<td class="nump">6,396,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">2,427,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">6,187,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled / Forfeited (in USD per share)</a></td>
<td class="nump">7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in USD per share)</a></td>
<td class="nump">6.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">$ 4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 34,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period, intrinsic value</a></td>
<td class="nump">20,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, intrinsic value</a></td>
<td class="nump">$ 33,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember', window );">Inducement Grant Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,345,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member', window );">Equity Incentive Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of remaining shares available for issuance (in shares)</a></td>
<td class="nump">2,180,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266930672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,296,472<span></span>
</td>
<td class="nump">4,360,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Expired (in shares)</a></td>
<td class="num">(64,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">4,360,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 5.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod', window );">Expired (in USD per share)</a></td>
<td class="nump">101.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in USD per share)</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 5.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights', window );">Weighted-Average Remaining&#160;Contractual Term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which each class of warrants or rights outstanding may be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price, Expired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830266905344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 1,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139830269765152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade', window );">Milestone and royalty payments made</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>crdf-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crdf-20230331.xsd" xlink:type="simple"/>
    <context id="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iffbad54a6e314ec7a91b4f82d14d8c58_I20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="id39cc1c335a2480bb994dbe1468e726e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i625cb66267e34938aa47627512641649_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i513f89ebc35b472384751be31e33c9f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad5f47b73dd845b2a15839bc67e13da2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f054b7c0fba4ca390235d3bcec938b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3499e99d669043a3a672f5cc7e2b80b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9369609104e54b8f8837281b23259c18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0c82f644f9548afad75b06a3b3e3078_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f6cd88fbdbf46e5b08b5efb099ce7cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaef2a38416fe413590b0a41deaabca5d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d580a3c0da44ca5948a74430fd58deb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c2ae96f6ece4865b96a161ff3cc5b3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5db1c32cd33f4668b275596ad8be6a6a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i520146e8778c40ae9eb4a93caac2fe59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i418e8e7b86764323b476f1d50de103ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icec11a5a664c422a8f8bb66e71f667c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i312615150ad54e8b8d7ee70fc2dcedbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba4a48706535442182a401a22e0833cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42050ca6d82e4a29b7edc3cb14f3acbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id339c48d6a3a4d6592fec24cc7e87bb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ac3d1f533bf441187db6cfa7f411097_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i655faf9854f5497db018bcda11ed5d2a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01fd1e0a05b74674a646b0e7b49d5719_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icecb01efdaee4f5eb0d5b8746d4473bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b8eb414426a4def9317db8dd1cd7e44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb1f50eb8e1b461e962af45f4e1a5c62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9cd1787e90ae440190ac383d58430aa1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c7e74213a944e54a6eee24c81cf7d25_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i763f3b32bb3545939639acdaf8121701_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3a4251f19c164493b2b76424bd16af85_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d1205c295fa4d9794c43e94594a82e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7fdced6a9590488d8697eadc09ac6fa3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i054cdb809097460ca761353ae6210cc9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i82a56f311afa4d95bf226426a02fdbd6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia73118633db044fc86e52f359f9c2460_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia393d1580134431ba101c107da135d75_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id83c4f0e9e4a451ca913256b9e5f597f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06ac5b81410b4bf28610539018816ecd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iadbe5009217d4badb543dd22d06f60e2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i43a893b54a584722bc9f379ccff4de09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieb0e4ef118b14652a430f88a52c45456_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e3433f486c24b5a9838fa5cba54506f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a18ba240d5446bc8347fa7f49ec834c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic9255f0347be4834bcce2c2deeec2732_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b8aae50d3074837b6dd46d96505a08b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5c3f8c1e34bb4619a3c18a295e8be522_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd4b24ac3b0b445db0c74e63f0dfa82d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i25ba2ec1957f486fb4644d20669a8566_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f6a34a9ab63435e9e30203c9e13b9cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c1e0f24df864659b5fbe3ec7f9f9dc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib59231fb89fe4a75a07204111d7f9e85_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic878b552744b4b8daa3463b73139acb6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaec7632bb7d2489d8455f7f8065f000c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i802ba24afa954ef4826966d738099742_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2cc3dabb65af4dd0aa0f9da83cd7e7fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifa38a89ab23143729bc687fe3de028af_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia76de84abd4642d6912042f6e398c5f2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b403184690c419ca8ad63e8f06ff051_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i892bc082ed364fbcaf928358c35a36a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib9ef9ba624674f31b18f18a906991514_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a4d10a2ed2244df86b13b190473888e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida80c3febeab4dc4a386f3c9f4d1da86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9f13704c46b54f4fbf4035b2d602b428_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e672eae8a32483281e04e1d168d302e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i513e270303294364a1063483a8eeb9c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia539bc90716e46c09badc816a75cecca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i480abc2b1cc54cd6b4b92497a9b2b557_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a288026edfb48cf85b99f21c805ca40_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c2764d1efaa46eb9c63af6bc2f8f380_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26052de731df412fb0a0af634dfdb211_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07f0fe39986f424cb855eb97e5214800_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e187a8a013f49e79490f667b361da3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i402153b7427c4b18b5c17b418ea38847_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i377211d696ec45e693cc525f829d66a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8a48087fd894a06a7d66a19e113dfe3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i018fdf48beb241fb957140c7fcaac86f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7faedaea947747a5a4e0f9b27f03b9cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0ead035a27f4309bd93a8a213d35ec8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia48c99f9f8d74d1f9306f416c00c75e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16048614cfcc4e4fa5865a9839662003_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i06ef613858db4f6888a94e03efa94a80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb8d6d09727649149a6395ee1730cce9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81e061d7484e40f7b79b0410a81d34ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f0f79dc42ce4acdbb7a7a3d6e44d0ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c5569fef827456f88c86fc64506a47e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78ed6fd9046d4b9aad7e2742322a47d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9703732e3290451893b9ecbdcd26e17b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1499c884251e45e7a08301c1113c2751_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8910674f7c1d4eb3baab8a3e1449ffcd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5efc9d19f6324825ba0f19f6c6910ca8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib717e8f89b554e5eb31a6287f9e82e85_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i697c1cde53a841b785441aa2b8d391c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8083c2b5a8b7482f8d5695f5d867a671_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i257ef2c7502e4c17b99a926adafc1eaa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0dabcab786cc401a8d99c89cf5a850b6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibf26532bf0944c0db1e554d2d335e401_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i28bed919b46e4cecb29c4d54fde5db47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c11618796914158ab65134841e05e6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75e356158c614afd81168c0f32199528_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i179bfe81b1274a7a937ce14950a79b45_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib47a6f257b464e95b0785df5d930d8e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1c7a694fbd140b28864630b1eb4070b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5126a1d0a76b4750b3c4596fed29b417_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i71dab6497dbc4a9cad98744b1d6939ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12564752dbbc4764bc02ded3b8f49b4c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5702ca6a9f36479296c15ba3f0c29b9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib815e5c326e04a1ca507261df4fef728_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i159aae27f4f5465b9e015d53d086eadd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieaeff0f9b3d243b4a63f8742a58aa35b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie0322636ad15484f8481e2fe8512a156_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia65d202a9f424f4cbe0609279095d19a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a4a5e322fb148e2b3a3f3d9b7aff411_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa186393af9947d7bf2ba374ed2adbf7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70854879aa3545448398e24f78c213d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a6ecc60f1194619954b3f1533e7e224_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7083de34860a440bb7091d697390058a_I20220609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-06-09</instant>
        </period>
    </context>
    <context id="ic1bf0ee8aea9404384a42f661f35f008_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i027341bbc88b4f83ab80a25ed8de872e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide0886b6ea844e829c14276a57c0e37f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i29d8a3984a4442faa0609e1a6e8e6e77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09428b9805e4498b813fd5573384236f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb7d01a9fe044b8e98c079c7e41f1974_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0242e50efc164b19b23a214ef33fdeea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if640bbe0a9704fa8a6e92d02c5bd50ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1de3c3d99592416a9ecb1656c220de10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7223daf79bf460387c65ef8a997c31b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a1b8cd013904ade8b00a3ec6d18c509_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y180LTEtMS0xLTQ2NzA5_eb9de4f7-8096-4b8f-a472-203623a25c2e">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y183LTEtMS0xLTQ2NzA5_b2bd98d2-22a8-44a5-bba0-11c47cdb9f6a">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y184LTEtMS0xLTQ2NzA5_2d4f31e6-8369-43dc-943e-e7b48eaf49e3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y18xMi0xLTEtMS00NjcwOQ_b22f8e55-8b5f-4fa0-b8e7-62fe875e95cc">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80L2ZyYWc6YzQ3NGQyODRhNmI2NGRmNWI4N2VmM2VmMzdhOGM5MDMvdGFibGU6YWFkZWM3ZmMyZTIyNDU4ZWI3N2JjNmQyZDYxNGEyOGMvdGFibGVyYW5nZTphYWRlYzdmYzJlMjI0NThlYjc3YmM2ZDJkNjE0YTI4Y18xMy0xLTEtMS00NjcwOQ_4b41f755-68f6-4b87-9bd8-684653852990">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU1_845e64f5-28ae-4076-815a-f32faea8fee5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmEzMTA2MjI5NzE3NGM1MmI4OTAwNGUwNjFiODgwNTcvdGFibGVyYW5nZToyYTMxMDYyMjk3MTc0YzUyYjg5MDA0ZTA2MWI4ODA1N18wLTAtMS0xLTQ2NzA5_4a6edcbc-bcc8-4257-a673-927c3580de50">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xMzc_bf362698-c85e-4e7e-84f3-1744face817a">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6OTIwZDc2YjQ0YzRjNDBiZGIyZGY1YjgxZjk3OWYyZDEvdGFibGVyYW5nZTo5MjBkNzZiNDRjNGM0MGJkYjJkZjViODFmOTc5ZjJkMV8wLTAtMS0xLTQ2NzA5_5258bfa7-ea6f-47e0-9c0d-07d21992f3a4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU2_e34a64d4-d637-4ecc-9b7f-557b59fc66a6">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU4_fb6c1b92-168a-4702-b6cd-5436ac24484f">CARDIFF ONCOLOGY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8wLTAtMS0xLTQ2NzA5_b756b45a-37e9-48b9-8c1c-c7019818b00c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8wLTItMS0xLTQ2NzA5_5881b576-9a86-4fa0-84df-26ffccd68e8d">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfNA_cfd94e54-89d5-4826-b78d-29fbfccfa236">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfOA_3686e1df-4ad5-4b5d-b42b-faa7f63e2657">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTAtMS0xLTQ2NzA5L3RleHRyZWdpb246YjNjNDA5YmUwZmY3NDMwMjhkODIwYjQ5YWM0ZjI2YzVfMTI_33d6d70a-85c3-4d3a-9ba3-0c26ce0dbf46">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF8zLTItMS0xLTQ2NzA5_146aac41-c892-4ced-84c7-3d444685fb12">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF82LTAtMS0xLTQ2NzA5L3RleHRyZWdpb246ODYzOWIwNjM1NzQwNDIzNzlkMmVmMDNlYzYwMmYwOWJfNQ_c6ce76f9-1c1d-487b-bff0-8e35ab7aaeee">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6NDYzYjcwMTA1YjhkNDQ1OTlkNjVjY2E4NTBmNjQ4YjQvdGFibGVyYW5nZTo0NjNiNzAxMDViOGQ0NDU5OWQ2NWNjYTg1MGY2NDhiNF82LTAtMS0xLTQ2NzA5L3RleHRyZWdpb246ODYzOWIwNjM1NzQwNDIzNzlkMmVmMDNlYzYwMmYwOWJfOQ_f19c1db7-d7ed-4725-b956-439d8920c5e6">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmVjMjQwMTI1N2MxNDlkNGIxZDU0ZDkzY2MyNDJlNmQvdGFibGVyYW5nZToyZWMyNDAxMjU3YzE0OWQ0YjFkNTRkOTNjYzI0MmU2ZF8xLTAtMS0xLTQ2NzA5_eb8d0fc6-742b-4027-8811-fe24d2369479">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6MmVjMjQwMTI1N2MxNDlkNGIxZDU0ZDkzY2MyNDJlNmQvdGFibGVyYW5nZToyZWMyNDAxMjU3YzE0OWQ0YjFkNTRkOTNjYzI0MmU2ZF8xLTItMS0xLTQ2NzA5_7914bc18-6a0a-4b05-8c13-422d0b7743ba">CRDF</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODU5_8c95d943-0c1a-47fb-bf61-90de139caa63">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODYw_7af636af-1b6a-4555-993a-f4a95c604540">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTQtMS0xLTQ2NzA5L3RleHRyZWdpb246YTY1NTA2OTRiNzFlNGYxMTk2NzFkNWNjYjY5NGZhNTVfNA_a99bbdf3-2652-4251-9b91-d8a88573cd9f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTYtMS0xLTQ2NzA5L3RleHRyZWdpb246OGQzMjdkM2M5M2NkNDg3ODhjNjFjM2IyOTk4NzBjNDFfMzA_6a592384-d164-4d6b-94d2-3a6e79c73dd7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGFibGU6YTlmNjc4ZGQ1ZGRkNDZhMmI0ZWRiZTA3NmE1MTMwYWMvdGFibGVyYW5nZTphOWY2NzhkZDVkZGQ0NmEyYjRlZGJlMDc2YTUxMzBhY18wLTgtMS0xLTQ2NzA5L3RleHRyZWdpb246YzczZTg3NzYwMDJiNDY3YWIxZGRhNTI1YmNkOGE4NDlfMjg_ba873b12-1e13-451c-80d4-70eddad04f37">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODYx_36809457-bb46-42ef-aa9a-b6ec7e279b9c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iffbad54a6e314ec7a91b4f82d14d8c58_I20230427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xL2ZyYWc6NzEzZjYxODE0MDhiNDM0ZGI2NWNmN2E3MWQxNzUxOTMvdGV4dHJlZ2lvbjo3MTNmNjE4MTQwOGI0MzRkYjY1Y2Y3YTcxZDE3NTE5M18xODA1_2d734aea-635a-4363-8b67-cc06792ea37c"
      unitRef="shares">44677169</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMy0xLTEtMS00NjcwOQ_365c950d-402d-4e19-b61f-c7dcb97430a9"
      unitRef="usd">15017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMy0zLTEtMS00NjcwOQ_efd19d6f-6317-4c56-b6fd-666372a6bd5f"
      unitRef="usd">16347000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNC0xLTEtMS00NjcwOQ_ce62fbe0-f32b-4990-81f8-e675258be77e"
      unitRef="usd">81951000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNC0zLTEtMS00NjcwOQ_589a4143-19df-4df1-93d5-bfdba6592b06"
      unitRef="usd">88920000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNS0xLTEtMS00NjcwOQ_1bc6f67f-dcc5-4089-a8aa-f2da67dc5f13"
      unitRef="usd">676000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNS0zLTEtMS00NjcwOQ_0e7aa078-8e83-44d5-8457-72e80996f785"
      unitRef="usd">771000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNi0xLTEtMS00NjcwOQ_92cdc9fb-33aa-4ba9-b821-54afc5fc5ee1"
      unitRef="usd">4109000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNi0zLTEtMS00NjcwOQ_c5f6035a-bed4-493b-bf89-8b8eaee2c080"
      unitRef="usd">5246000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNy0xLTEtMS00NjcwOQ_4b69c1d5-9e05-4b60-8ee3-5f26e158ea2b"
      unitRef="usd">101753000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNy0zLTEtMS00NjcwOQ_db653099-4c8d-49c2-9c76-0f52df7cbc79"
      unitRef="usd">111284000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfOC0xLTEtMS00NjcwOQ_4578dab8-b1b4-4b70-b017-732c28eb801e"
      unitRef="usd">1320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfOC0zLTEtMS00NjcwOQ_db2be495-e4c2-4927-96d8-83cbab8ae738"
      unitRef="usd">1269000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTAtMS0xLTEtNDY3MDk_b053479a-3bde-4339-a254-2e5be5b54aa0"
      unitRef="usd">2115000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTAtMy0xLTEtNDY3MDk_44b53dcd-8bc2-4737-b6c5-5c462749e02e"
      unitRef="usd">2251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTEtMS0xLTEtNDY3MDk_f13445c1-8636-403f-93b5-5fdd215bcbc4"
      unitRef="usd">1361000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTEtMy0xLTEtNDY3MDk_a8d914cf-361b-4126-bbce-05824a7aa61c"
      unitRef="usd">1387000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTItMS0xLTEtNDY3MDk_10effa23-aeaf-48c1-bf77-d21181045c2a"
      unitRef="usd">106549000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTItMy0xLTEtNDY3MDk_7cf1a2c1-1961-41de-933e-4847eb780cbc"
      unitRef="usd">116191000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTYtMS0xLTEtNDY3MDk_dd6b0014-3f70-4959-830e-3f296ac051f6"
      unitRef="usd">2914000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTYtMy0xLTEtNDY3MDk_f5d8ea72-67be-48a5-b79a-8d41d57f7f41"
      unitRef="usd">1956000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTctMS0xLTEtNDY3MDk_0321e66a-4e5c-41c7-a1dd-956a1031d97e"
      unitRef="usd">4555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTctMy0xLTEtNDY3MDk_fdbdd07b-320c-4f4e-b19b-081217a11361"
      unitRef="usd">5177000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTktMS0xLTEtNDY3MDk_a3eec2f8-6bab-449a-ad22-ea57b3c21780"
      unitRef="usd">679000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMTktMy0xLTEtNDY3MDk_6ac0792b-5e1f-474e-b032-3a5d276b5a3a"
      unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjItMS0xLTEtNDY3MDk_16ad5c5b-88a2-4b31-b738-03048f611f43"
      unitRef="usd">8148000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjItMy0xLTEtNDY3MDk_2fac596c-77da-4ad3-92f2-c6c8ab0f21d7"
      unitRef="usd">7808000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjUtMS0xLTEtNDY3MDk_76856503-b6e3-4c85-8cda-d0de93ba7d28"
      unitRef="usd">1898000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjUtMy0xLTEtNDY3MDk_260c5b38-745b-49a3-a619-9b1b1a414b77"
      unitRef="usd">2040000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjgtMS0xLTEtNDY3MDk_6faf91b2-b9fd-48c7-a1fb-7b7106739b19"
      unitRef="usd">10046000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMjgtMy0xLTEtNDY3MDk_9643d62f-3493-4f84-a6a0-adabb597d520"
      unitRef="usd">9848000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzAtMS0xLTEtNDY3MDk_ed5ca265-d121-4dbf-b673-2ac41d8585b6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzAtMy0xLTEtNDY3MDk_94d03d79-6ec0-4013-a8a3-3a996f178ca0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMQ_51399c98-a3f9-45fe-a788-64ca11400c1b"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMQ_754d0594-3876-40a8-abc0-9d69c4d31965"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMTk5MDIzMjU1Nzgw_01708ab1-cc08-42e5-9b53-421e7478a2c4"
      unitRef="usd">1050000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo0NDcxMjNhNzRlMGU0NzZlOWE2OTA5MzIzMGU5OWRlOV8yMTk5MDIzMjU1Nzk4_3580daf3-3592-4334-bcc6-fbfc3e8d1e0d"
      unitRef="usd">1044000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMS0xLTEtNDY3MDk_fb0fc4b1-1b66-47a7-9230-b8c3b1cbd828"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzMtMy0xLTEtNDY3MDk_d2878e80-3574-4f13-9881-8313bf60bccb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8xOQ_8eb6159b-ef24-4e82-8fc0-cffc377b81f2"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8xOQ_e4f61aea-65af-4c47-93d8-529575da4cfa"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8zMw_14c6846b-35cb-4ca0-8e18-a7f0ef7a90ef"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml8zMw_d1d7e29c-6323-4ce7-835d-165d1b970957"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml81NQ_0ab653fb-7da9-46bf-a6d9-c10a4a4f03d2"
      unitRef="shares">44677000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml81NQ_90046ad1-42aa-47a7-9faf-f6b52d0e3d18"
      unitRef="shares">44677000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml82Mg_0983402b-d36a-4839-a81e-55aa3798e924"
      unitRef="shares">44677000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMC0xLTEtNDY3MDkvdGV4dHJlZ2lvbjo3MWFiMGUyMjVlOTA0NTA1OWViMjdhMzVjODYwZWI1Ml82Mg_961a079c-4f29-48c5-ad8a-284498f59810"
      unitRef="shares">44677000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMS0xLTEtNDY3MDk_b5d719a0-69bf-449a-b3ac-cdf79c0f0910"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzQtMy0xLTEtNDY3MDk_fcaf2f8a-1d71-4f44-930b-af8b0ca3a2b0"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzUtMS0xLTEtNDY3MDk_3df9baca-8663-48f9-9409-3357d5016808"
      unitRef="usd">405898000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzUtMy0xLTEtNDY3MDk_0eeb5fff-1af1-4fc0-8984-565008a3c372"
      unitRef="usd">404834000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzctMS0xLTEtNDY3MDk_10338a09-c589-409b-8a22-df646a52a6af"
      unitRef="usd">-76000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzctMy0xLTEtNDY3MDk_9be5d440-cd8b-4f33-8e3a-84a2211abc07"
      unitRef="usd">-395000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzgtMS0xLTEtNDY3MDk_986be885-e612-492f-8a1e-5c9e063305bd"
      unitRef="usd">-309323000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzgtMy0xLTEtNDY3MDk_c9bdd195-eb33-4e13-a059-427fdcab7e00"
      unitRef="usd">-298100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzktMS0xLTEtNDY3MDk_19d68850-bce0-4dd7-8823-7bf945ae34b7"
      unitRef="usd">96503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfMzktMy0xLTEtNDY3MDk_ea269e5a-d645-45ca-b54e-a7a112161d1a"
      unitRef="usd">106343000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNDAtMS0xLTEtNDY3MDk_51d713c0-400d-4d64-b3b3-8f57bc2552cd"
      unitRef="usd">106549000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xNi9mcmFnOjBiZDhhMWU0YTFlOTRiZjJiMTJlMWMyZmRhNjQ2YWM5L3RhYmxlOmMxZmVlOTE4NzQ4NzQwN2I5MjVhMWNmMjBmZWI3Mzk1L3RhYmxlcmFuZ2U6YzFmZWU5MTg3NDg3NDA3YjkyNWExY2YyMGZlYjczOTVfNDAtMy0xLTEtNDY3MDk_de76ac11-42f5-49db-8139-80f212a7d15f"
      unitRef="usd">116191000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfNS01LTEtMS00NjcwOQ_4cafd4aa-f9ba-4314-b2f3-f0e81e713cb7"
      unitRef="usd">83000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfNS03LTEtMS00NjcwOQ_afcf6862-31f6-4704-aa3e-e10caf0c51cf"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOC01LTEtMS00NjcwOQ_51503775-48df-4be8-9fbe-676a94fa555e"
      unitRef="usd">9052000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOC03LTEtMS00NjcwOQ_689d00df-649b-430b-9c5c-1d4b0eae4452"
      unitRef="usd">7208000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOS01LTEtMS00NjcwOQ_09dcb377-0009-4c04-afc4-290c07419a8a"
      unitRef="usd">3083000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfOS03LTEtMS00NjcwOQ_58a3012c-f2af-4131-95a2-d4d5bcbe0bd6"
      unitRef="usd">3940000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTItNS0xLTEtNDY3MDk_1ea0decc-700e-427c-bc78-9e024764cc60"
      unitRef="usd">12135000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTItNy0xLTEtNDY3MDk_db618a86-8392-4378-9970-23d342798b09"
      unitRef="usd">11148000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTQtNS0xLTEtNDY3MDk_032cde07-8750-4d06-b95c-643e57bfc005"
      unitRef="usd">-12052000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTQtNy0xLTEtNDY3MDk_4981b203-7192-4811-ad6c-e9db6ebb9a3d"
      unitRef="usd">-11074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTctNS0xLTEtNDY3MDk_e19e054f-bd88-4c47-9472-2a32b35d8575"
      unitRef="usd">940000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMTctNy0xLTEtNDY3MDk_2023c176-3a47-491d-9afd-6c9fd7c67123"
      unitRef="usd">130000</us-gaap:InterestIncomeOperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjEtNS0xLTEtNDY3MDk_3a2a5cc9-2a09-40f1-a0e6-ab7c2fc9797c"
      unitRef="usd">-111000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjEtNy0xLTEtNDY3MDk_2a3fc105-4d0c-4339-9a48-89f99570a5d8"
      unitRef="usd">-49000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjItNS0xLTEtNDY3MDk_befd520a-818c-490a-95ea-b6cc5f1dc2df"
      unitRef="usd">829000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjItNy0xLTEtNDY3MDk_01a90832-0db3-4eb2-bbab-ffbc6fcc13b6"
      unitRef="usd">81000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjQtNS0xLTEtNDY3MDk_b04f4aea-836b-48cc-9c3d-a1829065b685"
      unitRef="usd">-11223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjQtNy0xLTEtNDY3MDk_3e716ea3-ebbe-4a08-8b6c-4f944f99fa84"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjYtNS0xLTEtNDY3MDk_9162aec0-a93a-4434-acf3-f1a8df9e64b5"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMjYtNy0xLTEtNDY3MDk_83e59611-ef5d-447b-bfe2-481af252222e"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzItNS0xLTEtNDY3MDk_6b30937e-dbcc-44ab-bdcf-0c8dc2c44105"
      unitRef="usd">-11229000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzItNy0xLTEtNDY3MDk_ffae240c-6625-4c62-b50b-632323c3d9f2"
      unitRef="usd">-10999000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNS0xLTEtNDY3MDk_8924ab59-8b4b-46cb-9e3f-6cd6978af34f"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNS0xLTEtNDY3MDk_b3e1fb7a-619d-437e-b255-3daf66adc741"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNy0xLTEtNDY3MDk_842c0eba-c626-4ed9-b86b-5db64e82b3b5"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzQtNy0xLTEtNDY3MDk_bda18a5f-33a6-4ad5-bf29-9ed3ced3343c"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNS0xLTEtNDY3MDk_3c23de98-359e-40bd-8a2c-4db4a2365c29"
      unitRef="shares">44677000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNS0xLTEtNDY3MDk_90b96cd4-afe3-4239-b657-60c996553489"
      unitRef="shares">44677000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNy0xLTEtNDY3MDk_d50da61f-167e-46de-a618-f32c0a4d4686"
      unitRef="shares">43231000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8xOS9mcmFnOjYxM2Y2NzFhMDNiMDRhZTU4YTY2MzA2OGFiM2NjNmRkL3RhYmxlOmU4YjY2NjkwNmRiMjQyOGNhZjNhMGZjNjczNWUwMWY2L3RhYmxlcmFuZ2U6ZThiNjY2OTA2ZGIyNDI4Y2FmM2EwZmM2NzM1ZTAxZjZfMzctNy0xLTEtNDY3MDk_e3709f2b-1138-4f94-99c0-7db9d59d283e"
      unitRef="shares">43231000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMi01LTEtMS00NjcwOQ_8a1b5ed9-e051-4a9b-84ab-46c0499d9b84"
      unitRef="usd">-11223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMi03LTEtMS00NjcwOQ_6d72013a-70cf-4023-b707-59fe74e0b1e8"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNC01LTEtMS00NjcwOQ_83dc247b-0c9e-4a73-b728-9556525bf199"
      unitRef="usd">319000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNC03LTEtMS00NjcwOQ_d7ea76a3-f334-45b3-8807-88cfb1cdaf08"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNS01LTEtMS00NjcwOQ_8b73eaae-6656-48a6-94eb-6955af048dd3"
      unitRef="usd">-10904000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNS03LTEtMS00NjcwOQ_0ea19ad5-a6c2-4ce1-9473-d8f583ad1b5c"
      unitRef="usd">-11599000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNy01LTEtMS00NjcwOQ_cfb53f3b-930f-4005-bff9-1b1bf2b29881"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfNy03LTEtMS00NjcwOQ_08b94da2-28d3-4af3-aa34-c82738bb0243"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMTMtNS0xLTEtNDY3MDk_f6afed7f-2e42-4bf1-905f-e4e5c85688b5"
      unitRef="usd">-10910000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yMi9mcmFnOmJlZGY2NDhjNmMzMjQwM2E4ZmIyYWE0NjUxMmVkZjk3L3RhYmxlOmI2MDk4M2IyNjg0MjRiMjZhNmYwYzZlODI2NWI2NWFlL3RhYmxlcmFuZ2U6YjYwOTgzYjI2ODQyNGIyNmE2ZjBjNmU4MjY1YjY1YWVfMTMtNy0xLTEtNDY3MDk_786af4de-43ae-4132-aed6-8aec582b4574"
      unitRef="usd">-11605000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="i513f89ebc35b472384751be31e33c9f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xLTEtMS00OTkzOA_526db02d-c85a-4f5b-a0f0-4b6124252da8"
      unitRef="shares">61000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i513f89ebc35b472384751be31e33c9f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0zLTEtMS00OTkzOA_ff627922-b186-4b74-a421-c935c8fc443a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="iad5f47b73dd845b2a15839bc67e13da2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS01LTEtMS00OTkzOA_fe079e66-9791-4e63-b999-30d82d8a33fd"
      unitRef="shares">44677000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iad5f47b73dd845b2a15839bc67e13da2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS03LTEtMS00OTkzOA_a9f780a7-e517-4bb6-b0e0-da30406cce50"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f054b7c0fba4ca390235d3bcec938b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS05LTEtMS00OTkzOA_6e301625-672e-44e4-81f6-46eb4cbfa009"
      unitRef="usd">404834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3499e99d669043a3a672f5cc7e2b80b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xMy0xLTEtNDk5Mzg_7a0a4c45-faca-40c7-87b0-3207359b08a4"
      unitRef="usd">-395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9369609104e54b8f8837281b23259c18_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xNS0xLTEtNDk5Mzg_442474c3-50db-48fd-8a51-7feae474aa2e"
      unitRef="usd">-298100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMS0xNy0xLTEtNDk5Mzg_adb197d0-1512-4721-887b-af3a5b845255"
      unitRef="usd">106343000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie0c82f644f9548afad75b06a3b3e3078_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMi05LTEtMS00OTkzOA_8e88c6ad-5b72-4521-bd13-bfd717cf4866"
      unitRef="usd">1064000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMi0xNy0xLTEtNDk5Mzg_398739a9-b222-4d7a-a49c-94ad6e29ec94"
      unitRef="usd">1064000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f6cd88fbdbf46e5b08b5efb099ce7cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMy0xMy0xLTEtNDk5Mzg_f8b7b19a-80f8-4216-9704-d1d37247c04b"
      unitRef="usd">319000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfMy0xNy0xLTEtNDk5Mzg_cabfdb30-002f-4562-b09f-5a884547251b"
      unitRef="usd">319000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iaef2a38416fe413590b0a41deaabca5d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNC0xNS0xLTEtNDk5Mzg_7302a67c-b31d-4373-bf16-f166f3b365a3"
      unitRef="usd">-11223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNC0xNy0xLTEtNDk5Mzg_8e41a08a-92e4-4d5e-8719-530aeb44f2d5"
      unitRef="usd">-11223000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xLTEtMS01MzgyMA_74bbee38-7033-4ed7-859d-53b619872f89"
      unitRef="shares">61000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6fc090b9b7f64838a14379d6d5e2adb8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0zLTEtMS01MzgyMA_fc1fc7b5-58c3-401d-9d07-e4d7321c3e9d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i1d580a3c0da44ca5948a74430fd58deb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS01LTEtMS01MzgyMA_86197836-a388-4ba6-917d-8ca971d5fc15"
      unitRef="shares">44677000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i1d580a3c0da44ca5948a74430fd58deb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS03LTEtMS01MzgyMA_806eb9ce-ba25-4d5e-80c5-c11247a1516b"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c2ae96f6ece4865b96a161ff3cc5b3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS05LTEtMS01MzgyMA_44733045-bddd-49b8-9de2-91550a6d119f"
      unitRef="usd">405898000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5db1c32cd33f4668b275596ad8be6a6a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xMy0xLTEtNTM4MjA_a21375cc-6d14-40d6-b685-3aa5a677e0b8"
      unitRef="usd">-76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i520146e8778c40ae9eb4a93caac2fe59_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xNS0xLTEtNTM4MjA_6d7980ab-a78b-4482-91df-a3e27569e272"
      unitRef="usd">-309323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOjExMDM3MzVkOTUxZDQxOTRhNWU1ZjcwMTNkOTk0Y2E1L3RhYmxlcmFuZ2U6MTEwMzczNWQ5NTFkNDE5NGE1ZTVmNzAxM2Q5OTRjYTVfNS0xNy0xLTEtNTM4MjA_bc7b9b10-2b2a-40d6-b472-ba224a1f7721"
      unitRef="usd">96503000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i418e8e7b86764323b476f1d50de103ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xLTEtMS00NjcwOQ_7e8ff0c7-f505-4f82-ad42-08d833f5e0d5"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i418e8e7b86764323b476f1d50de103ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0zLTEtMS00NjcwOQ_b6015bec-c577-4b2f-b8fa-7a171a145264"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="icec11a5a664c422a8f8bb66e71f667c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS01LTEtMS00NjcwOQ_ff4db6ad-61a8-43aa-81bc-e0c12755f5eb"
      unitRef="shares">41964000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="icec11a5a664c422a8f8bb66e71f667c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS03LTEtMS00NjcwOQ_e3a5f38b-73a8-446a-ab34-8a296c828fcb"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i312615150ad54e8b8d7ee70fc2dcedbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS05LTEtMS00NjcwOQ_63bc3388-c430-4266-8e0f-40de703f5b83"
      unitRef="usd">400503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba4a48706535442182a401a22e0833cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xMS0xLTEtNDY3MDk_19b0c25d-0cd6-4e03-84cd-18b06ad0b083"
      unitRef="usd">-139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42050ca6d82e4a29b7edc3cb14f3acbc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xMy0xLTEtNDY3MDk_3917ba0d-86ba-4b88-ae29-01ca9fdd3d32"
      unitRef="usd">-142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id339c48d6a3a4d6592fec24cc7e87bb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xNS0xLTEtNDY3MDk_a733d5fa-0d32-477a-b991-cc423d3bf6e6"
      unitRef="usd">-259810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ac3d1f533bf441187db6cfa7f411097_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMS0xNy0xLTEtNDY3MDk_6b2afd19-84fc-471e-9fa7-20348cb1141a"
      unitRef="usd">140417000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i655faf9854f5497db018bcda11ed5d2a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMi05LTEtMS00NjcwOQ_e10cbd83-e713-49f9-b0e4-e3570ee7c6bd"
      unitRef="usd">1152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMi0xNy0xLTEtNDY3MDk_f2165a0e-0e02-44ca-9850-cb5356d38b51"
      unitRef="usd">1152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i01fd1e0a05b74674a646b0e7b49d5719_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNi0xMy0xLTEtNDY3MDk_dcf87e49-4d22-4631-b84c-a437eded55c4"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNi0xNy0xLTEtNDY3MDk_93495e4f-797f-4a18-b3b3-caf7e42d995b"
      unitRef="usd">-606000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0xLTEtMS00NjcwOQ_dd8eac65-59c5-49fa-8a57-566729cf3481"
      unitRef="shares">-328000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib63de662d4ec4f019e9b422eae09a463_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0zLTEtMS00NjcwOQ_3bc465a2-8c90-41a0-8632-1191979ddfed"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icecb01efdaee4f5eb0d5b8746d4473bd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy01LTEtMS00NjcwOQ_0d81b330-cff3-4ec9-813a-051d1921785f"
      unitRef="shares">1342000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfNy0xNy0xLTEtNDY3MDk_aeb63c85-8930-4335-9aa0-35a3aeb5550e"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOC0xNS0xLTEtNDY3MDk_5047658a-cf1c-42c5-8106-d3d09147c660"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOC0xNy0xLTEtNDY3MDk_5f0c060a-e260-49cd-a3e0-af9af2030d0e"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i5b8eb414426a4def9317db8dd1cd7e44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOS0xMS0xLTEtNDY3MDk_6b0324dc-0d5a-4970-8fe5-0dc840571c3a"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfOS0xNy0xLTEtNDY3MDk_c03c7e4d-15d1-4d9e-96b9-6f6f2e03e449"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i81d9bf03f45e4182a49dd149c11ecf23_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTAtMTUtMS0xLTQ2NzA5_eefee823-e791-431e-accc-d67b539edb7e"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTAtMTctMS0xLTQ2NzA5_69b0923a-e75a-492b-a9b2-778d262cc0f1"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMS0xLTEtNDY3MDk_36a4b3e7-96c4-46d4-8d7e-9a18b2fa79b4"
      unitRef="shares">388000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7a8dbfcf04534b89b6c6282bfe57a253_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMy0xLTEtNDY3MDk_c593be98-4363-4f41-abc3-b4fc50fbe9d1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtNS0xLTEtNDY3MDk_13f62bbd-8661-4ef4-8ccd-dae12e9ffef0"
      unitRef="shares">43306000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i21f0fb5630ca4530bf2046c03fac0cc3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtNy0xLTEtNDY3MDk_93f81e2b-fcd9-494b-b0c0-f4dec3b7a5f4"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb1f50eb8e1b461e962af45f4e1a5c62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtOS0xLTEtNDY3MDk_2972af58-8b14-4adf-82bd-66951cb37ef9"
      unitRef="usd">401655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cd1787e90ae440190ac383d58430aa1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTEtMS0xLTQ2NzA5_109f4c58-3830-428b-9dbc-02f2a91c26e5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c7e74213a944e54a6eee24c81cf7d25_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTMtMS0xLTQ2NzA5_5f61a56f-bcfe-40ff-92e7-2e3824325dbf"
      unitRef="usd">-748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i763f3b32bb3545939639acdaf8121701_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTUtMS0xLTQ2NzA5_4fea6f94-dde5-4dd1-b82e-ae227c484768"
      unitRef="usd">-270809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8yNS9mcmFnOjkzNjA2YmU0YjUyODQ3OTA4M2E0YWUxZGM4YTVmN2RkL3RhYmxlOmFjNDUwZTVhYjc3ZDRlNzk4ZTdkOGFjZGQ3MTEzMjEzL3RhYmxlcmFuZ2U6YWM0NTBlNWFiNzdkNGU3OThlN2Q4YWNkZDcxMTMyMTNfMTEtMTctMS0xLTQ2NzA5_8ae9595a-76af-47da-b949-a42d23e1e19f"
      unitRef="usd">130102000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMy0xLTEtMS00NjcwOQ_0601e1be-133f-4045-91fd-7be90d65bed2"
      unitRef="usd">-11223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMy0zLTEtMS00NjcwOQ_b9474388-d1ee-4d72-b97d-47e46f3fbcdc"
      unitRef="usd">-10993000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNy0xLTEtMS00NjcwOQ_4ba63316-99fd-4a45-8e0c-2874a84d5a0e"
      unitRef="usd">90000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNy0zLTEtMS00NjcwOQ_babe4710-0f31-4a33-8f57-54e91c76ca66"
      unitRef="usd">31000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfOS0xLTEtMS00NjcwOQ_d10b21f1-4374-46ba-a6bf-6faa56a5f619"
      unitRef="usd">1064000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfOS0zLTEtMS00NjcwOQ_5f5a98a2-c9ed-407d-8e43-b2fe277997c3"
      unitRef="usd">1152000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTQtMS0xLTEtNDY3MDk_e2d001d3-604c-474a-a8a4-9f4a82fe7139"
      unitRef="usd">163000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTQtMy0xLTEtNDY3MDk_847e4bdd-6a43-40ba-8ffc-31ef721d2f14"
      unitRef="usd">-346000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTgtMS0xLTEtNDY3MDk_3c0ef3cd-bb4d-432c-a690-f9e5e742aeb3"
      unitRef="usd">0</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMTgtMy0xLTEtNDY3MDk_1e12908b-8a2f-4aff-8b21-bfcc1979ce3a"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjAtMS0xLTEtNDY3MDk_be4ab83e-0838-4748-814a-7edb1fe75b58"
      unitRef="usd">-26000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjAtMy0xLTEtNDY3MDk_cba24d62-da28-4ceb-96ba-29b75fa8efec"
      unitRef="usd">-51000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjEtMS0xLTEtNDY3MDk_b09f01ba-186e-474d-8284-8c04beadf5b3"
      unitRef="usd">-95000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjEtMy0xLTEtNDY3MDk_3e17c03c-ea61-48bf-8859-facacdb8d414"
      unitRef="usd">-88000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjItMS0xLTEtNDY3MDk_a0486333-96a4-4915-bfc2-5d8c7e9f8860"
      unitRef="usd">-1251000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjItMy0xLTEtNDY3MDk_2df3e33b-1b0e-4d92-a45b-fd0a646332e5"
      unitRef="usd">1141000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjMtMS0xLTEtNDY3MDk_df72d14f-545c-49cc-ac2e-e63c067677c7"
      unitRef="usd">-136000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjMtMy0xLTEtNDY3MDk_246e7655-9545-4597-8769-8d1d3bd100a3"
      unitRef="usd">-136000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjQtMS0xLTEtNDY3MDk_37401aa4-ecde-4b6d-b8e1-4901d182db08"
      unitRef="usd">203000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjQtMy0xLTEtNDY3MDk_ec41a9ca-f593-41be-bb2c-a96e742c64b3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjUtMS0xLTEtNDY3MDk_909aa1bb-b8d6-4f8a-ab50-1c1d3b65616c"
      unitRef="usd">-138000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjUtMy0xLTEtNDY3MDk_99b08376-d5b1-4504-a7a3-eacd2dfcf852"
      unitRef="usd">-16000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjYtMS0xLTEtNDY3MDk_39a97d18-7566-49e4-90ee-247b9dde1684"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjYtMy0xLTEtNDY3MDk_ed669a55-9e51-4f5d-aa2c-d01730bff6c2"
      unitRef="usd">-42000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjctMS0xLTEtNDY3MDk_d7087bcc-b588-40d9-9d13-c2ac81421bc4"
      unitRef="usd">-8659000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMjctMy0xLTEtNDY3MDk_d9be7edd-8643-4382-bdda-f2f95ea9960d"
      unitRef="usd">-10249000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzEtMS0xLTEtNDY3MDk_22f5bc92-6e59-4974-9452-221036846d77"
      unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzEtMy0xLTEtNDY3MDk_31e4a4b0-a7d0-4a3e-b067-58b152575f4f"
      unitRef="usd">171000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzMtMS0xLTEtNDY3MDk_007677c6-8eb7-4b34-ad99-40dd13328c98"
      unitRef="usd">42983000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzMtMy0xLTEtNDY3MDk_ad2c328b-8bf1-4247-9877-60cec9681c97"
      unitRef="usd">38217000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzQtMS0xLTEtNDY3MDk_5b9d5992-ab3d-46f7-a2e1-beb22b5c4ab5"
      unitRef="usd">37327000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzQtMy0xLTEtNDY3MDk_86aeffb8-c528-4108-98cf-5edad54aea71"
      unitRef="usd">36773000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzUtMS0xLTEtNDY3MDk_7db9c6f8-ca36-44e0-862c-f629ebf60817"
      unitRef="usd">1681000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzUtMy0xLTEtNDY3MDk_2281f1ee-2195-4554-a5b1-f4da10c1194c"
      unitRef="usd">17085000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzYtMS0xLTEtNDY3MDk_55b51683-37d1-4ed1-b2b0-009938c94f6c"
      unitRef="usd">7329000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfMzYtMy0xLTEtNDY3MDk_f731b3d1-f21f-4935-a367-8aad542d5c54"
      unitRef="usd">18358000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNDktMS0xLTEtNDY3MDk_16e5d6dc-6c1d-4244-b32b-60025f9aabef"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNDktMy0xLTEtNDY3MDk_33db6b36-e819-4cce-9694-abcbaf702d6d"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTEtMS0xLTEtNDY3MDk_02734f72-da72-4923-9c80-1a4d020cbfc4"
      unitRef="usd">-1330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTEtMy0xLTEtNDY3MDk_514bc07e-49eb-47ea-8949-f1cacf705f61"
      unitRef="usd">8109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTItMS0xLTEtNDY3MDk_47dcfdac-6b9e-4cb3-b887-479d10208aa7"
      unitRef="usd">16347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ac3d1f533bf441187db6cfa7f411097_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTItMy0xLTEtNDY3MDk_152e6ac6-7bd0-470d-b216-94dd59cc0e4c"
      unitRef="usd">11943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTMtMS0xLTEtNDY3MDk_227cae87-8931-40d9-be1f-42e3faaed5c5"
      unitRef="usd">15017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTMtMy0xLTEtNDY3MDk_99f98495-bd9f-4c02-b906-33d536ab5511"
      unitRef="usd">20052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTYtMS0xLTEtNDY3MDk_36cc6edb-e6cf-42bd-86db-12e8fb2190d6"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTYtMy0xLTEtNDY3MDk_b643f3f5-192e-405c-981d-d47e1a09fbb6"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTktMS0xLTEtNDY3MDk_aeb11fd2-b863-474f-a835-57066e569c1f"
      unitRef="usd">133000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV8zMS9mcmFnOjRlYzgwNTBmZDU4YTQ5ZDM5ZWU3MDM3NWViNmQzNTdkL3RhYmxlOjBmYzIyN2NkOTA1MTRlOGJiM2FkOTkzNGE5MjAxOGJmL3RhYmxlcmFuZ2U6MGZjMjI3Y2Q5MDUxNGU4YmIzYWQ5OTM0YTkyMDE4YmZfNTktMy0xLTEtNDY3MDk_25a6239c-fb1f-4aec-9be6-41ee1a7a3b1b"
      unitRef="usd">27000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80MC9mcmFnOmZhN2QwMjgxZWU0NDRjODBiMmRjMmM2ODRiMGU3NmNlL3RleHRyZWdpb246ZmE3ZDAyODFlZTQ0NGM4MGIyZGMyYzY4NGIwZTc2Y2VfMzMyMQ_cb84f05b-e9a0-4b97-87bd-7acfe8874312">Organization and Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology, Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#x201c;PLK1&#x201d;) inhibition to develop novel therapies across a range of cancers. The Company&#x2019;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard-of-care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#x2019;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard-of-care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2022, has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2022, included in the Company&#x2019;s annual report on Form&#160;10-K filed with the SEC on March&#160;2, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of March&#160;31, 2023, the Company had $97.0&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80MC9mcmFnOmZhN2QwMjgxZWU0NDRjODBiMmRjMmM2ODRiMGU3NmNlL3RleHRyZWdpb246ZmE3ZDAyODFlZTQ0NGM4MGIyZGMyYzY4NGIwZTc2Y2VfMjY1Nw_efc96411-612a-468b-b562-830148343985"
      unitRef="usd">97000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk3MQ_8a130a27-cacb-49cb-ab86-47fcf9aecee1">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,694,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,300,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures, and will adopt this standard on January 1, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk3NA_b0ab1984-b397-41ae-9e7b-da326810df56">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk4MA_b93f3cf5-cc4c-494c-ae8f-90692675a985">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,467,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,694,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,300,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d1205c295fa4d9794c43e94594a82e8_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMi0xLTEtMS00NjcwOQ_d7b38277-de07-48e0-a08a-5271b153e507"
      unitRef="shares">6396895</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7fdced6a9590488d8697eadc09ac6fa3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMi0zLTEtMS00NjcwOQ_c5530f2d-c398-41f2-84d4-baa435c8fe12"
      unitRef="shares">5467611</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i054cdb809097460ca761353ae6210cc9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMy0xLTEtMS00NjcwOQ_db30dc8e-fb14-4a24-a0db-2499c49acbc1"
      unitRef="shares">4296472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82a56f311afa4d95bf226426a02fdbd6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfMy0zLTEtMS00NjcwOQ_1ebd6ee6-dc11-4393-b111-f8f2e733ec41"
      unitRef="shares">4490159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia73118633db044fc86e52f359f9c2460_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNS0xLTEtMS00NjcwOQ_1cfdbbc7-f83d-450c-be07-3e51555d12c1"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia393d1580134431ba101c107da135d75_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNS0zLTEtMS00NjcwOQ_8a4870a9-5923-410c-9a4b-e5ef04f9e13d"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id83c4f0e9e4a451ca913256b9e5f597f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNy0xLTEtMS00NjcwOQ_ae4c0a0b-1a3c-40e3-9347-62972838e11b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i06ac5b81410b4bf28610539018816ecd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfNy0zLTEtMS00NjcwOQ_a2b705d5-c563-498d-a693-66a6883ba263"
      unitRef="shares">1342250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfOC0xLTEtMS00NjcwOQ_e1e2ec68-f217-4235-a7cf-1f862c0a0eed"
      unitRef="shares">10694244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RhYmxlOjIyZmQxZmZhMDEyZDRhZjViMzJkYTE5YzUxOTI5ZDkyL3RhYmxlcmFuZ2U6MjJmZDFmZmEwMTJkNGFmNWIzMmRhMTljNTE5MjlkOTJfOC0zLTEtMS00NjcwOQ_ae62b760-0936-413e-9b86-b4aad97a8451"
      unitRef="shares">11300897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80My9mcmFnOmQzNzE0MzlhMzliZjQ2ZjViMWE3NDFjM2MxMjRhYTE3L3RleHRyZWdpb246ZDM3MTQzOWEzOWJmNDZmNWIxYTc0MWMzYzEyNGFhMTdfMjk2OA_32e44293-f562-46b3-89ab-3db3a2564e91">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023, for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures, and will adopt this standard on January 1, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RleHRyZWdpb246N2NlMzgxZDhlNjY2NDkzZGI1YWMzNGU0NzE0MjAzODdfNTY5_6c2b4f03-3dbd-4e01-bbb8-53c65ccc9f91">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2023, and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Included in short-term investments in the accompanying balance sheets. &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2023</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RleHRyZWdpb246N2NlMzgxZDhlNjY2NDkzZGI1YWMzNGU0NzE0MjAzODdfNTcw_51adc1e2-2ada-45ea-afb9-19ee63fe9275">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March&#160;31, 2023, and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;(1) Included in short-term investments in the accompanying balance sheets.</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iadbe5009217d4badb543dd22d06f60e2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy0xLTEtMS00NjcwOQ_30cd3b26-b0b8-4131-81fc-ff41633190c6"
      unitRef="usd">14158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i43a893b54a584722bc9f379ccff4de09_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy0zLTEtMS00NjcwOQ_c0f3e08a-f14a-4871-aab9-27b77dae3f86"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb0e4ef118b14652a430f88a52c45456_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy01LTEtMS00NjcwOQ_66ef14e5-31f9-4dd2-b977-c376be492bf1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e3433f486c24b5a9838fa5cba54506f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMy03LTEtMS00NjcwOQ_e6840fda-60a0-4615-af0b-62ddc86d2642"
      unitRef="usd">14158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS0xLTEtMS00NjcwOQ_407a7f4d-fb38-40dc-86ec-244dba9f6745"
      unitRef="usd">14158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS0zLTEtMS00NjcwOQ_8b79dd54-8681-4b88-87b6-d23f08343fd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS01LTEtMS00NjcwOQ_df1bb1d0-5024-49ef-b6c1-8a27951f1521"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfNS03LTEtMS00NjcwOQ_f00b2378-d124-4dd5-b278-1407c3dcd132"
      unitRef="usd">14158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c3f8c1e34bb4619a3c18a295e8be522_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC0xLTEtMS00NjcwOQ_4865c7db-3528-46ee-8839-4cf694e3ed34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd4b24ac3b0b445db0c74e63f0dfa82d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC0zLTEtMS00NjcwOQ_62ee7908-6707-4748-bb8b-ea6071a6fa1e"
      unitRef="usd">13925000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25ba2ec1957f486fb4644d20669a8566_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC01LTEtMS00NjcwOQ_10f390d1-b9ba-4405-9d63-2e8fe7e197ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f6a34a9ab63435e9e30203c9e13b9cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOC03LTEtMS00NjcwOQ_e04dee57-377e-4f29-b789-aa8deda18452"
      unitRef="usd">13925000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c1e0f24df864659b5fbe3ec7f9f9dc1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS0xLTEtMS00NjcwOQ_8f8710b3-93df-4caf-9e5c-dcbcabb5b6f6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib59231fb89fe4a75a07204111d7f9e85_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS0zLTEtMS00NjcwOQ_c57d8970-6aab-47d6-b865-dce2db9ced2a"
      unitRef="usd">32828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic878b552744b4b8daa3463b73139acb6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS01LTEtMS00NjcwOQ_33c1592c-cc73-4fe6-b0c7-22cde74f8075"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaec7632bb7d2489d8455f7f8065f000c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfOS03LTEtMS00NjcwOQ_a7a29659-6ece-41e7-a28f-044ed1c8a3a2"
      unitRef="usd">32828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i802ba24afa954ef4826966d738099742_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtMS0xLTEtNDY3MDk_740b5161-4d7e-46d6-b8cd-2b79b1fde12c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2cc3dabb65af4dd0aa0f9da83cd7e7fc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtMy0xLTEtNDY3MDk_9d3246de-715b-45ab-b685-771dac81c1c6"
      unitRef="usd">10398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa38a89ab23143729bc687fe3de028af_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtNS0xLTEtNDY3MDk_f803436b-3a0f-48d9-b716-e78cf3a4f666"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia76de84abd4642d6912042f6e398c5f2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTAtNy0xLTEtNDY3MDk_be16e89e-5c9a-4f12-add7-84ef4a2cf6b0"
      unitRef="usd">10398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b403184690c419ca8ad63e8f06ff051_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMS0xLTEtNTAwNDY_61d5fb17-1b2a-499b-9de9-4236c1f00035"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i892bc082ed364fbcaf928358c35a36a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMy0xLTEtNTAwNDY_bfc38b22-b7a3-4410-b37b-edae7cccb0bd"
      unitRef="usd">7842000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9ef9ba624674f31b18f18a906991514_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNS0xLTEtNTM4MTY_dd0ee9f5-9d47-473d-8d9d-1bd449da9f27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a4d10a2ed2244df86b13b190473888e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNy0xLTEtNTAwNDY_acb45fac-f14d-46ab-858a-050af65f3941"
      unitRef="usd">7842000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida80c3febeab4dc4a386f3c9f4d1da86_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMS0xLTEtNDY3MDk_458c371c-4558-4f77-8a5c-9486d7aeec3c"
      unitRef="usd">16958000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f13704c46b54f4fbf4035b2d602b428_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItMy0xLTEtNDY3MDk_4b151a85-efca-42ef-8cf9-646fd5835d7c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e672eae8a32483281e04e1d168d302e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNS0xLTEtNDY3MDk_02a1d0c3-caa3-48d9-ba60-e282e96bf242"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i513e270303294364a1063483a8eeb9c1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTItNy0xLTEtNDY3MDk_000c110f-b7c9-4e46-a613-3440604ef7bb"
      unitRef="usd">16958000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtMS0xLTEtNDY3MDk_86694ebd-ff52-417d-a74a-ffa6cf7c3619"
      unitRef="usd">16958000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtMy0xLTEtNDY3MDk_efd1e3db-066e-48ea-836e-e9acf445c281"
      unitRef="usd">64993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtNS0xLTEtNDY3MDk_2ab47361-e0e8-4e1b-aaf8-2369b7906126"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTMtNy0xLTEtNDY3MDk_cd3bf29c-69d1-44e6-9d48-a02fb9f4c7ca"
      unitRef="usd">81951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a18ba240d5446bc8347fa7f49ec834c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtMS0xLTEtNDY3MDk_82183953-e3c6-4582-b7f4-94f7971c28d5"
      unitRef="usd">31116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75e9b8d3a75d4d15b02d248652d8c47c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtMy0xLTEtNDY3MDk_00d33249-9d17-400a-8848-f9139a3db4f1"
      unitRef="usd">64993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic9255f0347be4834bcce2c2deeec2732_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtNS0xLTEtNDY3MDk_53e51092-b9ca-47f0-b6ff-25c3fbd658cc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b8aae50d3074837b6dd46d96505a08b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjYxZGU3NTcwNDRjNTQzMzBiMzQzZmEyYWJmZjQzZDdkL3RhYmxlcmFuZ2U6NjFkZTc1NzA0NGM1NDMzMGIzNDNmYTJhYmZmNDNkN2RfMTUtNy0xLTEtNDY3MDk_9095011b-a9bb-489b-bf92-44968f6b8ea9"
      unitRef="usd">96109000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia539bc90716e46c09badc816a75cecca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy0xLTEtMS00NjcwOQ_138006b2-e29e-4b78-8102-af556901de13"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i480abc2b1cc54cd6b4b92497a9b2b557_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy0zLTEtMS00NjcwOQ_7426c3a5-f218-4160-b66a-57c4d7c67106"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a288026edfb48cf85b99f21c805ca40_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy01LTEtMS00NjcwOQ_242875ec-185d-48bc-b6e8-dd33fb2a256a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c2764d1efaa46eb9c63af6bc2f8f380_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMy03LTEtMS00NjcwOQ_68c902ff-dc0e-4501-928e-4853ba4b1f4a"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26052de731df412fb0a0af634dfdb211_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS0xLTEtMS00NjcwOQ_b6320dce-0f74-4970-be56-d1edfd240c1d"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS0zLTEtMS00NjcwOQ_b7f6c02a-cc2c-4cfe-b12a-a9c8179e0f6d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS01LTEtMS00NjcwOQ_5a948854-f901-4b3d-9021-2bffd13639d0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfNS03LTEtMS00NjcwOQ_0247661e-fde2-46fc-9059-650b5375287b"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i377211d696ec45e693cc525f829d66a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC0xLTEtMS00NjcwOQ_3b8b8d8f-bfcd-49ac-b33a-c44609d79fe2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8a48087fd894a06a7d66a19e113dfe3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC0zLTEtMS00NjcwOQ_6f8c853b-a4b5-4945-b21d-17940cc5b164"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i018fdf48beb241fb957140c7fcaac86f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC01LTEtMS00NjcwOQ_59da48b5-5c2b-40ac-a3d5-e237aa1fa2a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7faedaea947747a5a4e0f9b27f03b9cb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOC03LTEtMS00NjcwOQ_499bf55d-7d92-4d8b-a331-6ee9a73c6dec"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0ead035a27f4309bd93a8a213d35ec8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS0xLTEtMS00NjcwOQ_3da8d3d7-8f53-4604-859e-4d41eaafca21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia48c99f9f8d74d1f9306f416c00c75e2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS0zLTEtMS00NjcwOQ_b00b9a04-307a-4bed-b3a2-be4e558978b3"
      unitRef="usd">49535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16048614cfcc4e4fa5865a9839662003_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS01LTEtMS00NjcwOQ_4e36f9b1-2ef0-4df1-a73c-410ea8c66b0b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06ef613858db4f6888a94e03efa94a80_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfOS03LTEtMS00NjcwOQ_8cb0dcf6-9e75-4685-939e-d4114a43e5bc"
      unitRef="usd">49535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb8d6d09727649149a6395ee1730cce9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtMS0xLTEtNDY3MDk_92d0c17e-b354-4dfb-9b74-3360b1460ca9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81e061d7484e40f7b79b0410a81d34ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtMy0xLTEtNDY3MDk_b6cfad38-cabd-4fb3-9d09-7d0153b6bb9f"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f0f79dc42ce4acdbb7a7a3d6e44d0ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtNS0xLTEtNDY3MDk_66ecc51f-b4e0-46cb-98a6-9b098ab53c1c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c5569fef827456f88c86fc64506a47e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTAtNy0xLTEtNDY3MDk_3af53731-21ad-4a10-8518-c1448f03beae"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78ed6fd9046d4b9aad7e2742322a47d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtMS0xLTEtNDY3MDk_c86c84eb-09dd-46af-a967-557e76ba8746"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9703732e3290451893b9ecbdcd26e17b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtMy0xLTEtNDY3MDk_44b7d2b2-3ba2-4fe9-b594-b4fc6ae660f0"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1499c884251e45e7a08301c1113c2751_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtNS0xLTEtNDY3MDk_be9ce39d-5485-4ad7-b9d5-0a05715e1328"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8910674f7c1d4eb3baab8a3e1449ffcd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTEtNy0xLTEtNDY3MDk_a038f068-f4b4-423a-a5e7-3200defa4796"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5efc9d19f6324825ba0f19f6c6910ca8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItMS0xLTEtNDY3MDk_44d171a7-131a-4430-9e9b-11916196070a"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib717e8f89b554e5eb31a6287f9e82e85_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItMy0xLTEtNDY3MDk_f33c3298-424a-4049-b325-aeba9adb42d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i697c1cde53a841b785441aa2b8d391c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItNS0xLTEtNDY3MDk_9c26f8db-2d3d-4f67-b75b-9f967b09c5d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8083c2b5a8b7482f8d5695f5d867a671_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTItNy0xLTEtNDY3MDk_db8e1e38-8b6f-4cc1-b3fd-731b0d786249"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26052de731df412fb0a0af634dfdb211_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtMS0xLTEtNDY3MDk_79daf600-bb9d-4b50-87b1-038debdfccad"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtMy0xLTEtNDY3MDk_2ac18254-9abf-4a65-8cbc-714ea776f035"
      unitRef="usd">81033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtNS0xLTEtNDY3MDk_913a2b2d-8517-43c7-9426-a7a87254b7c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTMtNy0xLTEtNDY3MDk_f2bda5f6-1748-41a2-bc3b-9f9308f45194"
      unitRef="usd">88920000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26052de731df412fb0a0af634dfdb211_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtMS0xLTEtNDY3MDk_16dee509-bda4-487f-bc43-c94e40d70aef"
      unitRef="usd">23609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07f0fe39986f424cb855eb97e5214800_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtMy0xLTEtNDY3MDk_112cd88b-d642-483e-8b0d-344dffb58153"
      unitRef="usd">81033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e187a8a013f49e79490f667b361da3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtNS0xLTEtNDY3MDk_fcaba531-3042-4c09-98a1-50dfaae21509"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i402153b7427c4b18b5c17b418ea38847_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80Ni9mcmFnOjdjZTM4MWQ4ZTY2NjQ5M2RiNWFjMzRlNDcxNDIwMzg3L3RhYmxlOjRmYWEyN2Y5MDIyZDRkNGNhNDg3OWI0OGY4NDU5ZDc3L3RhYmxlcmFuZ2U6NGZhYTI3ZjkwMjJkNGQ0Y2E0ODc5YjQ4Zjg0NTlkNzdfMTUtNy0xLTEtNDY3MDk_49019ce8-5b56-4ac8-b04a-6458a409faa0"
      unitRef="usd">104642000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ5_ca313ec5-65cd-44e2-a1d0-28f275d7682c">Supplementary Balance Sheet Information&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments available for sale&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses in investments available for sale debt securities at March&#160;31, 2023, were substantially due to increases in interest rates, not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ1_b6b8ed62-63ca-4179-9f5f-c54e879c84ac">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy0xLTEtMS00NjcwOQ_50a44503-f684-4ad0-a2df-b2199502541d"
      unitRef="usd">13964000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy0zLTEtMS00NjcwOQ_257457c8-5422-413e-81c2-c580719a5087"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy01LTEtMS00NjcwOQ_83f9dda6-3592-47ae-8f0e-2f88401a3415"
      unitRef="usd">40000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i257ef2c7502e4c17b99a926adafc1eaa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMy03LTEtMS00NjcwOQ_79934e7d-dd81-4a41-8e5d-36f80057dc55"
      unitRef="usd">13925000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC0xLTEtMS00NjcwOQ_d2d257d7-f0bd-4f25-bd41-9bcf136f4a46"
      unitRef="usd">22258000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC0zLTEtMS00NjcwOQ_e1118f1e-a1d7-41df-b33a-0cbdd6c9b2e2"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC01LTEtMS00NjcwOQ_118bf0f5-8d94-488b-ba39-1a24e5b7fbdd"
      unitRef="usd">118000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNC03LTEtMS00NjcwOQ_41dd9262-13e7-44f4-b099-9b80e5fc6e40"
      unitRef="usd">22144000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS0xLTEtMS00NjcwOQ_24b58e64-090d-4269-afea-74d3c4367d09"
      unitRef="usd">10402000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS0zLTEtMS00NjcwOQ_035b0303-9f5c-4e79-96de-0fd85679e77f"
      unitRef="usd">3000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS01LTEtMS00NjcwOQ_1efce7f3-a6e3-4fb6-b857-3c517d3286de"
      unitRef="usd">7000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibf26532bf0944c0db1e554d2d335e401_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNS03LTEtMS00NjcwOQ_5ae6d552-c5dc-41e7-90f7-b86604c20c82"
      unitRef="usd">10398000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy0xLTEtMS01MDE4Mg_50712c2f-8def-44f3-af9f-7a14ab24eca1"
      unitRef="usd">4049000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy0zLTEtMS01MDE4Mg_b0be871f-9a62-45bc-ad4b-e44549a75635"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy01LTEtMS01MDE4Mg_b07677dd-53eb-49f6-a0a0-accee7c80f69"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfNy03LTEtMS01MDE4Mg_53d9fd3e-5c2a-488d-8c9b-6b506b2914ea"
      unitRef="usd">4053000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC0xLTEtMS00NjcwOQ_4107190b-fa2d-4c9a-89a1-ed673b3ce25f"
      unitRef="usd">50673000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC0zLTEtMS00NjcwOQ_b7f8018d-b77b-4ae3-83a7-a498327ed257"
      unitRef="usd">12000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC01LTEtMS00NjcwOQ_c24de179-374a-464a-a369-a59155bd42a3"
      unitRef="usd">165000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfOC03LTEtMS00NjcwOQ_58c7b45f-af1e-458d-b21c-01663b4f0cc1"
      unitRef="usd">50520000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtMS0xLTEtNDY3MDk_364f8599-a3d9-40c0-993d-aa0fc943d270"
      unitRef="usd">10687000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtMy0xLTEtNDY3MDk_7c54e43e-1f88-469c-9484-0b572913f490"
      unitRef="usd">24000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtNS0xLTEtNDY3MDk_c5cb83b9-7527-40c0-a07c-d97f817e361c"
      unitRef="usd">27000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTAtNy0xLTEtNDY3MDk_d0ddae49-4d93-4682-b015-74455b4ae5b2"
      unitRef="usd">10684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMS0xLTEtNTAxNjY_b761840e-7f6c-4764-aebd-cc82fe0180a9"
      unitRef="usd">3781000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMy0xLTEtNTAxNjY_cbf4e1fd-b882-4e8c-adec-fddb67e4c35e"
      unitRef="usd">8000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNS0xLTEtNTAxNjY_43dd7f25-7731-47c8-a5b8-5b6b7ad499df"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie8063b6ae1d14a3ea30a504b5b0451a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNy0xLTEtNTAxNjY_81060b00-4e43-4f34-91d5-1f5316fbfa56"
      unitRef="usd">3789000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMS0xLTEtNDY3MDk_6f943016-ad21-4752-aa9a-ba3a9267fa1b"
      unitRef="usd">16886000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtMy0xLTEtNDY3MDk_5d3f0207-089c-4439-b86f-c5bdf968e0be"
      unitRef="usd">72000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNS0xLTEtNDY3MDk_be3f3b9b-90ea-4887-9836-1a48029e3fc0"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i28bed919b46e4cecb29c4d54fde5db47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTEtNy0xLTEtNDY3MDk_06cdc28a-66cc-4bfd-9848-b9923f4e0f99"
      unitRef="usd">16958000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItMS0xLTEtNDY3MDk_35ab6203-e8ed-44e2-9965-d42e454ee16e"
      unitRef="usd">31354000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItMy0xLTEtNDY3MDk_dcd587f7-468b-4622-8e77-62facd94f2d5"
      unitRef="usd">104000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItNS0xLTEtNDY3MDk_02d91f36-2fbe-4875-852f-6289a6321887"
      unitRef="usd">27000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTItNy0xLTEtNDY3MDk_08de4ae7-8518-49c3-ac6b-c0dd8618d7a6"
      unitRef="usd">31431000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtMS0xLTEtNDY3MDk_3764ddba-8a6b-4dd0-a138-357818eb89e4"
      unitRef="usd">82027000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtMy0xLTEtNDY3MDk_fcbf8041-94ee-4b32-b318-c30fe2449556"
      unitRef="usd">116000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtNS0xLTEtNDY3MDk_df134491-c256-43ec-b1d0-8544c1ac1f2c"
      unitRef="usd">192000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjM2MzAwYjJiM2IzNjQ0OTU5Yzg3MDViMzMwMjYwNTMwL3RhYmxlcmFuZ2U6MzYzMDBiMmIzYjM2NDQ5NTljODcwNWIzMzAyNjA1MzBfMTQtNy0xLTEtNDY3MDk_76d64a23-2395-4a43-b39c-3826735022c3"
      unitRef="usd">81951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i0c11618796914158ab65134841e05e6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy0xLTEtMS00NjcwOQ_2aa53f9e-ba04-492a-a604-74c3dc2ce70b"
      unitRef="usd">16101000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i0c11618796914158ab65134841e05e6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy0zLTEtMS00NjcwOQ_ca752c8e-825e-4239-87bf-8fbf2f9f2059"
      unitRef="usd">3000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i0c11618796914158ab65134841e05e6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy01LTEtMS00NjcwOQ_a84c1a07-74eb-4dc2-be00-240445c1852f"
      unitRef="usd">81000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0c11618796914158ab65134841e05e6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMy03LTEtMS00NjcwOQ_781fd62a-89f8-4a02-8c94-aa13a3fd1aec"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC0xLTEtMS00NjcwOQ_29e18d80-74af-466f-bb84-31ac6f5e5507"
      unitRef="usd">44806000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC0zLTEtMS00NjcwOQ_f8467924-c8a1-4af5-859d-6adf8ebfe13a"
      unitRef="usd">8000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC01LTEtMS00NjcwOQ_da973679-73b7-4528-9e71-6faffa0d6d7f"
      unitRef="usd">275000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNC03LTEtMS00NjcwOQ_99fd3e9e-b0f6-4737-8277-f5b157fa0223"
      unitRef="usd">44539000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS0xLTEtMS00NjcwOQ_bb3b3a65-aa37-48fc-8106-c04fc0bcea2d"
      unitRef="usd">13203000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS0zLTEtMS00NjcwOQ_bfe9907c-8b56-4379-b906-f9d81187ec7e"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS01LTEtMS00NjcwOQ_cb3df61a-0823-440e-99a7-3f3d690d960c"
      unitRef="usd">20000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i179bfe81b1274a7a937ce14950a79b45_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNS03LTEtMS00NjcwOQ_96b906ed-7197-48ea-ac1a-dee8fd761a20"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi0xLTEtMS00NjcwOQ_d678359a-b39e-4887-9ac8-87b16ee8e7dc"
      unitRef="usd">2284000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi0zLTEtMS00NjcwOQ_46cdd498-2efd-40f7-b96e-aca75a919df4"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi01LTEtMS00NjcwOQ_8b5f8beb-f015-4dcc-b135-5e35c4fcb01f"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib47a6f257b464e95b0785df5d930d8e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNi03LTEtMS00NjcwOQ_408a2a5a-237d-4882-acd2-7b8df9749e40"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy0xLTEtMS00NjcwOQ_e7da5c6d-7d3c-4493-a2af-b9b8dc83b595"
      unitRef="usd">7905000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy0zLTEtMS00NjcwOQ_72e20181-4d91-4834-b70c-af6987aebdc5"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy01LTEtMS00NjcwOQ_6b8a1d97-2aee-492a-8dc3-451c44ee8c99"
      unitRef="usd">18000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic1c7a694fbd140b28864630b1eb4070b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfNy03LTEtMS00NjcwOQ_0468c5d3-8e46-4156-8c43-003ecee4bc15"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC0xLTEtMS00NjcwOQ_e2a38226-83a0-4ece-886f-7d4aa2ac7a68"
      unitRef="usd">84299000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC0zLTEtMS00NjcwOQ_5033ed02-267b-44a1-92d6-abe70ca22452"
      unitRef="usd">19000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC01LTEtMS00NjcwOQ_702becf0-293f-4c76-a490-58213c0f9215"
      unitRef="usd">394000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfOC03LTEtMS00NjcwOQ_df95ec6e-98b1-42d9-b6d4-77747e5375a9"
      unitRef="usd">83924000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtMS0xLTEtNDY3MDk_070f46f9-d5d7-4dbe-be75-33476de8a240"
      unitRef="usd">5016000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtMy0xLTEtNDY3MDk_ad27f1b6-1514-445f-9b03-5bfff382c9a4"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtNS0xLTEtNDY3MDk_0c48d594-c046-4a59-895a-126380974924"
      unitRef="usd">21000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i75e356158c614afd81168c0f32199528_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTAtNy0xLTEtNDY3MDk_46769219-bc08-4d7c-b291-38f5f6d306c1"
      unitRef="usd">4996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItMS0xLTEtNDY3MDk_4981078a-bfd6-49b3-91a7-add6a08777cd"
      unitRef="usd">5016000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItMy0xLTEtNDY3MDk_8f64e3ee-efc1-4589-98fb-aaa00b3cd52c"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItNS0xLTEtNDY3MDk_94696363-b21d-4597-98aa-3e286f60e196"
      unitRef="usd">21000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTItNy0xLTEtNDY3MDk_0d0aebd2-dbb8-4582-920e-35f1ae1a6751"
      unitRef="usd">4996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtMS0xLTEtNDY3MDk_c03e4359-5cdb-4668-b692-ae78871f7071"
      unitRef="usd">89315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtMy0xLTEtNDY3MDk_92fb2c01-c5fc-4267-8ead-34ad5c5a4316"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtNS0xLTEtNDY3MDk_8b2fe51f-d33a-43c7-b3d9-2a74287ef06e"
      unitRef="usd">415000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmM5OTk3MTM4NmViMzQ5MDdhNTQyOTA5ZDg5MWJjZjU0L3RhYmxlcmFuZ2U6Yzk5OTcxMzg2ZWIzNDkwN2E1NDI5MDlkODkxYmNmNTRfMTQtNy0xLTEtNDY3MDk_c9c33138-41f8-4606-af36-0c907dd642ee"
      unitRef="usd">88920000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ0_0e482f45-6be3-4f50-8fd8-3a5d05fbda58">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmQyNTIyYTFiZmExZTQ0ZWFiYmNkNzg4YjllZWQ4OGNlL3RhYmxlcmFuZ2U6ZDI1MjJhMWJmYTFlNDRlYWJiY2Q3ODhiOWVlZDg4Y2VfMy0xLTEtMS00NjcwOQ_86f34a95-c71c-4514-be12-613e57c87e30"
      unitRef="usd">8151000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0dabcab786cc401a8d99c89cf5a850b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmQyNTIyYTFiZmExZTQ0ZWFiYmNkNzg4YjllZWQ4OGNlL3RhYmxlcmFuZ2U6ZDI1MjJhMWJmYTFlNDRlYWJiY2Q3ODhiOWVlZDg4Y2VfMy0zLTEtMS00NjcwOQ_5e58bfba-0dfa-4e80-8705-e411cb044fec"
      unitRef="usd">58000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODM5_c3e32121-da8d-4370-a25d-1d593af7014e">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5126a1d0a76b4750b3c4596fed29b417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMS0xLTEtMS00NjcwOQ_4e2966de-bc9b-40de-8379-3fc4db0f4a0f"
      unitRef="usd">1066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i71dab6497dbc4a9cad98744b1d6939ff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMS0zLTEtMS00NjcwOQ_81d5c020-20d7-4b8a-b5b7-4b118854adc5"
      unitRef="usd">1066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i12564752dbbc4764bc02ded3b8f49b4c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMi0xLTEtMS00NjcwOQ_9ee19013-dc1a-4a7f-8d23-6eb9003d8a1f"
      unitRef="usd">2560000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5702ca6a9f36479296c15ba3f0c29b9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMi0zLTEtMS00NjcwOQ_e94849ff-cb94-4133-8430-9d56cb6b5d7a"
      unitRef="usd">2560000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib815e5c326e04a1ca507261df4fef728_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMy0xLTEtMS00NjcwOQ_6bb8cfae-d998-41a5-b5d2-828e29fed8aa"
      unitRef="usd">1153000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i159aae27f4f5465b9e015d53d086eadd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfMy0zLTEtMS00NjcwOQ_10e775e4-e13f-4b85-8057-f29a0f35db1c"
      unitRef="usd">1056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNC0xLTEtMS00NjcwOQ_e1fd60c2-179e-4968-a1a0-1baa44a16648"
      unitRef="usd">4779000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNC0zLTEtMS00NjcwOQ_8235c970-ed34-4473-8104-4869e30ea070"
      unitRef="usd">4682000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNS0xLTEtMS00NjcwOQ_22b36df8-5841-4f19-a209-b63cfc3a2a6b"
      unitRef="usd">3459000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNS0zLTEtMS00NjcwOQ_fe9715c0-294a-41ab-a2c1-15c71f9550c2"
      unitRef="usd">3413000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNi0xLTEtMS00NjcwOQ_aed883ed-af66-4c13-b62b-efc2ae3b1ae2"
      unitRef="usd">1320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOmE4ZjRjOTBmMmQyYzQxNTA5MjlmOTVlY2ZiMWFhMDYxL3RhYmxlcmFuZ2U6YThmNGM5MGYyZDJjNDE1MDkyOWY5NWVjZmIxYWEwNjFfNi0zLTEtMS00NjcwOQ_7fe35d14-d8ee-4e1f-9086-ffe454bebfaf"
      unitRef="usd">1269000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RleHRyZWdpb246MTc1N2YxMTcxYjRhNDBkNWI5YTI2NmRkN2I0ZjYxOGNfODQ4_30a300c3-e1a5-4dee-b43f-895a878ea202">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMS0xLTEtMS00NjcwOQ_f3769189-da0b-465c-aa93-6b92af3020de"
      unitRef="usd">983000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMS0zLTEtMS00NjcwOQ_f6d4a77a-dd79-4afa-9e8c-5f08d9bd4c5b"
      unitRef="usd">1849000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <crdf:AccruedClinicalTrial
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMy0xLTEtMS00NjcwOQ_d175082b-8e04-4eef-9b42-b080bf2c05da"
      unitRef="usd">2709000</crdf:AccruedClinicalTrial>
    <crdf:AccruedClinicalTrial
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMy0zLTEtMS00NjcwOQ_e6d54f89-f537-4d00-acb6-a8147897458a"
      unitRef="usd">2333000</crdf:AccruedClinicalTrial>
    <crdf:AccruedResearchAgreements
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNC0xLTEtMS00NjcwOQ_368ea328-f73b-4ba4-a145-6602cd238297"
      unitRef="usd">571000</crdf:AccruedResearchAgreements>
    <crdf:AccruedResearchAgreements
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNC0zLTEtMS00NjcwOQ_fe7f5949-7b97-47ba-9e39-ec9fff3c03a6"
      unitRef="usd">509000</crdf:AccruedResearchAgreements>
    <crdf:AccruedDirectorFees
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNS0xLTEtMS00NjcwOQ_ee5d745e-90f1-44ba-acb8-b915e739b462"
      unitRef="usd">125000</crdf:AccruedDirectorFees>
    <crdf:AccruedDirectorFees
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNS0zLTEtMS00NjcwOQ_dea147d2-b21d-4874-a00b-4e6f116db708"
      unitRef="usd">125000</crdf:AccruedDirectorFees>
    <crdf:PatentLicenseAndOtherFeesPayable
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNy0xLTEtMS00NjcwOQ_1ed083c6-0c89-4496-8c73-bb2770176fef"
      unitRef="usd">59000</crdf:PatentLicenseAndOtherFeesPayable>
    <crdf:PatentLicenseAndOtherFeesPayable
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfNy0zLTEtMS00NjcwOQ_080ff5d3-73f9-4b85-961a-96b75f062671"
      unitRef="usd">24000</crdf:PatentLicenseAndOtherFeesPayable>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfOS0xLTEtMS00NjcwOQ_86d3fe0d-a80c-4a65-ac8c-a7f7cb3d4337"
      unitRef="usd">108000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfOS0zLTEtMS00NjcwOQ_dd4f3c33-ab0b-43cf-980b-dddbcde63420"
      unitRef="usd">337000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMTAtMS0xLTEtNDY3MDk_245d2e66-a362-4ec5-826d-1609cd35e22a"
      unitRef="usd">4555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV80OS9mcmFnOjE3NTdmMTE3MWI0YTQwZDViOWEyNjZkZDdiNGY2MThjL3RhYmxlOjZkODAyYTYyZjMwYTQ1ZmVhMjgwY2U1MTE3MmUyYzNiL3RhYmxlcmFuZ2U6NmQ4MDJhNjJmMzBhNDVmZWEyODBjZTUxMTcyZTJjM2JfMTAtMy0xLTEtNDY3MDk_ba638a98-8af7-4b7c-b72a-a94411ff9bff"
      unitRef="usd">5177000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzcy_49f7edbc-b888-4329-a6b5-2ead1d339a6e">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently leases office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $61,000 per month with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (excluding the three months ended March&#160;31, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzc3_5f35621f-09fe-48dd-a927-5cdeebacdacd">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently leases office and lab space in San Diego that expires on February 28, 2027. The lease currently requires monthly payments of approximately $61,000 per month with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (excluding the three months ended March&#160;31, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfMzc2_e5686d4d-d448-4f9a-ab2e-7990f779d5e8"
      unitRef="usd">61000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfMzk0_115227dc-5c1b-4a94-b4de-7be0369abe61"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzcz_f43c8b19-0738-4bb0-9c24-9213af7ad799">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfMi01LTEtMS00NjcwOQ_283b69d4-6c39-47ec-ab80-bda242362e65"
      unitRef="usd">183000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfMi03LTEtMS00NjcwOQ_4b09625d-47ec-490f-ace4-cf532934a1a2"
      unitRef="usd">191000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfNC01LTEtMS00NjcwOQ_b66db059-4154-4b3e-91fd-170bc3f0e509"
      unitRef="usd">183000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjgxM2JjMTQ3N2Q5MjRjNjJhNWJiYTQ5YjljYjdjNTY5L3RhYmxlcmFuZ2U6ODEzYmMxNDc3ZDkyNGM2MmE1YmJhNDliOWNiN2M1NjlfNC03LTEtMS00NjcwOQ_51baef62-94c6-4d1c-8b5f-506a191f5f9e"
      unitRef="usd">191000</us-gaap:LeaseCost>
    <crdf:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzY4_0c2943a0-1071-4052-a119-8241ea565e6f">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMS0xLTEtMS00NjcwOQ_00a88e89-ef69-4001-8968-941eeaee9975"
      unitRef="usd">2115000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMS0zLTEtMS00NjcwOQ_2692443b-9d51-4e37-ab20-ff02c869255d"
      unitRef="usd">2251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMy0xLTEtMS00NjcwOQ_1f1ee8b0-c505-4b76-a18c-a0efb33caac9"
      unitRef="usd">679000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfMy0zLTEtMS00NjcwOQ_3a630c04-f18b-4fbd-a021-85564a9f6c19"
      unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNC0xLTEtMS00NjcwOQ_5e128f6a-485a-4ac4-b5f9-f8b9a625777b"
      unitRef="usd">1898000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNC0zLTEtMS00NjcwOQ_6cb23390-c471-4d2e-883d-340f4ee0db13"
      unitRef="usd">2040000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNS0xLTEtMS00NjcwOQ_b9d3b909-f043-4f30-81d4-438e2e3158fc"
      unitRef="usd">2577000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNS0zLTEtMS00NjcwOQ_dd44e147-734c-4483-8a88-92d44bc4c5b9"
      unitRef="usd">2715000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNy0xLTEtMS00NjcwOQ_584d6549-8d82-43b7-bae8-cf6dbbd75b63">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfNy0zLTEtMS00NjcwOQ_85f9c522-9792-4e04-8554-653e0c218993">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfOC0xLTEtMS00NjcwOQ_d854f8c7-c637-4389-a588-55d671915d2f"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjg5MjNjMWExZmEzYzRhMzNiMTE4YzFkZDE2MzBlNWRhL3RhYmxlcmFuZ2U6ODkyM2MxYTFmYTNjNGEzM2IxMThjMWRkMTYzMGU1ZGFfOC0zLTEtMS00NjcwOQ_85d128e5-593e-4a80-a805-6922368aedae"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOmE2OGQ4MjUwYzRmOTRhYzA5OGFjZmFlYmM1ZDhlODU5L3RhYmxlcmFuZ2U6YTY4ZDgyNTBjNGY5NGFjMDk4YWNmYWViYzVkOGU4NTlfMy01LTEtMS00NjcwOQ_9d4fdefb-9012-4ad4-866e-faaa6d2fad7f"
      unitRef="usd">185000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOmE2OGQ4MjUwYzRmOTRhYzA5OGFjZmFlYmM1ZDhlODU5L3RhYmxlcmFuZ2U6YTY4ZDgyNTBjNGY5NGFjMDk4YWNmYWViYzVkOGU4NTlfMy03LTEtMS00NjcwOQ_c6a22a3c-576b-40b9-9eb2-9c1b61c6ae3d"
      unitRef="usd">70000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RleHRyZWdpb246YWNiZWI2Y2Q0MGFkNDUxZjlhOTZiZjNjOTlmZjliOGFfNzY0_4e800014-c771-452c-b9ef-8928741e399e">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (excluding the three months ended March&#160;31, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNC0xLTEtMS00NjcwOQ_6542f794-8065-43b0-bbec-f8cd48db76b5"
      unitRef="usd">491000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNS0xLTEtMS00NjcwOQ_0716b6d8-22b2-431b-ad0e-59c83d57438d"
      unitRef="usd">754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNi0xLTEtMS00NjcwOQ_4c185e43-e2fc-4e0e-82e6-f226631efb33"
      unitRef="usd">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfNy0xLTEtMS00NjcwOQ_4b5c3376-71ae-4c68-9b40-c4375c5abeb8"
      unitRef="usd">796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfOS0xLTEtMS00NjcwOQ_d6f005f7-0cf3-4c79-969c-3a0aaf179ad3"
      unitRef="usd">136000</crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTAtMS0xLTEtNDY3MDk_70044bf6-56f9-4946-95f8-67ca16b50f6c"
      unitRef="usd">2952000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTEtMS0xLTEtNDY3MDk_09076220-f427-4eac-b9d6-663010ba8aa2"
      unitRef="usd">375000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81Mi9mcmFnOmFjYmViNmNkNDBhZDQ1MWY5YTk2YmYzYzk5ZmY5YjhhL3RhYmxlOjRjYWQwYTU2Y2I3ZTQxMTM5OWYyODdjMzI5MGQ0NmZlL3RhYmxlcmFuZ2U6NGNhZDBhNTZjYjdlNDExMzk5ZjI4N2MzMjkwZDQ2ZmVfMTItMS0xLTEtNDY3MDk_78de2b20-c611-4b79-8321-67f47ab7d575"
      unitRef="usd">2577000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY4Mg_bad3e109-314c-45e1-ae2c-ba4ba09197aa">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at March&#160;31, 2023, net of estimated forfeitures, was $10.1 million, which is expected to be recognized over a weighted-average remaining vesting period of 2.7 years.&#160;The weighted-average remaining contractual term of outstanding options as of March&#160;31, 2023, was approximately &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5 years. The total fair value of stock options vested during the three months ended March 31, 2023 and 2022, were $1.9 million and $1,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The expected term for options granted after January 1, 2023 is estimated based on the Company's historical employee data. Prior to January 1, 2023, the Company used the "simplified method" to estimate expected term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,187,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 Plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022, the shareholders approved an increase of shares authorized in the 2021 Plan to 5,150,000 from 3,150,000. As of March&#160;31, 2023, there were 2,180,898 shares available for issuance under the 2021 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of March&#160;31, 2023, an aggregate of 1,345,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY4NA_2ea42fb3-1d5a-4a04-a88a-d1f3e59dcf59">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieaeff0f9b3d243b4a63f8742a58aa35b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfMy01LTEtMS00NjcwOQ_eae3bfaf-3136-4d01-be06-d75764fbb7b1"
      unitRef="usd">394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0322636ad15484f8481e2fe8512a156_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfMy03LTEtMS00NjcwOQ_34b7313d-e4fb-42f2-9da5-af4118c0f730"
      unitRef="usd">335000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia65d202a9f424f4cbe0609279095d19a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNC01LTEtMS00NjcwOQ_50f2b2ab-8408-4c09-8e6d-e9320028daff"
      unitRef="usd">670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a4a5e322fb148e2b3a3f3d9b7aff411_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNC03LTEtMS00NjcwOQ_50cf1f11-7994-49c1-b322-f33bf6c8966d"
      unitRef="usd">817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNy01LTEtMS00NjcwOQ_4bb3d810-ee09-4375-8ccb-1af99690ad23"
      unitRef="usd">1064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmVlYmIzODE1M2EwZTQyODg5ZGJkODZiOTAyNDNhOTc2L3RhYmxlcmFuZ2U6ZWViYjM4MTUzYTBlNDI4ODlkYmQ4NmI5MDI0M2E5NzZfNy03LTEtMS00NjcwOQ_1d403a6c-2dab-4876-a5b8-7ddeb90fdcb4"
      unitRef="usd">1152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMzA2_68e474fc-5410-4f40-b6b9-1956fc43283e"
      unitRef="usd">10100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMzk3_781081c7-cf5f-4329-ac57-c33ad3c0ff66">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTAw_c76a1730-451e-4604-b051-07390d88dd51">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTc2_f84341bf-2243-44d7-82d6-888791ab5f76"
      unitRef="usd">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfNTgz_7dda679b-0aa7-43db-bfae-53fb4499ddba"
      unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2Ng_a6641ba4-57ed-4d49-9f6f-c2b373c718c3">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMi0xLTEtMS00NjcwOQ_7cfc1494-98cd-4263-af5b-d88d5cb9c8a4"
      unitRef="number">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMi0zLTEtMS00NjcwOQ_00b71b79-10f6-4d70-a08c-a0f4ff905c23"
      unitRef="number">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMy0xLTEtMS00NjcwOQ_e3d06aa0-5966-4aaf-87c1-9350bc96381c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfMy0zLTEtMS00NjcwOQ_e707703e-d278-4c51-a2c4-af558db1db12"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNC0xLTEtMS00NjcwOQ_239c891f-8633-4600-92b1-88a262e20605"
      unitRef="number">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNC0zLTEtMS00NjcwOQ_1096459f-83d3-406b-af50-761ced7bd68f"
      unitRef="number">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNS0xLTEtMS00NjcwOQ_6f556fcd-f79b-4b56-b403-c1c095d783df">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d2aaae3163347d1bf6edcb0b1aa971b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjJlN2YxODRjMTUwMjQwZjQ4NDE0Y2M0OTJhZTk1MmVhL3RhYmxlcmFuZ2U6MmU3ZjE4NGMxNTAyNDBmNDg0MTRjYzQ5MmFlOTUyZWFfNS0zLTEtMS00NjcwOQ_7fd62302-bc06-4bb0-8632-14b6759f5890">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2Mw_41f04b5d-4f24-42f7-be90-af08b23837b9">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,187,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS0xLTEtMS00NjcwOQ_f472371c-686b-488d-9b0f-48d84a1047ec"
      unitRef="shares">5069458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS0zLTEtMS00NjcwOQ_7eb66b98-1ddb-46e8-b534-90dcfba653dd"
      unitRef="usdPerShare">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9a6ecc60f1194619954b3f1533e7e224_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMS01LTEtMS00NjcwOQ_6b8d19bf-00c1-45e9-b348-215f94129653"
      unitRef="usd">19322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMi0xLTEtMS00NjcwOQ_2c8fe54f-c14c-420c-aa6f-10d4c519219a"
      unitRef="shares">1806008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfMi0zLTEtMS00NjcwOQ_737eb0f1-fd5c-4f02-9285-924532ef14be"
      unitRef="usdPerShare">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNC0xLTEtMS00NjcwOQ_b15ae540-559d-4f92-a41a-22199f293a8f"
      unitRef="shares">1725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNC0zLTEtMS00NjcwOQ_22167702-db54-4317-9a07-5856543ee740"
      unitRef="usdPerShare">7.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNS0xLTEtMS00NjcwOQ_9e177c93-b21d-4d96-b25e-05544c189e71"
      unitRef="shares">476846</crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="i70854879aa3545448398e24f78c213d1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNS0zLTEtMS00NjcwOQ_312bf183-306d-458f-8b7c-0f1c887ce188"
      unitRef="usdPerShare">6.93</crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi0xLTEtMS00NjcwOQ_28192e46-bc9b-4117-aafc-140da1ba1c49"
      unitRef="shares">6396895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi0zLTEtMS00NjcwOQ_dd37f680-e4fc-416a-b7f3-01bf975b63a8"
      unitRef="usdPerShare">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNi01LTEtMS00NjcwOQ_ae43bde6-3bd9-42ef-8844-247f087733e3"
      unitRef="usd">34107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy0xLTEtMS00NjcwOQ_1044a72a-c6c0-44d8-a30d-552e9d257af9"
      unitRef="shares">2427304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy0zLTEtMS00NjcwOQ_c1c2146a-0ee2-4c8b-8c63-db11594f9998"
      unitRef="usdPerShare">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfNy01LTEtMS00NjcwOQ_cf7669e8-f234-4ee3-ac53-bcd2c439500e"
      unitRef="usd">20517</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC0xLTEtMS00NjcwOQ_8d6538bb-afcf-4ef9-987f-c359738e7f2f"
      unitRef="shares">6187656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC0zLTEtMS00NjcwOQ_beb67409-2c87-4349-80e3-72d6e17b1649"
      unitRef="usdPerShare">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="iaa186393af9947d7bf2ba374ed2adbf7_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmFmNDg2NjY2MGY5ODRjMGJiMGUxZDM0NmE4OTA4YjYyL3RhYmxlcmFuZ2U6YWY0ODY2NjYwZjk4NGMwYmIwZTFkMzQ2YTg5MDhiNjJfOC01LTEtMS00NjcwOQ_3d55169f-5f19-4357-8d71-116ed2d4e303"
      unitRef="usd">33160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTEzNQ_49166e77-e9fa-4d16-a1a7-9caa3ef74062"
      unitRef="shares">3150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7083de34860a440bb7091d697390058a_I20220609"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQyOA_d2c1d105-1b81-47b1-803b-808447940338"
      unitRef="shares">5150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3a4251f19c164493b2b76424bd16af85_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQzNg_49166e77-e9fa-4d16-a1a7-9caa3ef74062"
      unitRef="shares">3150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic1bf0ee8aea9404384a42f661f35f008_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTQ2MQ_c29d97e8-5c52-4fef-ab40-baa9a803bbb1"
      unitRef="shares">2180898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i027341bbc88b4f83ab80a25ed8de872e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMTgzNw_3f77d7a0-00fc-497f-8656-7c85a3cc335c"
      unitRef="shares">1345208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY3NA_9e929aa2-ac83-46f0-b926-b9902c52d475">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS0xLTEtMS00NjcwOQ_889e82c4-b511-44b7-b5ba-2cd2b34da8b3"
      unitRef="shares">4360968</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i4a3ac9c6f1af4cc0bc6f5c7248570134_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS0zLTEtMS00NjcwOQ_40e7e44b-66e8-426f-9cdf-3b25316cc6ea"
      unitRef="usdPerShare">5.33</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="ide0886b6ea844e829c14276a57c0e37f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfMS01LTEtMS00NjcwOQ_d38223f7-24ec-451e-b789-a0c5b5120bb9">P2Y1M6D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNC0xLTEtMS00NjcwOQ_ec33050d-d9c8-4039-898a-bdebacb84bc7"
      unitRef="shares">64496</crdf:ClassOfWarrantOrRightExpiredDuringPeriod>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNC0zLTEtMS00NjcwOQ_c6028de2-0051-486f-afb9-fe73c4ae39a9"
      unitRef="usdPerShare">101.52</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS0xLTEtMS00NjcwOQ_60715707-89aa-41a5-9708-cffb24ad1627"
      unitRef="shares">4296472</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="id39cc1c335a2480bb994dbe1468e726e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS0zLTEtMS00NjcwOQ_0d78233f-a72e-4bbf-a2cf-94491106b199"
      unitRef="usdPerShare">3.89</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOmU1ZDFjMjFkZjBmYjRlNWViNmM1ZTBhM2E0ZDliY2MxL3RhYmxlcmFuZ2U6ZTVkMWMyMWRmMGZiNGU1ZWI2YzVlMGEzYTRkOWJjYzFfNS01LTEtMS00NjcwOQ_97080410-f80a-4d5d-9c48-a1c624f4dfc8">P1Y9M18D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RleHRyZWdpb246ZDRlYTU2ZDJiODZiNGIxOGEyOTQyOWY4ZTMzNTkwZWVfMjY2OQ_997a9b9c-cac5-4c49-9188-78202f235a2f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi0yLTEtMS00NjcwOQ_0ea89f27-f71c-4488-91c5-abd8ad4637ad"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi00LTEtMS00NjcwOQ_2edd3d29-3dca-4985-8e71-24dd0faa1876"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi04LTEtMS00NjcwOQ_8d775004-d2c2-41ba-9f19-75bee170e798"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i29d8a3984a4442faa0609e1a6e8e6e77_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMi0xMC0xLTEtNDY3MDk_1ec0fe85-5529-426a-bdc7-aef34203fc74"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i09428b9805e4498b813fd5573384236f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy0yLTEtMS00NjcwOQ_5ddf6de1-ef0a-482b-bc31-25cb5dbb9a66"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i09428b9805e4498b813fd5573384236f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy00LTEtMS00NjcwOQ_7c392638-136e-4788-a941-d3d426e414da"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i09428b9805e4498b813fd5573384236f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy04LTEtMS00NjcwOQ_a65b42e6-5835-49ba-86f0-1c95fc53ea15"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idb7d01a9fe044b8e98c079c7e41f1974_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfMy0xMC0xLTEtNDY3MDk_19e0acee-0cb7-4c8b-9360-8c32d667d973"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC0yLTEtMS00NjcwOQ_2f33b071-c067-439a-a405-ca85468d004f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC00LTEtMS00NjcwOQ_1bdc49a6-f702-4869-b360-48fa2791ffb4"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0242e50efc164b19b23a214ef33fdeea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC04LTEtMS00NjcwOQ_08983c2e-fcee-4386-a78b-12cdd1305b97"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if640bbe0a9704fa8a6e92d02c5bd50ac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNC0xMC0xLTEtNDY3MDk_026985c7-9a69-4a8f-b00c-0c7bb950421a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS0yLTEtMS00NjcwOQ_49eeb84c-e1c5-42d3-a3a9-013737b3c623"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS00LTEtMS00NjcwOQ_28b7da63-ad11-403e-b372-02191487b69c"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9b33ec557e9a4cdfac469ce46d23b3ec_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS04LTEtMS00NjcwOQ_da5b49a7-2cb3-454c-a33b-771fd9351966"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1de3c3d99592416a9ecb1656c220de10_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNS0xMC0xLTEtNDY3MDk_265597f8-9858-409a-a3fe-9269763ac50f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi0yLTEtMS00NjcwOQ_64589c39-7f42-4840-9788-25af8917503c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi00LTEtMS00NjcwOQ_da9dcf6e-2461-4db5-acfe-fc299429f81c"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib7223daf79bf460387c65ef8a997c31b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi04LTEtMS00NjcwOQ_784b3516-8c1f-4785-b54d-2fc73768c40f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8a1b8cd013904ade8b00a3ec6d18c509_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV81OC9mcmFnOmQ0ZWE1NmQyYjg2YjRiMThhMjk0MjlmOGUzMzU5MGVlL3RhYmxlOjIwYzE3NDI2YzQyYjRhMTZhMzBmNDExYWMyY2VmZjRkL3RhYmxlcmFuZ2U6MjBjMTc0MjZjNDJiNGExNmEzMGY0MTFhYzJjZWZmNGRfNi0xMC0xLTEtNDY3MDk_d7d07e25-5a4e-4e39-b16b-44eab2d887a7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTk0Mg_1a1b90f9-a87e-4126-9292-296618618be4">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: (a) dosing of the first subject in the first Phase III Clinical Trial for the first Product, a registration enabling Phase II Clinical Trial, or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and (b) upon filing of the first NDA or equivalent for the first product candidate. During the three months ended March&#160;31, 2023 and 2022 no milestone or royalty payments were made. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The Company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three months ended March&#160;31, 2023 and 2022, payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise &lt;/span&gt;&lt;/div&gt;from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
      contextRef="i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTA5OTUxMTYzMTAyOQ_355e6bfd-8c96-48b3-a94b-ffbc58af9b37"
      unitRef="usd">0</crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade>
    <crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
      contextRef="i625cb66267e34938aa47627512641649_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3Y2M4NWZhYzY0YzQ3NzQ4ZjAwZDc1ODYyYTlmOWZlL3NlYzo2N2NjODVmYWM2NGM0Nzc0OGYwMGQ3NTg2MmE5ZjlmZV82MS9mcmFnOmQ1NTE4ZDQyMGVhZDQzY2NhOTU3ZGY2MjFmYjQ5OTZlL3RleHRyZWdpb246ZDU1MThkNDIwZWFkNDNjY2E5NTdkZjYyMWZiNDk5NmVfMTA5OTUxMTYzMTAyOQ_ba71fe4b-0896-4d19-b49e-1b0b7b9b5ea0"
      unitRef="usd">0</crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>5E.Z;XQY3<J6J33/B>NXW8:X./]\ F$-=S=A=MHOLZ 6V? -7R=-_CFBBK
MNE2$+\D7EM$L9#0A,RZ9*;1?HX54 LOM=Y/5DMMKYM9;\$+F-(2AA7M,@EB#
M%7S\T/:=STW&_Q/93AHZ=1HZ^]B#&6X?$ (B@C47/IP3&6,!2$(+%7/!_N*+
M4USW<O2L*14E?]?PZ\-C'>!18GX#>[UM\X# '0M>;<';:^&:/18LHF;5<F,'
MLA":I)8\_I:"MM-]*;,IR/.:)79KB=V]$L<\35%=E>*<"K*F20$FM7I_Y2#*
M%#=FN.3N;2ER6IBU]@OA[X;M2/=KZ?X1TH^N#O_5HK>[S>5Q2.2.@U[MH'>\
M R9E\;[ZWBM-GN?W>J_%'Q"XH[U?:^\?KQUO9:GP$&;9ZCT#_4,-'!!8&K"W
M+AU]X>.QOF*9) DL$>JT>L@ARDNT["B>FWMHP17>:J89XW<'"!V [Y><J^>.
MOMKJ+YG@'U!+ P04    "  7@*16R?%W<Z$$  "H$   &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;*U8;6_B.!#^*U9N=6JEMHD37GN 1&E76VG[HL+>
M?CC=!T,&$C6).=M ^^]O[$!XB9/M2OU28F=F\CR>L1]/>QLN7F4$H,A;FF2R
M[T1*+:]=5\XB2)F\XDO(\,V<BY0I'(J%*Y<"6&B<TL3U/:_EIBS.G$'/S#V+
M08^O5!)G\"R(7*4I$^\WD/!-WZ'.;N(E7D1*3[B#WI(M8 SJQ_)9X,@MHH1Q
M"IF,>48$S/O.D%Z/:%<[&(N_8]C(@V>BJ4PY?]6#^[#O>!H1)#!3.@3#GS6,
M($ET),3QWS:H4WQ3.QX^[Z)_->21S)1)&/'D9QRJJ.]T'!+"G*T2]<(WWV!+
MJ*GCS7@BS5^RV=IZ#IFMI.+IUAD1I'&6_[*W[4(<.& <NX._=?!/'1H5#L'6
M(3!$<V2&UBU3;- 3?$.$ML9H^L&LC?%&-G&FTSA6 M_&Z*<&HZ?'V[O'\=TM
MP:?QT_?[V^$$!^,)_CS</4[&Y.DK>7J^>QE.[M& 7)(?XUMR]N6<R(@)D"3.
MR"3B*\FR4%Z0+T?CGJL0HOZ0.]O"N<GA^!5P O+ ,Q5)<I>%$![[NTBMX.?O
M^-WXM0$?F+@B ;T@ON<'%CRCC[O[-7""8KD#$R^HB'>?S7@*9*R8 MP,BOPS
MG$HEL)C_M2U6'JQA#Z9W^+5<LAGT'=S"$L0:G,&??]"6]Y>-Z2<%.^+=*'@W
MZJ(/7O@[2U0,UI+(75O&51\[ZT$'4[4^Q%XV:3<*DR-$S0)1LS83(RZ5)%BE
M!-[P3)0@KVW8FI^9@4\*=L2W5?!MU6< (S(QBPSE$-9X@"]U!=I(YY&:!ZO=
M]9K^24K*1FW?Z]B3TBY MFM!CO$XC[/%!5E !H(E!BP+\=R+]2[1)[X-;[L$
M)?!*)60QZC8\.]Y.@;=3BW?"%8)$3=78LD512C:0G=+WJ4^#Y@E*BQ6EC8IE
M[18PN[4POW,IR5SP= >59U:(W=+'+ZE?SKS-C'I5&Y)Z>RGR:F'>9PJP\!5J
MB#XE+T@&UO+<ACFJSX-,YB M1C2H2#<]4$M:"_%)12"V^,C9-MWGU4BI;:GH
M*52+5:-; =7?0_4_4IN_"=@O0>GXW5.\%B-: 7<OC+16?P:/>&5-L$ZMJ +;
M,OK^Z1:WVGG=;E !;J]>M%Z^GO%N"4) 2/!"-GLE8;R.0\"S:<G>V30!@A?2
M,0C4-S(D(YZM0:A8S^\=Q]K12JY1!MTZ)59K<TQJ+X"T5F^*%2=,*1%/5\HP
M49Q@K:1(R%"->!*"L&>E61)EDY52N=CL,"M5%;Y7-%HO:04!/-0*T/I6BK=4
MO-K',W*&M]&0)PD3N9%Y>VXEDW^J<PC2N_)/C^=?FAU3V>L>K1>^.BIAG*P4
M5M!OD&E_C,ROS([)[$61UJOB3],[07C)<!]@+[AK%;"+E H572OE88;RUW8F
M93UL-%KM]BD3BUG@!U6'TEXW:;UP?HS)88+JN)1UT\K%8F;AXA[T?"F(A6F%
M)=;.*E-Y>U3,%NWVT#29)_,WN@TWO>0^3-[#8_.SB#-)$IAC2.^JC9A$WA;G
M \67IK.<<H5]JGF,@.%YH0WP_9QSM1OH#Q3_G!C\#U!+ P04    "  7@*16
M7,IV-UX#  "P"0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U676_B
M.!3]*U9F-)J1EN:+CZ8#D2AE-)6V!35T]F&U#R:Y$*M.S-@&9O;7[W5"4Z!N
MM ]]@=B^Y_B<>_TUW OYI'( 37X5O%0C)]=Z<^6Z*LVAH.I";*#$D960!=78
ME&M7;230K (5W T\K^\6E)5./*SZYC(>BJWFK(2Y)&I;%%3^O@8N]B/'=YX[
M'M@ZUZ;#C8<;NH8$].-F+K'E-BP9*Z!43)1$PFKDC/VK263BJX ?#/;JZ)L8
M)TLAGDSC-ALYGA$$'%)M&"C^[6 "G!LBE/'SP.DT4QK@\?<S^[?*.WI94@43
MP?]BF<Y'SJ5#,EC1+=</8O\=#GYZAB\57%6_9%_'#D*'I%NE17$ HX*"E?4_
M_77(PQ$ >>R X  (S@'=-P#A 1!61FMEE:T;JFD\E&)/I(E&-O-1Y:9"HQM6
MFBHF6N(H0YR.)[/[F^E],KTAR6*\F-Y-[Q<)F7TCD]G=_&'Z'8=N?TS)G[,D
M(1WRF-R0SQ^_D(^$E621BZVB9::&KD8AALY-#Y->UY,&;TP:DCM1ZER1:9E!
M=HIWT4#C(GAV<1VT$MY1>4%"_P\2>$%HT3/Y__"@14[8)#6L^,(W^!)-->!2
MUT2LR$04N+]RL_!W0&[+5!1 _AXOE9:XAO^Q9:]F[]K9S;Z^4AN:PLA!8@5R
M!T[\Z8/?][[:K+\3V4DBNDTBNFWL\3T>0UPHZQ*ID?T*:<Z:7=SQ_<"4;W<L
MWQ;F1=%+V(FP7B.LUUJAF<Y!DO2D-$;HE4UI[SW+\4YD)Z[[C>M^:SD>2SSH
M.?L7,K+& YY\-I:_$#Q-%:1;R30#1>B.,DZ7'#IX1W04Y6#+23U1[Z@LH1^=
ME>YU3*?O]>V%&S06!JT6%D)3;BF<3>/@]?RX=+SNF4Q;F-^+(KO0RT;H9:O0
M.5Y'("6F&L_P](ED;,<R*#.RH;]-=DW6$Y FXV,\(\H=2,U,_PLP,4";L4M+
M8L],M8:<&(H:0U&KH<FKG!.JM63+K:[\:&'*4IC%9'3G@F<@K76)K%O:]\XL
MV,)P(_3.;+A'EU\!<EV]"11JV9:ZOD&:WN;9,:YNV[/^:WR.U*^'%YKZ+8/W
MPYJ5BG!8(:5W,<"\ROI]4#>TV%17[%)HO+"KSQR?5"!- (ZOA-#/#3-!\TB+
M_P-02P,$%     @ %X"D5I$9%X_(!@  2C   !@   !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6R]FVMOVS84AO\*X15; M2UJ)OM+C'0R+H$:Y,L3C<,PSXH
M$AT+U<65:*?]]R-EU;8HFK:'@WV))?N<AQ3YDB)?*5>O1?FE6A!"T;<LS:OK
MWH+2Y?O!H(H6) NK=\62Y.R7>5%F(66GY<N@6I8DC.ND+!WHFF8/LC#)>Y.K
M^KN'<G)5K&B:Y.2A1-4JR\+R^PU)B]?K'N[]^.(Q>5E0_L5@<K4,7\B,T,_+
MAY*=#;:4.,E(7B5%CDHRO^Y]P.\#O4ZH(_Y(R&NU=XSXI3P7Q1=^<AM?]S1>
M(Y*2B')$R#[6Q"%IRDFL'E\;:&];)D_</_Y!]^J+9Q?S'%;$*=(_DY@NKGNC
M'HK)/%RE]+%X#4AS01;G145:U7_1:Q.K]5"TJFB1-<FL!EF2;S[#;TU#["5@
MXT""WB3H8H)](,%H$HQ32S";!%-(T(<'$JPFP1)+&!](L)L$6T@P#I4P;!*&
M8I4.->NH21C5O;OICKHOIR$-)U=E\8I*'LUH_* 61)W-NC#)N79GM&2_)BR/
M3IS[NZE[-W.G:/;TX<G]Y-X]H7N/G=P[OP7W'Z?NX^P7Y/[^^?;I+]1'GV=3
M=/'F$E6+L"052G+TM"A659C'U5OTIG5^-:"L>KR00=14Y693%?U 59X*&J:2
M-$>=]L#$3LJ2Q&A&B^B+!#!5 YPBR]@H.I3MJK,_Q''"1V&8HH<PB?NW.7+"
M92*_%$_-FI%RG40$/9*().OP.242AG^D/E&TRE9I2%F#W-,%*1&[/C:M+?A\
MLR;H8U')^B8XG3HE\R1*:!LR8+K;BD_?BD^OJ>8!ZDV8AGE$WJ)G\I+D>9*_
MH NFH8VZ+E%(65G1.V3@MTC7="R3E+( /O&_KY9A1*Y[K DJUKRD-_GY)VQK
MO\J$MH%9-8Q/^NO)$-M7@_6^EKHQ)A[;9CO*A:R6!PGS(6$!$*PE'F,K'N-<
M\9PBF W4WNL_;&HF'K8[T)&$"4+H1H@BD$1HFJ49[3"O&];'QK@=Y,N"3+T=
M%$B"=&L\PMHVKM72YK:ES3K1.-#2MWG$ED4501>L=>NC2S[5UQ/FHDAC4E;L
M'O%UE=#OZ._'(DT16U:\AF7\CZP#3,@1"PF;0L)<2)@'"?,A80$0K*5+:ZM+
M2SD#U +L\Y5KC")VDV-WN)#?BF6JLSK3-L:6,'X<97'GJ@D2YIY2?0^R1!\2
M%@#!6BJQMRJQE2K9+(*BUB+HA6WJT$7*ED*7,K'8G=;NVYJP$'"4I9XK%DB8
M"PGS(&'^*0T; )78$LMP*Y:A4BRW5;7BJPI4S+ED^+Z@XK,,6BW9853D:W:S
MXWMN]CM;K2=L$^2R!3;_FB9LO8Z$W<C^>E:F-&5MSKT9#KNM:^@C8=G2#<*&
MN)!P(:OE0<)\2%@ !&LI;;15VNA_59I,7:.N((15K#.2K"L%Q2BOX]RY"1+F
M0<)\2%@ !&LI:[Q5UEBIK)TP-H**DW42DSR6*60LF9 %A2@+._<^!PES(6$>
M),R'A 7*/FHI!&L[UT]3:N21I/6.CD\^[+<D"E-$RX3]G:_RF.^E^9R4T(SD
M5*:;!M^^C0A[5D==AW.E TIS06G>*<WA@Q890-': MJSC;%20'>$HE1N)=XT
MJ>W[CC8>&Z(^E$6<K0](F@M*\T!I/B@M.-Y;;8GLS%U\HKM+-C.*8.U^"LNM
M4Z=+903J[>*N<6N,Q,6Q),@T#'&'XH+6S .E^:"T (K6EM#.XL4G>KR-A$Z2
MC2&9BS6LB68/[KJEFBB'XQZOI#13P[9E"=[,\=)\":H_- 6)!K(H?:B-M/&!
M\;IS>;'2K#OS:8R\[4'-W8:V?ZFVN#F1Q)BF/1R*W01JQX+2?%!: $5KBVAG
MR6*U)WO\J8Q<.!*#4[,-L[-DL(X/VFY(9]!V2S,U<V28XJ %=50EI?:-L26.
M;TF4SI_A''B(@W<^*+;_Q\<X&-(8=$!I4U":"TKS0&D^*"V HK4%NO->L=I\
M/>=Y#I;XF)KX&-Y1%WBVK"!I[DE7X(&6Z8/2 BA:6RX[ Q6K'=3_\& '=QU1
M W=L"T@G< I*<T%I'BC-/Z5Q Z@BVYK96:-8[8TJ;0N)T8:QKG?6(*".*"C-
M!:5YH#0?E!8<[ZWV*VD[:U176Z-GV!:&](TT2)O/T;O.8F</)(F1[8% *^:!
MTGQ06@!%:RMHYXWJ:F_TB&LA5PWN[%K&=N==,4<2)NY_)"&=MQ,E(9HU&@M>
M@Z>^SK/[N%MJ?R@^_)<%&=K8Z(SKP=X[S_PM>];";,-9H93,6:;V;LB&0[EY
M<7US0HME_1KT<T%ID=6'"Q*R70\/8+_/BX+^..%O5F__?6#R+U!+ P04
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M$K>F5)DB=S;PT,=<@ZR5?1EEIR_('HF/1OO"B1N=4_Z0?P"<6[#I!NQE^JK
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MG*E]<RE%)5M>@/FYP>4\=%C![N^=FW\!4$L#!!0    ( !> I%9S3)O0Q 0
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MU:B7TA%IPO>'\.!T[?_SS[5S6OGE$@5EF07H?:&UVSRP@^U'H-G?4$L#!!0
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MUP)\J6D#UI=*V<,#'=!_$+S^'U!+ P04    "  7@*1627+_;4 %  !(#
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MW#S38X6K/GG>@/65PW#O7SC ^,_#XF]02P,$%     @ %X"D5JB\<SNV!
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MQM.3*'SF] 9%RQMH?6:,7P_8P>95._H?4$L#!!0    ( !> I%8"$QU_)@,
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MLKK@5H86A;U4SH7&*ZH=IOB? *1QP/6%0 G6AMF@^9<Q^0]02P,$%     @
M%X"D5H5+EQ#M!0  \0\  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
MS5??;]LV$/Y7#FY0Q( 2B_JM-#&0I$M7H%V#INT>ACW0$FT3E425I)*V?_WN
M)%EQ4T7+ACWLP99(D7??W??Q2)[>*?W9;(6P\+4L*G,VVUI;GRP6)MN*DIMC
M58L*OZR5+KG%IMXL3*T%S]M)9;'P7#=:E%Q6L^5IVW>MEZ>JL86LQ+4&TY0E
MU]\N1*'NSF9LMNMX+S=;2QV+Y6G--^)&V(_UM<;68K"2RU)41JH*M%B?S<[9
MR45,X]L!GZ2X,WOO0)&LE/I,C=?YV<PE0*(0F24+'!^WXE(4!1E"&%]ZF[/!
M)4W<?]]9OVICQUA6W(A+5?PN<[L]FR4SR,6:-X5]K^Y^%7T\(=G+5&':?[CK
MQ[HSR!IC5=E/1@2EK+HG_]KGX2D3O'Z"U^+N'+4H7W++EZ=:W8&FT6B-7MI0
MV]D(3E9$RHW5^%7B/+N\:>JZ$)AEBY3 !2]XE0FX:?7PNNI(I^P=?N"K0ICY
MZ<*B5YJ[R'H/%YT'[Q$//KQ5E=T:^*7*1?[C_ 6B'2![.\@7WJ3!MUP?@\\<
M\%S/G[#G#RGP6WO^(_;>Z0VOY/<V3@<N5654(?,N;%[E<*V%H?RT'6H-5[+"
M)$E>P UVMKDS\,?YREB-&OMS+$,=@& < *V[$U/S3)S-:O*E;\5L^?P9B]P7
M$^$%0WC!E/7E#:[CO"D$07]=W0IC.\3GMUP61.H1LGQD>"'&D$_:'D>^[X3O
MG  Z 7("&298&DMP[);Z"RP,LMJ<P+FA3J0WV[;\'LH*AZC&( MF#N>ETE9^
M%SERA/-?:64,?*RP%!5M[RLL0>;G[C?8%@:NN-1D^S,*^Q,O&H$-VVAIOP'J
MVJ C7@&#;X+K$[@4Z&DM,Z27(.6B5D9:. #F.VD4T O^#@-WWO=Y(8+2M=(T
M(Q<K"T9D9%VB:\]SO#"!  X92^;49$& X\M2Z%9'-:^%!N8Z@>N!#X?QG!I^
MFL#'XYMCV*A;H2M**&"=1.FAS<!Q@Q1-/G^6>,Q[0>W0AP_*HKGRL< @=)TH
M]H%Y""4*Y]0./?<^$PRL J\=:TXF(D)T41*#AR%Y'=@H"1X'ZSMQPB 9P%([
M[89;Y,DT6'KVK4=.DD00>\,$[$DQ@P_"VT=+@O'# *'TF+ =^*R?8K8HG2,K
M= ER3YT'D'B.Z\5$(HN(499Z1&G"T!_K!?E29*)<(4%]S?'^E\*,'.:2*'T*
M(V'SK@\KY 2-0> D;H3$8,90#=@,_71$F+[CN3[IUT/!8XLA][]A,7Q(..H<
M97 O2FHGC_,<.ZD;#H,/:6W$R'S\MS). L=+4V I'/II,(>$5F#PSV4<.B[2
MSC NS%?@I&DT*;%'AS\NK]3Q68@ON,BH7K"P55>"<%V8J.WA4-O#R=H^7<\1
M#'#:T*RL&E3K0_'!-8D'=[6QPO]TQR,U'LFRL.6W E9"5!V.[!Y'<X^C(!QU
MCZ,UL,%OF,J.<%6)HY;R?[UK_+R\1A?BA$J0,(>%;<$/D_D$:]' 6O3D'1D7
M6XU!4AZQ=:WQM*U1=W3N^.5+(VM*\1@]DQ[&]^4?C(N=\8G,/BQS#Q(]4AVO
M&EU)7#JB]:'66*G$GBLL28X;1</S#=8$L55%#K*L-=:13E">$T9N__^&KX@5
MA97CW@Y#/GRR$4:X#N,8-T+<@#RT9TQ?3GB6-653()\Y54DML)X-)SK>%>S^
M9.L[09C.VR?SYS">)@<JT07@MVN9.5Z43BWA>!!#_&0QG&>9;DB0DJ]DT:IO
MC/M)@^/<[RP7]Y9WQ(O\/Z%^YR%#0>.=K<OM :2)WV8KP=/*)4+%K:O S0 W
M%^(Y=E/\]WT?WB/2UCS']=_K@ @@_"@B++XQP^-*"B\E<HEZ@+6@HP(>O.AW
MC403206.K4PO/XRI'Q:F=%9YUW;PD50P-P'?WVT\8R,.4&)A2*4\=%@<CS*_
MV+N&X0ZZ:2^;E.>FLMV-;.@=[K/GW37N?GAW&<94;^C04(@U3G6/8RS'NKM@
M=@VKZO92MU(6KXCMZQ;OY$+3 /R^5LKN&N1@N.4O_P)02P,$%     @ %X"D
M5IM 9P9 !    @L  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULI5;;
M;MLX$/V5@=HM$B"U+K8L.[4-)&F#+;!I@R3=8K'8!UH:6T)%4B6I./G[#BE9
M=ES':;$O%$EQ#L_,' XY64GU3>>(!AYX*?34RXVI3GU?ISERIGNR0D%_%E)Q
M9FBHEKZN%++,&?'2CX)@Z'-6"&\V<7/7:C:1M2D+@=<*=,TY4X_G6,K5U N]
M]<1-L<R-G?!GDXHM\1;-E^I:T<CO4+*"H]"%%*!P,?7.PM/SH5WO%OQ=X$IO
M]<%Z,I?RFQU\S*9>8 EAB:FQ"(P^]WB!96F!B,;W%M/KMK2&V_TU^J7SG7R9
M,XT7LOQ:9":?>B,/,ERPNC0W<O4GMO[$%B^5I78MK)JUPX$'::V-Y*TQ,>"%
M:+[LH8W#EL$H>,8@:@TBQ[O9R+%\SPR;391<@;*K"<UVG*O.FL@5PB;EUBCZ
M6Y"=F?V%Y)*&HSLV+U$?3WQ#H/:7G[8 YPU ] Q 'ZZD,+F&#R+#[*F]3V0Z
M1M&:T7ET$/"*J1[TPQ.(@JA_ *_?>=AW>/W#'OY[-M=&D0C^V^=C S'8#V$/
MQJFN6(I3CY2O4=VC-WOS*AP&[PX0''0$!X?09[?->0"Y ,<5/CS0D:,O$QG<
MUE55(IT"PTJX8#J'2SI'\%$TYY&$O<^=@QON=^<N1T@EKZ2@O;0E4SHRV))9
MH2)&&A:R) +Z%.YRA?@D^4"I2W.7NZ-"@,EEK<D'?>Q2:9L(/E>HB+98MO"I
MU 9>0SCJVW8<PB<J1/*E14^BDMJH+&Q4;,"DR5%!L8D/E8Z2&6)G9 .G845^
M_']77#8J5F0$I(!Q6=O %2(M:XO@S! X;5DKQW43U+)@\Z(L3(&T^R8DG2?$
M34F^&P?M8A!3FP1P0'AQ)[SX!>%M1?&<E4RD"+?N*GA!7[^!.V]QFROF]_*R
M$_HS)\M-9IKQ>TR1SRGG=FI77C>?OQ"B1F-C%YV$8>R^41S"1:V42\J.R59N
M:.TP&;LVAD]2O$U_P28\&8U'M$<P".!.VA <WB$ZB9/$?1-B]]5=(YB]9?=D
MM$2*DKU:-\8&%7_S:A2%X;N?Y-'OC>$1F=(PZ$5M[R? K-"IE2J0+3Z'E/0"
M^*-I#PAMV EM^*L5[K(V=!K@BESB-6\+WC5[M&K1^Z1V$/F94N:BO@D<$Z*V
M=4)R7ABW$=1TR!4(FU*KSM+>?FV V9**0;/*GFMDI#8B;L]R$U%T!6)+=L!V
M2N..;O\A,UM6+)=GU-I>4JZX'.&#+2%VVFYJ7''B37'"G>)D#8Y)/ ,JBM0?
M0!(/;">&A"1+G2$DXR$5.*K>;$':@; _;&6Y:%+!VU0TWE=M*DB.XS@B7II*
M&J]JXRH: 2"5XJ-^$A^W*&L![Y.)O_4NX:B6[O6EP<FO>:)TL]T#[ZQYUVR6
M-Z]#<GE9"$TL%V0:]!(J0:IY<34#(ROWRIE+0V\FU\WID8K*+J#_"RG->F W
MZ)Z]LQ]02P,$%     @ %X"D5@Y[DD#V!0  \0\  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULE5=M<]HX$/XK.[37)C,N^-TF39B!)+WKAUXS3:[]
M<',?A"VP)L:BDH#D?OWMRL9 (83[ +:EW6=?].Q*NEQ)]:@+S@T\S<I*7W4*
M8^87O9[."CYCNBOGO,*9B50S9O!337MZKCC+K=*L[/FN&_=F3%2=P:4=NU.#
M2[DPI:CXG0*]F,V8>A[Q4JZN.EYG/?!-3 M# [W!Y9Q-^3TW?\WO%'[U6I1<
MS'BEA:Q \<E59^A=C%*2MP+?!5_IK7>@2,92/M+'Y_RJXY)#O.29(02&CR6_
MYF5)0.C&SP:STYHDQ>WW-?HG&SO&,F::7\ORA\A-<=5).Y#S"5N4YIM<_<&;
M>"+"RV2I[3^L:MDDZ4"VT$;.&F7T8":J^LF>FCQL*:3N"PI^H^!;OVM#ULL;
M9MC@4LD5*))&-'JQH5IM=$Y4M"CW1N&L0#TSN#<R>RQDF7.EW\/MSX4PSW#V
MP,8EU^>7/8,F2+"7-7"C&LY_ 2Z +[(RA8;;*N?YKGX/76O]\]?^C?RC@%^8
MZD+@.>"[?G $+VCC#2Q>\'_B_5,:#G\/Q]HH9,D_A\*N4</#J%0Y%WK.,G[5
MP=+07"UY9_#NC1>['X_X'+8^A\?0!_=8B?FBY" G8/W_,$(>YG M9UB;FEEZ
MWS[1.S_D^U'TP[[79L;63+9MAM=FL!Y+9G#22+AF*A>3"7RMD(QR^@R\SBI;
MX82&@BTYC#FG&L[DM!+_HIJH /N*0LQJBN,::T@#TS"1);8)?0$/A>)\ATR
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M[:?$ *%H.$QB)PUCFHB[_>"P6[\P.':"/FKU(U0*NW%,;3!T/#=!6*XRH>D
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M=>DJR8YA)TN[>R[XVK^R SO&.6^D$Z),6+LYD-3$Z06H<B/C18"*35AJ8IV
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MUSH^K3HC[8-NPY8* .<"8ULJ0*4N+#6Q3J"N8(HM9=#<0Z/I_$N\,D3\MU:
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M9F434+__6!3\VY/F[L2GNU$O_P=02P,$%     @ %X"D5OU=R!>#!P  KC4
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MQCG0^49K>S#<+'4O8?H'4$L#!!0    ( !> I%:Y4 Z[8 ,  -\.   9
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M")-4U<-<=8PLW=NVE@9?2M?,\5L&E#7 ^:V4YK%CG\OFZRC] U!+ P04
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M9R.;[Q*^"=B:O3FS3I9*W=O%QW3B]:T@R"%!R\!IV, ,\MP2D8Q?#:?7EK3
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MHO.PIDP$6>KV;E66RM9P)N!6$=W6-56_9L#E9A(,@NW&'5M5QFZ$6=K0%2S
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M    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;*U6:V^;,!3]*Q:KIE9:RRM
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M&:V55;9F6.%X+/@:";-;LYE!E9L*K=T09H[Q7@E]EVB<BF] YT"B<W1=JE(
MNB6,T)*B:AW-\:L^,B71Z0P4)KD\TSL?[V?H].0,G2#"T$/&2XE9*L>VTG(,
MJ9TTH:_JT-X'H6^QN$"^^P5YCN=WP*?]\!DD+=Q[#[=U$MI,>&TFO(K/_X#O
M9P$"*\*6M?=.0S7#H)O!O'&7LL )3"S]2DD0*[#BSY_<T/G:9>\_D;TSZ[=F
M_3[VV*0<G<)+DI>IL:PRT#\!@"AG*I,(6 HITD>49'70S4&==>6E#A96P4SA
M6,6#D3NV5]MV>P4=:7?0VAT<LCOHTEVC@BW=43#8T=W+?*3NH-4='-(==.D.
M]G5'P8[N7N8C=8>M[O"0[K!+=[BO>Q3NZ.YE/E)WU.J.>G4_9*"_A0L%HDM]
MM*?>]7?5]_(?J7[8JA_VJ^<*YVA1%W+:%/*\*N1%4\B[; WW;'FCP-OQU1OY
M2%^CUM>HU]<-2(D(+4JE2Q)A^G1 JBXGHSTGY_[>>]$;ZT@GKO/VN74.GU'G
MM]+9JZ%>$$4[XKMV1>Z;Q5J5O=4/F&9,E_$E85(_"PL-<RXBG2)1]S?U1/&B
M:A&>N-(-1S7,=$\(PFS0]Q><J\W$=!UMEQG_!5!+ P04    "  7@*16WO-Y
M+/,#  #F$   &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RU6-MNVS@0
M_15"6^RV0!+=?$O6-M X*78?B@WB9OO,2&.+B"2J)&4G^_4[I&19<AFA*=07
M2Z(XA^<<\3+C^9Z+)YD */*<I;E<.(E2Q97KRBB!C,H+7D".;S9<9%3AH]BZ
MLA! 8Q.4I6[@>1,WHRQWEG/3=B>6<UZJE.5P)X@LLXR*EVM(^7[A^,ZAX9YM
M$Z4;W.6\H%M8@WHH[@0^N0U*S#+()>,Y$;!9.!_]JY4_T0&FQ[\,]K)U3[24
M1\Z?],/?\<+Q-"-((5(:@N)E!RM(4XV$/+[5H$XSI@YLWQ_0/QGQ*.:12ECQ
M]"N+5;)P9@Z)84/+5-WS_5]0"QIKO(BGTOR2?=W7<TA42L6S.A@99"ROKO2Y
M-J(5$(Q?"0CJ@. DP!^]$A#6 :$16C$SLFZHHLNYX'LB=&]$TS?&&Q.-:EBN
M/^-:"7S+,$XMUXI'3PE/8Q#R#W+[K63JA9P3TWRN_8G)BF<X:20UMM\^ZWL@
M[V] 49;*#]CY87U#WK_[0-X1EI,O"2\ES6,Y=Q7RTZ.X4<WENN(2O,(E))]Y
MKA));O,8XFZ\B[H:<<%!W'70"_B9B@L2^F<D\(+0PF?UX^%!#YVP\3HT>&&?
MU[6I4=M4J$RU.58ACNR(>HU?R8)&L'!P$4L0.W"6O__F3[P_;7(' NN('S7B
M1WWHRR]<T91(;0%YFP45[L3@ZEUIM_2]R6CN[MK2+)W\<=!TZE >-Y3'O93_
M*30U278@%<1G9$.9(#N:EE::%=:XS>#2\TYH6CK9.4X:CI->CO?XH:B($H)+
MCMS #O?E G=9=5BH-J:]B&^=4P.!=<1/&_'3P1?4=$CQ X%UQ,\:\;-?M*!F
MWTW"\/)T/5GZA&/[5+UL"%_V$E[C6<WR[1G90@X"N>LI2V,\U)A4@NKCO(]U
M+_A;/]Q 8!T??.]XYGJ#S]L:<B#]0Z%U#6@E'?XOFKLU<'MB3J:GNVS=J7T:
MS/RI??;ZP9%T\$/'@>*D*''+1=XZ-\J0L/F@5KJ]D&_^:@.A=0TXIB_^\/F+
M/V@",Q1:UX!C"N/WYS /N8"(;W/VWZD#$9?**M^6O/C?I07]X_ZLKF.>X_<G
M.E]-L0/Q.=WAQKP%K,]T!8B;M<E]]+4 P7A,L&XDM0=:MU5R_U@!><&$19(9
MR:IDWP](3%]LY<*J'^IG;3FF5GY_;G58\%C]2H6'E3F\]K57Y.!5A#($5J,E
M[F@IV]A70?] L]J32>V)U8M!$RVW53%F(+:FD):HI<Q555\UK4VQ_M&4J"?M
MU[J(-Y7H$:;Z!P"KIRU#]U+8(*1W,<6/*:JBNGI0O#!UZ2-76.6:VP0H%J*Z
M [[?<*X.#WJ YJ^-Y?]02P,$%     @ %X"D5DW/(#V.!P  MC@  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&ULS5M=;]LV%/TKA#=L*=#8$O5A.TL,
M)):Z=4"WH$';9\:B8R&2Z)*TT^S7CY04RY04VN[N@/:AD63=0^H<D;Q')"^?
M&'\4*THE^I9GA;@:K*1<7XQ&8K&B.1%#MJ:%^F7)>$ZD.N4/(['FE"1E4)Z-
ML..$HYRDQ6!V65Z[Y;-+MI%96M!;CL0FSPE_OJ$9>[H:N(.7"Q_3AY74%T:S
MRS5YH'=4?EK?<G4VVJ$D:4X+D;("<;J\&ER[%[$7ZH#RCL\I?1)[QT@_RCUC
MC_KD?7(U<'2-:$874D,0]6=+YS3+-)*JQ]<:=+ K4P?N'[^@ORL?7CW,/1%T
MSK(O:2)75X/) "5T23:9_,B>_J#U P4:;\$R4?Z/GNI[G0%:;(1D>1VL:I"G
M1?67?*N)V O P2L!N [ K0#7?R7 JP.\8P/\.L _-B"H \I''U7/7A(7$4EF
MEYP](:[O5FCZH&2_C%9\I85^4>XD5[^F*D[.[B1;/*Y8EE N?D7QUTTJG]$Y
M*B^CO]>EF-=:3'W]+**2I)EXH^[X=!>ALY_?7(ZDJH7&&BWJ$F^J$O$K)7KH
M ROD2J"X2&ABQH]4[7>/@%\>X09; 3\0/D2>^Q9A!WL]]9D?'XY[PB-[>$07
MUO#8'O[GIA@B9]H7;I#A[?3T2CSO-3U7A--SW702-&>YZD\$J43DG!0/5+5Q
MB>Z?T?Y]M^2YO'S]1'CRME9=O$7729+J0Y*A*!6+C(D-IZ)/\:I.?G^==%]W
M(=9D0:\&JC,3E&_I8/;+3V[H_-8G%R18! D6 X$9POH[87T;^NQZ(U>,I_\H
MO8363J"-:C\<R15%ZXP4Z"PMZE]Z&Z45_52)*K"@!--#T7;FN8&C_EV.MOOL
M0Q8:=PL-6H4:Q 8[8@,KL?7KCB1#ZPU?K%23T"TG5VVF[ 7[R+0BGDHF)%@$
M"18#@1FRA#M90FM']J4<XFER3K:4JY0%$:&2F4JK/DE"2$D@P2)(L!@(S)!D
MO)-D;&TI'U/Q>+[DE**TD%3A2\2)I'UJ5$"NL]=8G:'C!1.S@YCWW^=._%9'
M8JW8J1P"@1D<3G8<3JP<1BJ32FB1H.>49@DZ(P(1M*9\H0;@WGZ[@ION$]3B
M\. =D;5*I[('!&:P-]VQ-[6R%W];*X.AAL MRU1:DY5)Z4$*IQV"W*';(K'O
M'B=L\6BMW*D\ H$9/+I.D_8[QS&I&G)^YO;G\7:( #U3P@7R4%XE].X$)>2Y
MKW>>'X **ZB^WM,>>2KI4&@FZWMFR[4.:G]M\GN5L['E2Y+=2[L+.92!HD6@
M:#$4FJD&;M3 UK?NAJB\>4$1VT@A29&DQ0,BLLRH[^E#6A3Z@M*J3+$I3UER
M*,FN"S1R5"><^IUQSUZSDU6!1(NAT$Q5&@/K6FW4['?E4W7'=(AJKT.U.W%"
MQ^E0#>HG0=%B*#23ZL92NG9/.=>O?Y8ILD?H'>-+FAY#?->'G;MC'+1IA_1^
M$2A:#(5FTMX83M?N.-78F_(CB ZZ1/OC<.*';:I!'20H6@R%9E+=F$C7:HAL
M7;Q.PD_KW,..'J$W#2?3SJL/:A]!T6(H-%./QD&Z=@L9?U-Y>BK(?4:_7X=Q
M1P?LX['G^&T=(%UC!(H60Z&9.C0NU+7;T,_*O*L>2+4(1'=.@*&M]O2'Z)]T
MFX$[&8=!IUN"M)T1*%H,A6;2W]A8=WK4QRUT77_<JML%1;<\5=W5K3()Y1?Z
M7@$@;>@<%"T"18NAT,QII<8C8[LK_4Y_H&?&U&G5AGJ;4%WN9-\F#*>XU7[L
MM3M5&5"T& K-5*;QT=CJ# V/< 3=]12H:WS=&7MMOD&=,BA:#(5F\MTX96QW
MRI51Z/$)1Y"/N^2/A].V2[-7X&3R00TQ%)I)?F.(L=T0[]N%(_CVNGR'PVGG
M90=UQ:!H,12:R7?CBK'=%9_L&8X0Q>^*X@_#=L9DK]C)HH!Z9B@T4Y3&,^-#
MGOE(XW"$&$%?"PG&;3% 734H6@R%9HK1N&IL=]6'W,,1&H2=#,CO&9%!C30H
M6@R%9DK0&&D\_@'7^6!(#SP'18M T6(H-%/>QI]CNS]_692R-P:]U;/N/"U$
MND!;DFUZO6$-&^ZOS/%=I].W@5KSGD+=J8=;?B:&*M2DM/'<^-#<\>$1Y#B.
MI]WO3T[@=C@&-=:@:#$4FKE$L3'6GMU86\:/HQ2HX8VWW%.U:RE@K\7)*PE!
M#304FJE 8Z ]NX%^7R2;135(E%[:6/#;O\03=%8:%"T"18NAT$QI&J_MX?^^
M1L"#-+AS4+0(%"V&0C/5V%M.#3(;[?7,1GM^@#NST?;B3J8:=GGS_^&[O<9W
M>W;?76\^>%_HA5SIEJ);O:P9.]CM91S2W<Y!T2)0M!@*S92E<=Y>\ ,Z#0]T
MB34H6@2*%D.AF?(V7MZS>_EFN.%4;RS37[OJ#09D2]*LS)>7C*-4B$WY7>Q0
M5]B=)L?NQ)ET/OG:*W:R**#N'@JM$F6TMS\KI_RAW!@GT()M"EGM<]I=W6V^
MNRZWG+6NW[@7\VH+70-3[>C[0/B#RII11I<*TAF.%?^\VB17G4BV+G>!W3,I
M65X>KBA)*-<WJ-^7C,F7$UW ;JOB[%]02P,$%     @ %X"D5B52CJR5 P
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M=^KMPZ-T?NQYKO'\=U(=^F_=>/RP?&Y.V!EPMG -O?\%4$L#!!0    ( !>
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M<F]P<R]A<' N>&UL4$L! A0#%     @ %X"D5DYP7V7N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %X"D
M5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  7@*16%,F[<*0%  #7'0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %X"D
M5H[0,!C,!0  -!<  !@              ("!YPT  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( !> I%:+?2S6[P(  -4(   8
M      " @>D3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  7@*16R?%W<Z$$  "H$   &               @($.%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ %X"D5ES*=C=> P  L D  !@
M             ("!Y1L  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( !> I%:1&1>/R 8  $HP   8              " @7D?  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  7@*16X))_TEH&   /
M'   &               @(%W)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ %X"D5O^G\I$!!P  N1   !@              ("!!RT
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !> I%9@M96Z
M-08   H.   8              " @3XT  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  7@*168\)@Y50$   E#   &0
M@(&I.@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !>
MI%;1:67'*@<  .H1   9              " @30_  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ %X"D5G-,F]#$!   $!(  !D
M         ("!E48  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  7@*16O5;$#/@'   <%   &0              @(&02P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !> I%9)<O]M0 4  $@,
M   9              " @;]3  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ %X"D5JB\<SNV!   X0H  !D              ("!-ED
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  7@*16 A,=
M?R8#  #,!@  &0              @($C7@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( !> I%9_%,A,8 0  '$,   9
M  " @8!A  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M%X"D5H5+EQ#M!0  \0\  !D              ("!%V8  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  7@*16FT!G!D $   ""P  &0
M            @($[;   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( !> I%8.>Y) ]@4  /$/   9              " @;)P  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %X"D5I2_<? P @
M>00  !D              ("!WW8  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  7@*16_H=X_;T#  ##$0  &0              @(%&
M>0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !> I%;:
M01XF=@D  )E:   9              " @3I]  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ %X"D5OU=R!>#!P  KC4  !D
M     ("!YX8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !> I%:SU-0_;0(  $@&   9              "
M@;*:  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ %X"D
M5G)]\'0& P  & D  !D              ("!5IT  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  7@*166^\LCF@"  #!!0  &0
M        @(&3H   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( !> I%;OE6GI_0(  '$*   9              " @3*C  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ %X"D5M[S>2SS P  YA
M !D              ("!9J8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  7@*163<\@/8X'  "V.   &0              @(&0J@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !> I%8E4HZL
ME0,  ((-   9              " @56R  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ %X"D5K,AE\U5!   H1L  !D
M ("!(;8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  7
M@*16O7?'#& "  #+!0  &0              @(&MN@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !> I%8.01<G/ ,  /(3   -
M          "  42]  !X;"]S='EL97,N>&UL4$L! A0#%     @ %X"D5I>*
MNQS     $P(   L              ( !J\   %]R96QS+RYR96QS4$L! A0#
M%     @ %X"D5LE3B5:H P  21D   \              ( !E,$  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( !> I%:9/J*$? $  )86   :
M      "  6G%  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( !> I%:J9Q1AF $   L7   3              "  1W'  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     M "T ,@P  .;(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Supplementary Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</Role>
      <ShortName>Supplementary Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Supplementary Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables</Role>
      <ShortName>Supplementary Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crdf-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/CommitmentsandContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="crdf-20230331.htm">crdf-20230331.htm</File>
    <File>crdf-033123exhibit311.htm</File>
    <File>crdf-033123exhibit312.htm</File>
    <File>crdf-033123exhibit321.htm</File>
    <File>crdf-033123exhibit322.htm</File>
    <File>crdf-20230331.xsd</File>
    <File>crdf-20230331_cal.xml</File>
    <File>crdf-20230331_def.xml</File>
    <File>crdf-20230331_lab.xml</File>
    <File>crdf-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="447">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 447,
    "http://xbrl.sec.gov/dei/2022": 28
   },
   "contextCount": 140,
   "dts": {
    "calculationLink": {
     "local": [
      "crdf-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crdf-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 312,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 23,
   "keyStandard": 180,
   "memberCustom": 9,
   "memberStandard": 23,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Supplementary Balance Sheet Information",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation",
     "shortName": "Supplementary Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cardiffoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Supplementary Balance Sheet Information (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables",
     "shortName": "Supplementary Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.cardiffoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Organization and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i6b8aae50d3074837b6dd46d96505a08b_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
     "shortName": "Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i0dabcab786cc401a8d99c89cf5a850b6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
     "shortName": "Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i0dabcab786cc401a8d99c89cf5a850b6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails",
     "shortName": "Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Supplementary Balance Sheet Information - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails",
     "shortName": "Supplementary Balance Sheet Information - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i3a4251f19c164493b2b76424bd16af85_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i3a4251f19c164493b2b76424bd16af85_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "id39cc1c335a2480bb994dbe1468e726e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "ia7c4d6614d364743b28cacbcfe5a7cf1_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i418e8e7b86764323b476f1d50de103ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i418e8e7b86764323b476f1d50de103ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230331.htm",
      "contextRef": "i5ee36870f7de4eb78263dd4776830ae9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "crdf_AccruedClinicalTrial": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial",
        "label": "Accrued Clinical Trial",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrial",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedDirectorFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued director fees",
        "label": "Accrued director fees",
        "terseLabel": "Director fees"
       }
      }
     },
     "localname": "AccruedDirectorFees",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedResearchAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research agreements",
        "label": "Accrued research agreements",
        "terseLabel": "Research agreements and services"
       }
      }
     },
     "localname": "AccruedResearchAgreements",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_ClassOfWarrantOrRightExpiredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expired During Period",
        "label": "Class Of Warrant Or Right, Expired During Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which each class of warrants or rights outstanding may be exercised.",
        "label": "Class of Warrant or Right Term of Outstanding Warrants or Rights",
        "terseLabel": "Weighted-Average Remaining\u00a0Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price, Expired During Period",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Expired During Period",
        "terseLabel": "Expired (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in USD per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made",
        "terseLabel": "Milestone and royalty payments made"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "label": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "totalLabel": "Comprehensive loss attributable to common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Noncurrent",
        "label": "Debt Securities, Available-For-Sale, Noncurrent [Abstract]",
        "terseLabel": "Maturity 1 to 2 years:"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentAbstract",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2021",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "Equity Incentive Plan 2021"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_InducementGrantStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grant Stock Options",
        "label": "Inducement Grant Stock Options [Member]",
        "terseLabel": "Inducement Grant Stock Options"
       }
      }
     },
     "localname": "InducementGrantStockOptionsMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PatentLicenseAndOtherFeesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent, license and other fees payable",
        "label": "Patent, license and other fees payable",
        "terseLabel": "Patent, license and other fees"
       }
      }
     },
     "localname": "PatentLicenseAndOtherFeesPayable",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment For Services Received",
        "label": "Release Of Clinical Trial Funding Commitment For Services Received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitmentForServicesReceived",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.cardiffoncology.com/20230331",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums (discounts) on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52",
      "r110"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less\u2014accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r116",
      "r355",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r83",
      "r318",
      "r359",
      "r360",
      "r396",
      "r397",
      "r398",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r402",
      "r403",
      "r404",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r80",
      "r81",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r88",
      "r97",
      "r112",
      "r139",
      "r171",
      "r174",
      "r178",
      "r192",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r283",
      "r285",
      "r299",
      "r385",
      "r414",
      "r415",
      "r450"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r105",
      "r118",
      "r139",
      "r192",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r283",
      "r285",
      "r299",
      "r385",
      "r414",
      "r415",
      "r450"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r186",
      "r199"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r48",
      "r185",
      "r199",
      "r350"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Total available for sale investments",
        "totalLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r47",
      "r199"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r47",
      "r108",
      "r199"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r107",
      "r370"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r36",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r87"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r139",
      "r156",
      "r157",
      "r160",
      "r162",
      "r166",
      "r167",
      "r192",
      "r210",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r222",
      "r223",
      "r226",
      "r230",
      "r237",
      "r299",
      "r369",
      "r391",
      "r400",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r92",
      "r101"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r208",
      "r209",
      "r365",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r402",
      "r403",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 44,677 shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r124",
      "r126",
      "r131",
      "r352",
      "r357"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r380",
      "r382",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r199",
      "r406"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r199",
      "r406"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r190",
      "r201",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r190",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Investments Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r189",
      "r376",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Investments Available-for-sale in a Continuous Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]",
        "terseLabel": "Maturity less than 1 year:"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r34",
      "r170"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r68",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r153",
      "r156",
      "r160",
      "r161",
      "r162",
      "r164",
      "r290",
      "r291",
      "r353",
      "r358",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r160",
      "r161",
      "r162",
      "r164",
      "r290",
      "r291",
      "r353",
      "r358",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining vesting period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r103",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r165",
      "r193",
      "r238",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r289",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r318",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r292",
      "r293",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r219",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r293",
      "r322",
      "r323",
      "r324",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r219",
      "r241",
      "r246",
      "r293",
      "r322",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets and\u00a0Liabilities (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r219",
      "r241",
      "r246",
      "r293",
      "r323",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r219",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r293",
      "r324",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r219",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r322",
      "r323",
      "r324",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r202",
      "r203",
      "r221",
      "r235",
      "r287",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r376",
      "r408",
      "r409",
      "r410",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r417",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non U.S. government"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r31",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r399",
      "r447"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r314",
      "r384"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031, 2023)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r139",
      "r192",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r284",
      "r285",
      "r286",
      "r299",
      "r374",
      "r414",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r89",
      "r99",
      "r385",
      "r401",
      "r411",
      "r446"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r106",
      "r139",
      "r192",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r284",
      "r285",
      "r286",
      "r299",
      "r385",
      "r414",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r35",
      "r93",
      "r102",
      "r104",
      "r122",
      "r125",
      "r129",
      "r139",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r158",
      "r171",
      "r173",
      "r177",
      "r179",
      "r192",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r291",
      "r299",
      "r375",
      "r414"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r154",
      "r159",
      "r162",
      "r171",
      "r173",
      "r177",
      "r179",
      "r375"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncement Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r171",
      "r173",
      "r177",
      "r179",
      "r375"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r310",
      "r384"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r309",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r313",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r312",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on securities available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r61",
      "r123",
      "r126",
      "r130",
      "r300",
      "r305",
      "r306",
      "r351",
      "r356",
      "r396",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r28",
      "r46",
      "r133"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r137",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,050 and $1,044 at March\u00a031, 2023 and December\u00a031, 2022, respectively (Note 6)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r117",
      "r204",
      "r205",
      "r371"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r46",
      "r133",
      "r134"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r27",
      "r46",
      "r133"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Supplementary Balance Sheet Information"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r51",
      "r109"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r53",
      "r100",
      "r354",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r68",
      "r98",
      "r362",
      "r364",
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r103",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r193",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r289",
      "r359",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r168",
      "r169",
      "r172",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r239",
      "r240",
      "r349"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity and of Changes in Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r113",
      "r114",
      "r115",
      "r166",
      "r222",
      "r223",
      "r224",
      "r226",
      "r230",
      "r235",
      "r237",
      "r379",
      "r391",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r58",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of remaining shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled / Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term(1)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at the end of the period, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r90",
      "r91",
      "r96",
      "r394"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r139",
      "r156",
      "r157",
      "r160",
      "r162",
      "r166",
      "r167",
      "r192",
      "r210",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r222",
      "r223",
      "r226",
      "r230",
      "r237",
      "r299",
      "r369",
      "r391",
      "r400",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r61",
      "r103",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r165",
      "r193",
      "r238",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r289",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r318",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r165",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r14",
      "r61",
      "r62",
      "r68",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r15",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r45",
      "r385",
      "r401",
      "r411",
      "r446"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r138",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r238",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r221",
      "r235",
      "r287",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r408",
      "r409",
      "r410",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r372",
      "r380",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r372",
      "r380",
      "r382",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r153",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888252",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001628280-23-015692-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015692-xbrl.zip
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M_0"5DUAD  5$U=KU54 IB$.SWF@760RYBR)5A>^1+!CH!'AM^+D*T!28[W)
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M[^R=TW_B!EV-3DWG["[3,P5B@M'G?%]Y7&@T(=-8DG$$+C/&LSDK,UN4@#/
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M!EJB+**2J%%T'._7[TA)J5,G6UJTJPLT"&2)1][[<T=R_.1TYOH?+CV(99K
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MB[2"C-5Z"Q$76HJ,!:60HI)Q 12]$<(;(H*XJK]VL^QLI("()4B\56]!@[7
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M9V!T^B\>)%N&_2#M7]GVC;;=>11;4ZM<JHV.*3 ?7C;:C7I!3L*09:NAD]^
MG4O0OX[A*+_L)$="HWT_\?S_SQ9][?&&;*%3[EMO4Z;RPW^;>+AF/3WJ]$:%
M?I9XN+-/OF/IET7U1YC\2(OOP/[A&%805P5 96G!$Q9"K=X!6/O8O/WYXZD9
M#IE$2<&WC/ !F&A]I8T/G5_W(VSJ%K2WT;WG\G:G^7UV_YOS\@)\*&A"E+R]
M&^%/H-$MSOJTA"P1.6OY\)*']@,/7B]7S_*R6U^[G_P#4$L#!!0    ( !>
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M/^G%E9$ BH.7M[@\=OD]W^/.'@W,>$\\8\)2KK%SQO#@(N$2T)7*..K1Z5#
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M?,8*)BF0B"T63G&IN)5<.IP3S4T0BDPBTV<>AX[)"]I)%J*4-/#H><+$1./
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MZHN;7.0=VV[%?V^?[^^&8T>YW#N"NZVMBKWVQ]/]]AZ#MI]6H3WUM:U3>+:
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M>8&'Q]U^/M(=K2\:9?W&RFYTE7YS$!<KS00GGB]6(E"'\\I6'F>M+V:WU^S
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MG1]Y2<^^L\0008KG_WW2AX;U^_-;O/3ED&/OYVGAFQ\NJD?A2Y56!;PQM..
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M*!$L]\DNK. E +[;.R+<=IR.;:_R-<MW8G'W*SI7!D=G1!$OJJ>?"?=2<^F
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M=,=>9I?RJ&=QO+TJC:T."">^ Y'4XJ">&O:L1-('(>GMK0@)R$9;($!>:(.
M"3FD+:4H),FE%=1*FQ96U.T"4+>J:92QDEDTX,?3H-* )V/ -\M'N"@"YQCY
MH!U0(<:0C@S\&PYF3$A>BZD65IBYO57/1"QX_B,J5PA%B*GIFX-7%DJ9*'_8
MC@,++0KKMM>!?NM?$<?:4!JE9S8^.+I=5-)HZ:+6 D5)*.*&)N 3>=;<FX@E
M8UBX '"$S2*C[ F05(96IMBJQTXJ2JM^8:N^03*\<2$0 U;M@%_PF&M480'^
M E4I>.M4Q'AAA1J]2.Y(.9V(5;^VZM7]A]=^>DI]V_DO<3NN:9ZK1;G6"X&4
M6#4^K+J]SS Q00(!P<CYB!$/02&M*4/*)<.%C8P[<(B,7!3X-@$9<ZG;>:QL
M/?^6/ZZIH=+RG]GR;["4:*DT45@4)!>("V^1$SS7.;.$4"))(#87M)>+C,^,
MZ8\I8#(S/.;*_FI%MNK]><VO>F0DJF'W+C/HD] ]R;7$+E_M:9!W5V=.%/'^
M]P0[:&[&@F?8U62U$\J1X?E&!CAVBQ.*G''(BO+*.  GE!PYYAC222CGJ1#4
MA^'((+@94[[ ^*QIPH&M$E=+7)U:CEWBZHOBZLW*2U%)ZTE>IIF <9O@D";,
M()VWBJ96!2(2X"J1B\3<KK0QJ[A:4/(W PL/O5PA-8GJ2C2;W(T^O&S,93.N
MO)B/8'Z]ET>&HID[,5:LSZE5MG.>UZ=UN@.X^Z!;&1Q&P E[$IIYQA0P(L1.
M'SZE9L=V?+.(;-I!+':<6/KA>XX>Q@6TYKC;+S(REWNQ9?-RMC].FV%P>(E1
M5ZX:Z1#^?HEUH"XG@Q]?,BT=RFZLT+OR=VYM@692>:]%LE[F$CB*ZP3L1PDM
MJ37)I/@Y[^\VNNCPVQX2Q_8@(M>+]@NR"5YPV;9.[7E_X<VU?F@W.^AJI]_L
MKQ_V2DK/- "Q_QJ:,6![MU?4N5T&\(B]?!:TR4Y-6RJ'O3P$_NO7\E'@%&>4
MR7N,YZU6L@W\^<:NW"7[B>JHNE-'WZYNKVUM;%3JM;?U=S#T+0[!:JOV]L>&
M/#5MK]?6UFL[ZVN5G<9J8[VZ7FOL5.KP+N_7MU<;6_7:SM2_PF_-#J!K]P3N
M$?J+E7CF(PQXQ[$W7#I<L6T870?]WZ?_13Y>C@^WVSJ5HV[;]@X 'S,#$<.=
M> HK_C;J%/P$VMJRQ_VX?/GAC\L$[&:G>&)QT1^C>XV&J@RU-P-V64K#P]]1
M.)<VRT@\"AR.GCPZO%0<NL&WAL<475+LQX?Q$OFOGWN7TY?"_I#7)V1)$G/?
MUW_ ,7'_3GU08^G]&O2+(/(#=N<9G]3,K<??X?P/<>=EG%S]*S :1JEA](Z5
M*IQWV*^LPZ >AH46*HPL7G-EIK'/G_?,ASA>TRWD'-.]SY99]WGA^VQY-4\=
M1Q]B!;.BVM-W9MFQ9<?.UIESG_J_W3VWK<%YI1>_QLY)_/&ZP6F6TOTCL(_9
M]'YN)G-^]?)S,U$C8F12*YQ4B#PZI:ED(7"EI&;81O-YK9@ )YB@^\V$;P^M
M8Z/7;>>85F[";G-P^/:D#_T1>^MGOG62^W&UWX_P7YBF16+UG<MYFKVS*MVC
MM8N-P^I:K5E=VS[<;WSD>PUX^L4JK6]N-.%N1[7V]I?O\S1P_ BN.?IR"K\W
MJT<?SNN;M</]H]IA=1/^/O(7M=V/I]7=/7ISGF:_<=BLP;7UQBK=W]PZKZUM
M\3VZT:[2]=-]^+MV427[C=6S_:/]5-O!),_15'<PAGN>UC]\YMZFP*U%N?8%
MXHQPY&AB*.&H2<PSXSDE4C\Y)^I!)C(;L]HER+T&D)-4>"<EE2HR;IBVEBM)
ME2!4<B+Y$.3H)<C1$N2F .38#9"SR2>I)46,I+R%%^;(6A91)!C@#WM!?%[)
M/JYR(,\+<G-?=^-MMS\8)GC&L^,\X]M?GE6Z_!#Y_%IK)KW+^@-;6'K+T^TM
M%^BCEI289C#8COU8Q- S'@08.EO=XYSP,?.(,)]+@2?K/0Y59;43UKXKROIP
M#/E.J_Q_3IJ]&+8Z[WM=#PPK#S>SD0HX"^RK_O:6BRF(P$PI@;@."7$7-3+)
M1225M(8G*X0 "S&+6- IJL=6+OV??D>JM/=IL/>;WI;4)F ,I@Y"=8CG,L[&
M"X](X Y'&SD7%+RM18JGJ8KJ.(L"3#NIVHDM^/%@L7(0.[%G6P6YLJ'=[#3[
M@UZ1&#O7_&IVZ[=-DE^-M&9SJ#. NJO7-&8$O"6TC@U:;T?KL0G> 9="H&4&
M<9\#6<ES1 WV6'%BK+8+*VP1/SU@7Y9FG%[3'CN5*DW[Q4W[)FL2V@(84X\2
MS1L3$T:0$9:BP(-PWD7L@LRF;?CM*DI3NPO&=%.$:3ZS[-@9")[.0M&,[G',
M(-XY^#:;,M?4_NE3]#/-#,9.^NN7ZC/B /V2!(R+!%0;6X/:S0IET6+H2X\4
MQC'74/3(>:61B9@"Q^/>2[RP0N@B8;>K-D_C;/4$PJBOU?;'[A64MO^\MG^S
M8H*31%LMD6:&(LZRV1N%$66! 1(8[;#)%1,6"1]7X/1%,E4N6W&IUZ-UC\^6
MOS#=Y*7,!)G#]/Z\;44E];KM2[K=[;P*FCV# ^I#BI6/@4W_H&KYMZ'U^[8G
MY> ZOL'UPRUBC1GU(6*%M!*Y]"^6R!GAD>0L"N62QU@4Q/JN+(1R[X&Y,.<Q
M$.32G"=DSC>X,C>:.) 04B1S94T(LD%Z% VPZ.B<L2P47!G?D=4]R4T'2C(\
M+JHY$WSX]5+B8H>W2K/ P\IOH]CS[XN53AS,=SK_?<?C2=[C-24[;>5"&+$_
M&.EBH8$SKX"O/@5B[!,=EVHR9'#?"%W)U![$U/PMQRL2$['@";F@-<K5#)'A
MBB)J&75,!"T4.%[3E=50)BQ-^]1$::UCLM8;?E7&2D^41 PDA+@A 1F; I+>
MI*"\5(0R\*O8-%EKF2I3YB#-UIEEQ\Y <M>T^S4_<;#GVKUY';'J9YQZRGI3
MZW:ZUV/6WW*\2P9U?P9UM'[+WV&66N&] 0<G+]' B2"+HT36*4^3-\HHGR/3
MM_>\*&>9YL)RGW&6J;3<L5KN3=_'LN0)%GEVV"/.F '?AVND33)&*&Q%T LK
M=VP"-LN;6$\OOQFEK[]2EE-NM3OV"&^)G.-!SMM9ZRZF("BV2!,-R&G@DQ'1
M(B>]%XD$3T-:6-'TR?LGEIMJSZ.ECSTZ7%KZV"S]!D?"Q!JL&44X.(8 EBER
MSCJ44MZET7O"G 1+?_*&?B^\A?;3LG(>/EL_W;RDS&Z8<FI<BX-**Z><OVH*
M/(NCXG2$ $%_RD35YQ@P;^>=.\P3M\"%-9,.<>T],IX%9 G082R%DUH4B:J4
MWB[9<O_ PH-L91Y8\;P;__-%$4OC?S[CO\&6651$1LM0="XB;K%&&GQBQ)/A
M\,<DJSD8/UXT9NJ-OV3*CV.HS[28<XP<^KD7<\YP[O#[7DRQUXO9^+K^2R4T
MOS9#[(3*L3T?[K[<J>S K>&)JWD;YJ+A^??O%^[D"U\#3Y_S 7GLX>AO*E)H
MR-I(L_K#L7GG<F/[K?8QM*T<B1\T$N_=HN&&2&JCQ\@:9A'GC"/K\S9'Q.J0
M3)3< 0V73Q^$9Y1GS[GQCCW"7!KO<QKO#1JM611&$H)B$@&,5SGD4BR6?=I$
M!87_Q:DQWC*WLTR:G:TSRXXM.W:VSBQC$64LXI7-]-G!H-=T)X,BZC#HPMNV
MV]W.,"QQV&U!I\ULP:DG^R8SO*GJ7:\X/V[7"\U@KGZUS58VC$;W;6$6.U>L
MXF_;;_IRFF-L_MG%[?0_Z1@V3$44G/?@GUGPSX)/"'L=//6<$WPYQ_F4Y.GI
MB["4R#6OR/5"TZ\E<KTP<MV(+*5D(^78(Q"U0-Q+BIS #DE&X?^>!9/H:()V
M2I"K='V>[%@PZ/K0/<E$>EI]GWLU\?4X/\>Q]\WA.;2]6/GO?VE*Z!\5ER%R
MN#5PLW4RB*'T@:9EM'VU3.)][.UD)1VO+T1_2"C6;:\#_=:_?.Z(-HR8 2Z9
MP3V8P>V\36TH^#'"(.VX0UQZATQD"4D?I%':)L;3SQ>Y3%H/UH:(6&K"$S7!
ML4B24Q9)8D+>EB$B1X5 +-@DI0U><;*P@I?H[0U9IH,RELYN.43="YJ>Z/26
M0]0S ]/-M A./8[.(G!;)>(Q&.2T=$@$)WG4U+&<TS3->E .4>/1!!<LT58D
MQ)@%3;!!()>H <82F(<_C#,_U4-4.5->SI3/2+AH-B)&KS=HM%M\B0%9:)(]
MB,.(4;_2/1GT![:37V+^PD</2?4=*<T0@'^F-S.4"_Q#DC,4_G.G\E_JW.I0
MY6HG;1=[]32B-P75Z=>_ZU\YIS,^,G2[X#CSE(5H-&+"1,2Q"TA;ZA$/CEO*
MI/#43*O&W%*5<@[PV?7%8&>D#QS9%!GBE($;)85"$GMCI!",:] 7SA>E4K^F
MST^J<W(_3)ZA927E6#/VE2<E<DP..6YNV"MPL)(D1$"ZB,L0$7S5*#'JL>6!
M2RVG55]*;C()C8E,89.H0X0P790!0,9XC%1P)@@3_G_VOOVIC5QI^U]Q\;ZG
MOCU5B-7]DFQ1Q0+9P[YKDP2R6^&7E*YAB"\<7Y+ 7_]),S87&Q(,!L986[7$
M,/*,1JU^U-UJ/8TEB68])>N8S%)H+=-:DP,ZCQG0^;5, X__NN+KYF_ECR=>
M"7%:":?FWZ0SDVY<F3'6IWHM3[]@E]T\\+ZAK>UUXK//DOO?[0WCW8>]QO#8
M1SC6(U=$*$PX[!))H&N$HJN[MM#MV-7Q4<[!QJWO.7X834P&I[U!D73S5=^W
M];#XZE]_*]SP>&(Z7/G66/_@Y5>T&?02*-_ZE;H,*+T^%%=_'E^$&D_C8@-,
MW^LOT;".?7VEV]_TV6#MUVNOU"FZX.KX3;_ZK2\8PB.9>.1?%=3%):]75?)^
M%3'4]U.KV"==F[XTCOO)8OB?@@MK)0O:\E1=2U 9('2"28ZU"BKX3V)M\[!B
MJPB)I&*8IO-OO^K-F\1X,>:;OYG^KYNSD[Y<]W_Z2(S7:H$(XL8)O+WU?F?O
MS9O&?FM[_Z]H8ZQ72+;7VKY=RVO3]_W6SF[K8'>G<7"X=;C;W&T='C3VWS2V
M]YMOW^_^)U[:^WNW\=?^P4'M7^67HALAN#>*]W"#?]>_NQ\F2\7\?;U-FW[P
MM>JHU\5J41IM\57;^G3@7TT^O)[8"$6W['#YI=<=W?\<@76\Q"1<G0[/I^=5
ME\>0J]2&9"2A[MAJ&S]X#,@;)2!/F9C5-8$WN,*W7H8;Z%_U,)WNDY#Y\]='
M:(,3<=?7G^,:(W<>U/DZJ^YTVY]8\,^R&:AF'G]#Q*A2H*<)&<F? 4=5R2"N
MU+[1C.V.!XW=N("[1E/W[7&#H/5KWEL=Q_R1-V#G('BNMY!3W/\.VX<+*V?^
MD@8.SZ,%RU\:?7*N85EWF^=(2YB7M'6)<T3G>_EZ[W'4\)#W4@2FSYK%.##=
M^;-]],='W-HY/FEUFN?-DW??FGB7'G7VSC[^LPM;)Q^^-SM_?SDZ^4(N ]-[
MN+GSA3;QWEGKY#-LGJ3@]-%QJ_/QV\?SH_;^SAYN_9/^?].>#DQ_//GX;?_P
M\_G'DSV\O_/NK)6"TYU=?'3R>WS^!]H\^8@^IO__^3LT"XA24+IY &,_[+?]
M=Y^D1H:E!%(/&0)4*P-D.L9-N854*:=,253[4);JN53DF2O:99#+()?IN)<9
MY,@4R'$GHH2(!@+: &A<BX 14 "F@A?40X.\7  ;]Y. W"))F%'-29BK0L=I
M_Z;OCWUW4'SUI?G\:EGMYX5FX3SG/5:IW':U15#]_-#M^]B?<^\:GW71;?R2
MIN._$QGXP-M1OQ@F0G ]X?8 $=/!("+WTL_7EUG<]SE)P$MLV[X*;3>0P[SI
M]0_B]#FXF%M;[F0T&*9MZ6@][(=#_3W;!G/8!JWM60>(.(L3L3"T*6E8BV0;
M8 D48YQA9@)2:FV3H =7L,RENU?2RL]Z_CQZ/NT#..&UX)J 0 @%E!D"I(P^
M@)0V&&2=#C#Z !P^A$R\?D6^E\+,K^I]SYKY+]IJNIZ3N7IESAXO>'P#V%Z"
M:(ZR+ AA#V8M*2.(U]H#SAD'5&H.5)0LX-&4BNA*I7.DBK) 6O>:9\]W8F;U
MD.#Q;*^,!$^#!-.V%O0:J<1%H;G%@%J/(A)$Q\K)P"31#AEFRTTEM@ARS26M
M?AA5N8I\U<]N62BA0ETH$QZ]I&'=S>Q<TO#NB_$+7W)S2<.E65W/9NQL&PPC
M@1B@"$R[F3!Q/@4%D$$F8(.5E*@V1=&>P9!^X;J;*QHND>[.6,;2*.HT!E@Z
M J@.!&A-*+ 2"R*-@9B2VNAN/LK[N-QLS]V-E]<R#VP>V.5JF6D:[^?-YX*&
M2QR)V)[9ZEOE*H<_I&5YT3GE\P_ RW'C%K__:?LNW+3E\8+*C2V%V]<\;,Y0
M#0:N@W<B .PI!M0$!!1D 431,RL9ES(QMJ>]4007MB-R!X6J>66)#(VK"(V+
MWQ#.T%@C:)QBQA,R8B-U'E"BXP]$,-#><2"UMTQB0YFH3B!R.%O$H(;0>#-/
MVZ1C"Z2)>6(USHQJCS&@['9&M3DXMU*UETS#]E)HV)YOCJX.:=K!X?[V__UG
M_Z^=W?<'95$(\;JQ^^[#WN''VK]2)D_[T=>>GCQ-H?N0IY'$\\46SO/%-A2]
M'WO8CZ\1>K]OOI2^\@UV=ZJ[/*YW[JO<0/!NM'2/UM='C/D^W_MC0EZBK.[<
M5[&![GC7.U+O+4-XZ>83J?.]5/UHXJ;33Y-)4%4OF.--[["3M_2#LM7IC;K#
M%1Z4*GZ7I\D/1F3EY\A6[&MRY'6[40[(6UTXL-=M;.O38JC;BQV9Q]AE7J[1
MMG;4&;5UB@E6;#[7]_[_NMLQWQ<[&:\,SXX/A2U6637+<^ 5;E_9@KF(SOQW
M5 S/GH,O]EEMNM]U6W>M7V_\J;LCW3]KH/7&#QF'[T#F<6<*X25)GY^SI",B
M02IO+&&&"DPD%0P93Y GQ*J@/NVE746$?Y8W7QD7>X/!Z$HA\^?>!6Q=U,?Z
M<MXZV<(?.Q_@QY,/9_L[[\C^X19MXEWX\9\/WX_^:-*/AW]W6OA*?:R3W>_-
MG29IGO_]9?\PMMEY]WW_\/UQZY\/Z.C$?FL>MN+?O\"/>!=-[P(V#W>_-<]3
M_:QWK'7XYDMK9Y>U_MA%1^D9YUO?F_@=B_<ZB<\,S7%R1,J+C_<[W]_ZQ#!W
M!N(X4273@ 9F@(8! FHXPA0S['1BYY@MC74_$IYY.+27DHKTI:='S/W^2PI@
M-^2-+0J]KBRQU=)Z/<TA%-^] ^>^W\O8-A^VG4]A6P@<"X4Q,$CRB&B" DTQ
M E819F6PE!*=8C=E9?(5 [ALM=S5:M&.!2J,(,Y)R@S6B$FBC.7"(^(TOI_5
ML@R)34NB]FA:[3T4RG,.E% (4,\),$HI0*"3V$E-2'"W5I=^V5J?S9ILUCP6
MO-U@UF0<FP?'R!2.:16$A%H SY"(YHOAP$ /@=,$4LCCE&6PK R:(2Q#V"I#
M& V01>O>PF TM9HHB ESQ%@?+7UIV*(\LVRG/0C?V!2^<4\@XI@!+K 'E'H*
M) K14>/>4&N"AE!%?(-T79)50[DG/0Z9D?-%(><\)WX(5<HKY3A7D!)-=-3%
MP*P5'AL)C;@=.F]A?LQFX(,C],V+<SI?6//\\R>A85S6*(NSQ6I H15 "@,!
MP5 0I@R4FJYM$O600SI+!H\9RC*434.9(EQQJ!"D/EJ#,DA)!);(8(*9LD@N
M!,JR.;@XG+L\JEWA'*68"FH)8- 90&5P0&J&@ A>^WA%:QS-&:SD>IP<&>LR
MUKTLK)O'X8V&FE66!Z0#M1::^)%9@:ED B)"L\-;$X2;LN2T,T@)!P%B" ,J
M, (RFG) !Z*9D91A5I)1\'5"9^LAUM3C71!_4JU!J5048/2@/&'=.?7=07DH
M]5ZY8,O+ECK>*I]S(F92VRRF+*8LIBRF+*9:F,\>6HD#IS0H1J4.V@EF(-?$
M$$^@D'.3\%\6#1P<]B[/N:03+GO=\?F6,OVGM""VKQ@0[WTTNP?%T!_X_M?"
M^K?QY7ONO;>]S]WR+G_K]LAGJWQA5GDQLPTEO926:P>8$=$H9]$H-PX18((3
M2-A )>?1*%^'_,&;4#4&A5SN(Z\'64Q93#5>MA=>.R<OVTNT;,\$TXB2@BBM
M@,$XKMM.:*"ILD!1[;C'REM%Z[=NK\+)R>J\\?6RPI]U<;]HV?*60;_?"I2K
MU6<Q93%E,64Q93%E,3UKA9V7*?IYLD,#MT[*8)P)E'MFH#3,!P.5LEY8-[?'
M55J&M]#!7Q8(SX[1W1VCL]E\T2"-,$AI(&&0@&*43D)""AQR1& J+*1F;9.@
MV0K@+P<.7J;JOCC4?IEB>LZ85D;81T#8Z="3U28X0R" $ = &<<@KHD!,"TE
M951@AFJ'L*N0IA4G>%G4+J=EY:V.+*8LIBRF+*8LIBRFG"B319\U= %G++4/
M6!-)$0^>(L(4-%!3Y+S6QFIVEX#@+8<MH^E^Z:CFQ(E%>:^M[=ESEH) K+FP
MP!#D "4BY3HB#N+_/!!#.-.DK/N(\>PAI+GK/F9%KJ,B+[X(=E;DQU?DJ3"4
MC!BLH=1 84\!=<P#*9 "+(G04!JP8_52Y%7(?KK@C6_JOCUND,71QM]<.S>]
MS:V'/)<1Q^:C9^7!PFB&*","IY)(C>**IAR/VH"U,Q7MPQT"YYE4_K[(=$DJ
MCR(JG36W/@EJ3%Q@)!!QW 'U3@#)E(O 9#A24N @U>))Y1^J'LO!\_ H(% [
M$+TO"\2#1V=)H7'6PEL8+F:Z^D="S?,IU P6!2L, TS:B)HP.F?*00$\=8)@
M9(E7[I'HZI<<.K,MM1A;"CDFH286.DVIU4Q1J06E!(9XP7ES/ULJNX +@PPT
M!1DRFE-"$@XTD1)0HSE02#@@K58B2C-""GL<JOLE1XQL;&5C:X'&UL* ,[.G
M/A AR31"0NZ-LAX8C=DX1@8M Q8A3(5&#'&S<!+]#(X9'#,X7GBB%FNO>.#>
M>BHY,XIKQ%$(Q%IFB%^4)YIMRP<A)YM"3DH%(9 R8)QS@"HCHSOJ<30P&8.:
M.X142/3\;%TJF?&S'N3]-X]<!N0'#TV]T7BNK5]GD"78.D("Y5P:+!B+D.RD
M\5QS?3L<9\K_Q]H_N3C"==BDS9.M3QHC(IBU(,(L!10Z#@R7#!"MF8Z^O(=&
MKFT*OC 6[ <I1S97ZX,$V5Q].$!BB"CW4@AI:4J&\89J1:S6%@?/U$( ,ANN
MBT//BP2W,7IR)Y2$V@ MI &4RF2TN@ T\7&MXRK^Q&N;!*IU\J#$F!=EM&84
MS2BZ0*??$65MM#,)TYA*:(Q2U!D?@55Z@7EV^NN"G5.6I['"*(,@P ;KL>5)
M!4[A4TPU"D)@M+:I^#J#"ZY0\%SX^9.<Q,6=\L@M<\NZM<R3/[=<V99Y\N>6
M*]LR3_[<<F5;YLF?6ZYLRSSY<\N5;9DG?VZYLBWSY,\M5[9EGORYY<JVS),_
MMUS9EGGRYY8KVS)/_MQR95OFR9];KFS+//ESRY5MF2=_;KFR+?/DSRU7MF6>
M_+GERK;,DS^W7-F6>?+GEBO;LIS\OPZU:?OXKRN^;OX6?TR^<>5(I/7=H>^O
M52>(-W\S_5\W+TYL3K[VPXL_NF?Y_$F#\;G-^ )M?3KPKR8?7D_Z7W3+,\;E
MEUYW=/]ST9T< V6G,\<VR^=5EU]_*]SP^)52&U*A?ZU=:/WXP=55M%&>69Z,
MX[5K&&U(+F^]##?0K==^=%NVH2B^UUU_?(W0^WWSI?25;S"U+'U=IG&5&PBJ
M)>FKV("8+4E?'VM<,2%+T]?'F0/HCKKU$UMPF0H*W<RJ,-]+50OTT[R6G'HK
M<>-;O>W[X/M][QHEQ4=I:E2\\7.\Z1V8%Y=^4+8ZO5%WN,*#LMWK='K=/$U^
M,"(K/T>V8E\3!8UN-\H!>:L+!_:ZC6U]6@QU>X5'YL#WOQ;6-]Y[ZXNOR=-:
MX<'8LG;4&;7U,"+L_O#8]QM1E4[[_MAW!\57WT@U*_/PE,.SXT-ABU7&E,->
M0HYRP;E"0E;67Q*O&Q49V;7A6:GJEG_J[DCWSQI5>4N\@/*6L_Q>=R(/7"*:
MO!N++E$DO?3"2"XX)9@8*GA CD'G$22VXF-&"*]> <O.FY/6SH=O1X=_'W\\
ML>1HYWV[=?Z%'AVZ+_M_O#DYBL]K'NZ>-T]VSZ=I\&+?8.OP]W;KGS=%Z]Q]
M:?WQ(3[ON-W"[^C'?UI?XKM];QXVSYJ'K="\+& )6R?VV_Z[3\++$* 5(##(
M  T2 ^TH!E Z24A@'J;*N@+-$C _B +OYQJP'"2A]]3DVH'=?6E [_#^2XI@
MLT2?"X.O%\HB_W0@=CX%8H9#Q(RWP#(A #4X ".#!D(C@32B#'.ZMKG@(KRU
MA[!LF-S5,+'>(I3J#7!J*<9:!FD,YUZ@P+FPZGZ&R8LG[WTZA4=3"A\"=89K
M!SC2$E"B-9#(6."A1:G(1[1;4JTSM*[X@@N>U5[KL^&2#9?'@K=LN#P0Q\@4
MCGFB62#2 $$2CE&N@3:$ JFQXE9B&>SB:S9F"*N7)F<(^SF$$80Y8HA![1CU
MTD@GO!<P6.RL=\8\!,*RG;8P?&-3^,:)L205[+:40$ QYT!Z&%*UA2@]$IB1
M)%56A(LOLI!1KE[*OK(H-T]!+J.IIE) S@BC%".)-85(8^RA),2&VV%NQ2H6
M/F' ?!(T;^W$T=GY\@DI RUF#D#K.* >$B"I=0!) Z-+"@U,F(:(6EB]K0QE
M]=+H#&5WB99CR*#5W$GL:71GC/#.$FL0#41;8S.4/0.4G5V',J*0,!HZ(+G1
M@)IHJ&F/%8#(:A6<(X[@"&449RC+4+:Z4.8(499*QS71U'&F</ 64VN%E\(8
MOA HRU[HXG"N-66R:4&(8T$#& $-4"$T,$HA8"W%$>-,X)ZO;6*FUB6"&>LR
MUKTLK)NG(K2VQ*' 2%0*2A&2PAEN@Q8A_@*5R'&VFB#<E"7'#=;!(15=T6 C
MPB$/5)0:P)!0&8UN1)%.EAQ<IT@L2Z!M[BS34/ZW5%FFI:( HP<^O6/GU'<'
M.LGD7EFF-[S_DN1KE+G&^/6<$_%F>3_JDCKUR'OEW&0Q93%E,64Q93$MA9CF
M,)\YBUYF4)+1P*B*MC-$TEBG$?*..:P_[:03)!!!!,H/Y&=V])8[&0V&'=\=
M#@Y[ET?_TJ&_O>[XR%^9=5A:$-M7#(CW/IK=@V+HQ\?BWL:7[[GWWO8^=\N[
M_*W;(Y^M\H59Y<7,[K='T!HG"? "$4!54,! 3X$G3$#OA>7&1:-\';'9 &L&
MA7J#0L;N+*8LIBRFE1+3/)809M9PCKGPA"HBM::"8\$0YA1QJK(E])(MH9GX
M9,"(,PT]@!YB0*G5(%K)$%C#"...2,-0_4RA3+.96ZYLRSSY<\N5;9DG?VZY
MLBU7@=VGXL2RUSBQVC_BQ+K#(?HE].CNYWC?+.]EX3K(8LIBRF+*8LIBRF+*
M8LIB6@TQS7/@ :+@D(<:,B,H%U1SR@WTPE#EF$!W"=[?<O*A-+NO,='N=:,1
M[A,=;<L/]\.A_IZ#[7,$VUO%[+$N9X,4GBI '<: <H* D=0"38GPSCO&+%W;
MY'"6TW'NHPY9?S/,9C'=$V87L$>:8?;I8'9Z3U-%H3%/ Q!*!$ UDL 00X#5
M(:(O=DHQ4R.87873%(EZ,9%V-WHAQ?92Z8A!.F#1&)W&CU'Y8F<'22OC]8/X
MB/CDW<9V^>=AD>JY39<E6:U3&+>#UXVTF883YR-^.>HM#1 IKPS%V&L/E8YF
MQ_WQJQS\BD=S9]2/HUCE;%3\FML78MP/5V1WX&UL.BQ2-S.RW1W9SF8XP9V3
M7EO. %.6I;Q5#:1F C#.!58V$"K1VB;!\@' EG.W:J/;-] 0/;5BEQE86:\7
MK-?3--G$6,J9QD!:!0%%&@+)"08(*:2$<BYX=Q--=M;JVFKUW#S7!B(?G/;1
M;F7>0,>,%)0[2@4Q;NZDS(>NTSGE<F'*/DV1#9U$AA (; @$1"!70"*B 63(
M(861D"RDC$MR [M/SL.NM];G=/DLIBRF+*8LIBRF+*8LIJ7=I\CA@*<,\TUO
M8&AO.+&2 :D2.SLA#"BM(2!,DWB-,09];>(!JY"4?+G[4.U:N.)KX7S7Y:3D
MO-6=Q93%E,64Q93%E,64Q93%E,64Q53'8(%$3ID 2:#,T[* D7(.4641\C;@
MN^0.7(\1[(R=H,&%=U1&#;+W/X?WO[\]2XK/(!6<20UL0!90;!F0"'+@B(,*
M46$YAVN;-4E>S'I:PZ!>UM-'T=.I*!T+T$(.-?"80Q"!U %-/ 0Z*!VB7*!+
M4;J:Z.DJ)!F_]VVO!U6.<;R:NM48]HOX,\07BV]1IAX7)5?9BB40Y\V?+*8L
MIBRF+*8LIBRF+*9'+E9EI#<448JYILX'19!P1CJ'K!.>TCN[,+;OPJNQ6;<?
MML=&W6&RZ=Y4)MWVA467_9EY_)D;ZB=S PFFS@+HF([^C(! !L_BKU92R 2R
M1-]</SFK;KU5-R-L%E,6TS*3K>>%\!$7PNG GH7$1C/% <0< M0I#Q0W"O#
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MRVXD"UL.:HXQ._S@9O[R0<G<D9; ]N6LNK04.^/Y-5X];>]S-W;');;5L@;
MUQ(6DGE[I<2 *>N(V':\>6477%9GT:?1:CSMIQHY90&C"Y[\*W<[+GP_T0.<
M)7OT-FKLR@^XB<DO$WS<A> #0;@!JXCCO P?E&U(?#=VBWE),]#];OLSAH_;
M'YH[6\?.8OHDW"D8+2=Y2C($*G0IS8'JXU73;%QF9EBZ%=>I6>_#MW+'!+CG
M'))?*@]W%&_A!O]>%%_*4LR&=Z->=&DKD;^-=F=9QVU\E*)RQ*L::>-9D:(-
M>\E42=T?-[LP JK?K]B7Y0SZY:^T4H^KFBQL<%>*C.8J"?8XQ&GBG;Z6:_Y>
M]W0TG!UJG(?ZH4/]H=O[Z3"3/,SW&>;#WE"W5XM?J<+)5W>9+@^B:;C+/+IW
MQD7N9*T[N:##"E6R"ZRS-C5[77_6Z%3U6U,%EH?D4]Z8W?-T1NH=7_E_'_2*
M2YJX-%N:3#OC&80*(^&HB;\Q2IS#V$$>./3XEM)DY*;29%M=-U6=[(8]@KME
M))'EC)6.,Y(^?C]*U<H.[;=4R:QU^.Z\>?Y[T3Q_=W[4V3W[^,^?G:.3^'G'
M?9G.2&J=O/ER=&A1ZWPK53)#K9WF>?./O?/63JOS\?#/V/:H$S]_:>'W-_&
M$&@=,9@# TWB.R((2!0L"($B'F6HH.5KFXBN(R9KE$F]H),4&:1>*$A1HJ4B
M$9HTDU1@;*P*1"AKX[QV'JI'!JD;CGIE?+H3/LWPL<% ?*)N#(AJ0*5 0&NC
M !9&"*<]"9*_X*->&:!>*$!Y SWU 2%I$.4,:TI@D%(S;"FCC&> JBE H2F
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M4^RX0AA2'+B/2&Y9>&3+.Z_3#U3KJ77:>,2]5!XPJS2@ 6$09Z\ ,CE5&MO
M#:SA.IVY@S)WT ,A[\/&P4;C<R_VIUO66-6??=?FC(P?(#\T%!(D*5?04J2L
MEMIQXF6 / 3(<D9&/4%_[S+F<K@5G_7Q$T>.!8,$0 9'T%?* .6\ A03;E$*
M\Y.\V;,*&BT5-A9*[!WA-!BK@\*2,&D)TX3K1];H;,L]4*W/KJNU"99(@W%T
MS#0!E"((#!$&>*>]L-8::-S:IEB7%+]@I;['/>;(85(^**,YIES00)!!,B"I
M%>1*(8;H587Y/BA>=8OVN"SMO34F*\5<2G$1MTA]//SXR3GHO0KIF --!YB(
M ](I%Y<^1ZER6@4LTC2:TH>\X#P.\;"F#D$=%QR<: >#Y 81@Q2,@I%2^KS@
MU%JWIA8<;0UE0=M4O\$!RK4!DDD-((,Z<!:(HJA^"\[J4!&4+NZP7Y:?/7OH
MH8.5"&XZ+:$EP1NO#766:B)Y(%:%"%OQVB.G,V9\6I"?.PYNTN3)"&0!94P"
M&H0 4C,+%)7<">V])79M$_%U52MB]+QEL6"M5@$1 :FEW# :HJ,;*"3,8,<A
M-A3+'+BJJT)/[590$YTL+1GPP6I L0] VJ  ISPX)@ES(B<+K8)&<\\%]MI+
M33"5!$OD(?7((2X=@?B1_8BLT0]WS\<:#;%&+II<P.H4LRK3"C2'P&.)O>(F
MX%2[)&OTB]=HAHC' D:=Q8H23C6"G$35UM)[HQ[[N&^VO!<4&9BH-806(1B
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M$@H>@YDG,$&&ZEP_2C!GN2.)VR4T\TIXVV+B!M>HP^:HD$&KZ]MG(09X47F
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MC.KB+Y#XX<MN>/U_9ZW3C P_*/H>W.^/=L^?+)B$[_Y]1<)?PWNAT]A[S1I
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M:2:EK\[Z?="NJQ$A]4 _V66$5(,VOKT\WS_^L]6@[[XUC]_CW;V/8O_;(6O
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MH^0(&QP0I](@FZ)%B@?F.9,JY%)H!&]R/',IG^4[9RGB/2_Q+JZ!!0OVN&L
M,^$P+%C.\?2(QYSM*4-$. 4MI#)1J;2Q/7-=V"+32^P:6*A0%]? [$(]X1J(
MR4>5&+(R,L23D\AIH1#S@JC J 8)W]B>[/6YRK$0:R[/"Z#@Q3&P.(D>=PP(
M&V40(L=<!E#3)"ID<%(@UE)B[BGVFM;\FYF9C^:>+GA@^0KWK<HGUSXJX^/6
MWUO580_&T\T%/"I[&+N^!&7\!/:CQI(Y:2,)A%L6+<-68+#;'>:"6%$\+RN
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M4Q$1I\P@K5Q".KE$DTD4BUQ.O4!4@:A5"119*$:M;W?WI\.H\>[N5N>0$*R
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M/Y68^D"9ID9M; NUABU^BH@^!E,H(CJKB$X&[JLD##=(.0.,0+GL$F$&16]
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M+>=NRJO<Z^^T!K[=&YSUEZ5HUB(6F'T6B0E)24(8Q!QQ'0)@-E5(^! C@&^
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M>3TMC)F[$*ZUQI[S[*R-/I^[=5+4^$/4>//5A%$"+"LX+, >(8(C[EA$AJ2
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M-^"SNV\_?FM\^P@@\D][/,?R8.=#.P//P<Z?K=V=@U;S[;NONV]?7^SNO;\
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MTMI222/%$@NPB\G,L#J?-H2+A]4%..K6'GAF9',%>%8 >,;9',%&<F$ >%@
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MU3&5AYF*,3>8T+9-13'D0/,UV5 ](KLXC<8V/4I56Z$VFTNM]*S7RU,Z^G^
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M35_"H8ULE &^?K)04-S3*?IJK@X> T1VSR(E #O-BS2A>8_]E*5C$A<8'_*
M(@-8@I03N$2Z26,07+",:T <:906\#!\0//9DX<!8/VX#.A;:9>\D8(T!S%8
MK3V,LKR0\M+[2OT":7_RY<=K9 -'1T?2'APGJIO2989OJ38F+LO2H/0+6#'
MZRK*BXR#&EB %^.;JN?,/*:'/(2$</0(@E%,V5VP+'+7'?!24N @MQ*! 4>"
MBP#(P#>X),#ITWT<#N<-HSR'A[UC0-SUWDCE"!X=1O'<QO$&N)7^KXQN +(
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MLK(7P!X4Y;$ (2Q@N'>.*\#E-:Z$8_41"O 1<R%9W(8F*2S:CQ) +[SQX_X
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MYM-A[DMD4=7:&BR=^^0F<@PSA7"%$TGV=OUG+JI*9>S9Q,J2WC4?):O.QG"
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MMT?Q*W$;-^'2[(HDT0]!O<SIEH/!@9 "*QI0]PHT>N M$T;PH@G[4- -8 A
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M.DY:5926'+71E_;.3B_/SXXOV#%_/#_;.]C'DVUW3\;-@.Q@TJ44I.)^E/O
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M-*"[AME\;+4?A^W6?:/7>&RVAY_:[=$P[Y@G@V@)J(E1'XJ10Q$#$0X(@4"
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M=\/QX0G)3Y;VYY/Q(A'WMIS\/AO&$0V'1!^=#7$Z0*^9<TX!!F- !>XAB,P
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M@M<SORXF4$IY\%X&X$H*IDQF=GOST#FL7541^J'#JE/3/<VRS:6K ER$WJM
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MSKS>DUX;!VBE )5#;4CF[%KOE-Z*8#\VP_>/.WWXK7T)>6*.5Y-N\=+\4,3
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MM'CN&>^7"O,=<;X]Z?K+^6_ F+ZR_/%NP>+=SN1EP>JE+KYP+2,%LY(D*R)
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M)9UCGJ%&-%=$*^.L4%05A8(Q3<R1<*6G?GDM/Y[3A$>2%JF32E1WP'J@31^
M=0C>!L2!1T*SO6CX,_534NLL$B'BK!M&458QTI4\=Z7FQ(=MD2I%4A0E%&89
MTA0I\Q06N>;)&"/),R)2(IU4(WT9-D2RJ/5_/G?3__'687:,<XMN"$Q6WO1]
M/H2H?>4;<%]BY[[,ZE<=W3.8!W+JOI]_$Q*_>S2B&6,:\3QFB,,TEA%$2@=N
M!>8*1@K)2%&BHUXG^74O5@V-OG?(H]J2ASS0?^.[^F_,+%?4^3EBI00W6:O
MU=/J[A-L/[W?RW#@WJ=_C+%@!!K/!C,,[ (]C#%@9=,?:0#8A=$S^^\]O.OQ
MCKJ Q]OO3W(JRL72K'],N=G;%:^6BX^SQ7_(1;VC*&C,49IG,$,RA2@M,E,&
M3$&:1D6!BUAAZG1HV+;AP1$X_\]E697K;_EI;H38%B\U,YN4_Z=:7::<KKY_
M3<J4UZ)2FV)X]:5T=<Y)&O^=Y=NL>\URD31 7X1>-6U,!FV;P=IHP)8+H,T&
M+WJRY'?WV!4J;UG[ELWVG*#O!L9A+K[C_=<DEWS5/%KK[WPPG:P_WY66>4'C
M7&*>0!R9ZMA*<,@DP5!PAB+$N:*Y4]AZMK6AL=EJT6UC+5B;VU%E_CS4=FSD
M#<# %'0%=AV35BY@XC6%Y51;-TAHN>#V\?262S?YT+9MI<.MA+RJ-TNY2<*,
M&8\HB@HH<CT-1AG#L##:6@RE&*4D0JQ(N^O:GF]\:$2S)Z]ZE5SM!=CM6"84
MF(%)YX.L*BE'X$"N=NW!R\ALES#95$<,D2?;!;D@&K47FKZA/JT=*.>U:2V?
MT8W'WM%R7FNAW.G7J3X9U&KN%]V\CL7$I^D7,RLUZBGZ@H^SZ7S]3Y,[4VVW
M E0<F]/\"F)ILG6Q2"$E*8)IG-!<*,DD<I(.]&K=T)C0.-=(RH+'QI7'LZ>-
M>^@_.\:\6:\$IM2Z0U:"48UK]0R]Y1Q8>P=T<+?QK[ZJ[6&=+5@%VM<)@KXG
M6O9K6Z^\'036?6(/TT@WYC>GV1<O9F%Q-M6\LYJ9I5%.<Z7)F\5&_!6E"E(5
MI1 3E/&<B@(+I]6]HZT,C8D;(\'&RHYSWN.(VG'JU3@%YD9WB)R)[2P$G@CJ
M>!N]$LU9-_<)X_S%;A^^D.7X3H<8PH09[R;T?IR+C"*B/_8L):D.UU0,B8IR
MR''*!&,2$VZ57'?PY*%]X!OC@+'.[JL^A.O\EWP5"*%W)^W\M_YD3_IZY#.M
M)/_I?O;\L[ZG^4+U#]L/\_!)O7R,)QU8?X"G+PA=V7Z,L"PR66 H*&,013B#
M!.<$LB0SJ@E(XC1WS!&V;-KIL^TI@;B6T'IJ%4@OCY2M#U6UWGME^@%Q0H?J
M\[>H+>\Y '!H>* UXD^%"AV>X&/I^_6L6HRQPD7&,8$%,Y7>.9:0"*1@CJ-4
MT$A@9!=(G&YB:!'%=MFUKKH&N+;QFJ7L&L8N"]:NX 1FE8/EZ-?G@+ERR;GM
M>Y"%Y;J!&RX?MQT\OTB\<V7'Y,]Z36*S1+$5A1HG."H0I1%D0BF(<ISJ>8(H
M8*X(CI'*2,0+EXCD9$M#"T"^F38 ;=8"']=K?W0!U';M=C8%%&R7_DQZIF,\
M<AIX.T+P F?H&4AMXPALUUA;@G(>LQTO0>$K@_%D._UF)5YR]R#3\.(-'6."
MQ8.<FV6*N7R0TZI\EMN#13HP^:2^T>_CF# N8I9 $D<Y1"I&D*(<P8P1A;&D
M&45NY5TM&AU<W&!L-I(.6Z/!/2VGX >3Q>V8L&V%NF50X1G+T&%&#>..O;OG
M!D=U??29,LHQ'L,/!Y1\!20V3?8;HCB <!"TN-S;68IA_^F;;R'5H0J+$PYI
ME$9&O3R!C.0,4D:BB(@\Y[ET"63.M#7,4&:7>-S/&I\#UXYH/$$6F%\LF644
M_'BR!5S^)!M.MM2W;,,EEX](-UR\Y<K\F/,;M?7.[%8H.B4I$Y1E,,IB"E&J
MPQV:$:8G3$F2,LQHFLA.>3 N5@PM]/G*'Z183N2ZOK+I-#I]J6LBX+]5IU(N
M%@]ZOF7.M6UR+QJY?CZ[G];E./6?6[.*>CKV92\3X_5$S^%*5>JK?YWJSJ_;
MOWLR9S;F)5U(\$$^Z\Y?&=9ZVO\J]21[SA]>.F;E.+TU=@0:_%T(3*WM+)O+
MJ36K3)IO-;\&D1V_"D_?>3-.-MPF/Z8+3"?S8#H]K*/V<)TPN[MJUOKX<II%
MN504BM2<_D@0A@R3""8<L50DBG/LIC]\MKFA<7.77.P+@-JQF3^8 M/6B7SK
M*E Q!#M<?.D0GV^L7RUB*\</](CM[NI8+UV_"!_UJW'WO:S&*(L120N3TUP7
MP!(I))@0&!>($51D122L*C@>>_C06,'8!HQQX#=CGF,ZW YL=FS0%8S W[XU
M#NZUM(\X[*MR=OO1_=;)/N+4057L8]=TW+=:BWN^F\V_THE\(]EB>XK^CO/E
MHY'/D.+O<SU__W4ZEW1B)@Y_I^7TE52SN5% 'E-<4$RR!").<I,+IR#3'S3,
M9!PAF>993IR4^;Q8-;1%I-I6L#46&&M==[N\=)?ESEC?G1"8B(S]+761T5:X
M&&ICH7%1_V[K%CC:82/ :M_\KHU[Q=K7-IT7F_K=TO,)X\'VG]>'NZ<?OYTN
M3#IS4S'BBWR:S4VT9D[H+JMQBI*,QFD$<VJ$12A&D$9"P @SEN@_T"*R.G]_
MJ:&A15F-K9N*)AMK06.N?;;R673/$Z9/S )S8%>XG)*;;;#HE.M\]L&]I3[;
MN-?.A+:ZON/D:J>^U*;LU-[9_?>/3^9$-T,IPXHPR"C"$#%60)KI:1A)9"PT
M220L3=;EXRRG7P[-6WT$N^7D0D_03E22VR@,&3UQ.3?+JW>FG..SU!UG?F];
M4>WZ+LM)3G&""UA$B3!5/KC^25#(S/]F29[+-.U0\2]PO]VR#." .L]RUNZ[
M+WJ:U>_""%H%!P\471KC/<[[.T#F:UW I>E^UPTZ@'*PKM#E&5?DO#6;EA]G
MC5K5=#$NHIBA(LD@0AF%*$,1)+R(((T3PK.82J2H<Y+;?BM#"V&;=*PF3[9#
M"ML!B':\<S4T@0FF066=^;HUT7,^VBD$?":@';31?\;9*3>/IIB=O-C/$N-V
MSKP[@QXS_9E+9,)209$Y/I]!2D4&,SV3C1C&HB!.B1^V#0^-$%:)\YNR6J::
M8:7M7YW>ZR!T8MT%62104:0(DH)H%A9)#HN\D+"0A)&8ZVY 3F7E@G1!#VNU
M=9[%+W3^3[EHTBT"X=UM)=8'BK=?; VW>GH)GT +I">;O>D:Z"4P+BUS7KR_
MVZA0BR^_HI44)I5-3JM:7O!N/M=O41UFOGK97K*2[KK[G<[%IR=S874G1"T?
M3"?;<QC51KU.)!&C,C(9RHF">DRI2T45$--"\"1"F./<92@):NW0QI_:$\B,
M*Z#M+FCY:\X[MZ];^0QJITVB1^VV_NPWCK>.+#F.7F%?%3L*'LP+$)BWFSY]
M9=GWKSKT?1 UQ5ZZQ].P$=;67L>:7F#?'Z#Z:?0VH]K;[W+.R\H,OQ^7CTS.
MQTE,<JF2%!8J91 1A&"!T@B*+(\Q295*N5-%+^\6#FWT:AEHLMM-3KI9%UZE
MIS_)>3F[HHZJ_P[N9_RYJMO^0&-.R\\1:#P=SBASLA,&,K(<VO>'&DU.PNM[
M!#G=4,=18_GT-*D;IA,C0_-N,OO]_53/DQ\;P]:A*I4TSK(4PR0AL2FR(*!1
M!H8B59%0F,F$N(T%=NT.C>%;9L]?@-@,XH;C:\4KI?U8"UR]_-61X"W[PI*V
M_2,<FHQ;%C<25\9FT#(Z3 #O!I0OPK1LM5\:=(/B@-P<;P\4Z%87./3=;*[D
MNEK-YSHJ^X<L[Q\64MP]RSF]ERN6E9_G)9=C)2BB5$A(E68\%-%,1\12PBA6
ME,8L0C1"7N-@SPX,C41?4_TR3G0D]3-8>2*;L/C7KV^V]1!]1\>^WPI/P?,-
M^WH L75E&URW8# EV1H@1F -!5AAL0["3;*-1J/'^#M0/_85GOLV?UC1>Z#.
M<0[N0]G1;2!](Y_FDI=-<26I1^[:VJFX>S1YHO]5_WY<R"PG>H2#,8DD1 EN
M=F2AX+%24:S'O\(I+\:FT:$-6&V;W48E*XCM1A+?P 7?A=V:.P(;@VL1B+;)
M_BC:!2!/M&K59*]4Z +"/GTYW7O=D=Q5C84\+T2A\@CFG'&(3+H'HPF"DO((
M9P5%S*UJQ>[CAT8CK>.HG>I4[(%G1QO=(0E,$ YH=#Z>&Z06Q=[#;W)$]WSU
MB1-7N7VR?"[4JH[%>VW;U!2Y-@_6>,2_R'K_($UDII3*($WUG!AA4>C/EU*8
M8\SCC&9Q'EFE.EQN:FB?\JJLRL9:4+_-QEZ[3]H"W/.?MU_( G_JI]$"OS7&
M6C*A!6QBQI?U"E0=6O4#WTZ;@WKIK)G3'I"&1<WUAAK3*$WCFAXMGM +5=I[
MLJ9-ASO\21AMRGVN:T-^D8:L]4,_J7=EQ>GD/R2=CY6>=2&*")1U948J,"2H
M(!!G)EK*E<)NLB7=31D:!9N7#_P@O_/)4IACI&:+?:%?3@D>9]/%0V6VWJ4P
MF;3\X2]_UD/1W])X9+Z6U'%E\8K>LPO1^NF3P!SO5M=V!#;^F*VSQB-@7 HK
MQ>0&:T"9)DM#;B[AY :8C;R3XQ,[[A&M3XQ]4NN-J&W:)<&,F0,?,&$JAX@G
M.:12Q#J*C:.(H$@6W$DR[EQC0V/-[=%(_=EM]EBM,B/=@;;<(O$$7^CMC.[(
MN>\V6$#B:V?@7%/]KN);.'VPXFYS3U>]DSLA] M4U6U\FM<%FK0CXX)G*#8Z
M!E(B'9(13B!).8*%1(@3P2EF5B'9I8:&1AV-K6!E[*@Y9:TA!6N#715/3N![
MGC5\HA9ZVML9L Z:)^?1N$+SY,2#>]8\.>_>H>;)A>NO%!5_/WU:+JI:?'J]
M[E"0#*,D2:$21CJ\0"ED(M=S9*P0S7 LF70**LZT-31B^'^7LX44S1RKWI<T
M6_3-/^OB=7)UG+%J?F?.E+X79IJM8[W591L)\>;?;7WI'VK7F]_'CE.W<QUF
M%YQXZH; 3-/6YFX,':VDT2U6V+HK;Y_&Q+>^]I&6;J.B?=KEDUK99V[IL"*_
M)_VV=V+24@JN)=D0\TA&+,H@SD@"440$)(07D),(Q5F2LRBV.OD>PKBA$=TU
M,II!.L]BC^"&71*8],Z<\W[G(JKY:B.J:27V$;Y7';8P;MB[/6UZW*B7W39.
M G7#V:T6WVWVMSD3"*V=[9Q0;5R1LLXNG_IA)_("/^D 8J&CXW)ZOY</V"R>
MZM^_GDWK58\EG7R3\\=DS'+*429BR&@>0R0H@TSR"*:\2!21F)#82I;UACX,
M;?Q?>0)F6U=&X/=U"C)=I2#SK1=@4BI'_99;O"J6Z[3#?@%"+_]Z/"GZJ?W^
M'*2P;]  +3B P<-S.OMM^M)G1GO/'O2?U'Z;+CJ:UWXC4VXCAM"R>'567F4)
MRU(<0:G#,%-+O8 DB6*8I7$B4J8BS.FX.>+_=4'G"X=!U:>=+HRY;VTX\GQ%
M)^;,5WO@7 LD,'E?3FNV&XA,PI&N)X5D22)AAI2"*(D4)'&"((^Q0%AQ3(IU
MU[^=6NI7#Z#CU[;>I-L'I(MQV.$.\="MNO"/&NT,31?C9"<,1!?CT+YAG:SK
M"J]O78S3#76L1DZKA[NI,/\QF:'/=&)2E>J2:#).$>.1'@XB22#20S\D.4<P
MR66!8D(YI:G+Q/IT4T.;_]99+^8 5_U#R]A.=>;.0&Q'P'Z "\RDG3%S+SE^
M$0Y?%<=/-]1OP?&+#A_4&[]\1T>A:4-%W_2]]>M+(I%$).-0X(B9,[-ZKI#'
M.2R21$@14T(CXJ0FW7[ZT$BA-@X8ZSJQP"YR=A]^9SP"?^OV4+CK#!]SV9>8
M\,ZS^U4,/N;6@2SPT8LZ+@RLBME_4G6AB5<O=8GYNDSY.,WSG#&*H>1&XPHE
M!+*TR*!D,A$9(0BG;AI7I]L:VD>\-M7,R9JJ*CJXK\U=U7!W30L^ [/E[,H/
M>*'G2=UQ<Y_J7$;$UZ3E3$O]3C\NNWPPD;"XI1MU?)0+$SC4N81Z&'_U\JN>
MBKR?;DXWW#6J;T9;/^)YC&BN^2-/$$2%DI HJ2!E>13KZ4.>2>52R\"^:2=B
MZ:&:@;:\$<9;FB6"<@IFF_-!=&.T&[<X](,=U81!-S#S&&#K*<7:;,,\/_S:
MH/QCZQC6W668G:G('3%/S.30<*]$Y0[(/F]U>$+7<PVFJ-;\:3:OEUCJ#.G7
ML^5T,7]Y/1-R+$229(Q3F"ANJF%A 8LHPI!%-.)4AT<YMHJ"+-L;6B2T2MK?
ML;F5NK^R'!C37<\[G,?]/%<%0#,P0?D LL,Y""MXKC@.<?[Y/9^*L'+V\'"$
MW6T=J^L=/^RYJD$[IG%!\L+4U:-Z9H52KH.B1#'($ATN17'$5.8TQSK?W-#(
M93LJ3XRY8+(]Y^!8?N\\RA%5JB 2PSC'*40J2R E1:XY7$4"*RR4*,;/<LYF
M_>/<;C;@LNNJS/2L)\3M(DU_* 8F[W.G^%][KX9HA8JOLHCG&^NW/J*5XP>%
M$NWNZEK6VWPQBQ>C?[*XFPJS3/YD-MMT?#K6["&5% K&I*":5F)EDDL+R#)"
ML&!8)K%PDFL[T]C0J'MM:[V7(]>&CL!46AX5L$(X+V14("DA(RB!B.=Z>"2Q
MA (CS I&8VGV%NT7#KPAW,-203\(VQ&U+]P"T_3:S%$M!;6HD7N[1>[C&>0Z
ME+Z^#(FW4M=GFNJYM/5EIP]+65O<<^WNQ=O'I\GL1<JO<OY<<GDB?6)2=ZO^
MZ9/Z(OGL?FJ..#2ZPJ]GU6*U((]PAD3.!$Q,W5L4<Z.'@B)8<,:(*C@7*>NV
M[^'1RJ&-!T<K$&[354PY(..A.1=0;_X_E8OFA,G(R-_JV=:U&RL^WP#7+9D;
M]6OHS9QCR6Q>N_2*/9\ D'O?+?)IXXWVF0+ ?'J'*D1C7:7@SQV7JUOX)K\O
M7FE3_CDN4J1P1!6,&-;C12832'(L=;A*,"\01R+.W"3A[1L?W##0V@!^OZV1
MOE=SNCI7<_KZ#K&C[U P!V9EBW+>*]X%QGQ0V^^1@KO YDU>WJ'IGF7FW4$Y
ME)OO\ P?B])KX<%Q$N4HQDH:N1YA#G9P2'D60Y5E+,GSO$ (=U^,7C<S-,K:
MKNUM*M95P'3Q_F+I52ND&Y"[K(QV@:[O%=&UC:'60?<Q"++^N6GDANN>^XZ>
M7^\\N+J#ALX_J(GJ%Y6>G'\QQQ&K+[/)1/..R3,<ZU FPR(J8%(@!1&2*2P*
MBNN]$YD621(G5D)>%UL:&B\TYR9,(+.VVD$#Y2RDYRG *U"!66!M9CT#; P%
MOQE3P<I6#X&'-1YGY4'./J _K0\;/W:$.ZQNZ/#-?Y'UF/9)O=97&.6Y;_.2
M3MXMZR-#>K[U6-:1^[C .%8IEY 5)((H)006,=%$$!>(Y$2QO+!2]W1I=&A,
ML#*[+FJ[,APLC.5 -:8#OK'=@2-LN\""+@( &Y@YUIA^4F!M,ZB-!BNKP>N0
MF#IH2@7 MB>M*"\8N_&T(UAG*=OV6?VQMZ-W.T3N>F^WF=UF"<TD>S=G05?Z
MG@JIA)CB1+(H<HBBS!S"4A',XB(3&>>",ZOB1!=;&AI[KU6*%C/PI)_Y8+X(
M@_=LVAQ1<)O5G0;8;F+G!;9;+_PW=@>04KV(CJ=9W^EV>IWX771W?^YW^89K
M-U+OIHM2E).ET2G>KD:]K<O*2/%.NV 6XY>+U0K\6SHW8B759SFOWYIF_XPA
M+K(T1S 1$8:H2"0D3":08L0ECD7!I=.*N%_SAD90[37SMG^M55ZP]K!9F&KY
M:&Y:>VG*0#<2%-=NIGIY"UQW4?ONV] L>H-NO6)#U2?ZWG=2O1AWHRU4G\">
MWCOUVDK/(F,;:?"[JEH^-N&:R2W@"RG^?3;1CS$)G5_H0HX3E>8J8P3R/$E-
MK2($"V[RY7DF<OU'BIE3RF4/-@]MN%E;"9XW9H(?: 6H49XRY?[ZTIMRZ';+
MH618G=ECE-Y1DVI;)P&T/&\2>^I79.L\,-X/0*?*O:MNK5SE8/$?0\O*O0N\
MJ5MU:/HV@IGO9G,ER\52?_#OITURTEC&E,5,%#!&!3,*U!DD!8L@(1E/99Q0
MG(KQ5-X;&>[ H]=I*ZT(KF@(KFUK.)Y[;303)Q/-1C^#E<'RAO*(QWHV\/!T
M96_]88:CC41BRU.CD=#X.H#!YW)'W'JP.6/A'V-PN0RQ;ZG$<TUU3*]:/,CY
MQ]ETDS]D#A@_RE6Z]#CFG N<13#+D9[#))S"@IJ330JQ#*694&[U5L\W-[3I
M1VVM_JJ-B:9>=6WDCQV.-5U V8Z3_6$7F%X;V-J6@O<K#%?&GAX'W3.OK%#Q
ME8%UOK%^,[&L'#_(R+*[ZPHR,<PVEP_Z<>6S;)[^858=)(FVTD?%_UDVN=<?
MY>*3^D:_CQ.<HEAA 7-B9+M5SB E>0PCF1/.<Y30C#K3C@?#AD90K5))]U1'
M'S],M$,_ AW)5-N%6WIE/KNW7G6@N9[[*C0AOGX_ A;)\*.ZX!7XP;BJAQFJ
M]#L$MI[5F6O:,\_DZ1%KGS3KPZS^"=DCF$>IV^?S.\IKU_D(]:YN':M6=\O%
MPVQN2&A,,APEL0X7%<88HBCGD& 9P22)TISQE,K"JB*E15M#H^)5FD9E;!VM
MION ;LSMO@AP#F\[1O6$8F"2;.>YC)JI=P6VEGH4V[X,AR^U[3,M]2NW?=GE
M [UMBULZ$HB<+TI5ZFZ2U2?U1C[-JG*Q2DS"-*4Q$QAR(@@TPAF0I)3"B*0Z
M[BMPRH73?/-,6X,CD*VI9D==-+8Z<L49:"VYP@]@H;FB9:4!:V5G@"PO"SQ\
MD<69EOHEB\LN'Y"%Q2W=R*)53GZ,&"\RC&*S!&44=B35T05*("ER09 D*N>1
MB\).Z]E.9-"#H,XWTP;XT%7QK(V:W7??$8O W[D- ,Z?]!%7/7W"[2?W^LD>
M<6G_$SUVB8\3N:>J M9_-/4 XW'.L$"4%%#DJ9X59%Q_P80KR$6:94Q_MRER
M$JEQ-6!H(_W:8K@N.SO?E UM#D%H(Q[_\F>2Q/'??)[KM>@JRR6:@!T0>BEF
M_RSPF1JN]16>J[=VA2[($6*+YF]XN-@>G//'CAV>TS$!P\CPFA663ZI9D3%U
MB@[7:>Y85==)'6.419F,*<02*X@*3"!3IC(E8WK&0RE"D5MY;[?VAT:'&_--
M)+]C]WK;Z+>UZ:Y)XHX=8\=^ >$.3'Y>D'9/8>B&EZ_T!,?6^TT]Z ;-05I!
MQ\?TG&_VH9S*]]K0:DP3S!,I$(PHCB$B5).?R!A419Y(EBF1Q$YU&*\W:7"D
MV-(HO)RBM*=E6-<R^\WX!FKG7&GS^@ZV9-)>NRTTN5Z;5&;78_UED!V ?.N$
ML:U!?XS\L , O:6#'3[YRJG\*O_#5,A-6"KS#"821Q!%A,$B3CC,<I5'*L])
M8HY#VJ^Q';0PS)6V[31[E>75=:*] =)Q)MT%GMZFRF\O8=)]&KSOM^]Y[N;Y
MMYG([KMW<J9Z<&''8K:<+Q^7$Y/J?BY=8).2DU+%<X8R6"2(0)31%%*<2ZCC
M,"QR@01U6YIS;']H45?+?#"KLQCYSBS)I%<YULAU[! [V@@(<V!2:2/<Y(D>
MG8>N4Z!,J3P]5_6:]-01/%\5>QU;[[>F;S=H#JK^=GQ,!VVP#[*JI-Q=\+N;
M3I=T\D4'2[JM>:T\V)P6I?=RC(0D>:PGG%F"*42T0)!F9NJI.,JY2"*FK!BO
M4^N#X[O:5E"76RI7UH[69VNUO0YJ5LX=<9[I@L,;>N>R-GT$#O8;5I ;!\#[
M#>2?>X'<04DL)/0]28KY[P(W?;&N$)X5&G-^:'^*8UW]W9$>Z_R0KA55#_+<
M/BT7U8+64F?CC&"!9:Q@'N4Y1"*6D. 8029)5K DB9F*W JJGFMN:*-#8_&.
M -DF,;-EMFLMU;.(GQ\5_.,8>!BX%L(.551MD+FBB.K9Q_=<0]7&U<,2JE9W
MA:C%<?<XFR], JVI_;&N/IG'$2<,,XA3G$"4ZKDXH0F#<<)BC$5$$$I<%MS<
M31C:BMS&1F",]%E[XV@'V,VXP\(:F(6LCA[MPAZ@5FAW"'NIR7'4@ %5YC@'
MD%M]CK-/ZD9\&[&37W1XMIS7FQ?5YI?_J]3AW)P_O+R9F=R;<::D*E)A"M9A
M#A'.B9Z#YQ0F)!,42X&1<%+&<FI]:%%62]AH8VE]TN_CW;^#WQJ;'3=PW7K#
MC@"#81R8^ZZ#UYGD.L'DB=_<VNZ5VCK!LL]JW1[2\9 2K1Y,%HW^CRD"^JQI
MTU0V6+RF\_F+#A3K)L>RX%&4*PY)E-8U?RFD*DX@CG.<Q$662S>)/ZM6AT9@
MQMKZBZIK$LFMW8YGEZP0MR,K[S@&)JD-A/4/+9-'@"[ VNJ&QCR>;7)!R=<I
M)ZLV^SWOY +#P<DGIYL[;NI6E5Q4Z_D*2F21YKR G*<11(50D!2<0Q7+ J,4
MLX0ZG8+:>?K0YH)-=@9OC .T-M5Q W8'/,OMU:Z0A-X\K>T*,#4[ZK"O#<^=
M9_>[G7G,K8/-RJ,7=?M23]8/WQ;\E+&@JBAB2&)E5(%S"4DJ$\B0("+C62+M
M]A_MFQQ:O- 6&S<[P[.IH4SSK[4O]5"X<<3M>[?H CL2\ ML8&98&SL"M;F[
M  :ML6H/DR<^L6BP5Y*Q!V"?>1SN[!@XG%2%V5T@6H^.-,Y2G*A"DY'*(:+(
MR+?@"&9%C--<%#2/K;:[.K8_-**JEPY^H?-_RL6%T-L+^I:Q23A,A[ *[3^T
MZ8:7K^#'L?5^PZ-NT!P$4!T?TR';Z_5$3P$^J56AR4_SNLSDWOG.M]_EG)>5
M_#PON=Q<6ZTNKL:1IC0>H01B%,<0,40A+50$>1PG26(4!B,Q?JJU5;\NZ'QQ
MGNI\F>7RG>X;%^Z3W1R.7I]4ERLOP)-QP\1LOV_*JB[ XD$")N_+:7U\6O_1
M_**QMM:_^O7K&_//1@?+4@;+6[]G!2,Q33AD1:+GS3K\A@6+F9E!HTQF<185
MQ:K?WTXOB)K?KM?7I@VJSZ6.-@?6V^<'TUOT7^@E1.--JP*T)M6FRO&APL':
M*?!YW:&;VLCKFUSJ1_OH+H?,Q)Z[K;?ZIT_Z<?5$V'Q&OU_^""7E#X"O>_WW
M5@_.F^+6LVU:RT^>4AH]8G\VR]%'._TE/GI$92<7TN=SW=,CWZQ>_&_ZUG&L
MWS9$E8(<Y3IH0BJ#1$8*,HK22+*"2&Q5D77_P4.;\JUM \8X^\3&':S.#SW7
M(!!Z@F;EO%-*XC%/.R4?[CRHMS3#8^:W$PJ/_OTV57Q:28SG*.++;#+1LVUS
MXSA72A*5(4CS7$*4IQ06L4J@I(310N L84XJZ_V[,#3ZN!1J;:IC]EL'J,.[
M8;<8->P>#TR7/JL(M8 X(DFV]Q8%$>FY64_>6E6BNP-_#!6*JSO(=Q&C*RSI
M>LCGZR.=3%XMJW(JJVJ,)<FR" LH$W.J1_\,"UQD,$E)7! F2!%SMU,].\\?
MVJ"T.H-2VPC61KH>VME%\'*(>R4N@:G;#9(.AW"..G[%J9O=Y_5\S.:H,X?G
M:HY?UC$:WA2+KL_I/,PF^M[*;) N7C[.%G)_GKO=W"<RC6,E(D@+Q"&*9:PG
MJ5Q Q*3B69)@'>PZ!;5=+1D:#7Q=/C[2^4M[B?".+\KG<I5O\?K!\'==Q'"S
M'.A\RN_Z_K,,//OHE=#Q8RL/INW%OX#&#V <&1U9FPV:SW$ULK[BN<YV]!N6
M70O7071U]0/]G>!Y-Y?_N913OCFWP^(T$C'2X9))=T_-<>@<9Y!SA7F*B@)A
M)]E&BS:'QJ(M2\'&5(_'=/8AMZ-#ST &)KZ.&'HYBW,"E8 G</9;O/FYFQ,0
MV)RV.75K5]WL8P3WIJSX9&9:W 8%F91Q)(6>HL6,0*2$U.%=DD.19 H1DG/,
M'16S+5L>&OT<BQ-<-;%M0;>,Q$) &3KR.A5M@:W=.L@*$EZYPN5-!MNVW9X%
ML!WA.)2^=GW -6=P-IRX;6 C'A^32'*36D0Y,9K6$88D9A(F:2(2F1'$4Z?:
MAQ=;'!HW-0;_M<OQG'.XVM&05[0"T\_Z&$_K:'*;=P*L[ENCX_7,S[GV;G .
MR,+]XV>#;&[L>%ZH61VOOLWNN"8O_=RSN;3C)"5ZGB5BF$D20202#BGE$<P)
M17$2*:18,9[*>Z.\^,WA#)&;&5:?4M%\2@?&A/NL/NL'/9@:269!I7J8S1?0
M%%("Y?19-A5P'8\.NO:.'5.% +NG0T8KR\%B!E:VVU2U]GC6J!MTO@X>.;;>
M[RFD;M <'$GJ^)B.$\#R?EJ7C9PN[CB?+:=&\N_S;%)R_?SM1 0CG$C.,IAF
M5$(4YPED>MH'4X))5,0YHL*M6HA5LT,+KUKK]RT'P-8#L';!<4)HUPF6LT'O
MT(:>"IZ',M0LT DF7U- NT;[G?\Y 7$P^7.[NQM)?90+H^[P>3Y[+H44KUY^
MK:1X/]U(E*XVT<P!IYDQ8*E_M_KC;%IMIC&$*Q)E1K:!)A0B4^^MH)G0T\-,
M$!$AR63B0F)^S!H:R6VU>NG&?C<Z\]1==G37?R<$ID.CMU]KT*Q=,@EL/QBO
M=!C]8TM*>>O9"&Q] UOG@LQC_>+MB5<]&=4K[_H%<I^7/3^]<];7@YQ,3(X:
MG;Z,F4H$4SF#BL091'F40Q9'!<0Y88S%.:5V4EW''S\T'ETG.!D3P<I&YY2O
M-GSG^?!Z4 +SFA,>7?*]CKA]3;I7^W%]9WL=<>5(LM>QJVY^\L'DC+Y;9;#'
M*L4J5P@F"2X@8AF"1:+_*9#BJ<090X2.G^6<S6YPOJ%EJ,M7TC8W8!"P?&1R
M;B::*\-O=EJAW9^6$]";]U'H"6N84P?@-^,N6/D[S(,%1SID>(<'VD;^40\(
M' $ZX"& 8ZUYEE\[EMZ0,*8P5SH@S#C1 2%/(<MRHJ/"-!4D29!$3A-RE\:'
M%BY^73X]3>IN,RN,KZC^(Y<F6I*F0HZ:S1_K[O6DQ-8]V204QJ$W3LZJLP7/
M.>F"6FBQMIMGGG0!Q5K S5_^22,$H!F2LIF9'S_+%L<V&<"ZX4]L4MXWL^=?
MRHFL%K.IJ0'_9?9")]J\U:;.+U3(L<I%+&1,8"93961P$"2<8HAE'"64,"%B
M9%W_SJ-A0Z/$C;GUUSIO# 9/ZRW01VVRBT:*QQX\3Y6W[)? -+KC53O>':T/
M1IBN:KDV MM>U-Z!E7M@LY']R^UZT47QYC:]V9/R3<^]ZBAXXQ_Z\\(W'MOK
M40#'/TJ[0C@!GM]A&+[C?+Z4XHNLI"DT<7<_ETT-BG&JQTV<X@SB.$%&U#F&
MK,@32&G$LZ3($4-6^>GGFQG:$+FV$-"-B?6W6LGY<\EM-^XN0&LQVGD!+/#8
MM;(1S \Q\P*3PW#B!:Z>!H<NL+DQ_$4TSO+UZ;O[8]^+'NQPZ>6K.S#CU^:+
M_R*Y+)]-MM@OTBPACX6(L,Q( B.<2*.TR2#-900IBP@6:4RPPM:\>**1H;'B
MRDRPM=/A S\%I 4+>H G]-+U 3+@M\9(RX.3Y]\U>P;T %5/_.?P,KG1W@4(
MSI+>J7O[H[P+UN\0WJ5KNRTU'ZM3_:&DK)R4VX#SS5)^E-\7WWZ7DV?YRVRZ
M>*C&N% L29,81@09\1D<0X(+ 7F,8RJ(E%0X+3MW-61HM*E?,^2VOMRY"^S6
MFOL -C#A-BZ,6FE;'YI:]QL_1B:7GTD]=R[%"/R'#@G IZG'C/UK0?2T#-W9
MC%Z7I*\%:W]Y^NKGW3R?X_UT,2^G5<F;XG]*%$K%L8)Q0?4TFV!NRBTB**.,
M*H(4H\I*N"NXI4,CUY6];4GH$2C7)H-G]^(FX3K9CIT'T76AX^50 I,;CWU7
ME S>*\/+]]BS\X^:\G$<[H!9'R<:]%UW3S]OI:13I$BD5!00*U/_@ZL$LICK
MP8,0ELJHX(E;<2N+-H<V#)S-0QC5LM\=I8QL.L".V#W#&CK"GDWOX8?R63/O
M-_W[TJQIU(?& \@9.2 3O-3>ML5A)&T<0F!?;._PUHX*:N643GE))^^GU6)>
MKP[=?2]-P2E&8DD2F!=%!I$4.2R4(% 5$F>9GO,C[D0\)]H9&MELS 1;.\%O
MQE)7F;03N-KQB0>T G-(%Z#<M=#.P^!+_^Q$*_UJGIUW]4#G[,+EW<C@_93/
MS7S[C6S^^WZZ.J%:;1<BQUF1<J)9 2J*!$1(*$C3/(9IK'!:1'E*4+:6\[#C
M!IMFK5[]7?F.P%2QMA',MSL#)C993EDYF=3;?VY[*4Z]8,<CWI#MAU36YH(?
MU@;_:)1]-TC[W%#H I$GPK%JLE?V<0%AGXJ<[G4_%;G2[GB)$_:M7.@W7Z$<
MT51%,&581R8919#QC$"6\H+1*,W3S$JR[-C#AQ:.U$:9,TUQ\@/[<2U9XW H
M\@"]\[QQ+2:!^<$5#J<SD:?\[G0B\N!AO9V'/.5&^S3DR6NZA0V?YO=T6OY7
MO:SR>C:M9I-2-&LL4_&Y*1!8__.3VH0M7_5OF@R.8^<J)(NB!$L)9:9TB$%S
M"AF."E@@K.<D140H<=IN]&W@T&BB[5\=@[RB55DKBK6]<XM"O'>J7<1RRZX*
MS%YMUVK]B:US=:>UW3-]MYUB;3T,?^XF5 =XBIV\F]=KG!4*W/V8+%@[W2MR
M?EY7@GZCVQECP9."DP*F=9F3O$@@45A!:1:\>99$A%M5\3O9PM H>E.FLK$2
M:#.!L=.]7.<ND)?CN:OA"4R+SLATJN5YU/NKBGKN/K'WZIY''3I6YO/XA5VS
M)&;SQ3<Y?WR_E2<=L[3@ A44QIG,=;26Y+#@/(:)$"@70DE&W'3NCS0RM,_Y
MJP>EUJ-@VB827 =1\!P @XZQ#[RW0*?#COUI][UMMA]IHN=]\M-.'FYQG[FV
M0VK\L22L.LUJ\O+%4$JS23Y.$I&3@NKOO4@41,*<($H+/8KG":<Q0U(DS#I3
MWJ[-H1'!RD(P-R/8^J"M0V*X)=+G:2$0?J&WH4\E>JXQ_5)'!8W=_B%U2+WW
M#VU/F?A^('9+TG<#ZVS.ON6C^DOA=_-M)Z/?\=9N\9F1M]Z*7>_+8-<%^,84
MJ;0@DD"*4@J1D5&@191!F@G)5)YQKIP6URS:'!II7]!_KZ@YY%-;[KCK;X._
M783G&=70<[C+@OH7 76. AT@\A04VK38:XSH ,%^R.AR:S<R>CVA5;6J"/FA
MG,KW"_E8C1,L1907'&8BSR"*XPP6J2 0:?*/LR+AG"@7^CG:RM (IS9R4S(5
M_&8,!;6EC@1S'%,[2KD:J< DT@4D9](X"X(GFCC>1J_$<-;-?2HX?W''/<'C
M!WC&-(VY)%C -#5;>P4N8,%)#E'*2%((3IE1-)XMZ,1R:^]X.TX$L&DMX,ZU
M:0/,-F'XI$YSF:S,==:+/XFNC$0JL [F:!%#%$41+&(D(25)+E&<(I0[%1WQ
M@6X?:1(&73\(VE&I!UP"D^GITY,>MPK/H^!KQ^]$*_UNW)UW]6#_[<+EW3CU
MUZ]_GSW+^;3.]KR74[XJ:+0-XU:J ISG.IC*(QAQAC6U<@:95!G,61X74K&$
M(*>JCK8-#XT7?OWIZT_@?F,ZH"O;W:C"&G8[[@@!9F R^?4KV-H,UD;OEU&[
MK(OAS#"N6'FB'.MF>^4@5S#V2<GY_FN*SHZ5S"BEL8Y"4"KU_Q ""R0*R")&
MTT@AJB=]+H%>\]AAQG6-;5UJR#H5BAT0(USPN&.M5\^?\>JA-ZC:>NH3W/MK
M%SF_^@EW4_%A.W=HEI;K)9MMNAV)$<(T8S 3IG0,PRFD(F)0I2*5(D4QC3-[
M=3_+5H<6 +0DPB?7*H2[P7_^NPX&:B^??2U@VC):3RYJLU=+O, F+_$*:%U4
M P- W)>(H#>H':4%'2$[KS1H^[ >A0<=_=O5(72]N6,(Q?E<UNF:C[/Y8I7'
M^4F9Q,SZ8$V3Q?E8+A^K=NX0UF%5EI(<QCSA$.$4P<(4;T221CG32#%,.A3:
M[F:-U2?5?[WMM@]FK?EI93GX0:S]^1'H/_DHQ=VQ&RU#PG"]TI^X;.T ^*'M
MPH^F5S9>K!/C:S]&8;+)KD/25ZS:S8A^8]NK@#J(A:][6L<$5CG1?[W_NYS*
M.9WH)N[$8SDM3>U&(]/]]KO1A]DLZ"21(CJ.CF"61A%$"1>0JC2"L< \%R1-
M,C<1!*?6!Q=+-\:/P'UC?OUITAT'@&P\<,R#=>H3.W8,AG1@4MR _/<6R+NV
M@[7Q =;;.L'F*^/6J>U^4W&[P'*0H]OI(5V%'#:$:5;X5LHQBY=6PL>Z9G0J
M"XPBG$&%$Z&#1H4AH;'1?:&1***,B9BX<)Q]TT,CN);EHV9M>RTU98JPMI:Y
M+]>(OK93[$@N#-2!&<XCRAVT'EP!\Z;X8-UPS[H/KH <JC\X/Z&S-LWL46Y.
M*7XPG6V"1R.JQ&A!)%(4BBS7<1I#!21"<Q@G:<%27*@TL2J3;='6\$C+F+H]
M(0S6QG92K3H'LBTG>8$N. EU1*V+O,PE//RIRIQLJ6\QF4LN']&0N7A+S[K.
M[V@YKU4^[ZIJ^=@H@6IV^T4N'F9B-IG=OVQ&ZT+R"&.)H" ,011CL]69<U@P
MP?)<()&0N!>%9WN;AT9C_Y"F*I;4\^MG'1W?2T"W'O2D\>S0X99ST&%U8^B9
MZ_6ZS\;O1MP9M#ROX\.6[T$BPQ[[ZM9JT X6_S%TH=V[P)M"=(>F0QSL>CV;
M+LKI<K:L?IW.)9V4_R7%AUE5?9Y5I;$I3IH:"9_F1OI7SN\X7SXN)[5(HKYL
MG A"$$T2&,=%#A&.)"1Y$<$T2E$119106738. IJ]$#WE_X^U[:!K4? V.KS
M$-FU?6TW=MV^ZP9S<*V6:EJYN]^Q8.WQ",1)<ZBVTM\U:-P>@9;CYU\$SX??
M/'50+\?FKK5U0 ?N/,'N=E3/5Z.>9"(VR>[?9J^DJ=!TI_0$PA1I^J9?)SGF
M,A4D1BG,$X(ADHI#@AF#&8HIHAF7DN97:49<,&!H,Y]O#U+WFC'Q2HF#2\"?
M)_X^X S,Y3:%P[[-P*MUX;#:D:9\6.U*8/ROU)OPV ^W%I^XMC^NUZ.P!--9
MG.+2<V^K5&'I]479"MOG=$Q^T\.9*"=+LRFZ'?7>?N>3I9#BG7;33-*6:P'#
MMW0^U895G^6\F:.]''] O8:-\B@618HA3FFD)SIY"FE&.4PE2C-5%"JV&WQZ
ML'5HXU3;TMU].O=MAI!=;#>_&4C'!1X1._:9>P9=>#1]I=D%M+3?7+SPD!\D
M[/709,>ZQMML[+NIJ'4,'F83?7_5;$9O%NYCFB6%C"2DC)H,:6HF'R*!*B\H
MBUB.4FEU*,:UX:&1><ON>GF];?E?_DR2&/]ME9+A6-W8MB/L6#H$O*$G(7O(
MKA);0NQ9N*+CJRRQ;;/]EB%V!..@[+#K_5=L1U?OJVHIQ3A.%,IIG$$:YPE$
MFIA@D>0$YD5&,4VE0HR/GVKYWJ\+.E\X[!ZOFG#Y,/8;"O>-K [BC0"3]^74
M#!+@A](<N3"&_]AANW<-*.&1S&F.8:&8A"@A&20T+:"(D0[STUA'_6@%Z-NI
M97&JZ^!<-],#F+*N4.H)28<=[@[8]+$5;4Z+U(9YWB3><]?G;N[ZT?UON^XY
M=71_=/^:[D?;]%-:=/MZ.3?BN6.%1))($<%4*<V&A"K(*$*0<L%QI A+L--A
MBY,M#2T86QG:70WJ-*82"TISKB!%F1';,[7GLTSIH)?C)!$Z&C:8.H@P>,&T
M-UT&&@Y9RV4&'WB%7B18@;1SRGAEIM]#=F>1\'B.[G@[O1^5.^ONL=-PYV_H
MJAGUS53E6\Y;&=FKDU0XQDQF&8$HSP1$*DHA(TD*\Q1'*4<QB@KDIA)UJJFA
M,6ZM"[58&0NJC;6NNE GH;5C!S^ !::'7[^"M96AM9XNH>%-W>ED0SWK.5UR
M^%#!Z>(=@;*DJU,9<)^:I+>_ZRL7U?MI4VQFG<U[UR3SOOTNY[RLY.=YR>68
M9CJ84Y)"04BJ8Q(I(&.%-/-?D@L]\8V9DSA=C[8/C<=JR_70;>9\OWY] _2<
MLYG[=9GZ]=3]#C/+X75J'Q/7"SG4U84DZI7_(] @8.HG-QB,P!H%L((!K'$
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MM+ZS&QM]D<]RNI3OM,TFR<PDE/U#SS%?+_7,\O]6][4]<N/&NM_/KQ 0(-D
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M!03.*:!V+BP-J124?/)85R%_6O/E>@A@#\7U!^^/W/ZGM"M/H;],YR[CZFI
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MO6\^7 /J%7SC?@@E)QZ_(/:5&,C]P#A/1>YY?RJFM6VV5LM:N^O8A:&IH(:
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M!%(S+4I-*:/>5<IG9(S-1VW4S+9Z9HVB_H7)Y]#L=CJ),.K9NX3#$U2%? &
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MAH10]ATZ7(=B>(S@"4VJ..&2N&%C!4_CC^(%W_NN)$%R9S36CRT>'A?SFO#
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MM5I*8)>R!C!=*%&@'$F>AU!&GY44].T.P.[\V<G(%O7>SK16-/M!-ZK^N>[
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ME:5YR!S;5M%&Y3J4VE/Z8F%F-.A^WB$QE#U[BTLH]E :'P!0(G_B(W%0_Q(
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MJ&%K.3V,/JKC]+GGG"_9'Z\/]J?__J_-;^P?CJ?GO__K_P-02P,$%     @
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M0-;">-QZ[7;0Z#A;>;@P1T;#LQ.<YUHW^FH6/D]4\%XKET"Q6 ,FJZ&6^8!
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MC$;@F+S+2/NO>>Q>UX%@Z^HD8ACM/PRQ0U31 :@N,E/OP_>:EKJ,(A&+%+P
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M":EUNOD1<KJYR#NX(6ZEDP[2RSN=WW"?ZQC8#*(&;\JA!*^8 B9,":@R+W&
M*<UM3]>.<=MW<  .IK5#3]T^'6SW:EQ\WP+;\G0GIE"0_@_"NIIIR $B!:L0
M3;%D\ O*<NM@Y&X@?A@)W=P3'@R%1U314VE$=9D_>??JXZ=WS__7O[Y[\^+E
MAX\O__=?7W_Z]S;)H'N?/&PRZ,?,M$\&/=(>K1C%N) 93#*2MM: X+Q"P)RR
M8<9*P5IO/UL1=G@#QO.7?*H+9\***EYK!S:CK2/8'7@1$:1)Q3CD-JK6)RHW
M*>@F]=,("W=[,.XM[PX"@DOJSR12[?!BCG7 Q!_3U<2XZ&S@ :0SHI;8< C!
M1\@^6UM24*[Y9)A'">H$2WMH^B'0'"SV#C!TBX<7BY,PG4]L2%SHF$$[1^$Y
MN080##F*B4M9A'19Z]8IYWL)Z00SAROZ=GW P5+O #HW0X^_8#WYF^08I##1
M@5"J@#)U@H34 71DQDON67"M#V?NHV-<X#10[Z-AWAZR[@ OUZ* <P:"<2$Y
MS<&S8HB!8,^*TZ-VH9B@:E_']EFKFT2,>VC0'BF'2;D#F#PP,.*<&1*!-5IP
M*"%S$HVJ5C=9D"7*K#B72AQI6L<.\!DLU=D>/NVD/R*4-FF)C[C\-DT4R2><
M?JM.WSD/QC/4Q@=@)M=VGK9 C-$ "]YX9$)%<>LN_P-YH0=>,&[NL1TBF@FQ
M!YORX[$@YXQA94 AN7%91%!6,0C1. @N*^685UJV+HO=FKAQ\XD#V)I!M-(!
MW&Y/!KFPGE'IE)R$LAEHS.JT(U'[[O.()#YN4;6.JNZG9-P+D.V!U$#>':#F
M,MQ\0[R\IA]7$Z>3,,9IR)R3F4UFTW4Z@2/<.U,LQ9^M>R'=I:*3LIJ&B9O]
M!-P!1,@H+NL0ZQ=X]M_7\[N)T0^+V>S58OE[6.8)+]*;J!-@#@(4\0?.LP2%
M%^%CQ))3^Q80.Y'8289G3T3<Z0HQG'HZ0-^-;L"I!*F98.3[6PH%F$0(EEGR
M $VV&)*PV/K>V<X]F(>\,S2<HF];K7VEOC=BON)RNLBT-I;K1AO;G1%$@3/N
M4O2@E50D$(\UD$R0H^.&++LMK+4KM.<LJ"'O QT/0X=IH!LD717QK3XM'DA5
M;-9+)(%NJATHF-AH] ,2VZOI&L\CVO<;RBBN77R>;YYR-NLC42 A+1G^DFL1
M!/<.HF"T&1B*;J73K,365FUHGD;OV74TE'>%C@[VZZTFH":?@V8V@'"Z.M3:
M0'2U05XAD3LFF2BM1\'T/YWVF*AMKJ4.D+>1UIG+\N)T22'YV8(Z<V6>+^;?
MZ$VDRG?E[.?U-%XOU9Z@U\PYIP!#':L9N(<@,@,TQ7/#972E_0VO0R@>O2_9
M<3V)XVBV7QQO=H,?,QNR\2;D EAJ$U.%!8))'GSQNBB6R7$?9';NO@2/WA=M
M;!0/H-<.0'Q9%'ZSB&!"_C_JB 8T+;V:2J,]198,1:-*#%.(H34\'R!E]#YK
M1P->"UUT4IG_ 6=56K1(Z-=U0NVGY33,7IUN[OG7*H3IQA6?2.:5+8*#9%G4
M\@,&WAF$(EA6SAFKV79U^%N^</3.:H.#:3#Q=V"L;E[!]D+&Y#D#INN%E5KK
M%(V)(+FWP00>66E=(+3[U?<A>Z0=S3#M+_<.0',C11K(>-J<)4@=20J9490D
MF .9$8VU@679O&A^Y\3TD'W0QLE,[R+V _.)+^=M>CK>DQ7-WFM92@2#OC9^
M<.35^1# N,!L]$IFW_IB^)YYZ4$;HHV9F-Y%!4V!=,PN0<\^_NNK-^_^UK [
MT.43A^\*=#_Q[2^ /0^K+Z]FB]^OQH)P9A7%6YQ"K=H_SY%]\=+9.H12>15%
M5+%]1/TP/0V<G?K,]\M%C0KR;]__NJKSE"['"3Q+:XH7:LQ9)\U-YZ?TV?DO
M%_,KJ5B9'%J;(5E6^W=9!:YPLL2>1>%-B:9Y"K<-Y9T<_A^*M'M\J6.KM0,G
M[*8'R9V1465[UN)-^1PA1N]!V, -67$*: ?M?SPNM,9 P*,._2[JZ !+-T[R
MZC'</$UG>(.E3XLM)7PI3:VL\TED4&A=;;YJ("HG:NY.RLB+=J9US<$0?(Q;
MM= !LD<'1P<+Y 72F]-T(U7Z>88;_<_SLY/:?.D_-Y]/=#(V)JY Z-K?G$4D
MGFH#.\9%SI$9;-[E:ANZQC7-XZ/G=DJXM2H[@.=%N_2;5183ZW3TKEX8B55,
MGGMPFIB2+BDL6F@IFKOO]U(RK@WM#H(-U-4!Z)ZEM#Q;/-=63FU%O$J+TWIK
M>Y[?+_%D>GJR>CW_AN<:F- ZBE'&#$7)>DL@D:?/F ";4HG>*.YT:T]U/TK'
M+>3J#K1'4/?3.FFK+0_/RM=69_?U,$^DYLDXR<$%C+4Y"G$;M0:5$S<F<W2W
MSW@/.WR[AX9Q*[FZ@>TQ-=F!,;Z;1+X4Z'DEYE4#'^:""Z)6LM<&/CXKB)I\
MFV1,TE;RY)QL;("WIV[<RJYNT#NP6OL$;"W,O!+D:H6T?3"68S8IU&58?:)0
MP,5"K/'@;71"I.9CY;:CK+<+,6UP\6/X':JD+J;+W>6+O)N-%W-U\W[BDN&&
M[#P4%*)RI<%[DR%KIG5QGB-K'3UM0U=OMVB.!+P#%=0I[,AC_AJF^6)ZK/4N
M2(<<RF9H%6H)CHB%F(SP/I$C75K'1C^BJ;?K+$>"VP&*&15J&[?W$:F]J7__
M4&<(O2ODNFP,^ 0Q)%=J8WCK%8E.*?"<A!AB;==NDC>1;16U[/CBWBZ=-,76
MX)H8/UK^L;5^'[Y74UW3JRDM3XG :8C3V5E==Y)9^FP,&!^Q>L>R7HGT0*QS
MDFOR,;6^_+<?I;U=-SGREMM,B7V&'3<6Y 5KWR<DM^*BS:"-)*=6\ 11\#JM
M0FB;"T;M6A]?;DU<;S='CA5\-%!5GQB\$55=7U[$B[-"DN.!28-BO( 7Y.-*
M&3277#D>CX#"A\CK[2+)*$'PONKJ (G;5Q=,I-+>*%7OR7@+BE?G5Z B@7+!
M(U/&NP&N!FQ)W;A!2@<U&@,ILH,Q.0]P=G;$M+UPI7,6LT;(2!N#"K5KO6&T
M8RC,)5F2 FM]Q;D-Y9UT SM2S>:0:NW WI(G?=$N(_W'Z72)Q#\QM?[^?A;F
M:W*P:TW^U\T]LL YAL@]B(+D5T?ZPSN&9 V2TX:K(DOK5F+;4]=EM>>@V+G=
M'WP81?83TA,_"3&O7I'T_Q+6YU>Q-UFQ,\[K=*,PFZW>E8=G $Z,XP%KJZ.B
M>.TCFL@!$\4#]]S98&V1S>\/-"&\RYK/H^+[Z.KOT3H_S-H+C.2P.5YB$!H<
M2Z8Z;!:\J5/68Y+:&F]S;GTVN2.)7?K%H]KIABKMTUA7IAY;E!LVI4?AM:.X
MU" #98J&0!P3UX;GPC#9T/H&TZXTCGLVT -TAU1J!]9V>Q%/="Z9)\, -W,+
MO9,0T5BP62G)/ ]"M:Y8VIZZ<0\'.@#J0(KL-_?P:CH/\[2]<(7QV7/:1426
M$E1" P&Y B51JB"-5+YU5_$VE'<S5_HHN8<AU=JOO;V'ZPF+7ELM,@1?F[Z;
MG,$5F4!KK;(Q,K4/V[:GKLO<PZ#8V1N^.RFR XA6MNK_:_+D&SDXFW(ODM@T
MD;M<?T%1Y\T/KGWSK*7<W<.:-#NMU=XO_TA?POPS?B"C\K(4K!.820>.DTR2
MJ?,J,MF0(#B%I]GRQ#!SY5K/MCHNA]V,96]KOSN&20=.RT'2F109F'+6D8F(
MQ&S,% !;'NIIJ?8Z!:NQ=4[C((*[F?G>$<1W4F(WO>8/8QFUT-:Q" P%;:A&
M"'"T<,'I$A4:471I[6,/C]O!*G@ZQ>TN2NREI]GIUZ^SC2C#[$*4K^=EL3PY
M4^9E@*V8%C(Z8)OQ#[0.@2+N )9%7ORFM+/Y^);M2!NWAF<P) ZAF Y<Y+.+
M:)_"'[BJ<Q8FP7)NA'00&:^%Z4%"'>P&Z#U'B<A9\TSN+1)&;BHUA)KO%H#M
M+?,.(/-V,4\DF:M\W#Q?QHJ;&5R70HHEQ,QL@D+Q(=E?I\%%Q6CYE2P-TS'F
MYDVDMB5NW#;#P^6B!E%.!Z@[K\#<7*#)T_5I[5PZ3Z>5DM].UV\7ZW_']68U
M:12*Y8B0>:@#X)B &)4$6E$N1>183'O/;3O:1DXU#0.-.Q[; 'IJAK]A>H2^
M6WX.\_,.%F&>?PNKZ6I1WE][R4U&MNL3NL536_8*W96)1OU"K[_V^6*^6LRF
M.9RW4+K^\G?E'*QA=FD\KQ#KN-196PU1UGIL@1YB(9^_*%\<%P&5;IUZ:T+X
MP2.B#B&BMEJ9+5:T1#^1,G^;U4$&64=AM!6T*FNWP60TA!(\%.-IN:JD4;6N
M:VW-P[A6]OAXOC.0:DQ,=&ZI/YZ>G(3E]T7Y./T\GY9IJM659]?2ZA09$E6J
M1T)[6.LMG]S28N_#3".K??<UE] UI:!AQE H5(^BF"K@G)7 :IMQFYV1O/D(
MQ@>I.3@=\YADKU:(0XP:G0%,I3;W41Z\HC7+G"TZ)!VT:]X8;RO*1N[5V 8E
M=U(Q[972N=EZ%:;+S7"KOV"HMOFLG]P>5NK^![4T2EN0VL@&7;[I:L^ZMH'J
MP$/P$;3P&93*%,(8:R%+[P0OWF76^GK98_0<:H?N>_85TM&B#\HKL+$@,5LX
M!(Z:-FCR'((6*)L?5CQ*T+A6IQDN;MN==DKHW-Q<2X(NO_\69N0DXL<O6-N6
M769"]_.1MGAN6P]I5T:ZBFIE,N1CEP3,ZDT75P_!2@\69= 1*Z):YT^[B&H?
MO/QT7W2"6DHM9 '/L@*%PH/CY$E(6LJ&H)>R;NUO[D+?SQ"-[H+#>\K.A]%E
MYS9TTU)B+Q_M_%^VM(/W$=/(TIT]^A(JB?;6I#-M@$$PTJ#AX#EG$&36RA*&
M<A&-5^--"@[.J-WH";)Z5][@:K58WH=6[H44.2 4*VJ P2W$>F+#2TFQR,"U
MR*W-\];4C6MW#D#%G736, KIX$BK,H)XB[_K\6MRKAI#B74B7R!CZ 6)CRLC
MZP&S4;SU+97'*1KW%FM#2#44?.>[T#W#"??QVQ\8<=C*2_\!D<TFT]U^S=O%
M&J\!2KN,DITUR%.>:_)"T$%*26*(C)72O*+J48K:C\>L3[_/;I;LE70Z0W2.
M_#M?'3"N(J (BFMI$DO-1ZYN2]S8,^::8>;'HS-;J*=S>W35(W\5YOGL2LMG
MG.][Z/+8XYK.T=R6[$:FZMK[GMUZWQ5 +E'H-<5,WFNP7A,* V/@A \0K7+(
MG4RR>0/^G0@\N/1GFY==+1>-UK(D.?!4RZ=H$X> T8,L/!<NDXNR==9D-PK'
M-6G#8>M.*=!P>NO<S&UW,CO\<?.(Q\YC'3\3+HL-@0'CM7=G';'BLV-@G. Y
MH;#M+VX,=_S\,BSG]-AZR6PSXVOS_.]72X;V?V.-4) QULJ,+&G)6 TIU_XB
M4@G1W&?] 4G='CCO@HO;AJRE&CK(.[S%WZ\):KF8TX_I+.5[QMEM_K)B-DM=
M[]%H"KBU=>#0%+#.,NGJ;U3KI-ZN-(X\$7 8W VJJ)]B"_U4V]<,N(&>/__X
MV^=]C V_>3*56.WG"C*)>M$S)7":8D[OE=:19V53ZXFS ]9NI2^83S>-CNCY
M>3H[74^_76MR]/*/>D<;<VV(5.=FGEX<A=TV]U?KRX=- 289^L %J!P9!%?J
M^90MIB3)8OLZK^9<=+M%[X*^.]F4<97=N3&]MRAK?]OYV.,&KR4;T#(^6CED
M.6?6UAV595-'.!<(A!!(T7@=)>;$6Z_]HU2476LW?R[F_&[^H2Z<):V+S360
M:YXN!>D%5:$87=$2%<Z"K],Y @]<9:%=$JUS*WL1VG$%VBXX>K ";3"E=6[(
MMBGH.L0GW/KIQZY2&]#JM:D1"@3<@#*31.ND"D/[IO.< )X%MQ0(.Z%:]Q?O
MHE:MMLJ\<C-NM]3<J.U:?.9DBB$H"-Z+6B.:P"=;9R5XG0QRAMAZ^LHN]/T,
MM6J[X/"V>1U,EQTD?1[G[:_S)8;9]#^)K,5J]7ZQFE9)7VXWMUB/S/-41(82
M4=8ZFP0QZ0!>L*"B%CJ;UEY 0_+'317UCO+AD-#!(GBP&/6:LU18QE)['?M,
MSI(L"$&2C#$'IF5,W.36*9 ?4S5NX]3Q(=M8;QT@\5J^XLX,Q-MKS&F-P24H
M*B90 36X(C34;*YWIEXO:7V\OSUUX[:$'!^9 ^FQ\S#LO&)R[T#KQK]O7^@^
M8+!TJPHU!$=LU=&Z+GB"#HL0F+" 7!?.8K"QM$X*M2UWWSSM^6*UONW=$N%<
M1N(I*U[!RLFPUO):$Q,ZP9T,K?M /$!*5X7LN^C[;M7QX:(><>?:S)_>3)6N
MU3S7S-Q9-?4MIG16A6=&7&A9B#-BREF7P61/4I-!%^M_9"5V>F-7Q>G[P&0X
M^7;@[MQ7<7\Y;_=\(-3W6RRR))0H-H,4A229M(/:6(_^:K/A//#D6R=+]B!S
M7->\J7D:5D6=NS1WR[$/R",_]*QA;TT,Z/;\H [>Q8+.:P61MBQ0/@IPR@1
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M(S7RUHT,]B9V[!E$QX#L@.KKR]A61G_[_GP65M?8L3J*X-&0_'P")2-"3*I
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M^_-BKHV6.D^E;0H+5F_#<DE/_(8'Y,@>>%++Y-<VQ#;*:IV]ZA)'Q62ME;7
MO:!PWOC:L;UX<K<#K2<K2E*MDS W*3C(B7J#JQ7BNZ]8Y3;_O'GRYAK%[/L'
M4@CMX9N#!Y=D02XYN83"U]&=')P(%$1P;ZU 9U38;M;5=N\;-XET@()O>$8#
MR'9LG_L^EI[-YZ=A5CEZ/4_U>C"^QV6J"ON,DQ(RRSYET%E($A[3$,/FCRBD
M+(Q+QO<&SF-O'C>/-"2$FLF[&9B&W'^>+TZ^+N9UYUZ4S2<O__A:(XV#MZ,?
M/;C][K03*P-M5EJEPK."$C7!@VM"!C,&&'?1E10M<ZT+QMML5I>^WXVE4+M,
MU['2+$?C(3-;ZY3(D7-:(V2*-XLWT;G4FJ>[5/2U8^V@Y3OAU&$"[B"$NB+<
M>$\&-RK ( S%?M*!9PXAZ9(%\U8KW_J6V&Z .-K^<P @]A/GDXAMKIV8SQXX
M,#]XF]GA'>UWG'T9'&;S"24;I7. 4AL%*\L%!&?J_?"4/2'(^&%N!0RT^7R8
M?OZR?E?^2AX9.6ED)HVMHY 5!)4"+0^!$+V7D!3ZPGR4NGFM\:,$=;4E[:+[
MQ[>D0\2^MU7ZALNX:)5@OL'.10[I^T4&R2=M1:+=5F,=.L30@A<\@$"KO"5S
MG<.P[LQMBKK:R=KAZ"#!]PRD:W.!'%-<!,F!L=KKJV0+(14)+J@@)>W;*;:V
MN#\D:MQC^N'AM*?X>T;41#D;,V<4 8A<&PO'# XQ@[:6?A%C4<V[2CU RK@G
M]L.C9R=1=S!3YB8;?\.Z.6-^1J ,G\DMKU?4+G[Y"9<G?,*TE<EG8HA96A,I
M1O F*-!:!,-C])FW3I?O2N.XQ_F#8:RQ<CJ(]!_E[\5TE1:G\_6'L+Y(D$Y2
MT#RP6HI0YXDH'WQM5\F )?I42$^+;]C]\,<TCGN<?RSP':J<)Y&ZOAY]/P^K
M+Z]FB]^'2BT\\OQATPK;,C9,2L$Z+DR]F5H2LZ!D00C11,B:1^V+0OKO$THI
MG!\)KB:Y2*LYDV"DK\<XAD-DT8/%J*T1UD75>LC:_91TE4381=N/FZ.]!/TD
MC,ZKT]IDY"^TLY^<GMS@]6![\^-'MS<U.[(SC)7)AC/+0@#4F4"2R3N/6A=@
M67OKT,L4GI*5N5:V="G,4[SDUCGN!7(#WB=:92%*\-8:L$D9QI&B$W^<!-3]
M]'5ED79!QG818 .E=."9WU>W<!GC7O!W%H&0OFJAWBJ%V;]C6$XXHC,I.,C*
MD,]9:B\3%"3A'"R*HD/DK>L<]Z=VY-MN@R'HSAG@4=3Y5(!+8GU+.\VGWW'V
M[:RB:S610AM#HH20G*]CWQ5$13+.Q:M@H^0LMV[9NB^M(U^QZPJTAZKR"4&V
M+L=/OR\F(B'WTA4HSA-[B 9JSA%2\I$E[@ICK;N$[$CBR#?Y>@/H/HI[:K@D
MH.%$1!D4A5P@=.UE5FJ%9!$*$"/*)&5DV+XZ;4<B1[XRV"4V=U9>CV7,E]Q]
M6OQ&0>8T/ROTMBO^5+:^L.@@25WOLED/3AL$Y#KZ$)4NKNQ=R?R#EX]\P7!H
MT!U%)T_((DX*4]PK'P%)FJ!,%N!,$! \2SF67)@M(QG"D:\;]F;_=E)5!^>U
MC_+UUWD^/Y?!_/*/1%]]=E+_-M$F1!&=A)0Y R7JM7 3-23,FB?AT,6C!C</
M$3KRO<0NP-E$B:WGW[0O20E2ZQ"- YY] :4RAX!:@Y6:^ZA$L,U-Y"$E*>[)
M@ZZ%(GZ.$Y3)K2KWIF<H$S[&*<IMEB[/47X]4*0?UXOT]]J=G!18>PZNOV\^
MB41"KO>A<+[:,'?XK:X]W]2T U\#9AN=8-TEY>UB?64(DLU&9;0@G*-@S0D#
M02,'5Y1(7&8>L/7Y\N,4M9L<==& [6Q0+G[\0F;TM]L:>#;;/'+3). #IL7G
M>9TF]QZ7TT6N=UU69RVPM;+%H) @>&W5ICU"D.3FH9,2L[4A\=:;S"",C#P!
MJ!T6'QXV-9;:.P@KG_U.!NERMDWQCB$* 45J7WO&<?#*<D@BRFB81J-:U[C=
M(*"7:5.C >)VKY"]M=,!M!Z0VG(9YI_/^JG\]OWJ.^=.Q8;C*[;GN38=?AM.
M+D96,"^D+UD!MW7,1/(>HM")_JI9T(''P%J7  _!Q[A /P!6MVWHV#KN .>7
MQJ)N5>^^5@%<S+4/D@7F&#BL4VP+HY^DR1"=*,P7GA,/C<'Z(#$CF];1<?)
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M8FET,S$R+FAT;5!+ 0(4 Q0    ( !> I%8?Z@';  4  -$7   9
M      "  ;80  !C<F1F+3 S,S$R,V5X:&EB:70S,C$N:'1M4$L! A0#%
M  @ %X"D5DSM%%+Y!   LQ<  !D              ( ![14  &-R9&8M,#,S
M,3(S97AH:6)I=#,R,BYH=&U02P$"% ,4    "  7@*16AI.KCC,K 0"Q9@\
M$0              @ $=&P  8W)D9BTR,#(S,#,S,2YH=&U02P$"% ,4
M"  7@*16KYJZ(W8+  #>=   $0              @ %_1@$ 8W)D9BTR,#(S
M,#,S,2YX<V102P$"% ,4    "  7@*16B:3VL H:   ( @$ %0
M    @ $D4@$ 8W)D9BTR,#(S,#,S,5]C86PN>&UL4$L! A0#%     @ %X"D
M5@@$1'S()0  [*\! !4              ( !86P! &-R9&8M,C R,S S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( !> I%9#8+D>BY(   <P!@ 5
M  "  5R2 0!C<F1F+3(P,C,P,S,Q7VQA8BYX;6Q02P$"% ,4    "  7@*16
M;R,Y<N-0  #UM , %0              @ $:)0( 8W)D9BTR,#(S,#,S,5]P
<<F4N>&UL4$L%!@     *  H I@(  #!V @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
